Sentence,class,file
92http://www.openveterinaryjournal.com N.A.,Non-OADS,/arxiv_data1/oa_pdf/6b/89/OpenVetJ-6-89.PMC4935765.pdf
93http://www.openveterinaryjournal.com N.A.,Non-OADS,/arxiv_data1/oa_pdf/6b/89/OpenVetJ-6-89.PMC4935765.pdf
94http://www.openveterinaryjournal.com N.A.,Non-OADS,/arxiv_data1/oa_pdf/6b/89/OpenVetJ-6-89.PMC4935765.pdf
95http://www.openveterinaryjournal.com N.A.,Non-OADS,/arxiv_data1/oa_pdf/6b/89/OpenVetJ-6-89.PMC4935765.pdf
96http://www.openveterinaryjournal.com N.A.,Non-OADS,/arxiv_data1/oa_pdf/6b/89/OpenVetJ-6-89.PMC4935765.pdf
http://dx.doi.org/10.1371/journal.pone.0076413.,Non-OADS,/arxiv_data1/oa_pdf/6b/89/OpenVetJ-6-89.PMC4935765.pdf
97http://www.openveterinaryjournal.com N.A.,Non-OADS,/arxiv_data1/oa_pdf/6b/89/OpenVetJ-6-89.PMC4935765.pdf
"Email: junzaga@fcv.unlp.edu.arShort Communication DOI: http://dx.doi.org/10.4314/ovj.v6i2.5 Submitted: 07/03/2016 Accepted: 15/06/2016 Published: 28/06/201 6 Cryptosporidium varanii  infection in leopard geckos ( Eublepharis macularius )  in Argentina A. Dellarupe1,2, J.M.",Non-OADS,/arxiv_data1/oa_pdf/40/fe/OpenVetJ-6-98.PMC4935766.pdf
http://www.openveterinaryjournal.com A. Dellarupe et al.,Non-OADS,/arxiv_data1/oa_pdf/40/fe/OpenVetJ-6-98.PMC4935766.pdf
"Sequences were aligned and analyzed using GENEIOUS software (free available version 7.1, http://www.geneious.com).",OADS,/arxiv_data1/oa_pdf/40/fe/OpenVetJ-6-98.PMC4935766.pdf
http://www.openveterinaryjournal.com A. Dellarupe et al.,Non-OADS,/arxiv_data1/oa_pdf/40/fe/OpenVetJ-6-98.PMC4935766.pdf
http://www.openveterinaryjournal.com A. Dellarupe et al.,Non-OADS,/arxiv_data1/oa_pdf/40/fe/OpenVetJ-6-98.PMC4935766.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/Structure and functions of AGT HL u et al 500 Hypertension Research",Non-OADS,/arxiv_data1/oa_pdf/01/e1/hr201617a.PMC4935807.pdf
Available from: https://www.pcpcc.org/about/medical- home 2 Centers for Disease Control and Prevention [Internet].,Non-OADS,/arxiv_data1/oa_pdf/c7/7e/bmjqir-u209517-w4133.PMC4935809.pdf
Available from:  http://www.cdc.gov/asthma/nhis/2013/table2-1.htm 3 Centers for Disease Control and Prevention [Internet].,Non-OADS,/arxiv_data1/oa_pdf/c7/7e/bmjqir-u209517-w4133.PMC4935809.pdf
Available from:  http://www.cdc.gov/asthma/nhis/2013/table6-1.htm 4 Centers for Disease Control and Prevention [Internet].,Non-OADS,/arxiv_data1/oa_pdf/c7/7e/bmjqir-u209517-w4133.PMC4935809.pdf
"Available from:  http://www.cdc.gov/asthma/asthma_stats/severity_child.htm 5 National Heart, Lung, and Blood Institute.",Non-OADS,/arxiv_data1/oa_pdf/c7/7e/bmjqir-u209517-w4133.PMC4935809.pdf
"Available from:  http://www.cdc.gov/asthma/asthma_stats/default.htm 7 Nathan RA, Sorkness CA, Kosinski M, et al.",Non-OADS,/arxiv_data1/oa_pdf/c7/7e/bmjqir-u209517-w4133.PMC4935809.pdf
"See http://creativecommons.org/licenses/by-nc/2.0, http://creativecommons.org/licenses/by-nc/2.0/legalcode.",Non-OADS,/arxiv_data1/oa_pdf/c7/7e/bmjqir-u209517-w4133.PMC4935809.pdf
2015 [cited 2015 12 August];Available from: http://www.irci.info/.,OADS,/arxiv_data1/oa_pdf/ed/aa/rt-2016-2-6148.PMC4935820.pdf
2009 Available from: http://evs.nci.,Non-OADS,/arxiv_data1/oa_pdf/13/8c/rt-2016-2-6165.PMC4935821.pdf
Available from: http://www.oralcancerfoun- dation.org/facts/rare/mc/.,Non-OADS,/arxiv_data1/oa_pdf/3f/0c/rt-2016-2-6204.PMC4935825.pdf
Available from: http://www.cancer.gov/cancertopics/pdq/treatment/laryngeal/HealthProfessional/page 1#_299_toc 4.,Non-OADS,/arxiv_data1/oa_pdf/3f/0c/rt-2016-2-6204.PMC4935825.pdf
"190 http://taj.sagepub.com Ther Adv Chronic Dis 2016, Vol.",Non-OADS,/arxiv_data1/oa_pdf/68/db/10.1177_2040622316644481.PMC4935834.pdf
"Reprints and permissions:   http://www.sagepub.co.uk/journalsPermissions.nav Therapeutic Advances in Chronic Disease Introduction Approximately 80–85% of multiple sclerosis (MS) cases begin with a relapsing–remitting (RR) course [Compston and Coles, 2008].",Non-OADS,/arxiv_data1/oa_pdf/68/db/10.1177_2040622316644481.PMC4935834.pdf
C Kutz http://taj.sagepub.com 191 2010; Uz et al.,Non-OADS,/arxiv_data1/oa_pdf/68/db/10.1177_2040622316644481.PMC4935834.pdf
"Therapeutic Advances in Chronic Disease 7(4) 192 http://taj.sagepub.com served as a vehicle to determine if, by chance, these  patients kept blood glucose logs, with the under-standing that patients with MS usually do not.",Non-OADS,/arxiv_data1/oa_pdf/68/db/10.1177_2040622316644481.PMC4935834.pdf
C Kutz http://taj.sagepub.com 193 Table 1.,Non-OADS,/arxiv_data1/oa_pdf/68/db/10.1177_2040622316644481.PMC4935834.pdf
Therapeutic Advances in Chronic Disease 7(4) 194 http://taj.sagepub.com Table 2.,Non-OADS,/arxiv_data1/oa_pdf/68/db/10.1177_2040622316644481.PMC4935834.pdf
"C Kutz http://taj.sagepub.com 195 patients were reported as having elevated blood  glucose levels by the HCPs, while seven of these patients previously experienced hyperglycemia with corticosteroid treatment.",Non-OADS,/arxiv_data1/oa_pdf/68/db/10.1177_2040622316644481.PMC4935834.pdf
"Therapeutic Advances in Chronic Disease 7(4) 196 http://taj.sagepub.com Berkovich, R. (2013) Treatment of acute relapses in  multiple sclerosis.",Non-OADS,/arxiv_data1/oa_pdf/68/db/10.1177_2040622316644481.PMC4935834.pdf
Visit SAGE journals online  http://taj.sagepub.com SAGE journals,Non-OADS,/arxiv_data1/oa_pdf/68/db/10.1177_2040622316644481.PMC4935834.pdf
C Kutz http://taj.sagepub.com 197 Appendix Questionnaire: Acthar Gel Use in Multiple Sclerosis Patients with Diabetes Y ear of Birth _________ Gender  Male Female Race  White Black Hispanic Non-Hispanic Other Multiple Sclerosis History  •Year of Diagnosis _________  •Type of Multiple Sclerosis  Relapsing-Remitting Primary Progressive Secondary Progressive Progressive-Relapsing  •Disease Modifying Treatment  Yes List: __________________ No Diabetes History  •Year of Diagnosis _________  •Type of Diabetes  Type I Type II  •Treatment for diabetes  Yes List: _________________ No  •Does subject keep a glucose monitoring log?,Non-OADS,/arxiv_data1/oa_pdf/68/db/10.1177_2040622316644481.PMC4935834.pdf
Supplementary Information accompanies this paper on the Leukemia website (http://www.nature.com/leu).,Non-OADS,/arxiv_data1/oa_pdf/09/29/leu2015352a.PMC4935977.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ Supplementary Information accompanies this paper on the Leukemia website (http://www.nature.com/leu) SOX11 de ﬁnes two different subtypes of mantle cell lymphoma through transcriptional regulation of BCL6 Leukemia (2016) 30,1596 –1599; doi:10.1038/leu.2015.355 Mantle cell lymphoma (MCL) is an aggressive lymphoid neoplasm initially considered as derived from naive, pre-germinal center lymphocytes.1However, several studies have now shown that 15–40% of cases carry somatic mutations in the expressedimmunoglobulin ( IGVH ) gene, indicating that at least a subset of MCL is derived from antigen-experienced cells that have transi- tioned through the germinal center (GC).2The clinical impact of the IGHV mutational status on MCL has not been as well investigated as in chronic lymphocytic leukemia (CLL) but some studies have suggested a better outcome for patients with high load of IGHV mutations.3–5Intriguingly, the presence of Accepted article preview online 29 December 2015; advance online publication, 22 January 2016Letters to the Editor 1596 Leukemia (2016) 1580 –1627 © 2016 Macmillan Publishers Limited",Non-OADS,/arxiv_data1/oa_pdf/09/29/leu2015352a.PMC4935977.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/Letter to the Editor 996 Bone Marrow Transplantation (2016) 994 –996 © 2016 Macmillan Publishers Limited",Non-OADS,/arxiv_data1/oa_pdf/07/93/bmt20164a.PMC4935978.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/Revised criteria for SOS/VOD M Mohty et al 912 Bone Marrow Transplantation (2016) 906 –912 © 2016 Macmillan Publishers Limited",Non-OADS,/arxiv_data1/oa_pdf/a6/4f/bmt2016130a.PMC4935979.pdf
"To view a copy of this license, visit http:// creativecommons.org/licenses/by-nc-nd/4.0/ Supplementary Information accompanies this paper on the Leukemia website (http://www.nature.com/leu)Elevated FOXO1 in BCR –ABL1-independent resistance M Wagle et al 1501 © 2016 Macmillan Publishers Limited Leukemia (2016) 1493 –1501",Non-OADS,/arxiv_data1/oa_pdf/6a/e4/leu201651a.PMC4935980.pdf
Available	 from:	 	 http://www.artnscience.us/Med_Ethics/index.html.,Non-OADS,/arxiv_data1/oa_pdf/4d/be/PCR-7-109.PMC4936067.pdf
Available	 from:	http://www.cci.in/ pdf/surveys_reports/Pharmaceutical‑Industry‑in‑India.pdf.,Non-OADS,/arxiv_data1/oa_pdf/ae/4e/PCR-7-111.PMC4936068.pdf
Available	 from:	http://www.cdsco.nic.in/html/D%26C_ Rules_Schedule_Y.pdf.,Non-OADS,/arxiv_data1/oa_pdf/ae/4e/PCR-7-111.PMC4936068.pdf
Available from:  http://www.cdsco.nic.in/html/GCP1.html.,Non-OADS,/arxiv_data1/oa_pdf/ae/4e/PCR-7-111.PMC4936068.pdf
Available from:  http://www.ipc.nic.in/writereaddata/mainlinkFile/File416.pdf.,Non-OADS,/arxiv_data1/oa_pdf/ae/4e/PCR-7-111.PMC4936068.pdf
Available	 from:	http://www.ipc.nic.,Non-OADS,/arxiv_data1/oa_pdf/ae/4e/PCR-7-111.PMC4936068.pdf
Available	 from:	http://www.ipc.nic.in/ showfile.asp?EncHid=&lid=518.,Non-OADS,/arxiv_data1/oa_pdf/ae/4e/PCR-7-111.PMC4936068.pdf
Available	 from:	http://www.ipc.nic.in/showfile.asp?lid=453&EncHid.,Non-OADS,/arxiv_data1/oa_pdf/ae/4e/PCR-7-111.PMC4936068.pdf
It  consists numerous compounds which act as natural inputs for various  cheminformatics and virtual screening applicationshttp://chemoinfo.ipmc.,OADS,/arxiv_data1/oa_pdf/e3/f5/PCR-7-115.PMC4936069.pdf
IDMap has a huge implication in drug repositioning as it  builds a convenient environment for identifying the possible lead (or even  commercial chemical) and its drug targethttp://www.equispharm.,Non-OADS,/arxiv_data1/oa_pdf/e3/f5/PCR-7-115.PMC4936069.pdf
"The database contains  detailed information about miRNAs, their relationships, their expression  pattern, FDA approval status, etc., which significantly support the  development of drug, for example, miRNA therapeuticshttp://bioinfo.hrbmu.",OADS,/arxiv_data1/oa_pdf/e3/f5/PCR-7-115.PMC4936069.pdf
"The data  on expression of mRNA, genomic deoxyribonucleic acid, and protein  provide support to the hypothesis, establish disease predictors, and  provide inputs for algorithm developmenthttp://www.ncbi.nlm.",OADS,/arxiv_data1/oa_pdf/e3/f5/PCR-7-115.PMC4936069.pdf
Available 	 from: 	 http://www.clinicaltrials.gov.,Non-OADS,/arxiv_data1/oa_pdf/3d/78/PCR-7-123.PMC4936070.pdf
Available 	 from: 	   	 http://www.fda.gov/ohrms/dockets/ ac/02/briefing/3837b1_03_ICH%20e9.pdf.,Non-OADS,/arxiv_data1/oa_pdf/3d/78/PCR-7-123.PMC4936070.pdf
Available 	 from: 	 http://www.haad.ae.,Non-OADS,/arxiv_data1/oa_pdf/3d/78/PCR-7-123.PMC4936070.pdf
Available	 from:	http://www.ich.org/fileadmin/Public_Web_ Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf.,Non-OADS,/arxiv_data1/oa_pdf/0b/f0/PCR-7-132.PMC4936072.pdf
Available	 from:	http://www.ich.org/ fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/ E6_R2__Addendum_Step2.pdf.,OADS,/arxiv_data1/oa_pdf/0b/f0/PCR-7-132.PMC4936072.pdf
Available	 from:	http://www.frwebgate.,Non-OADS,/arxiv_data1/oa_pdf/0b/f0/PCR-7-132.PMC4936072.pdf
Available	 from:	 http://www.appliedclinicaltrialsonline.com/ subject‑recruitment‑and‑retention‑barriers‑success.,Non-OADS,/arxiv_data1/oa_pdf/2c/54/PCR-7-137.PMC4936073.pdf
Available from: https://www.farmaci.,Non-OADS,/arxiv_data1/oa_pdf/a5/5c/JPP-7-106.PMC4936077.pdf
Available from: http://www.bmscanada.ca/static/products/en/pm_pdf/ Fungizone_EN_PM.pdf.,Non-OADS,/arxiv_data1/oa_pdf/74/90/JPP-7-112.PMC4936079.pdf
Available from: http://www.fda.gov/ ForPatients/Approvals/Fast/default.htm.,Non-OADS,/arxiv_data1/oa_pdf/7d/b8/JPP-7-57.PMC4936080.pdf
Available from: http://www.fda.gov/Safety/Recalls/.,Non-OADS,/arxiv_data1/oa_pdf/7d/b8/JPP-7-57.PMC4936080.pdf
Available from: http://www.fda.gov/Drugs/DrugSafety/ ucm326580.htm.,Non-OADS,/arxiv_data1/oa_pdf/7d/b8/JPP-7-57.PMC4936080.pdf
Available from: http://www.fda.gov/Safety/MedW atch/ SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm349847.,Non-OADS,/arxiv_data1/oa_pdf/7d/b8/JPP-7-57.PMC4936080.pdf
Available  from: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/ DrugInnovation/UCM289229.pdf.,Non-OADS,/arxiv_data1/oa_pdf/7d/b8/JPP-7-57.PMC4936080.pdf
Available  from: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/ DrugInnovation/UCM381803.pdf.,Non-OADS,/arxiv_data1/oa_pdf/7d/b8/JPP-7-57.PMC4936080.pdf
Available  from: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/ DrugInnovation/UCM430299.pdf.,Non-OADS,/arxiv_data1/oa_pdf/7d/b8/JPP-7-57.PMC4936080.pdf
Available from:  http://www.fda.gov/Drugs/DrugSafety/ucm288186.htm.,Non-OADS,/arxiv_data1/oa_pdf/7d/b8/JPP-7-57.PMC4936080.pdf
Available from: http://www.fda.gov/Drugs/DrugSafety/ucm278267.,Non-OADS,/arxiv_data1/oa_pdf/7d/b8/JPP-7-57.PMC4936080.pdf
Available from: http://www.cancer.gov/about‑cancer/treatment/drugs/ fda‑vemurafenib.,Non-OADS,/arxiv_data1/oa_pdf/7d/b8/JPP-7-57.PMC4936080.pdf
Available from: http://www.fda.gov/ Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/ AdverseDrugEffects/ucm082196.htm.,Non-OADS,/arxiv_data1/oa_pdf/7d/b8/JPP-7-57.PMC4936080.pdf
Available from: http://www.ncbi.nlm.nih.gov/books/ NBK65148 26.,Non-OADS,/arxiv_data1/oa_pdf/7d/b8/JPP-7-57.PMC4936080.pdf
Author Help: Online submission of the manuscripts Articles can be submitted online from http://www.journalonweb.com.,Non-OADS,/arxiv_data1/oa_pdf/12/3e/JPP-7-80.PMC4936083.pdf
Available from:  http://www.uptodate.com/contents/drug‑induced‑myopathies.,Non-OADS,/arxiv_data1/oa_pdf/2b/c4/JPP-7-99.PMC4936087.pdf
Available from: http://factmed.com/ report‑GLIPIZIDE‑causing‑MYOPATHY.php.,Non-OADS,/arxiv_data1/oa_pdf/2b/c4/JPP-7-99.PMC4936087.pdf
Available from: http://www.ehealthme.com/ds/glipizide/ myopathy+toxic.,Non-OADS,/arxiv_data1/oa_pdf/2b/c4/JPP-7-99.PMC4936087.pdf
"• Tel: (822) 3010-5820  • Fax: (822) 3010-6196 • E-mail: donghyunyang@gmail.com This is an Open Access article distributed under the terms of  the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/3.0) which permits  unrestricted non-commercial use, distribution, and reproduction in  any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/a7/6d/kjr-17-445.PMC4936168.pdf
"Time-resolved, three-dimensional (3D) phase-contrast  (PC) magnetic resonance imaging (MRI), which is also  termed four-dimensional (4D) PC-MRI or 4D flow MRI, was  recently developed to investigate spatial and temporal  variations in the hemodynamic features of blood flow (8, http://dx.doi.org/10.3348/kjr.2016.17.4.445 pISSN 1229-6929  · eISSN 2005-8330Review Article  | Cardiovascular Imaging",Non-OADS,/arxiv_data1/oa_pdf/a7/6d/kjr-17-445.PMC4936168.pdf
http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/a7/6d/kjr-17-445.PMC4936168.pdf
"• Tel: (822) 2030-5500  • Fax: (822) 447-8726 • E-mail: ksm9723@yahoo.co.kr This is an Open Access article distributed under the terms of  the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/3.0) which permits  unrestricted non-commercial use, distribution, and reproduction in  any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/68/bf/kjr-17-463.PMC4936169.pdf
Retrospective electrocardiography  (ECG)-gated multidetector computed tomography (MDCT) http://dx.doi.org/10.3348/kjr.2016.17.4.463 pISSN 1229-6929  · eISSN 2005-8330Brief Communication  | Cardiovascular Imaging,Non-OADS,/arxiv_data1/oa_pdf/68/bf/kjr-17-463.PMC4936169.pdf
"• Tel: (1310) 267-8771  • Fax: (1310) 267-3631 • E-mail: EdwardLee@mednet.ucla.edu This is an Open Access article distributed under the terms of  the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/3.0) which permits  unrestricted non-commercial use, distribution, and reproduction in  any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/14/42/kjr-17-472.PMC4936170.pdf
"In the  United States, an estimated 23000 deaths from liver cancer http://dx.doi.org/10.3348/kjr.2016.17.4.472 pISSN 1229-6929  · eISSN 2005-8330Review Article | Intervention",Non-OADS,/arxiv_data1/oa_pdf/14/42/kjr-17-472.PMC4936170.pdf
http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2014/.,Non-OADS,/arxiv_data1/oa_pdf/14/42/kjr-17-472.PMC4936170.pdf
http://clinicaltrials.gov/ct2/home.,Non-OADS,/arxiv_data1/oa_pdf/14/42/kjr-17-472.PMC4936170.pdf
http://www.fda.gov/ohrms/dockets/dailys/00/jan00/010500/ aav0001.pdf.,Non-OADS,/arxiv_data1/oa_pdf/14/42/kjr-17-472.PMC4936170.pdf
http://www.fda.gov/ MedicalDevices/ProductsandMedicalProcedures/ DeviceApprovalsandClearances/Recently-ApprovedDevices/ ucm083605.htm.,Non-OADS,/arxiv_data1/oa_pdf/14/42/kjr-17-472.PMC4936170.pdf
"Index terms:  Breast; Breast neoplasms; Mammography; Mass screeningKorean J Radiol 2016;17(4):489-496http://dx.doi.org/10.3348/kjr.2016.17.4.489 pISSN 1229-6929  · eISSN 2005-8330Original Article  | Breast Imaging Received November 8, 2015; accepted after revision March 15, 2016.",Non-OADS,/arxiv_data1/oa_pdf/c9/2a/kjr-17-489.PMC4936171.pdf
"Korean J Radiol 17(4), Jul/Aug 2016 kjronline.orgSupplementary Materials The online-only Data Supplement is available with this  article at http://dx.doi.org/10.3348/kjr.2016.17.4.489.",Non-OADS,/arxiv_data1/oa_pdf/c9/2a/kjr-17-489.PMC4936171.pdf
"• Tel: (8231) 787-7605  • Fax: (8231) 787-4011 • E-mail: hakjlee@snu.ac.kr This is an Open Access article distributed under the terms of  the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/3.0) which permits  unrestricted non-commercial use, distribution, and reproduction in  any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/7c/6a/kjr-17-497.PMC4936172.pdf
"When siRNA is incorporated  into RNA-induced silencing complexes in the cytoplasm,  it promotes targeted gene silencing by sequence-specific http://dx.doi.org/10.3348/kjr.2016.17.4.497 pISSN 1229-6929  · eISSN 2005-8330Original Article  | Experimental and Others",Non-OADS,/arxiv_data1/oa_pdf/7c/6a/kjr-17-497.PMC4936172.pdf
"Corresponding author: Jeong Min Lee, MD, Department of Radiology, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea.• Tel: (822) 2072-3154 • Fax: (822) 743-6385• E-mail: jmsh@snu.ac.kr This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/d9/7f/kjr-17-509.PMC4936173.pdf
Multiphasic multidetector computed tomography (MDCT) http://dx.doi.org/10.3348/kjr.2016.17.4.509 pISSN 1229-6929 ·  eISSN 2005-8330Original Article  | Gastrointestinal Imaging Original Article  | Experimental and Others,Non-OADS,/arxiv_data1/oa_pdf/d9/7f/kjr-17-509.PMC4936173.pdf
"Corresponding author: Jeong Min Lee, MD, Department of Radiology, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea.• Tel: (822) 2072-3154 • Fax: (822) 743-6385 • E-mail: jmlshy2000@gmail.com This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/7a/1e/kjr-17-522.PMC4936174.pdf
"However, http://dx.doi.org/10.3348/kjr.2016.17.4.522 pISSN 1229-6929 ·  eISSN 2005-8330Original Article  | Gastrointestinal Imaging Original Article  | Experimental and Others",Non-OADS,/arxiv_data1/oa_pdf/7a/1e/kjr-17-522.PMC4936174.pdf
"• Tel: (822) 2019-3510  • Fax: (822) 3462-5472 • E-mail: yjsrad97@yuhs.ac This is an Open Access article distributed under the terms of  the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/3.0) which permits  unrestricted non-commercial use, distribution, and reproduction in  any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/e5/88/kjr-17-533.PMC4936175.pdf
"Cirrhosis is the most common cause  of benign PVT in adults and is present in 24% to 32%  of the patients with PVT, while the incidence of PVT is  also increased in the patients with primary or secondary http://dx.doi.org/10.3348/kjr.2016.17.4.533 pISSN 1229-6929  · eISSN 2005-8330Original Article  | Gastrointestinal Imaging",Non-OADS,/arxiv_data1/oa_pdf/e5/88/kjr-17-533.PMC4936175.pdf
"Corresponding author: Jae Hong Ahn, MD, Department of Radiology, Asan Foundation, GangNeung Asan Hospital, University of Ulsan College of Medicine, 38 Bangdong-gil, Sacheon-myeon, Gangneung 25440, Korea.• Tel: (8233) 610-3486 • Fax: (8233) 610-3490 • E-mail: jhahn@gnah.co.kr This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/ed/cc/kjr-17-541.PMC4936176.pdf
CT scans showed localized peritoneal http://dx.doi.org/10.3348/kjr.2016.17.4.541 pISSN 1229-6929 ·  eISSN 2005-8330Case Report  | Gastrointestinal Imaging Original Article  | Experimental and Others,Non-OADS,/arxiv_data1/oa_pdf/ed/cc/kjr-17-541.PMC4936176.pdf
"• Tel: (8231) 961-7823  • Fax: (8231) 961-8281 • E-mail: jeungkim@dumc.or.kr This is an Open Access article distributed under the terms of  the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/3.0) which permits  unrestricted non-commercial use, distribution, and reproduction in  any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/b2/ca/kjr-17-545.PMC4936177.pdf
"Although environmental regulations  and a subsequent decrease in exposure to asbestos have  led to a decline in its incidence in developed countries, its  incidence has yet to peak in developing countries because  disease onset lags exposure by approximately two decades (3).http://dx.doi.org/10.3348/kjr.2016.17.4.545 pISSN 1229-6929  · eISSN 2005-8330Original Article  | Thoracic Imaging",Non-OADS,/arxiv_data1/oa_pdf/b2/ca/kjr-17-545.PMC4936177.pdf
"• Tel: (90212) 224 49 50/4295  • Fax: (90212) 224 49 82 • E-mail: ulusoyolevent@gmail.com This is an Open Access article distributed under the terms of  the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/3.0) which permits  unrestricted non-commercial use, distribution, and reproduction in  any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/1e/06/kjr-17-554.PMC4936178.pdf
No craniovertebral  junction instability was detected in dynamic radiographic http://dx.doi.org/10.3348/kjr.2016.17.4.554 pISSN 1229-6929  · eISSN 2005-8330Case Report  | Pediatric Imaging,Non-OADS,/arxiv_data1/oa_pdf/1e/06/kjr-17-554.PMC4936178.pdf
"• Tel: (86571) 87236147  • Fax: (86571) 87072577 • E-mail: yujr0909@zju.edu.cn This is an Open Access article distributed under the terms of  the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/3.0) which permits  unrestricted non-commercial use, distribution, and reproduction in  any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/85/66/kjr-17-558.PMC4936179.pdf
"Seven years earlier, the patient had been diagnosed with http://dx.doi.org/10.3348/kjr.2016.17.4.558 pISSN 1229-6929  · eISSN 2005-8330Case Report | Thyroid",Non-OADS,/arxiv_data1/oa_pdf/85/66/kjr-17-558.PMC4936179.pdf
"• Tel: (90) 533-269-08-30 • Fax: (90) 252-421-04-15 • E-mail: serkanaribal@gmail.com This is an Open Access article distributed under the terms of  the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/3.0) which permits  unrestricted non-commercial use, distribution, and reproduction in  any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/63/b0/kjr-17-562.PMC4936180.pdf
Radiology  2000;214:183- 187 Korean J Radiol 2016;17(4):562-563http://dx.doi.org/10.3348/kjr.2016.17.4.562 pISSN 1229-6929  · eISSN 2005-8330,Non-OADS,/arxiv_data1/oa_pdf/63/b0/kjr-17-562.PMC4936180.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/eb/97/fnw161.PMC4936256.pdf
This  is  an  open access article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/35/ac/main.PMC4936329.pdf
http://dx.doi.org/10.1016/j.ijscr.2016.06.030 2210-2612/© 2016  The  Authors.,Non-OADS,/arxiv_data1/oa_pdf/35/ac/main.PMC4936329.pdf
The diagnosis of depressive disorder was classi ﬁ ed us- ing the International Classi ﬁ cation of Diseases (ICD-10)  (http://www.who.int/classi ﬁ cations/icd/en/).,Non-OADS,/arxiv_data1/oa_pdf/35/cf/eujmi-06-085.PMC4936330.pdf
Available at: http://www.who.int/food-safety/publications/campylobacteriosis/en/ 1–69 (2013) 4.,Non-OADS,/arxiv_data1/oa_pdf/54/ab/eujmi-06-118.PMC4936334.pdf
"1 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/87/e3/iew056.PMC4936373.pdf
"1 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/79/3f/iew055.PMC4936374.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any  medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/45/a2/bgw048.PMC4936385.pdf
"With the exception of one combination of radiation dose and repair interval (0.5 Gy and 16 h), which was not used for quantitative analyses, experimentswere performed in duplicates or triplicates (see Table Sup- plemental Digital Content 1, http://links.lww.com/HP/A52 which contains general information on the datasets).",OADS,/arxiv_data1/oa_pdf/dd/08/hp-111-75.PMC4936435.pdf
"Sequence reads were mapped to the human genome reference sequence hg19 (ftp://hgdownload.cse.ucsc.edu/ goldenPath/hg19/) using the workflow 'whole.transcriptome.pe'of LifeScope-v2.5.1 ‐r0 (Life Technologies, Carlsbad, NM, USA).",OADS,/arxiv_data1/oa_pdf/dd/08/hp-111-75.PMC4936435.pdf
"RNA-sequencing yielded between 23 and 64 millions of reads per sample (see also Table Supplemental Digital Content 1, http://links.lww.com/HP/A52).",OADS,/arxiv_data1/oa_pdf/dd/08/hp-111-75.PMC4936435.pdf
"A sub- set of these genes shows overlapping expression effects at different time points after irradiation; e.g., 218 genes showa dose-dependent increase in expression 0.5 h and 16 h after IR (see Tables Supplemental Digital Content 2 –5, (http:// links.lww.com/HP/A53, http://links.lww.com/HP/A54,http://links.lww.com/HP/A55, http://links.lww.com/HP/A56) which show differentially regulated genes in a dose depen- dent manner after different repair intervals).",Non-OADS,/arxiv_data1/oa_pdf/dd/08/hp-111-75.PMC4936435.pdf
"Principal component analysis (PCA) PCA of the RNA-Seq data (Table Supplemental Digital Content 6, http://links.lww.com/HP/A64 which contains the complete list of differentially expressed genes) revealed thatgene expression was comparatively homogenous within the samples from a given experiment; i.e., the first three princi- pal components (PCs) were strongly associated with indi-vidual experiments (as determined by multiple linear regression) (Fig.",OADS,/arxiv_data1/oa_pdf/dd/08/hp-111-75.PMC4936435.pdf
average downregulation (Table Supplemental Digital Con- tent 7 http://links.lww.com/HP/A57).,Non-OADS,/arxiv_data1/oa_pdf/dd/08/hp-111-75.PMC4936435.pdf
"This revealed similar gene sets to be overrepresented as ob- served for the repair intervals (Table Supplemental DigitalContent 7, http://links.lww.com/HP/A57); e.g., Parkinson ’s,Alzheimer ’s, and Huntington ’s disease (KEGG-hsa05012, KEGG-hsa05010, KEGG-hsa05016, respectively), Oxidativephosphorylation (KEGG-hsa00190), Citrate cycle (KEGG- hsa00020), Ribosome (KEGG-hsa03010) and Proteasome (KEGG-hsa03050).",Non-OADS,/arxiv_data1/oa_pdf/dd/08/hp-111-75.PMC4936435.pdf
Also 23 target sets of microRNAs werefound to be overrepresented (Table Supplemental Digital Content 7 http://links.lww.com/HP/A57).,OADS,/arxiv_data1/oa_pdf/dd/08/hp-111-75.PMC4936435.pdf
"In addition to that, a search for genes that were differ- entially expressed across the first three PCs of the count data (Table Supplemental Digital Content 7, http://links.lww.",Non-OADS,/arxiv_data1/oa_pdf/dd/08/hp-111-75.PMC4936435.pdf
"An explicit list of the geneswith altered expression is given in Tables Supplemental Digital Content 2 –5, http://links.lww.com/HP/A54, http://links.lww.com/HP/A55, http://links.lww.com/HP/A56.",Non-OADS,/arxiv_data1/oa_pdf/dd/08/hp-111-75.PMC4936435.pdf
"Nevertheless, several microRNA- related gene sets such as microRNAs involved in DNAdamage response (WP1545), microRNA-targeted genes in adipocytes (WP2001), and microRNA targets in ECM and membrane receptors (WP2911) were overrepresented (TableSupplemental Digital Content 7, http://links.lww.com/HP/A57).",Non-OADS,/arxiv_data1/oa_pdf/dd/08/hp-111-75.PMC4936435.pdf
"Here, 24 over- represented microRNA target sets were counted (Table Sup- plemental Digital Content 7, http://links.lww.com/HP/A57).When focusing on the genes differentially expressed across the third PC, which was also associated with the du- ration of the repair interval, signaling-related gene sets likethe TGF-beta (Receptor) signa ling pathway (KEGG-hsa04350, WP366), the Wnt signaling pathway (KEGG-hsa04310), and the (m)TOR signaling (pathway) (KEGG-hsa04150, WP1471)w e r ef o u n dt ob eo v e r r e p r e s e n t e d .I na d d i t i o nt ot h a t ,s e v e r a l cancer-related gene sets, such as Prostate cancer, Colorectal cancer, and Acute myeloid leukemia (KEGG-hsa05215,KEGG-hsa05210, KEGG-hsa05221, respectively), were over- represented as well as microRNA-related gene sets such as microRNA-targeted genes in lymphocytes, musclecells, epithelium, and squamous cells (WP2004, WP2005, WP2002, WP2006, respectively).",Non-OADS,/arxiv_data1/oa_pdf/dd/08/hp-111-75.PMC4936435.pdf
"(Table Supplemental Digital Content 7, http://links.lww.",Non-OADS,/arxiv_data1/oa_pdf/dd/08/hp-111-75.PMC4936435.pdf
"2010), several of which also showed expression differences in this study (see also Tables Supple-mental Digital Content 8-10 (h ttp://links.lww.com/HP/A58, http://links.lww.com/HP/A59, http://links.lww.com/HP/A60) that show differential expression results for the genes de-scribed by Ghandhi et al.",Non-OADS,/arxiv_data1/oa_pdf/dd/08/hp-111-75.PMC4936435.pdf
"2013), which compares to this study where FST was among the genes that showed consistent dose- dependent downregulation 16 h after IR (Table Supplemen-tal Digital Content 6 http://links.lww.com/HP/A64).",Non-OADS,/arxiv_data1/oa_pdf/dd/08/hp-111-75.PMC4936435.pdf
Available at: http://www.goldcopd.org/.,Non-OADS,/arxiv_data1/oa_pdf/d8/da/jtim-2015-0029.PMC4936450.pdf
Available from: http://healthcarevlogs.com/videos/series/muscular-dystrophy/.,Non-OADS,/arxiv_data1/oa_pdf/06/5c/jtim-2015-0020.PMC4936451.pdf
Available from: http://www.nytimes.com/2015/08/04/us/politics/planned-parent-hood-leader-defends-group-as-senate-blocks-bill-to-end-Its-funding.html?_r=0.,Non-OADS,/arxiv_data1/oa_pdf/06/5c/jtim-2015-0020.PMC4936451.pdf
Available from: http://www.npr.org/2015/08/27/435273173/planned-parenthood-says-experts-found-misleading-edits-in-videos.,Non-OADS,/arxiv_data1/oa_pdf/06/5c/jtim-2015-0020.PMC4936451.pdf
Available at: http://www.goldcopd.,Non-OADS,/arxiv_data1/oa_pdf/c7/6a/jtim-2015-0019.PMC4936452.pdf
"Available from: http://health.bih.nic.in/Docs/Guidelines-NPCDCS.pdf (Accessed on June 12, 2015).",Non-OADS,/arxiv_data1/oa_pdf/c7/6a/jtim-2015-0019.PMC4936452.pdf
"Available at:  http://www.goldcopd.org/uploads/users/files/GOLD_Report_2015_Apr2.pdf (Ac-cessed on 2 November, 2015).",OADS,/arxiv_data1/oa_pdf/42/97/jtim-2015-0022.PMC4936457.pdf
Available at: http://www.who.int/whosis/whostat/EN_WHS08_Full.pdf.,OADS,/arxiv_data1/oa_pdf/a0/95/jtim-2015-0013.PMC4936458.pdf
"OECD/European Union (2010), “Cancer Incidence”, in Health  at a Glance: Europe 2010 , OECD Publishing.http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/c5/d6/2224-4018.154291.PMC4936471.pdf
Available at:  http://www.scientia.ro/biologie/37-cum-functioneaza-corpul- omenesc/4050-epidemiologia-cancerelor-umane.html.,Non-OADS,/arxiv_data1/oa_pdf/c5/d6/2224-4018.154291.PMC4936471.pdf
"dehydrogenase into an orange-coloured, water-soluble formazan product (see Supplementary file, Supplemental digital content 1, http://links.lww.com/ACD/A157 ).",Non-OADS,/arxiv_data1/oa_pdf/6f/65/cad-27-609.PMC4936475.pdf
"Results Cytotoxic activity of peptidoglycan fragments Soluble peptidoglycan fragments that accumulated in the supernatant of a penicillin G-treated L. casei cell culture were fractionated in distilled water on a Sephadex G-50 column and successively in a Bio-Gel P2 column (see Supplementary file, Supplemental digital content 1, http://links.lww.com/ACD/A157 ).",Non-OADS,/arxiv_data1/oa_pdf/6f/65/cad-27-609.PMC4936475.pdf
"These were lyophilized and the residue was analysedby gas chromatography (see Supplementary file,Supplemental digital content 1, http://links.lww.com/ACD/ A157 ) for its amino acid content and composition.",Non-OADS,/arxiv_data1/oa_pdf/6f/65/cad-27-609.PMC4936475.pdf
"This could indeed be shown by MALDI-TOF mass spectrometry (see Supplementary file, Supplemental digital content 1, http://links.lww.com/ACD/A157 ), which indicated a com- plex mixture of presumably disaccharide moieties inter- connected with amino acid sequences of two, three and four amino acid residues.",OADS,/arxiv_data1/oa_pdf/6f/65/cad-27-609.PMC4936475.pdf
Keywords Hemophilia A; Immune tolerance; Regulatory T cells; FcRn; Fc fusion protein; Immunogenicity;  Factor VIII This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ef/80/nihms793458.PMC4936482.pdf
The findings of 51indicators resulting from the review provide a psychosocial framework for whichReceived: 13 January 2016 Revised: 30 March 2016 Accepted: 20 April 2016 Heliyon 2 (2016) e00105 http://dx.doi.org/10.1016/j.heliyon.2016.e00105 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
"As those from the social sciences increase their contributions to advance this research agenda, theycontribute to the growing recognition that social science efforts can expand and Article No~e00105 2 http://dx.doi.org/10.1016/j.heliyon.2016.e00105 2405-8440/© 2016 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
"Often addressing the problem of readiness from this meso (team) or macro (organizational) level of analysis ( Börner et al., 2010 ), findings associated with these types of studies relate behavior and individual performance as a response to these environmental Article No~e00105 3 http://dx.doi.org/10.1016/j.heliyon.2016.e00105 2405-8440/© 2016 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
"Contemporary issues associated with disparate groups ( Olson and Olson, 2000 ), the ethics of collaboration ( DuBois et al., 2012 ;Macrina et al., 1995 ), and the organizational antecedents necessary for productive scientific collaboration ( Katz, Article No~e00105 4 http://dx.doi.org/10.1016/j.heliyon.2016.e00105 2405-8440/© 2016 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
"This said, Article No~e00105 5 http://dx.doi.org/10.1016/j.heliyon.2016.e00105 2405-8440/© 2016 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
"Search engines used included the public Science of Team Science (SciTS) Mendeleygroup ( Falk-Krzesinski, 2015 ), Google Scholar, Scopus, and others that represent a Article No~e00105 6 http://dx.doi.org/10.1016/j.heliyon.2016.e00105 2405-8440/© 2016 The Authors.",OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
Article No~e00105 7 http://dx.doi.org/10.1016/j.heliyon.2016.e00105 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
Article No~e00105 8 http://dx.doi.org/10.1016/j.heliyon.2016.e00105 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
"Resource Acquisition: Accessing, acquiring, and deploying human and intellectual resources Motivation Indicators Threat Indicators Access to expertise Communication/IT infrastructure Access to administrative support Possess data set and/or tool that benefits others Access to trainee workforce Possessing expertise that others need Access to scientific materials Lack of available mechanisms to sustain a collaboration Access to funds Hard to find a funding mechanism to support collaborative research Need for division of labor Article No~e00105 9 http://dx.doi.org/10.1016/j.heliyon.2016.e00105 2405-8440/© 2016 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
An emphasis by funding agencies for collaborative teams can be frustrating for some researchers who feel this type of work is less productive yet supportive of Article No~e00105 10 http://dx.doi.org/10.1016/j.heliyon.2016.e00105 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
"For example, Sonnenwald (2007) concluded that “information and communication technologies (ICTs) can facilitate scientific collaboration and give rise to new types of collaboration ”(p. 660), the availability of which is key to the success of distance collaborations ( Shrum et al., Article No~e00105 11 http://dx.doi.org/10.1016/j.heliyon.2016.e00105 2405-8440/© 2016 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
Article No~e00105 12 http://dx.doi.org/10.1016/j.heliyon.2016.e00105 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
"In regard to funding directed at KPTs, some believe that funding agencies do not support or understand the need for such research that capitalizes on the benefits of collaborative engagements ( Castán Broto et al., 2009 ), or that despite increases in interdisciplinary research funding, the funds are spread too thin ( Laberge et al., Article No~e00105 13 http://dx.doi.org/10.1016/j.heliyon.2016.e00105 2405-8440/© 2016 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
Recognition and Reward: Mechanisms and methods by which human and intellectual resources are recognized Motivation Indicator Threat Indicators To obtain recognition Loss aversion Lack of external recognition/reward Concerns about getting promoted/tenured Lack of institutional recognition/reward Concerns about authorship Concerns that my referees won't be supportive Article No~e00105 14 http://dx.doi.org/10.1016/j.heliyon.2016.e00105 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
Article No~e00105 15 http://dx.doi.org/10.1016/j.heliyon.2016.e00105 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
Some have also reported that researchers are also concerned that the frameworks established to Article No~e00105 16 http://dx.doi.org/10.1016/j.heliyon.2016.e00105 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
Article No~e00105 17 http://dx.doi.org/10.1016/j.heliyon.2016.e00105 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
Motivation Indicators Threat Indicators Individual time constraints To solve problems faster Competition avoidance Best serves problem-centric science Interdisciplinary research pursuits Necessary for innovationInterdisciplinary illiteracy Article No~e00105 18 http://dx.doi.org/10.1016/j.heliyon.2016.e00105 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
"However, collaboration can also increase competition by requiring that individuals share valuable information ( Birnholtz, 2006 ;Fang and Casadevall, 2015 ) and receive criticism from others ( Bracken and Oughton, 2009 ), which can leave individuals Article No~e00105 19 http://dx.doi.org/10.1016/j.heliyon.2016.e00105 2405-8440/© 2016 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
"Interdisciplinary research pursuits Pursuing collaborative work in an effort to address specific research problems, either close to one ’s own research interests or in line with one ’s wider agenda, Article No~e00105 20 http://dx.doi.org/10.1016/j.heliyon.2016.e00105 2405-8440/© 2016 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
Article No~e00105 21 http://dx.doi.org/10.1016/j.heliyon.2016.e00105 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
Building Relationships: Utilizing resources and knowledge to establish or expand connections Motivation Indicators Threat Indicators A previous rewarding experience Personal enjoyment Social benefits Sharing passions Affinity toward helping/serving othersFear of rejection Don't wish to express need Dependency avoidance Conflict avoidance Power threat Status threat Article No~e00105 22 http://dx.doi.org/10.1016/j.heliyon.2016.e00105 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
These characteristics have become more commonly associated with Article No~e00105 23 http://dx.doi.org/10.1016/j.heliyon.2016.e00105 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
Article No~e00105 24 http://dx.doi.org/10.1016/j.heliyon.2016.e00105 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
Gender issues are also Article No~e00105 25 http://dx.doi.org/10.1016/j.heliyon.2016.e00105 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
"Maintenance of Beliefs Domain: Establishing, protecting, or building the value of science Motivation Indicators Threat Indicators Intellectual stimulation Value individual expertise Share interests Prefer hierarchical relationships Prefer unilateral decision-making authority Methodological biases Too hard to agree on a common goal Difficulty determining the appropriate level of cross-disciplinary integration Epistemological differences Article No~e00105 26 http://dx.doi.org/10.1016/j.heliyon.2016.e00105 2405-8440/© 2016 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
"These findings are seemingly contrary to contemporary trends in collaborative teaming, especiallybased on its implications for contemporary leadership trends ( Chen et al., 2007 ; Article No~e00105 27 http://dx.doi.org/10.1016/j.heliyon.2016.e00105 2405-8440/© 2016 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
Article No~e00105 28 http://dx.doi.org/10.1016/j.heliyon.2016.e00105 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
"Furthermore, the requirement of management of teams greatly affects their ability to understand differing constructs and mental models within the team Article No~e00105 29 http://dx.doi.org/10.1016/j.heliyon.2016.e00105 2405-8440/© 2016 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
Through thematic analysis of literature Article No~e00105 30 http://dx.doi.org/10.1016/j.heliyon.2016.e00105 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
"First,with an emphasis on within-domain relationships, some indicators are strongly tied Article No~e00105 31 http://dx.doi.org/10.1016/j.heliyon.2016.e00105 2405-8440/© 2016 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
Article No~e00105 32 http://dx.doi.org/10.1016/j.heliyon.2016.e00105 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
A hierarchy of motivations might be less static and unilateral and transferable amongst different KPTs but rather more dynamical suggesting that different Article No~e00105 33 http://dx.doi.org/10.1016/j.heliyon.2016.e00105 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
Article No~e00105 34 http://dx.doi.org/10.1016/j.heliyon.2016.e00105 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
"6/29/15, Policy http://www.apa.org/science/leadership/bsa/interdisci- plinary-joint-appointments.pdf .",Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
Article No~e00105 35 http://dx.doi.org/10.1016/j.heliyon.2016.e00105 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
Article No~e00105 36 http://dx.doi.org/10.1016/j.heliyon.2016.e00105 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
Article No~e00105 37 http://dx.doi.org/10.1016/j.heliyon.2016.e00105 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
Article No~e00105 38 http://dx.doi.org/10.1016/j.heliyon.2016.e00105 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
Article No~e00105 39 http://dx.doi.org/10.1016/j.heliyon.2016.e00105 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
"National Institutes of Health main campus in Bethesda, Maryland, June 3 –5.https://www.mendeley.",Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
Article No~e00105 40 http://dx.doi.org/10.1016/j.heliyon.2016.e00105 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
Article No~e00105 41 http://dx.doi.org/10.1016/j.heliyon.2016.e00105 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
Article No~e00105 42 http://dx.doi.org/10.1016/j.heliyon.2016.e00105 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
Article No~e00105 43 http://dx.doi.org/10.1016/j.heliyon.2016.e00105 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
Article No~e00105 44 http://dx.doi.org/10.1016/j.heliyon.2016.e00105 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
Article No~e00105 45 http://dx.doi.org/10.1016/j.heliyon.2016.e00105 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
Article No~e00105 46 http://dx.doi.org/10.1016/j.heliyon.2016.e00105 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
Article No~e00105 47 http://dx.doi.org/10.1016/j.heliyon.2016.e00105 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
Article No~e00105 48 http://dx.doi.org/10.1016/j.heliyon.2016.e00105 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
Article No~e00105 49 http://dx.doi.org/10.1016/j.heliyon.2016.e00105 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
Influence of a National Cancer Article No~e00105 50 http://dx.doi.org/10.1016/j.heliyon.2016.e00105 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
Article No~e00105 51 http://dx.doi.org/10.1016/j.heliyon.2016.e00105 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/23/05/main.PMC4936491.pdf
This  is  an  open access article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/be/7c/main.PMC4936497.pdf
The  initial  physical  examination  revealed  normal http://dx.doi.org/10.1016/j.ijscr.2016.06.028 2210-2612/© 2016  The  Authors.,Non-OADS,/arxiv_data1/oa_pdf/be/7c/main.PMC4936497.pdf
"21 (2015) 8125–8131, http://dx.doi.org/10.3748/wjg.v21.i26.",Non-OADS,/arxiv_data1/oa_pdf/be/7c/main.PMC4936497.pdf
"47  (2012)  788–791,  http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/be/7c/main.PMC4936497.pdf
"Esophagus 24 (2011) 131–137, http://dx.doi.org/10.1111/j.1442-2050.2010.",Non-OADS,/arxiv_data1/oa_pdf/be/7c/main.PMC4936497.pdf
"44  (2009)  e17–20,  http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/be/7c/main.PMC4936497.pdf
"Sohn,  Tracheoesophageal  ﬁstula  with  tracheal stenosis  resulting  from  retained  esophageal  foreign  body,  Auris  Nasus  Larynx 38  (2011)  753–756,  http://dx.doi.org/10.1016/j.anl.2010.12.013 .",Non-OADS,/arxiv_data1/oa_pdf/be/7c/main.PMC4936497.pdf
"[7]  X.  Zhang,  J.  Liu,  J.  Li,  J.  Hu,  F.  Yu,  S.  Li,  X.  Yang,  Diagnosis  and  treatment  of  32 cases  with  aortoesophageal  ﬁstula  due  to  esophageal  foreign  body, Laryngoscope  121  (2011)  267–272,  http://dx.doi.org/10.1002/lary.21366 .",Non-OADS,/arxiv_data1/oa_pdf/be/7c/main.PMC4936497.pdf
"43  (2011)  632–635,  http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/be/7c/main.PMC4936497.pdf
"5  (2011)  227–231,  http://dx.doi.org/10.1159/000327974 .",Non-OADS,/arxiv_data1/oa_pdf/be/7c/main.PMC4936497.pdf
"30  (2010)  475–477,  http://dx.doi.org/10.4103/0256-4947.70565 .",Non-OADS,/arxiv_data1/oa_pdf/be/7c/main.PMC4936497.pdf
"18  (2012)  5994–5998,  http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/be/7c/main.PMC4936497.pdf
"20 (2014) 7075–7078,  http://dx.doi.org/10.3748/wjg.v20.i22.7075 .",Non-OADS,/arxiv_data1/oa_pdf/be/7c/main.PMC4936497.pdf
"23  (2007)  1135–1137,  http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/be/7c/main.PMC4936497.pdf
"30  (2014)  1422–1424,  http://dx.doi.org/10.12669/pjms.306.5423 .",Non-OADS,/arxiv_data1/oa_pdf/be/7c/main.PMC4936497.pdf
"14  (2004)  1918–1925,  http://dx.doi.org/10.1007/s00330- 004-2430-1 .",Non-OADS,/arxiv_data1/oa_pdf/be/7c/main.PMC4936497.pdf
"2014  (2014),  http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/be/7c/main.PMC4936497.pdf
"67  (2014)  46–51,  http://dx.doi.org/10.1016/j.",OADS,/arxiv_data1/oa_pdf/be/7c/main.PMC4936497.pdf
This  is  an  open access article under the CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/9b/02/main.PMC4936498.pdf
Routine  blood  tests  were  within  normal  range http://dx.doi.org/10.1016/j.ijscr.2016.06.041 2210-2612/© 2016  The  Authors.,Non-OADS,/arxiv_data1/oa_pdf/9b/02/main.PMC4936498.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: Tourette syndrome Centromedian thalamus Motor cortexDeep brain stimulation 1.,Non-OADS,/arxiv_data1/oa_pdf/31/ff/main.PMC4936504.pdf
http://dx.doi.org/10.1016/j.nicl.2016.06.015 2213-1582/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/31/ff/main.PMC4936504.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/31/ff/main.PMC4936504.pdf
Neurosurgery [Internet] 38 (5) (Available from: http://journals.lww.,Non-OADS,/arxiv_data1/oa_pdf/31/ff/main.PMC4936504.pdf
"Jun 26 [cited 2015 Dec 4], Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3471287/ ).",OADS,/arxiv_data1/oa_pdf/31/ff/main.PMC4936504.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: Mobile appsmHealthDepressionAnxiety 1.,Non-OADS,/arxiv_data1/oa_pdf/87/29/main.PMC4936531.pdf
http://dx.doi.org/10.1016/j.invent.2016.06.003 2214-7829/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/87/29/main.PMC4936531.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/87/29/main.PMC4936531.pdf
http://dx.doi.org/10.1080/16506070903318960 .,Non-OADS,/arxiv_data1/oa_pdf/87/29/main.PMC4936531.pdf
http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/87/29/main.PMC4936531.pdf
http://dx.doi.org/10.1016/j.invent.2014.08.003 .,OADS,/arxiv_data1/oa_pdf/87/29/main.PMC4936531.pdf
http://dx.doi.org/10.1097/chi.,Non-OADS,/arxiv_data1/oa_pdf/87/29/main.PMC4936531.pdf
"38 (2), 66 –82.http://dx.doi.org/10.1080/16506070802694776 .",Non-OADS,/arxiv_data1/oa_pdf/87/29/main.PMC4936531.pdf
http://dx.doi.org/10.2196/jmir.2791 .,Non-OADS,/arxiv_data1/oa_pdf/87/29/main.PMC4936531.pdf
http://dx.doi.org/10.2196/jmir.1772 .,OADS,/arxiv_data1/oa_pdf/87/29/main.PMC4936531.pdf
http://dx.doi.org/ 10.2196/jmir.3084 .,Non-OADS,/arxiv_data1/oa_pdf/87/29/main.PMC4936531.pdf
Available from: http://www.imshealth.com (last accessed 20 Jun 2016).,Non-OADS,/arxiv_data1/oa_pdf/87/29/main.PMC4936531.pdf
"6 (1), 21 –37.http://dx.doi.org/ 10.1177/1745691610393527 .",Non-OADS,/arxiv_data1/oa_pdf/87/29/main.PMC4936531.pdf
http://dx.doi.org/10.1001/jama.289.23.3095 .,Non-OADS,/arxiv_data1/oa_pdf/87/29/main.PMC4936531.pdf
http://dx.doi.org/10.1001/archpsyc.62.6.617 .,Non-OADS,/arxiv_data1/oa_pdf/87/29/main.PMC4936531.pdf
http://dx.doi.org/10.2196/mhealth.4924 .,Non-OADS,/arxiv_data1/oa_pdf/87/29/main.PMC4936531.pdf
http://dx.doi.org/10.2196/jmir.1602 .,Non-OADS,/arxiv_data1/oa_pdf/87/29/main.PMC4936531.pdf
"Ann Behav Med 40 (1), 89 –98.http://dx.doi.org/10.1007/s12160-010-9203-7 .",Non-OADS,/arxiv_data1/oa_pdf/87/29/main.PMC4936531.pdf
"http://dx.doi.org/10.2196/jmir.3077 .Muñoz, R.F., 2010.",Non-OADS,/arxiv_data1/oa_pdf/87/29/main.PMC4936531.pdf
http://dx.doi.org/10.2196/ jmir.1463 .,Non-OADS,/arxiv_data1/oa_pdf/87/29/main.PMC4936531.pdf
http://dx.doi.org/10.2196/jmir.1852 .,Non-OADS,/arxiv_data1/oa_pdf/87/29/main.PMC4936531.pdf
http://dx.doi.org/10.1177/ 2167702615583840 .,Non-OADS,/arxiv_data1/oa_pdf/87/29/main.PMC4936531.pdf
Psychiatry http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/87/29/main.PMC4936531.pdf
http://dx.doi.org/10.1016/j.cpr.2012.02.004 .,OADS,/arxiv_data1/oa_pdf/87/29/main.PMC4936531.pdf
http://www.pewinternet.org/2015/04/01/us-smartphone-use-in- 2015/ .,Non-OADS,/arxiv_data1/oa_pdf/87/29/main.PMC4936531.pdf
http://dx.doi.org/10.1016/j.brat.,OADS,/arxiv_data1/oa_pdf/87/29/main.PMC4936531.pdf
http://dx.doi.org/10.2196/mhealth.2994 .,Non-OADS,/arxiv_data1/oa_pdf/87/29/main.PMC4936531.pdf
http://dx.doi.org/ 10.1016/j.invent.2015.03.002 .,OADS,/arxiv_data1/oa_pdf/87/29/main.PMC4936531.pdf
http://dx.doi.org/10.2196/jmir.954 .,Non-OADS,/arxiv_data1/oa_pdf/87/29/main.PMC4936531.pdf
http://dx.doi.org/10.2196/mental.3573 .158 E.G.,Non-OADS,/arxiv_data1/oa_pdf/87/29/main.PMC4936531.pdf
"To view a copy of this license, visit http:// creativecommons.org/licenses/by-nc-sa/4.0/ Supplementary Information for this article can be found on the Light: Science &Applications ' website (http://www.nature.com/lsa).Mirror-enhanced super-resolution microscopy XY a n g et al 8 Light: Science & Applications doi:10.1038/lsa.2016.134",Non-OADS,/arxiv_data1/oa_pdf/4f/7a/lsa2016134a.PMC4936537.pdf
http://dx.doi.org/10.1016/j.idcr.2016.05.006 2214-2509/ ã2016 Published by Elsevier Ltd.,Non-OADS,/arxiv_data1/oa_pdf/81/b6/main.PMC4936597.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).IDCases 5 (2016) 27 –28 Contents lists available at ScienceDirect IDCases journal homepage: www.elsevier.com/locate/idcr,Non-OADS,/arxiv_data1/oa_pdf/81/b6/main.PMC4936597.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: Motor networkDevelopmental coordination disorder Attention-de ﬁcit/hyperactivity disorder Resting-state fMRI 1.,Non-OADS,/arxiv_data1/oa_pdf/53/b0/main.PMC4936600.pdf
http://dx.doi.org/10.1016/j.nicl.2016.06.019 2213-1582/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/53/b0/main.PMC4936600.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/53/b0/main.PMC4936600.pdf
"The average time series of the voxels in left SM1 was computed from the preprocessed resting-state data to act as the regressor of interest in a time-series analysis using the general linear model (GLM), asimplemented in FEAT v6.0 (FSL, http://www.fmrib.ox.ac.uk/fsl ).",OADS,/arxiv_data1/oa_pdf/53/b0/main.PMC4936600.pdf
"These mapswere computed as Z-statistic images and corrected for multiple compar- isons based on a family-wise error rate to a signi ﬁcance level of p= 0.05, using AlphaSim of the AFNI analysis package ( http://afni.nimh.",OADS,/arxiv_data1/oa_pdf/53/b0/main.PMC4936600.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/af/7c/main.PMC4936605.pdf
"Contents lists available at ScienceDirect Indian Pacing and Electrophysiology Journal journal homepage: www.elsevier.com/locate/IPEJ http://dx.doi.org/10.1016/j.ipej.2016.04.001 0972-6292/Copyright ©2016, Indian Heart Rhythm Society.",Non-OADS,/arxiv_data1/oa_pdf/af/7c/main.PMC4936605.pdf
"Available online at www.sciencedirect.com ScienceDirect journal homepage: www.elsevier.com/locate/IPEJ indian pacing and electrophy siology journal 16 (2016) 3 e7 http://dx.doi.org/10.1016/j.ipej.2016.02.010 0972-6292/Copyright ©2016, Indian Heart Rhythm Society.",Non-OADS,/arxiv_data1/oa_pdf/54/eb/main.PMC4936606.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/54/eb/main.PMC4936606.pdf
Am J Cardiol 2013 Oct 15;112(8):1142 e7.http://dx.doi.org/10.1016/ j.amjcard.2013.05.063 .,Non-OADS,/arxiv_data1/oa_pdf/54/eb/main.PMC4936606.pdf
Europace 2007;9(6):335 e79.http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/54/eb/main.PMC4936606.pdf
http://dx.doi.org/10.1093/ europace/eup410 .,Non-OADS,/arxiv_data1/oa_pdf/54/eb/main.PMC4936606.pdf
J Cardiovasc Electrophysiol 2009Jul;20(7):715 e22.http://dx.doi.org/10.1111/j.1540-8167.2008.,Non-OADS,/arxiv_data1/oa_pdf/54/eb/main.PMC4936606.pdf
J Interv Card Electrophysiol 2015 Mar;42(2):91 e9.http://dx.doi.org/10.1007/s10840-014-9969-9 .,Non-OADS,/arxiv_data1/oa_pdf/54/eb/main.PMC4936606.pdf
J Thorac Cardiovasc Surg 2014 Apr;147(4):1411 e6.http://dx.doi.org/10.1016/ j.jtcvs.2013.06.057 .,Non-OADS,/arxiv_data1/oa_pdf/54/eb/main.PMC4936606.pdf
"ArrayCGH identified a 3.56 Mb copy  number gain on chromosome 1 short arm: arr[hg19] 1p21.3p21.2(96,420,239-99,981,342)x3, containing five annotated RefSeq (http://www.ncbi.nlm.nih.gov/refseq/) coding genes: PTBP2, DPYD, SNX7, LPPR5  and LPPR4 ,  and seven annotated Refseq non-coding RNAs (ncRNAs): antisense long non-coding RNAs (lncRNAs) DPYD-AS1  and DPYD-AS2 ,  microRNAs miR-137  and miR-2682 , and  uncharacterized long intergenic non-coding RNAs (lincRNAs) LOC10192824 , LOC729987  and  LOC100129620  (Fig.",OADS,/arxiv_data1/oa_pdf/d2/24/tnsci-2015-0007.PMC4936614.pdf
The closest in size are two pathological copy number gains listed in Decipher   (http://www.sanger.ac.uk): patient 279175 with 1.04  Mb duplication encompassing  Translational Neuroscience,Non-OADS,/arxiv_data1/oa_pdf/d2/24/tnsci-2015-0007.PMC4936614.pdf
"Using the lists of putative and experimentally  verified targets, we find no gene in sSMC(1) as the verified target of either miR-137 or  miR-2682 (http://www.mirbase.org, http://www.targetscan.org, http://mirdb.org).",OADS,/arxiv_data1/oa_pdf/d2/24/tnsci-2015-0007.PMC4936614.pdf
"In order to correlate both FRA1E range  predictions, we have converted the computationally revealed coordinates to hg 19 (chr1: 97,887,980-98,387,979) and retrieved the coordinates for the BAC clone RP11-359C24 (chr1: 97,817,963-98,003,396 [hg19]) from UCSC Browser (http://genome.ucsc.edu/).",OADS,/arxiv_data1/oa_pdf/d2/24/tnsci-2015-0007.PMC4936614.pdf
"Cytogenet., 2009, 2, 3 [10] Liehr T., Small supernumerary marker chromosomes, 2014, http://ssmc-tl.com/sSMC.html, accessed December 7, 2015 [11] Yeung A., Francis D., Giouzeppos O., Amor D.J., Pallister-Killian syndrome caused by mosaicism for a supernumerary ring chromosome 12p, Am.",Non-OADS,/arxiv_data1/oa_pdf/d2/24/tnsci-2015-0007.PMC4936614.pdf
SPM5 software (http://www.fil.ion.ycl.ac.uk/spm) was used to correct for head motion and global MRI signal shift.,OADS,/arxiv_data1/oa_pdf/6f/3e/tnsci-2015-0024.PMC4936632.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: Anthonomus grandisInsect reproductionEmbryo morphologyRNAi 1.,Non-OADS,/arxiv_data1/oa_pdf/b2/d7/main.PMC4936639.pdf
http://dx.doi.org/10.1016/j.mgene.2016.06.005 2214-5400/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/b2/d7/main.PMC4936639.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/b2/d7/main.PMC4936639.pdf
"Contents lists available at ScienceDirect Journal of Traditional and Complementary Medicine journal homepage: http://www.elsevier.com/locate/jtcme http://dx.doi.org/10.1016/j.jtcme.2015.01.001 2225-4110/Copyright ©2015, Center for Food and Biomolecules, National Taiwan University.",Non-OADS,/arxiv_data1/oa_pdf/7c/85/main.PMC4936652.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Journal of Traditional and Complementary Medicine 6 (2016) 257 e261,Non-OADS,/arxiv_data1/oa_pdf/7c/85/main.PMC4936652.pdf
http://dx.doi.org/10.4103/0973- 7847.134229 [Review].,Non-OADS,/arxiv_data1/oa_pdf/7c/85/main.PMC4936652.pdf
"Available online at www.sciencedirect.com ScienceDirect journal homepage: www.elsevier.com/locate/IPEJ indian pacing and electrophy siology journal 16 (2016) 19 e30 http://dx.doi.org/10.1016/j.ipej.2016.02.013 0972-6292/Copyright ©2016, Indian Heart Rhythm Society.",Non-OADS,/arxiv_data1/oa_pdf/12/24/main.PMC4936653.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/12/24/main.PMC4936653.pdf
"Contents lists available at ScienceDirect Journal of Traditional and Complementary Medicine journal homepage: http://www.elsevier.com/locate/jtcme http://dx.doi.org/10.1016/j.jtcme.2014.12.006 2225-4110/Copyright ©2014, Center for Food and Biomolecules, National Taiwan University.",Non-OADS,/arxiv_data1/oa_pdf/a6/23/main.PMC4936654.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Journal of Traditional and Complementary Medicine 6 (2016) 204 e208,Non-OADS,/arxiv_data1/oa_pdf/a6/23/main.PMC4936654.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/73/0c/main.PMC4936655.pdf
"Contents lists available at ScienceDirect Indian Pacing and Electrophysiology Journal journal homepage: www.elsevier.com/locate/IPEJ http://dx.doi.org/10.1016/j.ipej.2016.05.002 0972-6292/Copyright ©2016, Indian Heart Rhythm Society.",Non-OADS,/arxiv_data1/oa_pdf/73/0c/main.PMC4936655.pdf
Supplementary video related to this article can be found at http://dx.doi.org/10.1016/j.ipej.2016.05.003 .,OADS,/arxiv_data1/oa_pdf/e5/3f/main.PMC4936656.pdf
"Contents lists available at ScienceDirect Indian Pacing and Electrophysiology Journal journal homepage: www.elsevier.c om/locate/IPEJ http://dx.doi.org/10.1016/j.ipej.2016.05.003 0972-6292/Copyright ©2016, Indian Heart Rhythm Society.",Non-OADS,/arxiv_data1/oa_pdf/e5/3f/main.PMC4936656.pdf
"Contents lists available at ScienceDirect Journal of Traditional and Complementary Medicine journal homepage: http://www.elsevier.com/locate/jtcme http://dx.doi.org/10.1016/j.jtcme.2014.12.007 2225-4110/Copyright ©2014, Center for Food and Biomolecules, National Taiwan University.",Non-OADS,/arxiv_data1/oa_pdf/2f/3c/main.PMC4936657.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Journal of Traditional and Complementary Medicine 6 (2016) 199 e203,Non-OADS,/arxiv_data1/oa_pdf/2f/3c/main.PMC4936657.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/09/73/main.PMC4936658.pdf
"Contents lists available at ScienceDirect Indian Pacing and Electrophysiology Journal journal homepage: www.elsevier.com/locate/IPEJ http://dx.doi.org/10.1016/j.ipej.2016.03.004 0972-6292/Copyright ©2016, Indian Heart Rhythm Society.",Non-OADS,/arxiv_data1/oa_pdf/09/73/main.PMC4936658.pdf
"Contents lists available at ScienceDirect Journal of Traditional and Complementary Medicine journal homepage: http://www.elsevier.com/locate/jtcme http://dx.doi.org/10.1016/j.jtcme.2015.02.003 2225-4110/Copyright ©2015, Center for Food and Biomolecules, National Taiwan University.",Non-OADS,/arxiv_data1/oa_pdf/eb/83/main.PMC4936659.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Journal of Traditional and Complementary Medicine 6 (2016) 224 e229,Non-OADS,/arxiv_data1/oa_pdf/eb/83/main.PMC4936659.pdf
Available from: http://www.who.int/mediacentre/ factsheets/fs279/en/ .,Non-OADS,/arxiv_data1/oa_pdf/eb/83/main.PMC4936659.pdf
Available from: http://www.searo.who.int/india/ world_blood_donor_day_2014_message_wr.pdf .,Non-OADS,/arxiv_data1/oa_pdf/eb/83/main.PMC4936659.pdf
Available from: http://www.unaids.org/ en/media/unaids/contentassets/documents/unaidspublication/2011/ 20110826_APGettingToZero_en.pdf .,Non-OADS,/arxiv_data1/oa_pdf/eb/83/main.PMC4936659.pdf
Available from: http://www.wbhealth.gov.in/ wbsapcs/inner3.asp?param_page_id ¼3&param_link_id ¼1&param_text_ inner_id ¼1.,Non-OADS,/arxiv_data1/oa_pdf/eb/83/main.PMC4936659.pdf
"E-mail address: gdandamu@iu.edu Available online 3 March 2016 http://dx.doi.org/10.1016/j.ipej.2016.02.015 0972-6292/Copyright ©2016, Indian Heart Rhythm Society.",Non-OADS,/arxiv_data1/oa_pdf/29/9c/main.PMC4936661.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/ licenses/by-nc-nd/4.0/ ).indian pacing and electrophy siology journal 16 (2016) 1 e2 2,Non-OADS,/arxiv_data1/oa_pdf/29/9c/main.PMC4936661.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/18/2d/main.PMC4936664.pdf
"Contents lists available at ScienceDirect Indian Pacing and Electrophysiology Journal journal homepage: www.elsevier.com/locate/IPEJ http://dx.doi.org/10.1016/j.ipej.2016.03.003 0972-6292/Copyright ©2016, Indian Heart Rhythm Society.",Non-OADS,/arxiv_data1/oa_pdf/18/2d/main.PMC4936664.pdf
"PCR ampli ﬁcation Primers ﬂanking the exon-intron boundaries of all coding exons in three common genes ( KCNQ1 [NM_000218], KCNH2 [NM_000238] and SCN5A [NM_198056]); were designed using web-primer software available in Saccharomyces genome database (http://www.yeastgenome.org/cgi-bin/web-primer ).",OADS,/arxiv_data1/oa_pdf/18/2d/main.PMC4936664.pdf
Con ﬁrmation of the pathogenicity If variations identi ﬁed in this study were described in previous literature or listed in mutation database ( http://triad.fsm.it/ cardmoc/ and http://www.genomed.org/lovd2/home.php?,OADS,/arxiv_data1/oa_pdf/18/2d/main.PMC4936664.pdf
"mutationtaster.org ), Polyphen-2 ( http://genetics.bwh.harvard.edu/ pph2/ ), and SIFT ( http://sift.jcvi.org/www/SIFT_enst_submit.",OADS,/arxiv_data1/oa_pdf/18/2d/main.PMC4936664.pdf
"In addition, FATHMM ( http://fathmm.biocompute.org.uk ), I-Mutant ( http://folding.biofold.org/i-mutant/i-mutant2.0.html ), PROVEAN ( http://provean.jcvi.org/seq_submit.php ), PSIpred (http://bioinf.cs.ucl.ac.uk/psipred/ ), RaptorX ( http://raptorx.",Non-OADS,/arxiv_data1/oa_pdf/18/2d/main.PMC4936664.pdf
"Splice-sitevariations were investigated used BDGP ( http://www.fruit ﬂy.org/ seq_tools/splice.html ), AUGUSTUS ( http://bioinf.uni-greifswald.",OADS,/arxiv_data1/oa_pdf/18/2d/main.PMC4936664.pdf
"de/augustus/predictions/ ), GeneID ( http://genome.crg.es/ software/geneid/ ), GENSCAN ( http://www.genes.mit.edu/ GENSCAN.html ) and NetGene2 ( http://www.cbs.dtu.dk/services/ NetGene2/ ).",OADS,/arxiv_data1/oa_pdf/18/2d/main.PMC4936664.pdf
"Novel variations were also checked in dbSNP database ( http://www.ncbi.nlm.nih.gov/projects/SNP ), 1000 Ge- nomes ( http://browser.1000genomes.org/index.html ) or Exome Variant Server (EVS) ( http://evs.gs.washington.edu/EVS ).",OADS,/arxiv_data1/oa_pdf/18/2d/main.PMC4936664.pdf
J Clin Investig 2005;115:2018 e24.http://dx.doi.org/10.1172/JCI25537 .,Non-OADS,/arxiv_data1/oa_pdf/18/2d/main.PMC4936664.pdf
Circ J 2014;78:2827 e33.http://dx.doi.org/10.1253/circj.CJ- 14-0905 .,OADS,/arxiv_data1/oa_pdf/18/2d/main.PMC4936664.pdf
Heart Rhythm 2014;11:459 e68.http://dx.doi.org/10.1016/j.hrthm.2013.11.021 .,OADS,/arxiv_data1/oa_pdf/18/2d/main.PMC4936664.pdf
IntHeart J 2015;56:450 e3.http://dx.doi.org/10.1536/ihj.14-428 .,OADS,/arxiv_data1/oa_pdf/18/2d/main.PMC4936664.pdf
http://dx.doi.org/10.1016/j.hrthm.2009.05.021 .,OADS,/arxiv_data1/oa_pdf/18/2d/main.PMC4936664.pdf
Circulation 1998;97:2420 e5.http://dx.doi.org/ 10.1161/01.CIR.97.24.2420 .,Non-OADS,/arxiv_data1/oa_pdf/18/2d/main.PMC4936664.pdf
Circulation 1995;92:2929e34.http://dx.doi.org/10.1161/01.CIR.92.10.2929 .,Non-OADS,/arxiv_data1/oa_pdf/18/2d/main.PMC4936664.pdf
J Am Coll Cardiol 2000;36:1 e12.http://dx.doi.org/10.1016/S0735- 1097(00)00716-6 .,Non-OADS,/arxiv_data1/oa_pdf/18/2d/main.PMC4936664.pdf
http://dx.doi.org/10.1161/CIRCULATIONAHA.113.003985 .,Non-OADS,/arxiv_data1/oa_pdf/18/2d/main.PMC4936664.pdf
Circulation 2001;103:89 e95.http://dx.doi.org/10.1161/01.CIR.103.1.89 .,Non-OADS,/arxiv_data1/oa_pdf/18/2d/main.PMC4936664.pdf
Circulation 2000;102:1178 e85.http://dx.doi.org/10.1161/01.CIR.102.10.1178 .,Non-OADS,/arxiv_data1/oa_pdf/18/2d/main.PMC4936664.pdf
Circulation 2005;112:2602 e10.http://dx.doi.org/10.1161/CIRCULATIONAHA.105.572453 .,Non-OADS,/arxiv_data1/oa_pdf/18/2d/main.PMC4936664.pdf
Ann Med 2009;41:234e 40.http://dx.doi.org/10.1080/07853890802668530 .,Non-OADS,/arxiv_data1/oa_pdf/18/2d/main.PMC4936664.pdf
http://dx.doi.org/10.1038/ejhg.2014.54 .,OADS,/arxiv_data1/oa_pdf/18/2d/main.PMC4936664.pdf
Indian J Otolaryngol Head Neck Surg 2010;62: 44e8.http://dx.doi.org/10.1007/s12070-010-0008-6 .,Non-OADS,/arxiv_data1/oa_pdf/18/2d/main.PMC4936664.pdf
http://dx.doi.org/10.1016/ j.ihj.2013.08.025 .,OADS,/arxiv_data1/oa_pdf/18/2d/main.PMC4936664.pdf
http://dx.doi.org/10.1016/ j.mgene.2015.07.010 .,OADS,/arxiv_data1/oa_pdf/18/2d/main.PMC4936664.pdf
Circ J 2015;79:1185 e92.http://dx.doi.org/10.1253/circj.CJ-15-0322 .,Non-OADS,/arxiv_data1/oa_pdf/18/2d/main.PMC4936664.pdf
Am J Med Genet A 2012;158:2820 e8.http://dx.doi.org/10.1002/ajmg.a.35620 .,Non-OADS,/arxiv_data1/oa_pdf/18/2d/main.PMC4936664.pdf
Circulation 2007;115:2481 e9.http://dx.doi.org/ 10.1161/CIRCULATIONAHA.106.665406 .,Non-OADS,/arxiv_data1/oa_pdf/18/2d/main.PMC4936664.pdf
J Am Coll Cardiol2004;44:117 e25.http://dx.doi.org/10.1016/j.jacc.2004.03.043 .,Non-OADS,/arxiv_data1/oa_pdf/18/2d/main.PMC4936664.pdf
J Am Coll Cardiol 2009;54:2052 e62.http://dx.doi.org/ 10.1016/j.jacc.2009.08.028 .,Non-OADS,/arxiv_data1/oa_pdf/18/2d/main.PMC4936664.pdf
http://dx.doi.org/10.1016/j.jacc.2005.09.056 .,OADS,/arxiv_data1/oa_pdf/18/2d/main.PMC4936664.pdf
http://dx.doi.org/ 10.1161/01.CIR.99.4.529 .B.,Non-OADS,/arxiv_data1/oa_pdf/18/2d/main.PMC4936664.pdf
"Contents lists available at ScienceDirect Journal of Traditional and Complementary Medicine journal homepage: http://www.elsevier.com/locate/jtcme http://dx.doi.org/10.1016/j.jtcme.2015.03.004 2225-4110/Copyright ©2015, Center for Food and Biomolecules, National Taiwan University.",Non-OADS,/arxiv_data1/oa_pdf/72/21/main.PMC4936753.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Journal of Traditional and Complementary Medicine 6 (2016) 230 e236,Non-OADS,/arxiv_data1/oa_pdf/72/21/main.PMC4936753.pdf
2011;2011. http://dx.doi.org/ 10.1093/ecam/nen075 .E.P.K.,Non-OADS,/arxiv_data1/oa_pdf/72/21/main.PMC4936753.pdf
2011;2011. http://dx.doi.org/10.1093/ecam/nep195 .,Non-OADS,/arxiv_data1/oa_pdf/72/21/main.PMC4936753.pdf
http://nccam.nih.gov/health/whatiscam/ chinesemed.htm .,Non-OADS,/arxiv_data1/oa_pdf/72/21/main.PMC4936753.pdf
"Contents lists available at ScienceDirect Journal of Traditional and Complementary Medicine journal homepage: http://www.elsevier.com/locate/jtcme http://dx.doi.org/10.1016/j.jtcme.2016.01.004 2225-4110/Copyright ©2016, Center for Food and Biomolecules, National Taiwan University.",Non-OADS,/arxiv_data1/oa_pdf/82/c4/main.PMC4936754.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Journal of Traditional and Complementary Medicine 6 (2016) 316 e320,Non-OADS,/arxiv_data1/oa_pdf/82/c4/main.PMC4936754.pdf
"Contents lists available at ScienceDirect Journal of Traditional and Complementary Medicine journal homepage: http://www.elsevier.com/locate/jtcme http://dx.doi.org/10.1016/j.jtcme.2015.07.004 2225-4110/Copyright ©2016, Center for Food and Biomolecules, National Taiwan University.",Non-OADS,/arxiv_data1/oa_pdf/f1/4a/main.PMC4936755.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Journal of Traditional and Complementary Medicine 6 (2016) 269 e274,Non-OADS,/arxiv_data1/oa_pdf/f1/4a/main.PMC4936755.pdf
"Contents lists available at ScienceDirect Journal of Traditional and Complementary Medicine journal homepage: http://www.elsevier.com/locate/jtcme http://dx.doi.org/10.1016/j.jtcme.2015.07.003 2225-4110/Copyright ©2016, Center for Food and Biomolecules, National Taiwan University.",Non-OADS,/arxiv_data1/oa_pdf/4b/e1/main.PMC4936756.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Journal of Traditional and Complementary Medicine 6 (2016) 275 e280,Non-OADS,/arxiv_data1/oa_pdf/4b/e1/main.PMC4936756.pdf
"Contents lists available at ScienceDirect Journal of Traditional and Complementary Medicine journal homepage: http://www.elsevier.com/locate/jtcme http://dx.doi.org/10.1016/j.jtcme.2015.09.001 2225-4110/Copyright ©2015, Center for Food and Biomolecules, National Taiwan University.",Non-OADS,/arxiv_data1/oa_pdf/37/cf/main.PMC4936757.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Journal of Traditional and Complementary Medicine 6 (2016) 309 e315,Non-OADS,/arxiv_data1/oa_pdf/37/cf/main.PMC4936757.pdf
"http://dx.doi.org/ 10.1002/14651858.CD003415.pub3 .3.Bakr I, Ez-Elarab HS.",Non-OADS,/arxiv_data1/oa_pdf/37/cf/main.PMC4936757.pdf
"2014:5, 792708. http://dx.doi.org/ 10.1155/2014/792708 .",Non-OADS,/arxiv_data1/oa_pdf/37/cf/main.PMC4936757.pdf
http://dx.doi.org/10.1016/S0140-6736(08) 60527-9 .,OADS,/arxiv_data1/oa_pdf/37/cf/main.PMC4936757.pdf
2011 Jan 17;8:2. http://dx.doi.org/10.1186/1742-4755-8-2 .,Non-OADS,/arxiv_data1/oa_pdf/37/cf/main.PMC4936757.pdf
http://dx.doi.org/10.1002/ 14651858.CD004515.pub2 .,Non-OADS,/arxiv_data1/oa_pdf/37/cf/main.PMC4936757.pdf
"Contents lists available at ScienceDirect Journal of Traditional and Complementary Medicine journal homepage: http://www.elsevier.com/locate/jtcme http://dx.doi.org/10.1016/j.jtcme.2015.04.002 2225-4110/Copyright ©2015, Center for Food and Biomolecules, National Taiwan University.",Non-OADS,/arxiv_data1/oa_pdf/1f/3a/main.PMC4936758.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Journal of Traditional and Complementary Medicine 6 (2016) 247 e251,Non-OADS,/arxiv_data1/oa_pdf/1f/3a/main.PMC4936758.pdf
"Contents lists available at ScienceDirect Journal of Traditional and Complementary Medicine journal homepage: http://www.elsevier.com/locate/jtcme http://dx.doi.org/10.1016/j.jtcme.2015.09.003 2225-4110/Copyright ©2016, Center for Food and Biomolecules, National Taiwan University.",Non-OADS,/arxiv_data1/oa_pdf/c8/bb/main.PMC4936763.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Journal of Traditional and Complementary Medicine 6 (2016) 299 e304,Non-OADS,/arxiv_data1/oa_pdf/c8/bb/main.PMC4936763.pdf
"Contents lists available at ScienceDirect Journal of Traditional and Complementary Medicine journal homepage: http://www.elsevier.com/locate/jtcme http://dx.doi.org/10.1016/j.jtcme.2015.07.006 2225-4110/Copyright ©2015, Center for Food and Biomolecules, National Taiwan University.",Non-OADS,/arxiv_data1/oa_pdf/7d/a9/main.PMC4936764.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Journal of Traditional and Complementary Medicine 6 (2016) 289 e293,Non-OADS,/arxiv_data1/oa_pdf/7d/a9/main.PMC4936764.pdf
"Contents lists available at ScienceDirect Journal of Traditional and Complementary Medicine journal homepage: http://www.elsevier.com/locate/jtcme http://dx.doi.org/10.1016/j.jtcme.2015.06.001 2225-4110/Copyright ©2015, Center for Food and Biomolecules, National Taiwan University.",Non-OADS,/arxiv_data1/oa_pdf/85/3a/main.PMC4936765.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Journal of Traditional and Complementary Medicine 6 (2016) 252 e256,Non-OADS,/arxiv_data1/oa_pdf/85/3a/main.PMC4936765.pdf
2014. http://dx.doi.org/ 10.1002/alr.21466 .,Non-OADS,/arxiv_data1/oa_pdf/85/3a/main.PMC4936765.pdf
2015. http://dx.doi.org/10.1111/1750-3841.12787 .M.,Non-OADS,/arxiv_data1/oa_pdf/85/3a/main.PMC4936765.pdf
"Contents lists available at ScienceDirect Journal of Traditional and Complementary Medicine journal homepage: http://www.elsevier.com/locate/jtcme http://dx.doi.org/10.1016/j.jtcme.2015.03.003 2225-4110/Copyright ©2015, Center for Food and Biomolecules, National Taiwan University.",Non-OADS,/arxiv_data1/oa_pdf/f8/ae/main.PMC4936766.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Journal of Traditional and Complementary Medicine 6 (2016) 209 e218,Non-OADS,/arxiv_data1/oa_pdf/f8/ae/main.PMC4936766.pdf
"Falsetto S. The Practice of Plant Medicine: Herbal Medicine, Homeopathy, Natu- ropathy and Aromatherapy ; 2009. http://sharonfalsetto.suite101.com .",Non-OADS,/arxiv_data1/oa_pdf/f8/ae/main.PMC4936766.pdf
http://www.emecs.or.jp/guidebook/eng/pdf/07persian.pdf ; 2012.,Non-OADS,/arxiv_data1/oa_pdf/f8/ae/main.PMC4936766.pdf
INTECH; 2013. http://dx.doi.org/10.5772/ 55305 .,OADS,/arxiv_data1/oa_pdf/f8/ae/main.PMC4936766.pdf
"Contents lists available at ScienceDirect Journal of Traditional and Complementary Medicine journal homepage: http://www.elsevier.com/locate/jtcme http://dx.doi.org/10.1016/j.jtcme.2015.12.001 2225-4110/Copyright ©2016, Center for Food and Biomolecules, National Taiwan University.",Non-OADS,/arxiv_data1/oa_pdf/a7/63/main.PMC4936767.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Journal of Traditional and Complementary Medicine 6 (2016) 305 e308,Non-OADS,/arxiv_data1/oa_pdf/a7/63/main.PMC4936767.pdf
"Contents lists available at ScienceDirect Journal of Traditional and Complementary Medicine journal homepage: http://www.elsevier.com/locate/jtcme http://dx.doi.org/10.1016/j.jtcme.2015.10.002 2225-4110/Copyright ©2016, Center for Food and Biomolecules, National Taiwan University.",Non-OADS,/arxiv_data1/oa_pdf/0a/84/main.PMC4936768.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Journal of Traditional and Complementary Medicine 6 (2016) 294 e298,Non-OADS,/arxiv_data1/oa_pdf/0a/84/main.PMC4936768.pdf
"Contents lists available at ScienceDirect Journal of Traditional and Complementary Medicine journal homepage: http://www.elsevier.com/locate/jtcme http://dx.doi.org/10.1016/j.jtcme.2015.08.005 2225-4110/Copyright ©2016, Center for Food and Biomolecules, National Taiwan University.",Non-OADS,/arxiv_data1/oa_pdf/27/1f/main.PMC4936769.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Journal of Traditional and Complementary Medicine 6 (2016) 281 e288,Non-OADS,/arxiv_data1/oa_pdf/27/1f/main.PMC4936769.pdf
"Contents lists available at ScienceDirect Journal of Traditional and Complementary Medicine journal homepage: http://www.elsevier.com/locate/jtcme http://dx.doi.org/10.1016/j.jtcme.2015.03.002 2225-4110/Copyright ©2015, Center for Food and Biomolecules, National Taiwan University.",Non-OADS,/arxiv_data1/oa_pdf/ee/3b/main.PMC4936770.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Journal of Traditional and Complementary Medicine 6 (2016) 219 e223,Non-OADS,/arxiv_data1/oa_pdf/ee/3b/main.PMC4936770.pdf
"Contents lists available at ScienceDirect Journal of Traditional and Complementary Medicine journal homepage: http://www.elsevier.com/locate/jtcme http://dx.doi.org/10.1016/j.jtcme.2015.03.001 2225-4110/Copyright ©2015, Center for Food and Biomolecules, National Taiwan University.",Non-OADS,/arxiv_data1/oa_pdf/2f/54/main.PMC4936771.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Journal of Traditional and Complementary Medicine 6 (2016) 237 e246,Non-OADS,/arxiv_data1/oa_pdf/2f/54/main.PMC4936771.pdf
"International Workshop Innova-tion and Development in Health: Integration of Complementary and Tradi- tional Medicine in Public Health Systems, Florence October 28 e31, 2008. http://www.art-tuscany.org/documents/reports/MedCom_DeclarationEng.pdf ; Accessed 03.12.14.",Non-OADS,/arxiv_data1/oa_pdf/2f/54/main.PMC4936771.pdf
Available at http://saiindia.gov.in/english/ home/our_products/audit_report/government_wise/union_audit/recent_reports/union_performance/2004_2005/Civil_%20Performance_Audits/Report_ no_16/perfaudayush.pdf ; Accessed 03.12.14.,Non-OADS,/arxiv_data1/oa_pdf/2f/54/main.PMC4936771.pdf
http://apps.who.int/ medicinedocs/pdf/h2943e/h2943e.pdf ; Published 2001; Accessed 01.01.14.12.,OADS,/arxiv_data1/oa_pdf/2f/54/main.PMC4936771.pdf
Available at: http://ccrhindia.org/ Institute.asp ; Accessed 03.12.14.,Non-OADS,/arxiv_data1/oa_pdf/2f/54/main.PMC4936771.pdf
Available at: http://planningcommission.gov.in/aboutus/committee/strgrp12/st_ayush0903.pdf; Accessed 03.12.14.,Non-OADS,/arxiv_data1/oa_pdf/2f/54/main.PMC4936771.pdf
"Contents lists available at ScienceDirect Journal of Traditional and Complementary Medicine journal homepage: http://www.elsevier.com/locate/jtcme http://dx.doi.org/10.1016/j.jtcme.2015.06.003 2225-4110/Copyright ©2016, Center for Food and Biomolecules, National Taiwan University.",Non-OADS,/arxiv_data1/oa_pdf/0e/00/main.PMC4936772.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Journal of Traditional and Complementary Medicine 6 (2016) 262 e268,Non-OADS,/arxiv_data1/oa_pdf/0e/00/main.PMC4936772.pdf
2014. http://dx.doi.org/10.1179/ 1476830514Y.0000000144 .,Non-OADS,/arxiv_data1/oa_pdf/0e/00/main.PMC4936772.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/9f/36/amep-7-371.PMC4936805.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/9f/36/amep-7-371.PMC4936805.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Advances in Medical Education and Practice 2016:7 371–373Advances in Medical Education and Practice Dovepress submit your manuscript | www.dovepress.com Dovepress 371 CoMMEnt Ary open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/AMEP .S108074 national Medical School Matching Program:  optimizing outcomes  Adam EM Eltorai Alan H Daniels Warren Alpert Medical School, Brown  University, Providence, rI, USAAbstract:  The medical school admissions process is inefficient and costly to both applicants  and medical schools.",Non-OADS,/arxiv_data1/oa_pdf/9f/36/amep-7-371.PMC4936805.pdf
"•	College service fees for transmitting transcripts from a college registrar (estimated $25).Correspondence:  Adam EM Eltorai Warren Alpert Medical School of Brown University,  222 richmond Street,  Box G-9999,  Providence, rI 02903, USAtel +1401 330 1420Email adam_eltorai@brown.eduJournal name: Advances in Medical Education and Practice Article Designation: CommentaryY ear: 2016V olume: 7Running head verso: Eltorai and DanielsRunning head recto: National Medical School Matching ProgramDOI: http://dx.doi.org/10.2147/AMEP .S108074",Non-OADS,/arxiv_data1/oa_pdf/9f/36/amep-7-371.PMC4936805.pdf
"Advances in Medical Education and Practice Publish your work in this journal Submit your manuscript here: http://www.dovepress.com/advances-in-medical-education-and-practice-journalAdvances in Medical Education and Practice is an international, peer-  reviewed, open access journal that aims to present and publish research on Medical Education covering medical, dental, nursing and allied   health care professional education.",Non-OADS,/arxiv_data1/oa_pdf/9f/36/amep-7-371.PMC4936805.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Advances in Medical Education and Practice 2016:7submit your manuscript | www.dovepress.com Dovepress Dovepress Dovepress 373 national Medical School Matching Program  inefficiencies in the current system.,Non-OADS,/arxiv_data1/oa_pdf/9f/36/amep-7-371.PMC4936805.pdf
Available from: https://www.aamc.org/data/facts/applicantmatricu-lant/.,OADS,/arxiv_data1/oa_pdf/9f/36/amep-7-371.PMC4936805.pdf
Available from: https://students-residents.aamc.org/financial-aid/article/the-cost-of-applying-to-medical-school/.,Non-OADS,/arxiv_data1/oa_pdf/9f/36/amep-7-371.PMC4936805.pdf
Available from: http://www.kaptest.com/mcat.,Non-OADS,/arxiv_data1/oa_pdf/9f/36/amep-7-371.PMC4936805.pdf
Available from: http://ticas.org/sites/default/files/pub_files/Debt_Facts_and_Sources.pdf.,Non-OADS,/arxiv_data1/oa_pdf/9f/36/amep-7-371.PMC4936805.pdf
Available from: https://services.aamc.org/msar/home#null.,OADS,/arxiv_data1/oa_pdf/9f/36/amep-7-371.PMC4936805.pdf
Available from: http://www.nrmp.org/about/.,Non-OADS,/arxiv_data1/oa_pdf/9f/36/amep-7-371.PMC4936805.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/f7/5e/ndt-12-1609.PMC4936806.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Neuropsychiatric Disease and Treatment 2016:12 1609–1615Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  1609OrigiNal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/NDT .S10444 2Measuring illness insight in patients with  alcohol-related cognitive dysfunction using the   Q8 questionnaire: a validation study serge JW Walvoort1–3 Paul T van der heijden3,4 roy P c Kessels1,2,5 Jos iM egger1–3,6 1centre of excellence for Korsakoff  and alcohol- related cognitive  Disorders, Vincent van gogh institute  for Psychiatry, Venray, 2Donders  institute for Brain, cognition and  Behaviour, 3Behavioural science  institute, radboud University,   Nijmegen, 4reinier van arkel Mental  health institute, ‘s-hertogenbosch,   5Department of Medical Psychology,   radboud University Medical center,   Nijmegen, 6centre of excellence for  Neuropsychiatry, Vincent van gogh  institute for Psychiatry, Venray, the  NetherlandsAim:  Impaired illness insight may hamper treatment outcome in patients with alcohol-related  cognitive deficits.",Non-OADS,/arxiv_data1/oa_pdf/f7/5e/ndt-12-1609.PMC4936806.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/f7/5e/ndt-12-1609.PMC4936806.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/f7/5e/ndt-12-1609.PMC4936806.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/5b/02/dddt-10-2129.PMC4936807.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Drug Design, Development and Therapy 2016:10 2129–2136Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  2129Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/DDDT .S10544 1 comparison of cisplatinum/paclitaxel with  cisplatinum/5-fluorouracil as first-line therapy for  nonsurgical locally advanced esophageal squamous  cell carcinoma patients guofang hu1 Zhehai Wang2 Yuan Wang1 Qingqing Zhang1 ning Tang1 Jun guo2 liyan liu2 Xiao han2 1school of Medicine and life sciences,   University of Jinan, shandong academy  of Medical sciences, 2Department of  Oncology, shandong cancer hospital,   shandong University, Jinan, shandong,   People’s republic of chinaBackground:  To retrospectively evaluate the efficacy and toxicity of definitive concurrent  chemoradiotherapy (dCRT) with cisplatinum/paclitaxel versus cisplatinum/5-fluorouracil in  patients with locally advanced esophageal squamous cell carcinoma (ESCC) who received  nonsurgical treatment.",Non-OADS,/arxiv_data1/oa_pdf/5b/02/dddt-10-2129.PMC4936807.pdf
"Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDrug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/5b/02/dddt-10-2129.PMC4936807.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/5b/02/dddt-10-2129.PMC4936807.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/cb/a0/ott-9-4023.PMC4936808.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2016:9 4023–4035OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  4023Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S10705 0 chromatin assembly factor 1, subunit a (P150)  facilitates cell proliferation in human hepatocellular  carcinoma Meng Xu Yuli Jia Zhikui liu linglong Ding run Tian hua gu Yufeng Wang hongyong Zhang Kangsheng T u Qingguang liu Department of hepatobiliary surgery,   The First affiliated hospital of Xi’an  Jiaotong University, Xi’an, People’s  republic of china correspondence: Qingguang liu;  Kangsheng Tu Department of hepatobiliary surgery,  First Affiliated Hospital of Xi’an Jiaotong  University, no 277, Yanta West road,  Xi’an, shanxi province, 710061, Xi’an,  People’s republic of china Tel +86 29 8532 3909; +86 29 8532 3905 Fax +86 29 8532 3907 email liuqingguangvip@163.co m;  tks0912@foxmail.co mJournal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2016 Volume: 9 Running head verso: Xu et al Running head recto: CHAF1A in hepatocellular carcinoma DOI: http://dx.doi.org/10.2147/OTT.S107050 Abstract:  Several studies have revealed that the abnormal expression of chromatin assembly fac - tor 1, subunit A (P150) (CHAF1A) was involved in the development of some types of malignant  tumors.",Non-OADS,/arxiv_data1/oa_pdf/cb/a0/ott-9-4023.PMC4936808.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/cb/a0/ott-9-4023.PMC4936808.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/cb/a0/ott-9-4023.PMC4936808.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/be/bb/ott-9-3997.PMC4936809.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2016:9 3997–4003OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  3997Case repO rTopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S10439 8 Combined treatment with everolimus and  fulvestrant reversed anti-Her2 resistance in a  patient with refractory advanced breast cancer:  a case report Bing sun1 Lijuan Ding1 shikai Wu1 Xiangying Meng1 santai song2 1Department of radiotherapy,   2Department of Breast Cancer,   affiliated Hospital of academy of  Military Medical sciences, Beijing,   people’s republic of ChinaBackground:  Everolimus, an inhibitor of the mammalian target of rapamycin, shows promising  antitumor activity when combined with trastuzumab and chemotherapy for human epidermal  growth factor receptor-2 (HER2)-positive breast cancer or when combined with endocrine  agents for hormone receptor (HR)-positive tumors.",Non-OADS,/arxiv_data1/oa_pdf/be/bb/ott-9-3997.PMC4936809.pdf
"Poor responses and resistance to HER2-directed therapy Correspondence: shikai Wu Department of Radiotherapy, Affiliated  Hospital of academy of Military Medical  sciences, No 8 Dongda street, Fengtai  District, Beijing 100071, people’s  republic of China email skywu4923@sina.co m Journal name: OncoTargets and Therapy Article Designation: Case report Y ear: 2016 Volume: 9 Running head verso: Sun et al Running head recto: Effect of everolimus with fulvestrant in HER2 + breast cancer patient DOI: http://dx.doi.org/10.2147/OTT.S104398",Non-OADS,/arxiv_data1/oa_pdf/be/bb/ott-9-3997.PMC4936809.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/be/bb/ott-9-3997.PMC4936809.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/be/bb/ott-9-3997.PMC4936809.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/d1/70/rmhp-9-135.PMC4936810.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/d1/70/rmhp-9-135.PMC4936810.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Risk Management and Healthcare Policy 2016:9 135–142Risk Management and Healthcare Policy Dovepress submit your manuscript | www.dovepress.com Dovepress 135 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/RMHP .S105608Community knowledge and the role of health  extension workers on integrated diseases among  households in East Hararghe Zone, Ethiopia Ayichew Seyoum1 Kedir Urgessa1 T esfaye Gobena2 1Department of Medical Laboratory  Sciences, 2Department of  Environmental Health Sciences,   College of Health and Medical Sciences, Haramaya University, Harar,  EthiopiaBackground: Ethiopia constitutes approximately 1% of the world’ s population but it contributes  to 7% of the world’ s HIV/AIDS cases.",Non-OADS,/arxiv_data1/oa_pdf/d1/70/rmhp-9-135.PMC4936810.pdf
"Approximately 1.3 million adolescents living with HIV in sub-Saharan Africa were in Eastern and Correspondence: Ayichew Seyoum College of Health and Medical Sciences, Haramaya University, PO Box 235, Harar, EthiopiaTel +251 25 911 003 879Fax +251 25 256 668 081Email ayichewseyoum@gmail.comJournal name: Risk Management and Healthcare Policy Article Designation: ORIGINAL RESEARCHY ear: 2016V olume: 9Running head verso: Seyoum et alRunning head recto: Knowledge on Integrated diseases and the role of HEWs, EthiopiaDOI: http://dx.doi.org/10.2147/RMHP .S105608",Non-OADS,/arxiv_data1/oa_pdf/d1/70/rmhp-9-135.PMC4936810.pdf
"Available at http://http://www.who.int/mediacentre/factsheets/fs094/en/ Accessed December 9,2015]  3.",Non-OADS,/arxiv_data1/oa_pdf/d1/70/rmhp-9-135.PMC4936810.pdf
"Risk Management and Healthcare Policy 2016:9submit your manuscript | www.dovepress.com Dovepress Dovepress Risk Management and Healthcare Policy Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/risk-management-and-healthcare-policy-journalRisk Management and Healthcare Policy is an international, peer-reviewed,  open access journal focusing on all aspects of public health, policy, and preventative measures to promote good health and improve morbidity and mortality in the population.",Non-OADS,/arxiv_data1/oa_pdf/d1/70/rmhp-9-135.PMC4936810.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Dovepress 142 Seyoum et al  4.,Non-OADS,/arxiv_data1/oa_pdf/d1/70/rmhp-9-135.PMC4936810.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/05/20/ott-9-4037.PMC4936811.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2016:9 4037–4041OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  4037Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S9943 4icotinib versus docetaxel used in lung  adenocarcinoma patients who failed platinum- based chemotherapy: a retrospective study Wei he Yan Zhang Yu Xiong Feng-juan Dai Qing-xia Fan The Department of Oncology, The  First affiliated hospital of Zhengzhou  University, Zhengzhou, People’s  republic of chinaBackground:  The efficacy and safety of epidermal growth factor receptor tyrosine kinase  inhibitors have been studied worldwide.",Non-OADS,/arxiv_data1/oa_pdf/05/20/ott-9-4037.PMC4936811.pdf
"Progress in lung cancer treatment has accelerated due to the introduction of  new drugs and awareness of histological subtype.3–5 The epidermal growth factor receptor (EGFR) mutations are found in up to 50%  of Asian patients and ~10% of non-Asian patients.6,7 These mutations result in activa - tion of the tyrosine kinase domain, which is associated with sensitivity to the small  molecule tyrosine kinase inhibitors (TKIs), such as erlotinib, gefitinib, afatinib, and correspondence: Wei he; Qing-xia Fan The Department of Oncology, The  First Affiliated Hospital of Zhengzhou  University, 1 Jianshe east road,  Zhengzhou 450052, People’s republic  of china email hewei726@126.co m;  fqx2243@126.co m Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2016 Volume: 9 Running head verso: He et al Running head recto: Icotinib versus docetaxel in lung adenocarcinoma DOI: http://dx.doi.org/10.2147/OTT.S99434",Non-OADS,/arxiv_data1/oa_pdf/05/20/ott-9-4037.PMC4936811.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/05/20/ott-9-4037.PMC4936811.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/05/20/ott-9-4037.PMC4936811.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/41/c7/tcrm-12-1075.PMC4936812.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Therapeutics and Clinical Risk Management 2016:12 1075–1082Therapeutics and Clinical Risk Management Dove press submit your manuscript | www.dovepress.co m Dove press  1075Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/TCRM.S11186 2 Role of biologics in severe eosinophilic asthma –  focus on reslizumab Girolamo Pelaia1 Alessandro vatrella2 Maria T eresa Busceti1 Luca Gallelli3 Mariaimmacolata Preianò3 Nicola Lombardo1 Rosa T erracciano3 Rosario Maselli1 1Department of Medical and Surgical  Sciences, Section of Respiratory  Diseases, University “Magna Græcia”  of Catanzaro, Catanzaro, italy;   2Department of Medicine and Surgery,   Section of Respiratory Diseases,   University of Salerno, Salerno, italy;   3Department of Health Science,   University “Magna Græcia” of  Catanzaro, Catanzaro, italyAbstract:  Within the context of the heterogeneous phenotypic stratification of asthmatic  population, many patients are characterized by moderate-to-severe eosinophilic asthma, not  adequately controlled by relatively high dosages of inhaled and even oral corticosteroids.",Non-OADS,/arxiv_data1/oa_pdf/41/c7/tcrm-12-1075.PMC4936812.pdf
"venuta”, viale  europa – Località Germaneto, Catanzaro  88100, italy Tel +39 0961 3647 302 Fax +39 0961 3647 193 email pelaia@unicz.i t Journal name: Therapeutics and Clinical Risk Management Article Designation: Review Y ear: 2016 Volume: 12 Running head verso: Pelaia et al Running head recto: Reslizumab in severe eosinophilic asthma DOI: http://dx.doi.org/10.2147/TCRM.S111862",Non-OADS,/arxiv_data1/oa_pdf/41/c7/tcrm-12-1075.PMC4936812.pdf
"Therapeutics and Clinical Risk Management Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/therapeutics-and-clinical-risk-management-journa lTherapeutics and Clinical Risk Management is an international, peer- reviewed journal of clinical therapeutics and risk management, focusing  on concise rapid reporting of clinical studies in all therapeutic areas,  outcomes, safety, and programs for the effective, safe, and sustained  use of medicines.",Non-OADS,/arxiv_data1/oa_pdf/41/c7/tcrm-12-1075.PMC4936812.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/41/c7/tcrm-12-1075.PMC4936812.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/92/b3/dddt-10-2087.PMC4936813.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Drug Design, Development and Therapy 2016:10 2087–2094Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  2087Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/DDDT .S10758 7 Golimumab in radiographic and nonradiographic  axial spondyloarthritis: a review of clinical trials eric T oussirot1–5 Charline vauchy1 Delphine Binda1 Fabrice Michel6 1Clinical investigation Center in  Biotherapy, intitut National de la  Santé et de la Recherche Médicale  CiC-1431, 2Fédération Hospitalo- Universitaire integrated Center for  Research in inflammatory Diseases,   3Department of Rheumatology,   University Hospital of Besançon,   Besançon, France; 4Department of  Therapeutics, 5equipe d’accueil  eA 4266: “Pathogenic Agents  and inflammation”, University of  Franche-Comté, 6Department of  Neuromuscular examinations and  Diseases, University Hospital of  Besançon, Besançon, FranceAbstract:  Axial spondyloarthritis (Ax SpA) refers to chronic inflammatory rheumatic diseases  that mainly affect the axial skeleton, leading to erosions and new bone formation in the sacroiliac  joints and/or the spine.",Non-OADS,/arxiv_data1/oa_pdf/92/b3/dddt-10-2087.PMC4936813.pdf
"Recently, the Assessment of  SpondyloArthritis international Society (ASAS) has developed a set of criteria for the  detection of patients with early Ax SpA that includes evidence of sacroiliitis visible  by magnetic resonance imaging (MRI), chronic back pain, HLA-B27 positivity, and  other nonarticular symptoms.4 According to these criteria, patients may or may not Correspondence: eric Toussirot Clinical investigation Center in  Biotherapy, iNSeRM CiC-1431,  University Hospital of Besançon,  St Jacques, Besançon 25000, France Tel +33 3 81 21 89 97 Fax +33 3 81 21 85 22 email etoussirot@chu-besancon.f r Journal name: Drug Design, Development and Therapy Article Designation: Review Y ear: 2016 Volume: 10 Running head verso: Toussirot et al Running head recto: Golimumab in axial spondyloarthritis DOI: http://dx.doi.org/10.2147/DDDT.S107587",Non-OADS,/arxiv_data1/oa_pdf/92/b3/dddt-10-2087.PMC4936813.pdf
"Available from: http://www.ema.europa.eu/docs/ en_GB/document_library/EPAR_-_Product_Information/human/000992/ WC500052368.pd f. Accessed April 1, 2016.",Non-OADS,/arxiv_data1/oa_pdf/92/b3/dddt-10-2087.PMC4936813.pdf
"Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDrug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/92/b3/dddt-10-2087.PMC4936813.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/92/b3/dddt-10-2087.PMC4936813.pdf
The full terms of this license are available at https://www.dovepress.,Non-OADS,/arxiv_data1/oa_pdf/c1/6e/ce-11-011.PMC4936814.pdf
"com/terms.ph p and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/c1/6e/ce-11-011.PMC4936814.pdf
"For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Core Evidence Core Evidence 2016:11 11–22Dove press submit your manuscript | www.dovepress.co m Dove press   Pirfenidone in the treatment of idiopathic  pulmonary fibrosis: an evidence-based review of  its place in therapy George A Margaritopoulos1 Eirini Vasarmidi2 Katerina M Antoniou2 1Interstitial Lung Disease Unit, Royal  Brompton Hospital, London, UK;   2Department of Thoracic Medicine  and Laboratory of Molecular and  Cellular Pneumonology, Interstitial  Lung Disease Unit, University Hospital  of Heraklion, Heraklion, Greece Correspondence: George A  Margaritopoulos   Interstitial Lung Disease Unit, Royal  Brompton Hospital, Sydney Street, SW3  6NP London, UK   T el +44 20 7352 8121   Email gmargaritop@yahoo.g rAbstract:  The landscape of idiopathic pulmonary fibrosis (IPF) has changed.",Non-OADS,/arxiv_data1/oa_pdf/c1/6e/ce-11-011.PMC4936814.pdf
Available from: http://www.ema.,Non-OADS,/arxiv_data1/oa_pdf/c1/6e/ce-11-011.PMC4936814.pdf
"Core Evidence Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/core-evidence-journa lCore Evidence is an international, peer-reviewed open-access journal  evaluating the evidence underlying the potential place in therapy of  drugs throughout their development lifecycle from preclinical to post - launch.",Non-OADS,/arxiv_data1/oa_pdf/c1/6e/ce-11-011.PMC4936814.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/c1/6e/ce-11-011.PMC4936814.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/b8/92/ott-9-4015.PMC4936815.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2016:9 4015–4022OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  4015Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S10273 3 Clinicopathological significance of p15 promoter  hypermethylation in multiple myeloma: a  meta-analysis Bing Wei shuhua Yang Bo Zhang Y ong Feng Department of Orthopaedic Surgery,   Union Hospital, Tongji Medical  College, Huazhong University of  Science and T echnology, Wuhan,   People’s Republic of ChinaAbstract:  Published studies reported that loss of function of the p15INK4B gene is caused by  hypermethylation; however, whether or not the inactivation is associated with the incidence and  clinical significance of multiple myeloma (MM) remains unclear.",Non-OADS,/arxiv_data1/oa_pdf/b8/92/ott-9-4015.PMC4936815.pdf
"Epigenetic  alteration, particularly aberrant DNA methylation, is one of the best-characterized  epigenetic modifications contributing to tumor initiation, progression, and prognosis.7–9  CpG islands of tumor suppressor genes are aberrantly methylated (hypermethylation),  which result in transcriptional repression and loss of function of genes in many tumors correspondence: Yong Feng Department of Orthopaedic Surgery,  Union Hospital, Tongji Medical College,  Huazhong University of Science and  Technology, 1277 Jiefang Avenue, Wuhan  430022, People’s Republic of China email yongfengmd@yeah.ne t Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2016 Volume: 9 Running head verso: Wei et al Running head recto: Clinicopathological significance of p15 promoter hypermethylation in MM DOI: http://dx.doi.org/10.2147/OTT.S102733",Non-OADS,/arxiv_data1/oa_pdf/b8/92/ott-9-4015.PMC4936815.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/b8/92/ott-9-4015.PMC4936815.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/b8/92/ott-9-4015.PMC4936815.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/27/10/tcrm-12-1029.PMC4936816.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Therapeutics and Clinical Risk Management 2016:12 1029–1037Therapeutics and Clinical Risk Management Dove press submit your manuscript | www.dovepress.co m Dove press  1029Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/TCRM.S8754 3 Human von willebrand factor/factor viii  concentrates in the management of pediatric  patients with von willebrand disease/hemophilia A Giancarlo Castaman Silvia Linari Department of Oncology, Center  for Bleeding Disorders, Careggi  University Hospital, Florence, italyAbstract:  Several plasma-derived intermediate and high-purity concentrates containing von  Willebrand factor (VWF) and factor VIII (FVIII) are currently available.",Non-OADS,/arxiv_data1/oa_pdf/27/10/tcrm-12-1029.PMC4936816.pdf
"Correspondence: Giancarlo Castaman Department of Oncology, Center  for Bleeding Disorders, Careggi  University Hospital, Largo Brambilla 3,  Florence 50134, italy Tel +39 055 794 7587 Fax +39 055 794 7794 email giancarlo.castaman@unifi.i t Journal name: Therapeutics and Clinical Risk Management Article Designation: Review Y ear: 2016 Volume: 12 Running head verso: Castaman and Linari Running head recto: Use of VWF/FVIII concentrates in children with VWD or hemophilia A DOI: http://dx.doi.org/10.2147/TCRM.S87543",Non-OADS,/arxiv_data1/oa_pdf/27/10/tcrm-12-1029.PMC4936816.pdf
"Therapeutics and Clinical Risk Management Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/therapeutics-and-clinical-risk-management-journa lTherapeutics and Clinical Risk Management is an international, peer- reviewed journal of clinical therapeutics and risk management, focusing  on concise rapid reporting of clinical studies in all therapeutic areas,  outcomes, safety, and programs for the effective, safe, and sustained  use of medicines.",Non-OADS,/arxiv_data1/oa_pdf/27/10/tcrm-12-1029.PMC4936816.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/27/10/tcrm-12-1029.PMC4936816.pdf
"Available from:  http://www.itistudy-resist.com/index.ht m. Accessed May 18, 2016.",Non-OADS,/arxiv_data1/oa_pdf/27/10/tcrm-12-1029.PMC4936816.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/ff/c5/opth-10-1175.PMC4936817.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Ophthalmology 2016:10 1175–1185Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  1175Original researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OPTH.S10472 1 evaluation of cone function by a handheld  non-mydriatic flicker electroretinogram device Natsuko Nakamura1 Kaoru Fujinami1 Y oshinobu Mizuno2 T oru noda2 Kazushige Tsunoda1 1laboratory of Visual Physiology,   Division of Vision research, national  institute of sensory Organs,   2Department of Ophthalmology,   national hospital Organization,   National T okyo Medical Center,   T okyo,  JapanPurpose:  Full-field electroretinograms (ERGs) are used to evaluate retinal function in patients  with various types of hereditary and acquired retinal diseases.",Non-OADS,/arxiv_data1/oa_pdf/ff/c5/opth-10-1175.PMC4936817.pdf
"Among the six types of responses elicited  by different stimulus intensities under different states of adaptation,1 the light-adapted  30 Hz flicker ERGs have been used to assess cone function not only in patients with  hereditary retinal diseases, such as cone-rod dystrophy, achromatopsia,2 and retinitis  pigmentosa,3,4 but also in those with acquired disorders, such as acute zonal occult outer  retinopathy,5 paraneoplastic and autoimmune retinopathies,6 diabetic retinopathy,7,8  central retinal vein occlusion,9,10 and drug toxicities.11,12 However, ERG recordings  cannot be easily performed on young children except in the clinics with high expertise,  where skin electrodes or Dawson–Trick–Litzkow (DTL) electrodes are routinely used.13 Correspondence: Kazushige Tsunoda laboratory of Visual Physiology, Division  of Vision research, national institute  of Sensory Organs, 2-5-1 Higashigaoka,  Meguro-ku, Tokyo 152-8902, Japan Tel +81 3 3411 0111 ext 6615 Fax +81 3 3411 0185 email tsunodakazushige@kankakuki.go.j p Journal name: Clinical Ophthalmology Article Designation: Original Research Y ear: 2016 Volume: 10 Running head verso: Nakamura et al Running head recto: Evaluation of cone function by RETeval™ DOI: http://dx.doi.org/10.2147/OPTH.S104721",Non-OADS,/arxiv_data1/oa_pdf/ff/c5/opth-10-1175.PMC4936817.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/ff/c5/opth-10-1175.PMC4936817.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/ff/c5/opth-10-1175.PMC4936817.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/35/19/ott-9-3993.PMC4936818.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2016:9 3993–3996OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  3993Case repO rTopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S10974 6 aLK-positive anaplastic large cell lymphoma with  soft tissue involvement in a young woman Kehai Gao Hongtao Li Caihong Huang Huazhuang Li Jun Fang Chen Tian Department of Orthopaedics, Yidu  Central Hospital, shandong, people’s  republic of ChinaIntroduction:  Anaplastic large cell lymphoma (ALCL) is a type of non-Hodgkin lymphoma that  has strong expression of CD30.",Non-OADS,/arxiv_data1/oa_pdf/35/19/ott-9-3993.PMC4936818.pdf
"18F-fluorodeoxyglucose (FDG) positron emission  tomography (PET) scanning showed that accumulation of FDG was observed in the Correspondence: Kehai Gao; Chen Tian Department of Orthopaedics, Yidu  Central Hospital, renmin street,  Qingzhou, shandong, 261041, people’s  republic of China email kehaigao222@sina.co m;  spj_2004@126.co m Journal name: OncoTargets and Therapy Article Designation: Case report Y ear: 2016 Volume: 9 Running head verso: Gao et al Running head recto: ALK-positive anaplastic large cell lymphoma with soft tissue DOI: http://dx.doi.org/10.2147/OTT.S109746",Non-OADS,/arxiv_data1/oa_pdf/35/19/ott-9-3993.PMC4936818.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/35/19/ott-9-3993.PMC4936818.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/35/19/ott-9-3993.PMC4936818.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/e7/e4/copd-11-1505.PMC4936819.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of COPD 2016:11 1505–1514International Journal of COPD Dove press submit your manuscript | www.dovepress.co m Dove press  1505OrIg Inal researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/COPD.S10793 6 relationship between balance and physical activity  measured by an activity monitor in elderly COPD  patients Masahiro Iwakura1,2 Kazuki Okura2 Kazuyuki shibata1,2 atsuyoshi Kawagoshi2 Keiyu sugawara2 hitomi Takahashi2 Takanobu shioya1 1Department of rehabilitation, akita  City hospital, 2Department of Physical  Therapy, akita University graduate  school of health sciences, akita, JapanBackground:  Little is known regarding the relationship between balance impairments and  physical activity in COPD.",Non-OADS,/arxiv_data1/oa_pdf/e7/e4/copd-11-1505.PMC4936819.pdf
"For instance, pulmonary  function, dyspnea, body composition, extrapulmonary function, and health status have  been shown to have significant associations with physical activity in COPD.7,8 The latest systematic review of the determinants of physical activity in COPD  indicated that balance might also be associated with physical activity in COPD.8 Correspondence: Masahiro Iwakura Department of rehabilitation, akita City  hospital, 4-30 Kawamoto Matsuoka-cho,  akita City, akita 0100933, Japan Tel +81 18 823 4171 Fax +81 18 866 7026 email m.iwa.phys.ther@gmail.co m Journal name: International Journal of COPD Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Iwakura et al Running head recto: Physical inactivity affects balance in COPD DOI: http://dx.doi.org/10.2147/COPD.S107936",Non-OADS,/arxiv_data1/oa_pdf/e7/e4/copd-11-1505.PMC4936819.pdf
"International Journal of COPD Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journa lThe International Journal of COPD is an international, peer-reviewed  journal of therapeutics and pharmacology focusing on concise rapid  reporting of clinical studies and reviews in COPD.",Non-OADS,/arxiv_data1/oa_pdf/e7/e4/copd-11-1505.PMC4936819.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/e7/e4/copd-11-1505.PMC4936819.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/f5/08/copd-11-1495.PMC4936821.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of COPD 2016:11 1495–1504International Journal of COPD Dove press submit your manuscript | www.dovepress.co m Dove press  1495OrIg Inal researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/COPD.S10033 8Peripheral blood eosinophils: a surrogate marker  for airway eosinophilia in stable COPD netsanet a negewo1,2 Vanessa M McDonald1–4 Katherine J Baines1,2 Peter aB Wark1–3 Jodie l simpson1,2 Paul W Jones5 Peter g gibson1–3 1Priority research Centre for healthy  lungs, Faculty of health and Medicine,   The University of newcastle,   Callaghan, nsW, australia; 2hunter  Medical research Institute, Faculty of  health and Medicine, The University  of newcastle, Callaghan, nsW,   australia; 3Department of respiratory  and sleep Medicine, John hunter  hospital, newcastle, nsW, australia;   4school of n ursing and Midwifery,   Faculty of health and Medicine, The  University of newcastle, Callaghan,   nsW, australia; 5Institute for Infection  and Immunity, st george’s, University  of london, london, UKIntroduction:  Sputum eosinophilia occurs in approximately one-third of stable chronic  obstructive pulmonary disease (COPD) patients and can predict exacerbation risk and response  to corticosteroid treatments.",Non-OADS,/arxiv_data1/oa_pdf/f5/08/copd-11-1495.PMC4936821.pdf
"International Journal of COPD Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journa lThe International Journal of COPD is an international, peer-reviewed  journal of therapeutics and pharmacology focusing on concise rapid  reporting of clinical studies and reviews in COPD.",Non-OADS,/arxiv_data1/oa_pdf/f5/08/copd-11-1495.PMC4936821.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/f5/08/copd-11-1495.PMC4936821.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/67/49/ppa-10-1169.PMC4936822.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Patient Preference and Adherence 2016:10 1169–1175Patient Preference and Adherence Dove press submit your manuscript | www.dovepress.co m Dove press  1169OriginAl reseArchopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/PPA.S10762 1 impact of neuropathy on the adherence to  diabetes-related self-care activities: a cross- sectional study Bogdan Timar1 romulus Timar2 Adalbert schiller2 cristian Oancea3 Deiana roman1 Mihaela Vlad2 Bogdan Balinisteanu4 Octavian Mazilu5 1Department of Functional sciences,   2second Department of internal  Medicine, 3Department of infectious  Diseases, 4Department of Microscopic  Morphology, 5First Department of  surgery, “Victor Babes” University of  Medicine and Pharmacy, Timisoara,   romaniaPurpose:  The purpose of this study was to evaluate the impact of the presence and severity  of neuropathy and depression on the patient’s adherence to diabetes-related self-care activities  (DRSCA) in a cohort of patients with type 2 diabetes mellitus (T2DM).",Non-OADS,/arxiv_data1/oa_pdf/67/49/ppa-10-1169.PMC4936822.pdf
"Nowadays, it is estimated that 415 million people have diabetes, the prediction point - ing to ~642 million by 2040.1,2 Diabetes is a leading cause of new blindness cases among adults, kidney failure,  and lower limb amputations, excepting those caused by trauma.3 Owing to the pres - ence of peripheral neuropathy, patients are often at risk of its complications: falling,  presenting ulcerations, or having to amputate a limb.4 Sensorimotor distal symmetric  polyneuropathy is the most common neurological complication of diabetes, and it is correspondence: romulus Timar second Department of internal Medicine,  “Victor Babes” University of Medicine  and Pharmacy, 2 eftimie Murgu,  300041 Timisoara, romania Tel +40 7 4152 8093 Fax +40 256 46 2856 email timar.romulus@umft.r o Journal name: Patient Preference and Adherence Article Designation: Original Research Y ear: 2016 Volume: 10 Running head verso: Timar et al Running head recto: Neuropathy influences the adherence to diabetes self-care activities DOI: http://dx.doi.org/10.2147/PPA.S107621",Non-OADS,/arxiv_data1/oa_pdf/67/49/ppa-10-1169.PMC4936822.pdf
"Patient Preference and Adherence Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/patient-preference-and-adherence-journa lPatient Preference and Adherence is an international, peer-reviewed,  open access journal that focuses on the growing importance of patient   preference  and adherence throughout the therapeutic continuum.",Non-OADS,/arxiv_data1/oa_pdf/67/49/ppa-10-1169.PMC4936822.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/a1/db/ndt-12-1617.PMC4936836.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Neuropsychiatric Disease and Treatment 2016:12 1617–1621Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  1617OrigiNal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/NDT .S10612 3 effects of Astragalus  polysaccharides on memory  impairment in a diabetic rat model changping Dun1 Junqian liu1 Fucheng Qiu1 Xueda Wu2 Yakun Wang3 Y ongyan Zhao4 Ping gu1 1Department of Neurology, the  First hospital of hebei Medical  University, 2Department of cardiac  surgery, the second hospital of hebei  Medical University, 3Department of  endocrinology, the Fourth hospital of  hebei Medical University, shijiazhuang,   4Department of Nursing, Maternal  and child health hospital of Tangshan  city, Tangshan, People’s republic  of chinaObjective:  Astragalus  polysaccharides (APS) are active constituents of Astragalus   membranaceus .",Non-OADS,/arxiv_data1/oa_pdf/a1/db/ndt-12-1617.PMC4936836.pdf
"The hippocampus is important for memory formation.4 Although correspondence: Ping gu Department of Neurology, the First  hospital of hebei Medical University,  No 89 Donggang road, Yuhua District,  shijiazhuang, 050030 hebei, People’s  republic of china Tel/fax +86 311 186 3388 9939 email wjh19852008@126.co m Journal name: Neuropsychiatric Disease and Treatment Article Designation: Original Research Y ear: 2016 Volume: 12 Running head verso: Dun et al Running head recto: Effects of Astragalus  polysaccharides on memory impairment DOI: http://dx.doi.org/10.2147/NDT.S106123",Non-OADS,/arxiv_data1/oa_pdf/a1/db/ndt-12-1617.PMC4936836.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/a1/db/ndt-12-1617.PMC4936836.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/a1/db/ndt-12-1617.PMC4936836.pdf
"Instructional Activities The following instructional activities were designed basedon our three conceptual goals: a worksheet with informa- tion on CIP4, PDB images of CIP4, and questions for stu- dents to answer as they used the tools (Supporting Informa-tion Appendix B), an online clickable endocytosis landscape (http://cbm.msoe.edu/teaching Resources/jmol/coatedPit/), CIP4 hand-held physical models, and a Jmol molecular imag-ing tutorial (http://cbm.msoe.edu/teachingResources/jmol/ fbar/).",Non-OADS,/arxiv_data1/oa_pdf/aa/f8/BMB-44-326.PMC4936926.pdf
"Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which per- mits any noncommercial use, distribution, and reproduction in anymedium, provided you give appropriate credit to the originalauthor(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/a5/c7/40258_2016_Article_241.PMC4937076.pdf
2011. http://www.leapfroggroup.org/media/ﬁle/ FactSheet_EBHR.pdf .,Non-OADS,/arxiv_data1/oa_pdf/a5/c7/40258_2016_Article_241.PMC4937076.pdf
"Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which per-mits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commonslicense, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/f1/9e/10549_2016_Article_3862.PMC4937080.pdf
http://www.richtlijnen- database.nl .,Non-OADS,/arxiv_data1/oa_pdf/f1/9e/10549_2016_Article_3862.PMC4937080.pdf
"Funding Funding for this post hoc analysis and for the medical writing support was provided by AstraZeneca.Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which per-mits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commonslicense, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/7f/3e/40266_2016_Article_382.PMC4937081.pdf
Available from: http://www.ema.europa.eu/docs/ en_GB/document_library/EPAR_-_Product_Information/human/ 002322/WC500136026.pdf .,Non-OADS,/arxiv_data1/oa_pdf/7f/3e/40266_2016_Article_382.PMC4937081.pdf
"Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 InternationalLicense (http://creativecommons.org/licenses/by-nc/4.0/), which per-mits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commonslicense, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/db/21/40258_2016_Article_249.PMC4937082.pdf
Available at: http://gking.harvard.edu/publications/ why-propensity-scores-should-not-be-used-formatching .,Non-OADS,/arxiv_data1/oa_pdf/db/21/40258_2016_Article_249.PMC4937082.pdf
"Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 InternationalLicense (http://creativecommons.org/licenses/by-nc/4.0/), which per- mits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the originalauthor(s) and the source, provide a link to the Creative Commonslicense, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/7b/dc/10549_2016_Article_3856.PMC4937084.pdf
"Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which per-mits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commonslicense, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/04/18/10549_2016_Article_3857.PMC4937089.pdf
"Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which per-mits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commonslicense, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/b4/fa/10549_2016_Article_3848.PMC4937092.pdf
e-mail: jay.kimura@me.com ©2016 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.,Non-OADS,/arxiv_data1/oa_pdf/38/7f/jvms-78-1007.PMC4937134.pdf
Available at http://life.bio.sunysb.edu/morph/  19.,Non-OADS,/arxiv_data1/oa_pdf/38/7f/jvms-78-1007.PMC4937134.pdf
"Available at http://life.bio.sunysb.edu/morph/  20 Wiig, Q.",Non-OADS,/arxiv_data1/oa_pdf/38/7f/jvms-78-1007.PMC4937134.pdf
e-mail: kmaeda@yamaguchi-u.ac.jp ©2016 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the creative  commons Attribution Non-commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.,Non-OADS,/arxiv_data1/oa_pdf/19/3b/jvms-78-1013.PMC4937135.pdf
Available: (http://tree.bio.,OADS,/arxiv_data1/oa_pdf/19/3b/jvms-78-1013.PMC4937135.pdf
e-mail: otoi@tokushima-u.ac.jp ©2016 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.,Non-OADS,/arxiv_data1/oa_pdf/2e/91/jvms-78-1019.PMC4937136.pdf
e-mail: skazuaki@cc.tuat.ac.jp ©2016 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.,Non-OADS,/arxiv_data1/oa_pdf/84/30/jvms-78-1025.PMC4937137.pdf
e-mail: yamasita@rakuno.ac.jp ©2016 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.,Non-OADS,/arxiv_data1/oa_pdf/ab/11/jvms-78-1031.PMC4937138.pdf
e-mail: h-iwano@rakuno.ac.jp ©2016 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.,Non-OADS,/arxiv_data1/oa_pdf/e9/56/jvms-78-1035.PMC4937139.pdf
"On April 30, 2014, WHO released a statement of concern  regarding the emergence of antibiotic-resistant bacteria  (http://www.who.int/mediacentre/news/releases/2014/ amr-report/en/).",Non-OADS,/arxiv_data1/oa_pdf/e9/56/jvms-78-1035.PMC4937139.pdf
e-mail: mariaelena.gelain@unipd.it ©2016 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.,Non-OADS,/arxiv_data1/oa_pdf/12/f1/jvms-78-1039.PMC4937140.pdf
e-mail: rnozu@ciea.or.jp ©2016 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.,Non-OADS,/arxiv_data1/oa_pdf/c8/c8/jvms-78-1045.PMC4937141.pdf
e-mail:	amki@mail.ecc.u-tokyo.ac.jp ©2016	The	Japanese	Society	of	 Veterinary	Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.,Non-OADS,/arxiv_data1/oa_pdf/9e/7b/jvms-78-1051.PMC4937142.pdf
e-mail: tajima.atsushi.gb@u.tsukuba.ac.jp ©2016 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.,Non-OADS,/arxiv_data1/oa_pdf/e3/0c/jvms-78-1055.PMC4937143.pdf
e-mail: ahaga@mail.ecc.u-tokyo.ac.jp ©2016 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.,Non-OADS,/arxiv_data1/oa_pdf/76/9f/jvms-78-1059.PMC4937144.pdf
e-mail: morita@muses.tottori-u.ac.jp ©2016 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.,Non-OADS,/arxiv_data1/oa_pdf/16/11/jvms-78-1063.PMC4937145.pdf
e-mail: t-hori@nvlu.ac.jp ©2016 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.,Non-OADS,/arxiv_data1/oa_pdf/ad/64/jvms-78-1067.PMC4937146.pdf
"IUCN Red List of Threatened Species, Available  from: http://www.iucnredlist.org.",Non-OADS,/arxiv_data1/oa_pdf/ad/64/jvms-78-1067.PMC4937146.pdf
e-mail: kkadota@affrc.go.jp ©2016 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.,Non-OADS,/arxiv_data1/oa_pdf/b5/4e/jvms-78-1075.PMC4937147.pdf
e-mail: nishii@gifu-u.ac.jp ©2016 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.,Non-OADS,/arxiv_data1/oa_pdf/fc/74/jvms-78-1079.PMC4937148.pdf
e-mail: jeongks@knu.ac.kr ©2016 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.,Non-OADS,/arxiv_data1/oa_pdf/d1/22/jvms-78-1085.PMC4937149.pdf
e-mail: zhao.ruqian@gmail.com ©2016 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.,Non-OADS,/arxiv_data1/oa_pdf/f4/ac/jvms-78-921.PMC4937150.pdf
"Prediction and determination of miRNAs: The potential  miRNAs targeting the 3’ UTR of GR mRNA were predicted  with the Probability of Interaction by Target Accessibility  (PITA) algorithm [17] based on the online database of pig  microRNAs (http://www.mirbase.org/), using microRNA prediction tool (http://genie.weizmann.ac.il/pubs/mir07/ mir07_prediction.html).",OADS,/arxiv_data1/oa_pdf/f4/ac/jvms-78-921.PMC4937150.pdf
e-mail: yamasita@rakuno.ac.jp ©2016 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.,Non-OADS,/arxiv_data1/oa_pdf/05/2a/jvms-78-929.PMC4937151.pdf
e-mail: taniyama@rakuno.ac.jp ©2016 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.,Non-OADS,/arxiv_data1/oa_pdf/85/fe/jvms-78-937.PMC4937152.pdf
e-mail: csama@sina.com ©2016 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.,Non-OADS,/arxiv_data1/oa_pdf/e8/01/jvms-78-943.PMC4937153.pdf
"Predicting the effects of mutations and the altered amino  acids In order to predict the effects of mutations and the cor - responding substituted amino acids, the server PolyPhen was used [1, 3] which was available at http://genetics.bwh.",OADS,/arxiv_data1/oa_pdf/e8/01/jvms-78-943.PMC4937153.pdf
CpG islands of  the region were analyzed using the website “CpG Island  Searcher” [27] available at http://cpgislands.usc.edu/.,OADS,/arxiv_data1/oa_pdf/e8/01/jvms-78-943.PMC4937153.pdf
"BRCA1  MUTATION AND DNA METHYLATION 945 For designing bisulfite primers, the website “MethPrimer”  [15] available at http://www.urogene.org/methprimer/ was  used.",Non-OADS,/arxiv_data1/oa_pdf/e8/01/jvms-78-943.PMC4937153.pdf
e-mail: h-iwano@rakuno.ac.jp ©2016 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.,Non-OADS,/arxiv_data1/oa_pdf/a1/71/jvms-78-951.PMC4937154.pdf
©2016 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.,Non-OADS,/arxiv_data1/oa_pdf/6c/76/jvms-78-957.PMC4937155.pdf
2013. http://www.idf.org/diabetesat-las/introduction.,Non-OADS,/arxiv_data1/oa_pdf/6c/76/jvms-78-957.PMC4937155.pdf
e-mail: lacittadina@alice.it ©2016 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.,Non-OADS,/arxiv_data1/oa_pdf/e9/4f/jvms-78-963.PMC4937156.pdf
e-mail:kazuyuki@rakuno.ac.jp ©2016 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.,Non-OADS,/arxiv_data1/oa_pdf/7d/a8/jvms-78-971.PMC4937157.pdf
e-mail: kanusak@hotmail.com ©2016 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.,Non-OADS,/arxiv_data1/oa_pdf/9b/4f/jvms-78-977.PMC4937158.pdf
Available: https://www.tga.gov.au/auspar/auspar-dronedarone- hydrochloride.,Non-OADS,/arxiv_data1/oa_pdf/9b/4f/jvms-78-977.PMC4937158.pdf
e-mail: jinrho@gnu.ac.kr ©2016 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.,Non-OADS,/arxiv_data1/oa_pdf/8e/fc/jvms-78-987.PMC4937159.pdf
e-mail: anakaya@mail.ecc.u-tokyo.ac.jp ©2016 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.,Non-OADS,/arxiv_data1/oa_pdf/5b/48/jvms-78-997.PMC4937160.pdf
Availability and implementation: IGB is open source and is freely available from http://bioviz.org/igb.,OADS,/arxiv_data1/oa_pdf/a3/45/btw069.PMC4937187.pdf
"2089 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/a3/45/btw069.PMC4937187.pdf
Availability and implementation: SharpViSu is available as open source code and as compiled stand-alone application under https://github.com/andronovl/SharpViSu.Contact: klaholz@igbmc.fr Supplementary information: Supplementary data are available at Bioinformatics online.,OADS,/arxiv_data1/oa_pdf/2b/34/btw123.PMC4937188.pdf
"2239 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/2b/34/btw123.PMC4937188.pdf
Availability and implementation: DeltaNet is available on http://www.cabsel.ethz.ch/tools/DeltaNet.,OADS,/arxiv_data1/oa_pdf/b0/89/btw148.PMC4937192.pdf
"2120 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/b0/89/btw148.PMC4937192.pdf
"For DeltaNet-LASSO, we implemented GLMNET subroutines for MATLAB (http://www.stanford.edu/ /C24hastie/glmnet_matlab/).",OADS,/arxiv_data1/oa_pdf/b0/89/btw148.PMC4937192.pdf
"For E.coli , we retrieved microarray data from Many Microbe Microarrays Database (M3D, as of 29th October 2007)(http://m3d.mssm.edu) ( Faith et al., 2008 ).",OADS,/arxiv_data1/oa_pdf/b0/89/btw148.PMC4937192.pdf
"For evaluating the accuracy of the TF prediction, we used protein- chemical interaction database in Search Tool for Interactions ofChemicals (STITCH) (http://stitch.embl.de) ( Kuhn et al.",OADS,/arxiv_data1/oa_pdf/b0/89/btw148.PMC4937192.pdf
"2167 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/f3/53/btw151.PMC4937193.pdf
"Availability and implementation: http://rdf.disgenet.org/ Contact: support@disgenet.org 1 Introduction Advancements in experimental technologies give an unprecedented capacity of description of a patient from a molecular point of view.Translational bioinformatics envisions to push forward biomedicaldiscoveries and to enhance healthcare practice by bridging the gapbetween these two worlds ( Altman, 2012 ).",Non-OADS,/arxiv_data1/oa_pdf/7a/49/btw214.PMC4937199.pdf
"2236 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/7a/49/btw214.PMC4937199.pdf
The DisGeNET ontology is integrated into the Semanticscience Integrated Ontology (http://sio.semanticscience.org) (SIO) ( Dumontier et al.,OADS,/arxiv_data1/oa_pdf/7a/49/btw214.PMC4937199.pdf
We implemented aharmonized URI identification scheme for DisGeNET GDAs basedon the http://rdf.disgenet.org/ domain and a unique identifier builton association attributes.,OADS,/arxiv_data1/oa_pdf/7a/49/btw214.PMC4937199.pdf
"In addition, our RDF dataset isinterlinked to Linked Open Data (LOD) implementations of bio-medical databases and several disease terminologies such asMeSH, OMIM, Orphanet or ICD9-CM available through LinkedData projects such as Bio2RDF (see statistics at Datahub (http://datahub.io/ca/dataset/disgenet)).",OADS,/arxiv_data1/oa_pdf/7a/49/btw214.PMC4937199.pdf
"To address this issue, DisGeNET-RDF is availablewith a full provenance dataset description conformant to theW3C HCLS specification (http://www.w3.org/TR/hcls-dataset/) inorder to ease its discoverability and data reuse ( Fig.",OADS,/arxiv_data1/oa_pdf/7a/49/btw214.PMC4937199.pdf
"Thedetailed description of the RDF schema, ontologies used andthe URI scheme for the normalization of GDAs identificationare available at the DisGeNET-RDF web site (see http://rdf.disgenet.org/).",OADS,/arxiv_data1/oa_pdf/7a/49/btw214.PMC4937199.pdf
It is created by the data pro- viders following the Open PHACTS guidelines for exposing data as RDF (http://www.openphacts.org/specs/2013/WD-rdfguide-20131007/).,OADS,/arxiv_data1/oa_pdf/7a/49/btw214.PMC4937199.pdf
This dataset ismade available under the Open Database License (http://opendatacommons.org/licenses/odbl/1.0/) terms.,OADS,/arxiv_data1/oa_pdf/7a/49/btw214.PMC4937199.pdf
The RDF dump is gener-ated using a production system based on the D2RQ platform(http://d2rq.org/).,OADS,/arxiv_data1/oa_pdf/7a/49/btw214.PMC4937199.pdf
These services aresupported by Triple Store technology and they are provided by aninstance of the open source edition of the OpenLink Virtuoso ser-ver (http://virtuoso.openlinksw.com/).,OADS,/arxiv_data1/oa_pdf/7a/49/btw214.PMC4937199.pdf
"As a proofof concept, DisGeNET-RDF is currently implemented in severalapplications: (i) it is integrated in the Open PHACTS DiscoveryPlatform (https://dev.openphacts.org) ( Gray et al.",OADS,/arxiv_data1/oa_pdf/7a/49/btw214.PMC4937199.pdf
", 2014 ), which is an application for drug discovery based on Semantic Web technol-ogy and RDF linked datasets; (ii) it is used in KNIME workflowsto answer sophisticated research questions in drug discovery(http://www.myexperiment.org/workflows/4513.html), and for in silico target validation of cellular phenotypic screening ( Digles, 2016 ); (iii) it is available as one of the databases in Bioqueries, where a user can access and share, edit or publish queries overDisGeNET-RDF (http://bioqueries.uma.es/endpoint/disgenet); and(iv) it is used in the disgenet2r R package (https://bitbucket.org/albags/disgenet2r).",OADS,/arxiv_data1/oa_pdf/7a/49/btw214.PMC4937199.pdf
"A comprehensive list of examples of DisGeNET-RDF use cases, with supporting information on how to formulate the SPARQLqueries from our endpoint service are provided on the web site(http://disgenet.org/web/DisGeNET/menu/rdf#sparql).",OADS,/arxiv_data1/oa_pdf/7a/49/btw214.PMC4937199.pdf
"Availability and Implementation: A JAVA cross-platform command line executable of ARACNe, to- gether with all source code and a detailed usage guide are freely available on Sourceforge (http://sourceforge.net/projects/aracne-ap).",OADS,/arxiv_data1/oa_pdf/7d/8b/btw216.PMC4937200.pdf
"2233 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/7d/8b/btw216.PMC4937200.pdf
An accompanying Figure S1 is available at http://jaha.ahajournals.org/ content/5/6/e001815/DC1/embed/inline-supplementary-material-1.pdf *Dr Boden and Dr Lassance-Soares contributed equally to this work and are co–ﬁrst authors.,Non-OADS,/arxiv_data1/oa_pdf/96/bb/JAH3-5-e001815.PMC4937238.pdf
The online version of the article has been updated and is available at http://jaha.ahajournals.org/content/3/3/e000884.,Non-OADS,/arxiv_data1/oa_pdf/f0/08/JAH3-5-e002056.PMC4937239.pdf
The online version of the article has been updated and is available at http://jaha.ahajournals.org/content/5/5/ e003230.,Non-OADS,/arxiv_data1/oa_pdf/1e/c5/JAH3-5-e002067.PMC4937240.pdf
The online version of the article has been updated and is available at http://jaha.ahajournals.org/content/5/3/ e002875.,Non-OADS,/arxiv_data1/oa_pdf/9b/79/JAH3-5-e002075.PMC4937241.pdf
"Accompanying Videos S1 through S4 are available at http://jaha.ahajour- nals.org/content/5/6/e002233.full#sec-15 Correspondance to: Julien Plessis, MD, Service de Cardiologie, CHU de Nantes –H^opital Nord-Laennec, Bvd Jacques Monod, 44093 Nantes Cedex, France.",Non-OADS,/arxiv_data1/oa_pdf/0d/e1/JAH3-5-e002233.PMC4937242.pdf
Available at: http://plotdigitizer.sourceforge.net/.,Non-OADS,/arxiv_data1/oa_pdf/81/33/JAH3-5-e002846.PMC4937249.pdf
Clinical Trial Registration- —URL: http://www.clinicaltrials.gov.,Non-OADS,/arxiv_data1/oa_pdf/93/d7/JAH3-5-e002883.PMC4937251.pdf
2008. https://www.julkari.,Non-OADS,/arxiv_data1/oa_pdf/93/d7/JAH3-5-e002883.PMC4937251.pdf
"Accompanying Data S1, Table S1, and Figure S1 are available at http://jaha.ahajournals.org/content/5/6/e003048/DC1/embed/inline-supplement ary-material- 1.pdf Correspondence to: Yvonne T. van der Schouw, PhD, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, PO Box 85500, 3508 GA Utrecht, The Netherlands.",Non-OADS,/arxiv_data1/oa_pdf/a5/fa/JAH3-5-e003048.PMC4937255.pdf
Available at: https://www.feder- alregister.gov/articles/2001/05/17/01-12418/development-of-prototypes- for-the-paul-coverdell-national-acute-stroke-registry-notice-of.,Non-OADS,/arxiv_data1/oa_pdf/e9/a4/JAH3-5-e003056.PMC4937256.pdf
"Accompanying Figures S1 through S4 and Tables S1 through S4 are available at http://jaha.ahajournals.org/ content/5/6/e003122/DC1/embed/ inline-supplementary-material-1.pdf *Dr Portero, Dr Le Scouarnec, and Dr Es-Salah-Lamoureux contributed equally to this work.",Non-OADS,/arxiv_data1/oa_pdf/1c/b7/JAH3-5-e003122.PMC4937261.pdf
"was<0.1% in the Exome Aggregation Consortium (ExAC) non- Finnish European population (http://exac.broadinstitute.org/ , version 0.3, 33 370 individuals).",OADS,/arxiv_data1/oa_pdf/1c/b7/JAH3-5-e003122.PMC4937261.pdf
"Accompanying Tables S1 and S2 are available at http://jaha.ahajournals.org/content/5/6/e003171/DC1/embed/inline-supplementary-material- 1.pdf *Dr Liu, Dr Li, and Dr Chen contributed equally to this work.Correspondence to: Jiyan Chen, MD, FACC, FESC and Ning Tan, MD, FACC, FESC, Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Provincial Key Laboratory of Coronary Disease, Guangdong General Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, 106 Zhongshan Second Road, Yuexiu District, Guangzhou 510100, China.",Non-OADS,/arxiv_data1/oa_pdf/76/13/JAH3-5-e003171.PMC4937263.pdf
Available at: http://www.pcronline.com/eurointer- vention/AbstractsLondon2013_issue/2023/.,Non-OADS,/arxiv_data1/oa_pdf/df/7b/JAH3-5-e003191.PMC4937264.pdf
Clinical Trial Registration- —URL: https://www.clinicaltrials.gov/.,Non-OADS,/arxiv_data1/oa_pdf/64/f1/JAH3-5-e003202.PMC4937265.pdf
"An accompanying Figure S1 is available at http://jaha.ahajournals.org/content/5/6/e003202/DC1/embed/inline-supplementary-material-1.pd f Correspondence to: Kenichi Tsujita, MD, PhD, Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto 860-8556, Japan.",Non-OADS,/arxiv_data1/oa_pdf/64/f1/JAH3-5-e003202.PMC4937265.pdf
"An accompanying Table S1 is available at http://jaha.ahajournals.org/ content/5/6/e003205/DC1/embed/inline-supplementary-material-1.pdf Correspondence to: Jacob A. Doll, MD, 2301 Erwin Rd, DUMC 3845, Durham, NC 27710.",Non-OADS,/arxiv_data1/oa_pdf/77/0c/JAH3-5-e003205.PMC4937266.pdf
Clinical Trial Registration- —URL: http://www.Clinicaltrials.gov.,Non-OADS,/arxiv_data1/oa_pdf/80/6e/JAH3-5-e003323.PMC4937273.pdf
Available at: http://www.ibge.- gov.br/home/.,Non-OADS,/arxiv_data1/oa_pdf/e6/f3/JAH3-5-e003337.PMC4937275.pdf
Available at: https://docs.google.com/viewer?a=v&pid=sites&sr-cid=ZGVmYXVsdGRvbWFpbnx0aGVpcGFxfGd4OjE0NDgxMDk3NDU1YWRlZTM.,Non-OADS,/arxiv_data1/oa_pdf/e6/f3/JAH3-5-e003337.PMC4937275.pdf
Available at: http://www.who.int/diabetes/publications/en/.,Non-OADS,/arxiv_data1/oa_pdf/e6/f3/JAH3-5-e003337.PMC4937275.pdf
Available at: http://www.who.int/diabetes/publications/en/.,Non-OADS,/arxiv_data1/oa_pdf/e6/f3/JAH3-5-e003337.PMC4937275.pdf
Available at: http://www.who.int/nmh/publications/ncd_pro ﬁles2011/en/.,Non-OADS,/arxiv_data1/oa_pdf/e6/f3/JAH3-5-e003337.PMC4937275.pdf
Available at: http://bvsms.saude.- gov.br/bvs/publicacoes/saude_brasil_2010.pdf.,Non-OADS,/arxiv_data1/oa_pdf/e6/f3/JAH3-5-e003337.PMC4937275.pdf
Available at: http://portalsaude.saude.gov.br/images/pdf/2014/novembro/ 05/Guia-Alimentar-para-a-pop-brasiliera-Miolo-PDF-Internet.pdf.,Non-OADS,/arxiv_data1/oa_pdf/e6/f3/JAH3-5-e003337.PMC4937275.pdf
Available at: http://health.gov/paguidelines/ report/.,Non-OADS,/arxiv_data1/oa_pdf/e6/f3/JAH3-5-e003337.PMC4937275.pdf
An accompanying Table S1 is available at http://jaha.ahajournals.org/content/5/6/e003339/DC1/embed/inline-supplementary-material-1.pdf*Dr Chen and Dr Mohler contributed equally to this work.,Non-OADS,/arxiv_data1/oa_pdf/e6/ad/JAH3-5-e003339.PMC4937276.pdf
Clinical Trial Registration- —URL: http://www.isrctn.com/ISRCTN70913605.,Non-OADS,/arxiv_data1/oa_pdf/6b/1c/JAH3-5-e003403.PMC4937278.pdf
Accompanying Tables S1 through S5 are available at http://jaha.ahajournals.org/content/5/6/e003403/DC1/embed/inline-supplementary-mater ial-1.pdf.,Non-OADS,/arxiv_data1/oa_pdf/6b/1c/JAH3-5-e003403.PMC4937278.pdf
Clinical Trial Registration- —URL: https://www.clinicaltrials.gov.,Non-OADS,/arxiv_data1/oa_pdf/43/1a/JAH3-5-e003407.PMC4937279.pdf
Clinical Trial Registration- —URL: https://www.clinicaltrials.gov/.,Non-OADS,/arxiv_data1/oa_pdf/1f/24/JAH3-5-e003418.PMC4937281.pdf
"Accompanying Tables S1 through S5 and Figures S1 through S4 are available at http://jaha.ahajournals.org/content/5/6/e003418/DC1/embed/inlin e- supplementary-material-1.pdf *Dr Frangieh, Dr Obeid, Dr Duru, and Dr Templin contributed equally to this work.",Non-OADS,/arxiv_data1/oa_pdf/1f/24/JAH3-5-e003418.PMC4937281.pdf
Clinical Trial Registration- —URL: https://www.clinicaltrials.gov/.,Non-OADS,/arxiv_data1/oa_pdf/25/40/JAH3-5-e003529.PMC4937282.pdf
"Accompanying Tables S1 through S5 are available at http://jaha.ahajournals.org/content/5/6/e003529/DC1/embed/inline-supplementarymateri al-1.pdf Correspondence to: Patrick Rossignol, MD, PhD, Centre d ’Investigations Cliniques-INSERM CHU de Nancy, Institut Lorrain du C œur et des Vaisseaux Louis Mathieu, 4 Rue du Morvan, 54500 Vandoeuvre l /C18es Nancy, France.",Non-OADS,/arxiv_data1/oa_pdf/25/40/JAH3-5-e003529.PMC4937282.pdf
Clinical Trial Registration- —URL: https://www.clinicaltrials.gov/.,Non-OADS,/arxiv_data1/oa_pdf/bc/c3/JAH3-5-e003559.PMC4937283.pdf
"*Accompanying Tables S1, S2, and Appendix S1 (which lists the participating STREAM Investigators and countries) are available at http://jaha.ahaj ournals.org/ content/5/6/e003559/DC1/embed/inline-supplementarymaterial-1.pdf Correspondence to: Paul W. Armstrong, MD, Canadian VIGOUR Center, University of Alberta, 2-132 Li Ka Shing Center for Health Research Innovation, Edmonton, Alberta, Canada T6G 2E1.",Non-OADS,/arxiv_data1/oa_pdf/bc/c3/JAH3-5-e003559.PMC4937283.pdf
Dr Armstrong ’sﬁnancial activities outside the submitted work are posted and routinely updated through http://www.vigour.ualberta.ca/en/About/ ConﬂictofInterest.aspx.,Non-OADS,/arxiv_data1/oa_pdf/bc/c3/JAH3-5-e003559.PMC4937283.pdf
"An accompanying Table S1 is available at http://jaha.ahajournals.org/ content/5/6/e003576/DC1/embed/inline-supplementary-material-1.pdf Correspondence to: Ali Sha ﬁq, MD, Division of Cardiology, St Luke ’s Mid America Heart Institute, 4401 Wornall Rd, Kansas City, MO 64111.",Non-OADS,/arxiv_data1/oa_pdf/58/a8/JAH3-5-e003576.PMC4937284.pdf
A series of CMS revisions from 2009 to 2011 to the Interpretive Guidelines stipulate that individual hospitalsand anesthesiology service directors determine local policies with the expectation that these policies are underpinned by national guidelines (https://www.cms.gov/Regulations-and- Guidance/Guidance/Manuals/downloads/som107ap_a_hos pitals.pdf).,Non-OADS,/arxiv_data1/oa_pdf/79/fb/JAH3-5-e003629.PMC4937286.pdf
Large anesthesia registries are already operational with more than 30 millioncases entered in the National Anesthesia Care Outcomes Registry alone (https://www.aqihq.org/).,Non-OADS,/arxiv_data1/oa_pdf/79/fb/JAH3-5-e003629.PMC4937286.pdf
"An accompanying Table S1 is available at http://jaha.ahajournals.org/ content/5/6/e003632/DC1/embed/inline-supplementary-material-1.pdf Correspondence to: Jennifer N. Avari Silva, MD, Washington University SOM, 1 Children ’s Place, CB 8116 NWT, Saint Louis, MO 63110.",Non-OADS,/arxiv_data1/oa_pdf/2e/41/JAH3-5-e003632.PMC4937287.pdf
Accompanying Figures S1 through S6 and Tables S1 through S3 are available at http://jaha.ahajournals.org/content/5/6/e003699/DC1/embed/inlin e- supplementary-material-1.pdf *Dr P ﬁtzer and Dr Stehle share senior authorship.,Non-OADS,/arxiv_data1/oa_pdf/d3/19/JAH3-5-e003699.PMC4937289.pdf
Available at: https://www.census.gov/popest/data/historical/2010s/vin- tage_2011/index.html.,OADS,/arxiv_data1/oa_pdf/31/e7/JAH3-5-e003704.PMC4937290.pdf
Available at: http://www.nap.edu/read/21723/chapter/2.,Non-OADS,/arxiv_data1/oa_pdf/31/e7/JAH3-5-e003704.PMC4937290.pdf
Available at: https://www.optum.- com/content/dam/optum/resources/productSheets/5302_Data_As- sets_Chart_Sheet_ISPOR.pdf.,OADS,/arxiv_data1/oa_pdf/39/8d/JAH3-5-e003725.PMC4937291.pdf
All of her relationships with industry are available at https://www.dcri.org/about-us/con ﬂict-of-interest.,Non-OADS,/arxiv_data1/oa_pdf/36/e1/JAH3-5-e003748.PMC4937293.pdf
Available at: http://www.who.int/chp/knowledge/pub-lications/adherence_introduction.pdf.,Non-OADS,/arxiv_data1/oa_pdf/25/79/JAH3-5-e003827.PMC4937295.pdf
"Protein sequence alignments were performed using the ClustalW program (28), and a graphic representation of the results was gener- ated with ESPript.cgi Version 3.0 ( 29)(http://espript.ibcp.",OADS,/arxiv_data1/oa_pdf/4d/0a/gkw150.PMC4937300.pdf
"In contrast,such an evolutionarily conserved stretch was not found for rpl-3intron 1, although analogous alternative splicing reg- ulationoftheorthologousintronshasbeenreportedforthehumanRPL3gene (49) and predicted for the Drosophila RpL3gene (FlyBase, http://flybase.org ).",Non-OADS,/arxiv_data1/oa_pdf/bf/0d/gkw152.PMC4937301.pdf
Fly stocks and handling Transgenic flies were generated using phiC31 integrase- mediated site-specific transgenesis system ( 18)b yt h e BestGene company ( http://www.thebestgene.com/ ).,OADS,/arxiv_data1/oa_pdf/fc/b9/gkw176.PMC4937306.pdf
"Processing of DamID-seq fastqfiles Because reads with GATC sites contain the DamID adapter sequence, this sequence was first clipped from such reads using the software package ‘cutadapt’ (ver-sion 1.2.1; https://cutadapt.readthedocs.org/en/stable/ ).",OADS,/arxiv_data1/oa_pdf/fc/b9/gkw176.PMC4937306.pdf
All reads were then aligned to the Drosophila melanogaster genome (release 5) using the short read alignment software ‘bowtie2’ (version 2.0.0-beta2; http://bowtie-bio.sourceforge.net/bowtie2/index.shtml ).,OADS,/arxiv_data1/oa_pdf/fc/b9/gkw176.PMC4937306.pdf
"Data release DamID-seq and RNA-seq data are available from the Gene Expression Omnibus ( http://www.ncbi.nlm.nih.gov/ geo/), accession number GSE75835.",OADS,/arxiv_data1/oa_pdf/fc/b9/gkw176.PMC4937306.pdf
"Two GC-box sequences located at the positions -33 /-22 and -15/-2 of the TLR5 promoter is required for basal and butyrate-induced transcriptional activities To study the mechanism of TLR5 transactivation, we analyzed the TLR5 putative promoter for tran- scription factor binding sites using the softwareTRANSFAC R/circlecopyrtProfessional ( http://www.generegulation.",Non-OADS,/arxiv_data1/oa_pdf/87/60/gkw189.PMC4937308.pdf
Parame- tersareavailableat http://github.com/srnas/ff .Temperature replicaexchangeMDwasusedtoacceleratesampling( 40).,OADS,/arxiv_data1/oa_pdf/9e/cd/gkw239.PMC4937309.pdf
AVAILABILITY StopmotionmodelinghasbeenimplementedinthebaRN- Aba package freely available at https://github.com/srnas/ barnaba.,Non-OADS,/arxiv_data1/oa_pdf/9e/cd/gkw239.PMC4937309.pdf
"NucleicAcidsResearch,2016,Vol.44,No.12 5899 tool (BLAST) (available at https://blast.ncbi.nlm.nih.gov/ ) against genomic mRNA databases.",OADS,/arxiv_data1/oa_pdf/6a/5c/gkw241.PMC4937310.pdf
MATERIALS AND METHODS Datasets The dataset of translocation and deletion breakpoint co- ordinates in cancer genomes was obtained from the Cat- alogue Of Somatic Mutations In Cancer (COSMIC) at http://cancer.sanger.ac.uk/cosmic/ ) (file CosmicStructEx- port v70100814.tsv).,OADS,/arxiv_data1/oa_pdf/66/6b/gkw261.PMC4937311.pdf
A first control dataset (Contr1) of simulated genomic breakpoint positions was built using SAMtools( http://samtools.sourceforge.net ).Asecondcon- troldataset(Contr2)comprisedallgenomiccoordinateslo- cated 3000 bp upstream from the translocation breakpointcoordinates.,OADS,/arxiv_data1/oa_pdf/66/6b/gkw261.PMC4937311.pdf
The list of L1 retrotransposons was down- loaded from the European database of L1-HS retrotrans- posoninsertionsinhumans(euL1db)at http://eul1db.unice.,OADS,/arxiv_data1/oa_pdf/66/6b/gkw261.PMC4937311.pdf
"The dataset of microRNA gene coordinates was downloaded from miRBase, the mi- croRNA database at http://mirbase.smith.man.ac.uk (file hsa.gff3).",OADS,/arxiv_data1/oa_pdf/66/6b/gkw261.PMC4937311.pdf
All work was per- formed on Linux clusters at the Texas Advanced Comput-ingCenter( https://www.tacc.utexas.edu ).,OADS,/arxiv_data1/oa_pdf/66/6b/gkw261.PMC4937311.pdf
"Statistics To perform statistical tests, we linked our C++ codes to theBOOSTlibraries( http://www.boost.org ).Whenassum- ing unequal variance for the data, the two-sample Stu-dent’st-test implemented a Welch-Satterthwaite approxi- mation, which affords real number degrees-of-freedom pa- rameters, and hence high accuracy.",Non-OADS,/arxiv_data1/oa_pdf/66/6b/gkw261.PMC4937311.pdf
"For curve fitting, weused SigmaPlot12 ( http://www.sigmaplot.com ).",Non-OADS,/arxiv_data1/oa_pdf/66/6b/gkw261.PMC4937311.pdf
The pro- gram Circos was obtained from http://circos.ca; Perl mod- ules were downloaded from CPAN at http://search.cpan.,OADS,/arxiv_data1/oa_pdf/66/6b/gkw261.PMC4937311.pdf
"RESULTS Experimental design First, we downloaded the SNP variants for a HapMap sample NA12878 ( http://www.stanford.edu/ ∼ kuleshov/NA12878.vcf.gz , Supplementary Table S1).",OADS,/arxiv_data1/oa_pdf/c9/cd/gkw284.PMC4937318.pdf
"Significantly, to make our method easier to use, OP- Shap (in Perl) for encoding and decoding, with detailed in- structions, is available online at http://bioinfo.seu.edu.cn/ OPShap.",OADS,/arxiv_data1/oa_pdf/c9/cd/gkw284.PMC4937318.pdf
Our method is freely available athttps://github.com/Gabaldonlab/redundans .,Non-OADS,/arxiv_data1/oa_pdf/2f/11/gkw294.PMC4937319.pdf
All mentioned thresholdsandparameterscanbeadjustedbytheuser.Re- dundans pipeline and all programs mentioned in the textcan be access publicly ( https://github.com/Gabaldonlab/ redundans ).,OADS,/arxiv_data1/oa_pdf/2f/11/gkw294.PMC4937319.pdf
Redundans is freely available athttps://github.com/Gabaldonlab/redundans .,OADS,/arxiv_data1/oa_pdf/2f/11/gkw294.PMC4937319.pdf
AVAILABILITY TheW-testsoftwareisavailable at: http://www2.ccrb.cuhk.,Non-OADS,/arxiv_data1/oa_pdf/92/8a/gkw347.PMC4937324.pdf
"(2002) ThePyMOLmoleculargraphicssystem ,Version 1.7.4,Schr ¨odingerLLC, https://www.pymol.org/citing .",Non-OADS,/arxiv_data1/oa_pdf/7c/90/gkw367.PMC4937325.pdf
; http://www.pymol.org ).,Non-OADS,/arxiv_data1/oa_pdf/b2/99/gkw388.PMC4937326.pdf
The 2D representations (derived from 3D structures) were adapted from imagesstored at http://apollo.chemistry.gatech.edu/RibosomeGallery (57).,OADS,/arxiv_data1/oa_pdf/b2/99/gkw388.PMC4937326.pdf
"Other NTs were selected based on datafrom animal experiments and human epidemiology data (12,13), and other GCs and NGCs were selected based on U.S. and European international projects ( 14–16) and the International Agency for Research on Cancer monograph on human carcinogens ( http://monographs.iarc.fr/ENG/ Monographs/PDFs/index.php ).",Non-OADS,/arxiv_data1/oa_pdf/d9/1f/gkw450.PMC4937330.pdf
"In order to simply detect genes sensitive to chem-icals, or candidate feature genes at the stem cell stage, we performed microarray analysis of undifferentiated KhES-3 EScellsratherthandifferentiatedcellsorembryos.Therawdata obtained 48 h after exposure to 1 /2 dose were log 2- transformedandquantile-normalizedusingtheBeadArray (20) library of the Bioconductor ( http://bioconductor.org/ ) package in the R ( http://www.r-project.org/ )s t a t i s t i c a l computing language.",OADS,/arxiv_data1/oa_pdf/d9/1f/gkw450.PMC4937330.pdf
The microarray data are available on our website (http://stemcellinformatics.org/toxicology/ ) or the Gene Expression Omnibus (GSE60154).,OADS,/arxiv_data1/oa_pdf/d9/1f/gkw450.PMC4937330.pdf
Raw data from the qRT-PCR experiments and the sam- ple preparation information are available at our website(http://stemcellinformatics.org/toxicology/ ).,OADS,/arxiv_data1/oa_pdf/d9/1f/gkw450.PMC4937330.pdf
"As the details of the original TAO-Gen algorithm can be downloaded from our website (http://stemcellinformatics.org/toxicology/ ), we de- scribeonlytheadditionalimprovedalgorithmhere.Inorder to achieve more efficient and reliable sampling, we further improvedthisalgorithmbycreatingaversionoptimizedforparallelcomputation,basedonstandardensembleMarkov chainMonteCarlo(MCMC)samplingorreplica-exchange MCMC sampling ( 28,29).",OADS,/arxiv_data1/oa_pdf/d9/1f/gkw450.PMC4937330.pdf
The binary program and a detailed descrip- tion of RX-TAOgen can be downloaded from our website (http://stemcellinformatics.org/toxicology/ ).,OADS,/arxiv_data1/oa_pdf/d9/1f/gkw450.PMC4937330.pdf
"As a simple proof of study, we generated 1665 molecu- lar descriptors for our selected chemicals using E-Dragon(46)w e b s i t e( http://www.vcclab.org/lab/edragon/ ) and pre- dictedchemicaltoxicitycategorieswithourSVMusingthe sameschemeasBNs.Weexhaustivelytestedthenumberoffeature descriptors ranked by two-sample t-test (see Mate- rialsandMethods)from1tothefullrangeof1665,whichis more than 16 times larger than the range of BNs that haveonly 100 edge weight parameters.",OADS,/arxiv_data1/oa_pdf/d9/1f/gkw450.PMC4937330.pdf
We demonstrate the value of genomic context by using Goldmine to elu- cidate context dynamics in transcription factor bind- ing and to reveal differentially methylated regions (DMRs) with context-speciﬁc functional correlations.The open source R package and documentation for Goldmine are available at http://jeffbhasin.github.io/ goldmine .,OADS,/arxiv_data1/oa_pdf/b9/48/gkw477.PMC4937336.pdf
These tables (viewable at https://genome.ucsc.edu/cgi-bin/hgTables )containthebulk of extant annotation available for most species with as- sembled genomes.,OADS,/arxiv_data1/oa_pdf/b9/48/gkw477.PMC4937336.pdf
ENSEMBLgeneIDsweredirectlycopiedfromGoldmine’sgene-leveltableandpastedintoGeneMANIA( http://www.genemania.org/ ).,OADS,/arxiv_data1/oa_pdf/b9/48/gkw477.PMC4937336.pdf
ACKNOWLEDGEMENT TheauthorsacknowledgetheRoadmapEpigenomicsCon- sortium ( http://nihroadmap.nih.gov/epigenomics/ ) and the ENCODE Consortium ( https://www.encodeproject.org/ ) for generatingdata used inthis report.,OADS,/arxiv_data1/oa_pdf/b9/48/gkw477.PMC4937336.pdf
Structures are rendered from pdb file 2AW4 ( 54) (superseded by 4V4Q) using Chimera (http://www.cgl.ucsf.edu/chimera ).,OADS,/arxiv_data1/oa_pdf/4c/fb/gkw493.PMC4937340.pdf
Primer specificity was evaluated using the BLAST program ( http://blast.ncbi.nlm.nih.gov/Blast.,OADS,/arxiv_data1/oa_pdf/69/76/gkw499.PMC4937342.pdf
"Article, supplemental material, and publi- cation date are at http://www.genome.org/cgi/doi/10.1101/gr.200931.115.© 2016 Mühlhausen et al.",OADS,/arxiv_data1/oa_pdf/e8/e3/945.PMC4937558.pdf
This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publicationdate (see http://genome.cshlp.org/site/misc/terms.xhtml).,Non-OADS,/arxiv_data1/oa_pdf/e8/e3/945.PMC4937558.pdf
"After six months, itis available under a Creative Commons License (Attribution-NonCommercial4.0 International), as described at http://creativecommons.org/licenses/by- nc/4.0/.Research 26:945 –955 Published by Cold Spring Harbor Laboratory Press; ISSN 1088-9051/16; www.genome.org Genome Research 945 www.genome.org",OADS,/arxiv_data1/oa_pdf/e8/e3/945.PMC4937558.pdf
http://onlinelibrary.wiley.com/doi/10.1002/ 9780470015902.a0000531.pub3/abstract.,Non-OADS,/arxiv_data1/oa_pdf/e8/e3/945.PMC4937558.pdf
"Article, supplemental material, and publi- cation date are at http://www.genome.org/cgi/doi/10.1101/gr.197632.115.© 2016 Beltran et al.",OADS,/arxiv_data1/oa_pdf/71/ec/896.PMC4937559.pdf
This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publicationdate (see http://genome.cshlp.org/site/misc/terms.xhtml).,Non-OADS,/arxiv_data1/oa_pdf/71/ec/896.PMC4937559.pdf
"After six months, itis available under a Creative Commons License (Attribution-NonCommercial4.0 International), as described at http://creativecommons.org/licenses/ by-nc/4.0/.Research 896 Genome Research 26:896 –907 Published by Cold Spring Harbor Laboratory Press; ISSN 1088-9051/16; www.genome.org www.genome.org",OADS,/arxiv_data1/oa_pdf/71/ec/896.PMC4937559.pdf
"(2013).iCLIP data processing iCLIP data were processed with iCount (http://icount.biolab.si/) and filtered to remove any crosslinks overlapping a RepeatMasker feature, ncRNAs under 200 nt in length, or snoRNAs.",OADS,/arxiv_data1/oa_pdf/71/ec/896.PMC4937559.pdf
"Data access All iCLIP, RNA-seq, and ChIP-seq data from this study havebeen submitted to the NCBI Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/) under accession number GSE66831.PRC2 RNA and chromatin binding are antagonistic Genome Research 905 www.genome.org",OADS,/arxiv_data1/oa_pdf/71/ec/896.PMC4937559.pdf
"Article, supplemental material, and publi-cation date are at http://www.genome.org/cgi/doi/10.1101/gr.202440.115.",OADS,/arxiv_data1/oa_pdf/5b/52/863.PMC4937562.pdf
"This article, published in Genome Research , is available under a Creative Commons License (Attribution-NonCommercial 4.0 Interna- tional), as described at http://creativecommons.org/licenses/by-nc/4.0/.Research 26:863 –873 Published by Cold Spring Harbor Laboratory Press; ISSN 1088-9051/16; www.genome.org Genome Research 863 www.genome.org",Non-OADS,/arxiv_data1/oa_pdf/5b/52/863.PMC4937562.pdf
Power of rare variant tests We obtained the SKAT-O R package from http://www.hsph.,Non-OADS,/arxiv_data1/oa_pdf/5b/52/863.PMC4937562.pdf
"We repeated this analysis for a subset of the parameter space for two other rare variant association tests in Europeans using the rvtests software (http://zhanxw.github.io/rvtests/), in particularCMC (Li and Leal 2008), the test of Morris and Zeggini (2010), and CMC-Wald, which first runs CMC and then the Wald test.",Non-OADS,/arxiv_data1/oa_pdf/5b/52/863.PMC4937562.pdf
"2010) (0.63), and BURDEN (https://atgu.mgh.",Non-OADS,/arxiv_data1/oa_pdf/5b/52/863.PMC4937562.pdf
"Article, supplemental material, and publi- cation date are at http://www.genome.org/cgi/doi/10.1101/gr.202648.115.© 2016 Basler et al.",OADS,/arxiv_data1/oa_pdf/34/88/956.PMC4937563.pdf
This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publication date(see http://genome.cshlp.org/site/misc/terms.xhtml).,Non-OADS,/arxiv_data1/oa_pdf/34/88/956.PMC4937563.pdf
"After six months, it isavailable under a Creative Commons License (Attribution-NonCommercial4.0 International), as described at http://creativecommons.org/licenses/ by-nc/4.0/.Method 956 Genome Research 26:956 –968 Published by Cold Spring Harbor Laboratory Press; ISSN 1088-9051/16; www.genome.org www.genome.org",OADS,/arxiv_data1/oa_pdf/34/88/956.PMC4937563.pdf
Software availability The Qualitative Flux Control (QFC) source code is freely available in the Supplemental Material and at http://scholar.harvard.edu/yyl/qfc.,Non-OADS,/arxiv_data1/oa_pdf/34/88/956.PMC4937563.pdf
"Article, supplemental material, and publi- cation date are at http://www.genome.org/cgi/doi/10.1101/gr.204420.116.© 2016 Vakirlis et al.",OADS,/arxiv_data1/oa_pdf/e8/94/918.PMC4937564.pdf
This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publicationdate (see http://genome.cshlp.org/site/misc/terms.xhtml).,Non-OADS,/arxiv_data1/oa_pdf/e8/94/918.PMC4937564.pdf
"After six months, itis available under a Creative Commons License (Attribution-NonCommercial4.0 International), as described at http://creativecommons.org/licenses/ by-nc/4.0/.Research 918 Genome Research 26:918 –932 Published by Cold Spring Harbor Laboratory Press; ISSN 1088-9051/16; www.genome.org www.genome.org",OADS,/arxiv_data1/oa_pdf/e8/94/918.PMC4937564.pdf
"2015), and the project to sequence and analyze their genomes was recently initiated (http://www.y1000plus.org/).",Non-OADS,/arxiv_data1/oa_pdf/e8/94/918.PMC4937564.pdf
"Gene models were annotated for the seven newly sequenced ge- nomes with an annotation transfer pipeline that we developedwith the AMADEA Biopack platform (Isoft, http://www.isoft.fr/ bio/biopack_en.htm) ( Supplemental Methods ).",OADS,/arxiv_data1/oa_pdf/e8/94/918.PMC4937564.pdf
"The functional annotation of protein-coding genes has been established on the basis of homology with S. cerevisiae genes (SGD S288C ORF translations, release February 3, 2011, available at http:// downloads.yeastgenome.org/sequence/S288C_reference/orf_protein/) or the NCBI Reference Sequence (RefSeq) database (release 58 of March 11, 2013, available at http://www.ncbi.nlm.",OADS,/arxiv_data1/oa_pdf/e8/94/918.PMC4937564.pdf
Genome sequences and (re)annotations of the 10 Lachancea species are available on the GRYC website: http://gryc.inra.fr.,OADS,/arxiv_data1/oa_pdf/e8/94/918.PMC4937564.pdf
"The sequenc- ing reads and the seven new genome assemblies from this studyhave been submitted to the European Nucleotide Archive (ENA; http://www.ebi.ac.uk/ena) under the following accession num- bers: PRJEB12910, PRJEB12928, PRJEB12929, PRJEB12930, PRJEB12931, PRJEB12932, and PRJEB12933.",OADS,/arxiv_data1/oa_pdf/e8/94/918.PMC4937564.pdf
"Article, supplemental material, and publi- cation date are at http://www.genome.org/cgi/doi/10.1101/gr.205484.116.© 2016 Dhokarh and Abyzov This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publi-cation date (see http://genome.cshlp.org/site/misc/terms.xhtml).",Non-OADS,/arxiv_data1/oa_pdf/9a/55/874.PMC4937565.pdf
"Initial selection of Illumina TruSeq synthetic long-reads From the 1000 Genomes Project Consortium, a confident set of precise deletion breakpoints is available for the subject NA12878 (ftp://ftp-trace.ncbi.nih.gov/ 1000genomes/ftp/phase3/integra- ted_sv_map/supporting).",OADS,/arxiv_data1/oa_pdf/9a/55/874.PMC4937565.pdf
Determining heterozygous deletions using CNVnator We genotyped deletions in the NA12878 and corresponding par-ents using 2 × 250 bp read Illumina data with approximately 60× coverage (ftp://ftp-trace.ncbi.nih.gov/1000genomes/ftp/phase3/data/NA12878).,OADS,/arxiv_data1/oa_pdf/9a/55/874.PMC4937565.pdf
"To obtain a confident set of SNPs/indels, we carried out an intersection with the GATK confident set of variants for the trio (ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/technical/working/ 20131015_p3_high_cov_calls/HaplotypeCaller/CEU.wgs.Haplotype Caller.20131118.snps_indels.high_coverage_pcr_free.genotypes.",OADS,/arxiv_data1/oa_pdf/9a/55/874.PMC4937565.pdf
"Three-way consensus analysis For the haplotype with the deletion event, we used, “vcf-isec –f–n=4 –r file, ”where “-r file ”is as explained above; “-n = 4 ”spec- ifies intersection of positions that are present in exactly four files, these being the GATK VCF (see above for download information), Complete Genomics VCF (ftp://ftp2.completegenomics.com/ vcf_files/Build37_2.0.0/vcfBeta-NA12878-200-37-ASM.vcf.bz2),Illumina Platinum VCF (ftp://platgene_ro@ussd-ftp.illumina.com/ hg19/older_releases/IlluminaPlatinumGenomes_v7.0/merged_ platinum/NA12878.vcf.gz), with these three providing the three-way consensus VCF file; and the Illumina TruSeq VCF file obtained by our script above.",Non-OADS,/arxiv_data1/oa_pdf/9a/55/874.PMC4937565.pdf
"Article, supplemental material, and publi- cation date are at http://www.genome.org/cgi/doi/10.1101/gr.203513.115.© 2016 Hagey et al.",OADS,/arxiv_data1/oa_pdf/de/43/908.PMC4937566.pdf
This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publicationdate (see http://genome.cshlp.org/site/misc/terms.xhtml).,Non-OADS,/arxiv_data1/oa_pdf/de/43/908.PMC4937566.pdf
"After six months, itis available under a Creative Commons License (Attribution-NonCommercial4.0 International), as described at http://creativecommons.org/licenses/ by-nc/4.0/.Research 908 Genome Research 26:908 –917 Published by Cold Spring Harbor Laboratory Press; ISSN 1088-9051/16; www.genome.org www.genome.org",OADS,/arxiv_data1/oa_pdf/de/43/908.PMC4937566.pdf
2010) available at https://usegalaxy.org.,Non-OADS,/arxiv_data1/oa_pdf/de/43/908.PMC4937566.pdf
Enhancer DNA was randomized usingthis website: http://www.faculty.ucr.edu/~mmaduro/random.,OADS,/arxiv_data1/oa_pdf/de/43/908.PMC4937566.pdf
Data access Sequence data generated for this study have been submitted to the NCBI Sequence Read Archive (SRA; http://www.ncbi.nlm.nih.gov/ sra) under accession number SRP069283.,OADS,/arxiv_data1/oa_pdf/de/43/908.PMC4937566.pdf
"Article, supplemental material, and publi- cation date are at http://www.genome.org/cgi/doi/10.1101/gr.201996.115.© 2016 Weissbrod et al.",OADS,/arxiv_data1/oa_pdf/d1/09/969.PMC4937570.pdf
This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publicationdate (see http://genome.cshlp.org/site/misc/terms.xhtml).,Non-OADS,/arxiv_data1/oa_pdf/d1/09/969.PMC4937570.pdf
"After six months, itis available under a Creative Commons License (Attribution-NonCommercial4.0 International), as described at http://creativecommons.org/licenses/ by-nc/4.0/.Method 26:969 –979 Published by Cold Spring Harbor Laboratory Press; ISSN 1088-9051/16; www.genome.org Genome Research 969 www.genome.org",OADS,/arxiv_data1/oa_pdf/d1/09/969.PMC4937570.pdf
Updated versions will be available at https://github.com/omerwe/MKLMM.,Non-OADS,/arxiv_data1/oa_pdf/d1/09/969.PMC4937570.pdf
A full list of the inves-tigators who contributed to the generation of the data is available from http://www.wtccc.org.uk.,OADS,/arxiv_data1/oa_pdf/d1/09/969.PMC4937570.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), permitting all non- commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.1 Citation: Microbial Ecology in Health & Disease 2016, 27: 30971 - http://dx.doi.org/10.3402/mehd.v27.30971 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/b5/41/MEHD-27-30971.PMC4937721.pdf
"SCFAs decrease the activityof chromosome histone deacetylases (HDACs), therebyfacilitating the access of repair enzymes to the DNA.This promotes the improvement of the health state ofpatients with the excessive activity of these enzymes thatis characteristic of Parkinson’s disease, depression, andAlexander V. Oleskin and Boris A. Shenderov 2 (page number not for citation purpose)Citation: Microbial Ecology in Health & Disease 2016, 27: 30971 - http://dx.doi.org/10.3402/mehd.v27.30971",Non-OADS,/arxiv_data1/oa_pdf/b5/41/MEHD-27-30971.PMC4937721.pdf
"Inducible NOS is activated under 1Classifying acetaldehyde as a gas is somewhat arbitrary because this compound is in the liquid state at atmospheric pressure up to the boilingpoint of 20.2 8C.Neuromodulatory effects of microbial gasotransmitters Citation: Microbial Ecology in Health & Disease 2016, 27: 30971 - http://dx.doi.org/10.3402/mehd.v27.30971 3 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/b5/41/MEHD-27-30971.PMC4937721.pdf
"This enzyme is responsible for the anaerobic metabolism of CO, which is the sole carbonAlexander V. Oleskin and Boris A. Shenderov 4 (page number not for citation purpose)Citation: Microbial Ecology in Health & Disease 2016, 27: 30971 - http://dx.doi.org/10.3402/mehd.v27.30971",Non-OADS,/arxiv_data1/oa_pdf/b5/41/MEHD-27-30971.PMC4937721.pdf
"sulfates and sulfites) and organicNeuromodulatory effects of microbial gasotransmitters Citation: Microbial Ecology in Health & Disease 2016, 27: 30971 - http://dx.doi.org/10.3402/mehd.v27.30971 5 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/b5/41/MEHD-27-30971.PMC4937721.pdf
"Release ofH 2S from the lysate of cultures neurons and astrocytesAlexander V. Oleskin and Boris A. Shenderov 6 (page number not for citation purpose)Citation: Microbial Ecology in Health & Disease 2016, 27: 30971 - http://dx.doi.org/10.3402/mehd.v27.30971",OADS,/arxiv_data1/oa_pdf/b5/41/MEHD-27-30971.PMC4937721.pdf
"In the human organism, NH 3is predominantly formed by the intestinal microbiota and the cells of the GI tract, kidneys,Neuromodulatory effects of microbial gasotransmitters Citation: Microbial Ecology in Health & Disease 2016, 27: 30971 - http://dx.doi.org/10.3402/mehd.v27.30971 7 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/b5/41/MEHD-27-30971.PMC4937721.pdf
"Encephalopathy mayresult from the synergistic effect of ammonia and cytokinesAlexander V. Oleskin and Boris A. Shenderov 8 (page number not for citation purpose)Citation: Microbial Ecology in Health & Disease 2016, 27: 30971 - http://dx.doi.org/10.3402/mehd.v27.30971",Non-OADS,/arxiv_data1/oa_pdf/b5/41/MEHD-27-30971.PMC4937721.pdf
"It should be noted that behavioral analysis, monitoring neurotransmission in various pathways, exploring synap-tic plasticity in models such as long-term potentiation(LTP) and LTD, are the bread and butter of present-dayNeuromodulatory effects of microbial gasotransmitters Citation: Microbial Ecology in Health & Disease 2016, 27: 30971 - http://dx.doi.org/10.3402/mehd.v27.30971 9 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/b5/41/MEHD-27-30971.PMC4937721.pdf
doi: http://dx.doi.org/10.1007/978-3-319-20215_15 6.,Non-OADS,/arxiv_data1/oa_pdf/b5/41/MEHD-27-30971.PMC4937721.pdf
"Microbial Ecol Health Dis 2014; 25: 24145, doi: http://dx.doi.org/10.3402/mehd.v25.2414511.",Non-OADS,/arxiv_data1/oa_pdf/b5/41/MEHD-27-30971.PMC4937721.pdf
Front Cell InfectMicrobiol 2014; 4: 147. doi: http://dx.doi.org/10.3389/fcimb.2014.001 12.,Non-OADS,/arxiv_data1/oa_pdf/b5/41/MEHD-27-30971.PMC4937721.pdf
doi: http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b5/41/MEHD-27-30971.PMC4937721.pdf
doi: http://dx.doi.org/10.1126/scitranslmed.3000721 26.,Non-OADS,/arxiv_data1/oa_pdf/b5/41/MEHD-27-30971.PMC4937721.pdf
Front Physiol 2012; 3: 83. doi: http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b5/41/MEHD-27-30971.PMC4937721.pdf
"F1000PrimeReport 2013; 5: 28. doi: http://dx.doi.org/10.12703/P5-28Alexander V. Oleskin and Boris A. Shenderov 10 (page number not for citation purpose)Citation: Microbial Ecology in Health & Disease 2016, 27: 30971 - http://dx.doi.org/10.3402/mehd.v27.30971",OADS,/arxiv_data1/oa_pdf/b5/41/MEHD-27-30971.PMC4937721.pdf
Front Physiol 2012; 3: 101. doi: http://dx.doi.org/10.3389/fphys.2012.00101 34.,Non-OADS,/arxiv_data1/oa_pdf/b5/41/MEHD-27-30971.PMC4937721.pdf
"Microb Ecol Health Dis 2012; 23: 19260, doi:http://dx.doi.org/10.3402/mehd.v23i0.19260 35.",Non-OADS,/arxiv_data1/oa_pdf/b5/41/MEHD-27-30971.PMC4937721.pdf
"Microb Ecol Health Dis 2015; 26: 27458, doi: http://dx.doi.org/10.3402/mehd.v26.27458 36.",Non-OADS,/arxiv_data1/oa_pdf/b5/41/MEHD-27-30971.PMC4937721.pdf
"Microb Ecol Health Dis 2015; 26: 27878, doi: http://dx.doi.org/10.3402/mehd.v26.26878 37.",Non-OADS,/arxiv_data1/oa_pdf/b5/41/MEHD-27-30971.PMC4937721.pdf
doi: http://dx.doi.org/ 10.1111/odi.12157 41.,Non-OADS,/arxiv_data1/oa_pdf/b5/41/MEHD-27-30971.PMC4937721.pdf
doi: http://dx.doi.org/10.1053/j.gastro.2014.04.041 44.,Non-OADS,/arxiv_data1/oa_pdf/b5/41/MEHD-27-30971.PMC4937721.pdf
doi: http://dx.doi.org/10.1016/j.freeradbiomed.2014.09.017 49.,OADS,/arxiv_data1/oa_pdf/b5/41/MEHD-27-30971.PMC4937721.pdf
Front Physiol 2013; 4: 27. doi: http://dx.doi.org/10.3389/fphys.2013.00027 54.,Non-OADS,/arxiv_data1/oa_pdf/b5/41/MEHD-27-30971.PMC4937721.pdf
doi: http://dx.doi.org/10.1007/s10620-009-1012-0 60.,Non-OADS,/arxiv_data1/oa_pdf/b5/41/MEHD-27-30971.PMC4937721.pdf
doi: http://dx.doi.org/10.1152/ japplphysiol.01100.2013 67.,Non-OADS,/arxiv_data1/oa_pdf/b5/41/MEHD-27-30971.PMC4937721.pdf
"Deciphering nitric oxide stress in bacteria with quantitative modeling.Curr Opin Microbiol 2014; 19: 16 /C124.Neuromodulatory effects of microbial gasotransmitters Citation: Microbial Ecology in Health & Disease 2016, 27: 30971 - http://dx.doi.org/10.3402/mehd.v27.30971 11 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/b5/41/MEHD-27-30971.PMC4937721.pdf
Front Physiol 2015; 6: 33. doi: http://dx.doi.org/10.3389/fphys.2015.00033 73.,Non-OADS,/arxiv_data1/oa_pdf/b5/41/MEHD-27-30971.PMC4937721.pdf
Front Physiol 2012; 3: 448. doi:http://dx.doi.org/10.3389/fphys.2012.00448C 79.,Non-OADS,/arxiv_data1/oa_pdf/b5/41/MEHD-27-30971.PMC4937721.pdf
doi: http://dx.doi.org/10.1016/j.cca.,OADS,/arxiv_data1/oa_pdf/b5/41/MEHD-27-30971.PMC4937721.pdf
Nat Commun 2013; 4: 1366. doi: http://dx.doi.org/10.1038/ ncomms2371 86.,OADS,/arxiv_data1/oa_pdf/b5/41/MEHD-27-30971.PMC4937721.pdf
Front Physiol 2012; 3: 295. doi: http://dx.doi.org/10.3389/fphys.2012.00295 88.,Non-OADS,/arxiv_data1/oa_pdf/b5/41/MEHD-27-30971.PMC4937721.pdf
Front Physiol 2012; 3:43. doi: http://dx.doi.org/10.3389/fphys.2012.00043 89.,Non-OADS,/arxiv_data1/oa_pdf/b5/41/MEHD-27-30971.PMC4937721.pdf
Front Physiol 2012; 3: 324. doi: http://dx.doi.org/10.3389/fphys.2012.00324 99.,Non-OADS,/arxiv_data1/oa_pdf/b5/41/MEHD-27-30971.PMC4937721.pdf
Front Cell Neurosci 2015; 9: 59. doi: http://dx.doi.org/10.3389/fncel.00059 100.,Non-OADS,/arxiv_data1/oa_pdf/b5/41/MEHD-27-30971.PMC4937721.pdf
"(in Russian).Alexander V. Oleskin and Boris A. Shenderov 12 (page number not for citation purpose)Citation: Microbial Ecology in Health & Disease 2016, 27: 30971 - http://dx.doi.org/10.3402/mehd.v27.30971",Non-OADS,/arxiv_data1/oa_pdf/b5/41/MEHD-27-30971.PMC4937721.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), permitting all non-commercial use , distribution, and reproduction in any medium, provided the original work is properly cited.1 Citation: Journal of Extracellular Vesicles 2016, 5: 30741 - http://dx.doi.org/10.3402/jev.v5.30741 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/61/fb/JEV-5-30741.PMC4937767.pdf
"2 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2016, 5: 30741 - http://dx.doi.org/10.3402/jev.v5.30741",OADS,/arxiv_data1/oa_pdf/61/fb/JEV-5-30741.PMC4937767.pdf
"Full-scan spectra from 50to 1,500 Da were acquired, and individual spectra were summed to produce data points each of 0.2 s. Mass accuracy and reproducibility were maintained by using an independent reference spray (leucine enkephalin) viaPlasmalogen enrichment in nematode exosomes Citation: Journal of Extracellular Vesicles 2016, 5: 30741 - http://dx.doi.org/10.3402/jev.v5.30741 3 (page number not for citation purpose)",OADS,/arxiv_data1/oa_pdf/61/fb/JEV-5-30741.PMC4937767.pdf
"4 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2016, 5: 30741 - http://dx.doi.org/10.3402/jev.v5.30741",OADS,/arxiv_data1/oa_pdf/61/fb/JEV-5-30741.PMC4937767.pdf
"The murine exosome types display comparablePlasmalogen enrichment in nematode exosomes Citation: Journal of Extracellular Vesicles 2016, 5: 30741 - http://dx.doi.org/10.3402/jev.v5.30741 5 (page number not for citation purpose)",OADS,/arxiv_data1/oa_pdf/61/fb/JEV-5-30741.PMC4937767.pdf
"6 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2016, 5: 30741 - http://dx.doi.org/10.3402/jev.v5.30741",OADS,/arxiv_data1/oa_pdf/61/fb/JEV-5-30741.PMC4937767.pdf
"Dynamic light scattering analysis of vesicle size and charge is reported together with the polydispersity index (PdI) Exosomes Size (nm) PdI Z-potential (mV) H. polygyrus 12293 0.33 90.11 /C2821.391.56 MODE-K 122 919 0.46 90.03 /C2836.592.89 Raw 264.7 111 95 0.33 90.11 /C2834.090.56Plasmalogen enrichment in nematode exosomes Citation: Journal of Extracellular Vesicles 2016, 5: 30741 - http://dx.doi.org/10.3402/jev.v5.30741 7 (page number not for citation purpose)",OADS,/arxiv_data1/oa_pdf/61/fb/JEV-5-30741.PMC4937767.pdf
"8 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2016, 5: 30741 - http://dx.doi.org/10.3402/jev.v5.30741",OADS,/arxiv_data1/oa_pdf/61/fb/JEV-5-30741.PMC4937767.pdf
"**p B0.01, ***p B0.001, ****p B0.0001 based on ANOV A and Tukey’s multiple comparisons test.Plasmalogen enrichment in nematode exosomes Citation: Journal of Extracellular Vesicles 2016, 5: 30741 - http://dx.doi.org/10.3402/jev.v5.30741 9 (page number not for citation purpose)",OADS,/arxiv_data1/oa_pdf/61/fb/JEV-5-30741.PMC4937767.pdf
"10 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2016, 5: 30741 - http://dx.doi.org/10.3402/jev.v5.30741",OADS,/arxiv_data1/oa_pdf/61/fb/JEV-5-30741.PMC4937767.pdf
"**pB0.01; Unpaired t-test with Welch’s correction.Plasmalogen enrichment in nematode exosomes Citation: Journal of Extracellular Vesicles 2016, 5: 30741 - http://dx.doi.org/10.3402/jev.v5.30741 11 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/61/fb/JEV-5-30741.PMC4937767.pdf
"12 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2016, 5: 30741 - http://dx.doi.org/10.3402/jev.v5.30741",OADS,/arxiv_data1/oa_pdf/61/fb/JEV-5-30741.PMC4937767.pdf
"Authors’ contributions FS designed and performed lipidomic and biochemical experiments and drafted manuscript, JMC co-designed and assisted with DLS experiments, GC, MM andRMM provided support for the H. polygyrus life cyclePlasmalogen enrichment in nematode exosomes Citation: Journal of Extracellular Vesicles 2016, 5: 30741 - http://dx.doi.org/10.3402/jev.v5.30741 13 (page number not for citation purpose)",OADS,/arxiv_data1/oa_pdf/61/fb/JEV-5-30741.PMC4937767.pdf
"2014;3:25040, doi: http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/61/fb/JEV-5-30741.PMC4937767.pdf
"J Extracell Vesicles.2015;4:27066, doi: http://dx.doi.org/10.3402/jev.v4.27066 22.",OADS,/arxiv_data1/oa_pdf/61/fb/JEV-5-30741.PMC4937767.pdf
"14 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2016, 5: 30741 - http://dx.doi.org/10.3402/jev.v5.30741",OADS,/arxiv_data1/oa_pdf/61/fb/JEV-5-30741.PMC4937767.pdf
"2014;3:24641, doi: http://dx.doi.org/10.3402/jev.v3.24641 61.",Non-OADS,/arxiv_data1/oa_pdf/61/fb/JEV-5-30741.PMC4937767.pdf
"The ether lipid precursor hexadecylglycerol stimulatesPlasmalogen enrichment in nematode exosomes Citation: Journal of Extracellular Vesicles 2016, 5: 30741 - http://dx.doi.org/10.3402/jev.v5.30741 15 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/61/fb/JEV-5-30741.PMC4937767.pdf
"16 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2016, 5: 30741 - http://dx.doi.org/10.3402/jev.v5.30741",OADS,/arxiv_data1/oa_pdf/61/fb/JEV-5-30741.PMC4937767.pdf
"This is an Open Access artic le distributed under the terms  of the Creative Commons Attribution-Non-Commercial License (https://creativecommons.org/licenses/by-nc/3.0)DOI 10.1080/17453674.2016.1181818Background and purpose —  In Sweden, less than 5% of patients  who undergo total hip arthroplasty (THA) have revision.",Non-OADS,/arxiv_data1/oa_pdf/f7/c2/iort-87-31.PMC4937768.pdf
"The Swedish Hip Arthroplasty Regis-ter, Annual Report 2012. http://www.shpr.se/Libraries/Documents/Annual-Report_2012_Eng_WEB.sﬂ  b.ashx; 2013; 2015.",Non-OADS,/arxiv_data1/oa_pdf/f7/c2/iort-87-31.PMC4937768.pdf
"The Swedish Hip Arthroplasty Register, Annual Report 2013. http://www.shpr.se/Libraries/Documents/AnnualReport_2013-04-1_1.sﬂ  b.ashx; 2014;  2015.",Non-OADS,/arxiv_data1/oa_pdf/f7/c2/iort-87-31.PMC4937768.pdf
This is an Open Access artic le distributed under the terms  of the Creative Commons Attribution-Non-Commercial License (https://creativecommons.org/licenses/by-nc/3.0)DOI 10.1080/17453674.2016.1181820Background and purpose —  A criticism of total hip arthroplasty  (THA) survivorship analysis is that revisions are a late and rare outcome.,Non-OADS,/arxiv_data1/oa_pdf/05/f8/iort-87-37.PMC4937769.pdf
Available from  http://share.kaiserpermanente.org/artcile/fast-facts-about-kaiser-perma-nente/.,Non-OADS,/arxiv_data1/oa_pdf/05/f8/iort-87-37.PMC4937769.pdf
Available from http://share.kaiserpermanente.org/artcile/fast-facts-about-kaiser-permanente/.,Non-OADS,/arxiv_data1/oa_pdf/05/f8/iort-87-37.PMC4937769.pdf
"This is an Open Access artic le distributed under the terms  of the Creative Commons Attribution-Non-Commercial License (https://creativecommons.org/licenses/by-nc/3.0)DOI 10.1080/17453674.2016.1181816Abstract —  The International Society of Arthroplasty Registries  (ISAR) Patient-Reported Outcome Measures (PROMs) Work-ing Group have evaluated and recommended best practices in the selection, administration, and interpretation of PROMs for hip and knee arthroplasty registries.",Non-OADS,/arxiv_data1/oa_pdf/97/b4/iort-87-9.PMC4937770.pdf
http://www.euroqol.org.,Non-OADS,/arxiv_data1/oa_pdf/97/b4/iort-87-9.PMC4937770.pdf
"Gothenburg: University of Gothenburg; http://hdl.handle.net/2077/38458, 2015.",Non-OADS,/arxiv_data1/oa_pdf/97/b4/iort-87-9.PMC4937770.pdf
http://www.isarhome.org/statements.,Non-OADS,/arxiv_data1/oa_pdf/97/b4/iort-87-9.PMC4937770.pdf
http://www.marketingcharts.com/traditional/generational-differences-in-consumers-screen-preferences 51119/?utm_campaign=rssfeed&utm_source=mc&utm_medium=textlink.,Non-OADS,/arxiv_data1/oa_pdf/97/b4/iort-87-9.PMC4937770.pdf
http://www.sf-36.org.,Non-OADS,/arxiv_data1/oa_pdf/97/b4/iort-87-9.PMC4937770.pdf
http://www.nihpromis.org/about/overview.,Non-OADS,/arxiv_data1/oa_pdf/97/b4/iort-87-9.PMC4937770.pdf
This is an Open Access artic le distributed under the terms  of the Creative Commons Attribution-Non-Commercial License (https://creativecommons.org/licenses/by-nc/3.0)DOI 10.1080/17453674.2016.1193664The International Society of Arthroplasty Registers (ISAR)  was formed in 2004 at the American Academy of Orthopae-dic Surgeons annual meeting.,Non-OADS,/arxiv_data1/oa_pdf/e4/11/iort-87-1.PMC4937771.pdf
"Available at: http://www.isar- home.org/  Accessed April 14, 2016.",Non-OADS,/arxiv_data1/oa_pdf/e4/11/iort-87-1.PMC4937771.pdf
This is an Open Access artic le distributed under the terms  of the Creative Commons Attribution-Non-Commercial License (https://creativecommons.org/licenses/by-nc/3.0)DOI 10.1080/17453674.2016.1193663Background and purpose —  The effect of total joint arthroplasty  (TJA) on physical activity is not fully understood.,Non-OADS,/arxiv_data1/oa_pdf/71/bf/iort-87-44.PMC4937772.pdf
"This is an Open Access artic le distributed under the terms  of the Creative Commons Attribution-Non-Commercial License (https://creativecommons.org/licenses/by-nc/3.0)DOI 10.1080/17453674.2016.1181815Abstract —  The International Society of Arthroplasty Registries  (ISAR) Steering Committee established the Patient-Reported Outcome Measures (PROMs) Working Group to convene, evalu-ate, and advise on best practices in the selection, administration, and interpretation of PROMs and to support the adoption and use of PROMs for hip and knee arthroplasty in registries world-wide.",Non-OADS,/arxiv_data1/oa_pdf/0d/43/iort-87-3.PMC4937773.pdf
http://www.euroqol.org.,Non-OADS,/arxiv_data1/oa_pdf/0d/43/iort-87-3.PMC4937773.pdf
http://www.sf-36.org.,Non-OADS,/arxiv_data1/oa_pdf/0d/43/iort-87-3.PMC4937773.pdf
This is an Open Access artic le distributed under the terms  of the Creative Commons Attribution-Non-Commercial License (https://creativecommons.org/licenses/by-nc/3.0)DOI 10.1080/17453674.2016.1181817Background and purpose —  There is no consensus about the out- come of simultaneous vs. staged bilateral total knee arthroplasty (TKA).,Non-OADS,/arxiv_data1/oa_pdf/24/ac/iort-87-24.PMC4937774.pdf
(https://www.cihi.ca/en/data-and-standards/standards/classi-ﬁ cation-and-coding/canadian-classiﬁ  cation-of-health) 2015a.,Non-OADS,/arxiv_data1/oa_pdf/24/ac/iort-87-24.PMC4937774.pdf
(https://www.cihi.ca/ en/data-and-standards/data-quality) 2015b.,OADS,/arxiv_data1/oa_pdf/24/ac/iort-87-24.PMC4937774.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/ licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/5a/88/pcv185.PMC4937784.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/ licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/41/d8/pcw047.PMC4937785.pdf
The distri- bution of up-regulated and down-regulated genes to differentfunctional categories according to Cyanobase (http://genome.microbedb.jp/cyanobase) with necessary modiﬁcations is shown in Supplementary Fig.,OADS,/arxiv_data1/oa_pdf/41/d8/pcw047.PMC4937785.pdf
Gene annotation was performed according to Cyanobase (http://genome.microbedb.jp/cyanobase/Synechocystis).,OADS,/arxiv_data1/oa_pdf/41/d8/pcw047.PMC4937785.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/ licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/f5/bb/pcw083.PMC4937786.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/ licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/c2/86/pcw085.PMC4937787.pdf
Large-scale analysis of splice form abun-dances was performed by ﬁltering publicly available Col-0 RNA-seq data de- posited in the sequence read archive (SRA) of NCBI (http://www.ncbi.nlm.nih.,OADS,/arxiv_data1/oa_pdf/c2/86/pcw085.PMC4937787.pdf
KEA3 signals were quantiﬁed by densitometric analysis of Western bands and Ponceau stain usingNIH ImageJ software and associated plug-ins (http://imagej.nih.gov/ij/).,OADS,/arxiv_data1/oa_pdf/c2/86/pcw085.PMC4937787.pdf
Amino acid sequences were aligned using ClustalOmega (http://www.ebi.ac.uk/ Tools/msa/clustalo).,OADS,/arxiv_data1/oa_pdf/c2/86/pcw085.PMC4937787.pdf
"For sequence comparisons, se- quences of the KTN domain of E. coli KefC (EcKefC, P03819), AtKEA3, Arabidopsis KEA2 (AtKEA2, Q65272) and the ﬁrst RCK domain of V. parahaemolyticus TrkA (VcTrkA, A0A072LGS4) were aligned using ClustalOmega and shaded according to amino acid identity (black) and similarity (gray) using the Box-shade server (http://www.ch.embnet.org/software/BOX_form.html).",OADS,/arxiv_data1/oa_pdf/c2/86/pcw085.PMC4937787.pdf
All ADNI data are publicly available at http://adni.loni.usc.edu .,OADS,/arxiv_data1/oa_pdf/3c/14/wnr-27-948.PMC4937804.pdf
"ApoE genotyping was performed separately, on DNA samples obtained from participants ’blood, using an ApoE geno- typing kit, as described in http://www.adni-info.org/scien tists/ADNIStudyProcedures.aspx .",Non-OADS,/arxiv_data1/oa_pdf/3c/14/wnr-27-948.PMC4937804.pdf
In the ADNI public database ( http://www.adni.loni.usc.,Non-OADS,/arxiv_data1/oa_pdf/3c/14/wnr-27-948.PMC4937804.pdf
Private sector contributions are facilitated by the Foundation for the National Institutes of Health ( http://www.fnih.org ).,Non-OADS,/arxiv_data1/oa_pdf/3c/14/wnr-27-948.PMC4937804.pdf
Data used in preparing this article were obtained from the Alzheimer ’s Disease Neuroimaging Initiative (ADNI) database ( http://www.adni.loni.usc.edu ).,OADS,/arxiv_data1/oa_pdf/3c/14/wnr-27-948.PMC4937804.pdf
A complete listing of ADNI investigators may be found at: http://www.adni.loni.usc.edu/wp-content/uploads/ how_to_apply/ADNI_Acknowledgement_List.pdf .,OADS,/arxiv_data1/oa_pdf/3c/14/wnr-27-948.PMC4937804.pdf
Band intensities were analyzed using the ImageJ software (http://imagej.nih.gov/ij/ ).,OADS,/arxiv_data1/oa_pdf/72/09/wnr-27-916.PMC4937805.pdf
See http://apps.who.int/iris/bitstream/10665/44443/1/ 9789241500395_eng.pdf.,Non-OADS,/arxiv_data1/oa_pdf/d7/3d/aids-30-779.PMC4937807.pdf
http://aawconline.org//wp-content/uploads/2013/06/ AAWC-Venous-Ulcer-EvidenceTable-v33-23Jun13.pdf .,Non-OADS,/arxiv_data1/oa_pdf/1b/92/wocn-43-347.PMC4937809.pdf
http://www.sign.ac.uk/pdf/sign120.pdf .,Non-OADS,/arxiv_data1/oa_pdf/1b/92/wocn-43-347.PMC4937809.pdf
"Our results shed light on the role of C3a in regulating collective and  directional cell migration, and in ganglia network organization during enteric nervous system  This is an open access article under the CCBY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).",Non-OADS,/arxiv_data1/oa_pdf/bf/8d/nihms-793068.PMC4937886.pdf
Supporting information Supplementary data associated with this article can be found in the online version at http://dx.doi.org/10.1016/j.ydbio.2016.03.022 .,OADS,/arxiv_data1/oa_pdf/bf/8d/nihms-793068.PMC4937886.pdf
Individual ENCCs from in vitro  cultures on 2D-surfaces and FN-stripes were tracked  manually with the Manual Tracking plugin available from http://rsb.info.nih.gov/ij/plugins/ track/track.html  running under ImageJ/FIJI software.,OADS,/arxiv_data1/oa_pdf/bf/8d/nihms-793068.PMC4937886.pdf
Supplementary material related to this article can be found online at http://dx.doi.org/ 10.1016/j.ydbio.2016.03.022 .,OADS,/arxiv_data1/oa_pdf/bf/8d/nihms-793068.PMC4937886.pdf
Medicine (2016) 95:26(e3378)Received: 24 December 2015 / Received in ﬁnal form: 19 March 2016 / Accepted: 23 March 2016http://dx.doi.org/10.1097/MD.0000000000003378Clinical Case Report Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/c3/11/medi-95-e3378.PMC4937890.pdf
Medicine (2016) 95:26(e3727)Received: 21 January 2016 / Received in ﬁnal form: 23 March 2016 / Accepted: 17 April 2016 http://dx.doi.org/10.1097/MD.0000000000003727Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/d4/b0/medi-95-e3727.PMC4937892.pdf
Medicine (2016) 95:26(e3730)Received: 22 January 2016 / Received in ﬁnal form: 13 April 2016 / Accepted: 17 April 2016http://dx.doi.org/10.1097/MD.0000000000003730Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/4b/a5/medi-95-e3730.PMC4937893.pdf
Medicine (2016) 95:26(e3775)Received: 4 January 2016 / Received in ﬁnal form: 26 April 2016 / Accepted: 1 May 2016http://dx.doi.org/10.1097/MD.0000000000003775Clinical Case Report Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/b3/a5/medi-95-e3775.PMC4937895.pdf
Medicine (2016) 95:26(e3804)Received: 8 October 2015 / Received in ﬁnal form: 17 March 2016 / Accepted: 26 April 2016 http://dx.doi.org/10.1097/MD.0000000000003804Diagnostic Accuracy Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/79/c4/medi-95-e3804.PMC4937896.pdf
http://creativecommons.org/licenses/by-nc-nd/4.0 Medicine (2016) 95:26(e3815)Received: 19 January 2016 / Received in ﬁnal form: 16 April 2016 / Accepted: 26 April 2016http://dx.doi.org/10.1097/MD.0000000000003815Clinical Case Report Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/82/21/medi-95-e3815.PMC4937897.pdf
Medicine (2016) 95:26(e3818)Received: 12 January 2016 / Received in ﬁnal form: 9 May 2016 / Accepted: 9 May 2016 http://dx.doi.org/10.1097/MD.0000000000003818Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/81/80/medi-95-e3818.PMC4937898.pdf
Medicine (2016) 95:26(e3851)Received: 1 March 2016 / Received in ﬁnal form: 22 April 2016 / Accepted: 9 May 2016 http://dx.doi.org/10.1097/MD.0000000000003851Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/a5/03/medi-95-e3851.PMC4937899.pdf
Medicine (2016) 95:26(e3906)Received: 17 November 2015 / Received in ﬁnal form: 14 May 2016 / Accepted: 18 May 2016http://dx.doi.org/10.1097/MD.0000000000003906Clinical Case Report Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/60/cf/medi-95-e3906.PMC4937900.pdf
Medicine (2016) 95:26(e3911)Received: 6 April 2016 / Received in ﬁnal form: 10 May 2016 / Accepted: 13 May 2016http://dx.doi.org/10.1097/MD.0000000000003911Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/39/03/medi-95-e3911.PMC4937901.pdf
Medicine (2016) 95:26(e3929)Received: 1 March 2016 / Received in ﬁnal form: 10 May 2016 / Accepted: 20 May 2016http://dx.doi.org/10.1097/MD.0000000000003929Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/1f/f2/medi-95-e3929.PMC4937903.pdf
Acknowledgments The authors appreciate the CDC for providing the in ﬂuenza incidence data on the National Population and Health Data Sharing Platform.References [1] Word Health Organization (WHO) media centre (http://www.who.int/ mediacentre/factsh eets/fs211/en/).,Non-OADS,/arxiv_data1/oa_pdf/1f/f2/medi-95-e3929.PMC4937903.pdf
Medicine (2016) 95:26(e3935)Received: 4 February 2016 / Received in ﬁnal form: 15 May 2016 / Accepted: 21 May 2016 http://dx.doi.org/10.1097/MD.0000000000003935Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/dc/da/medi-95-e3935.PMC4937904.pdf
"Of these factors, hepatorenal syndrome, WBC, INR, total bilirubin level, MELD score, CLIF –SOFA score, and SIRS were found to be signi ﬁcant (Table 4, Supplemental Digital Content, http://links.lww.com/MD/B36).",Non-OADS,/arxiv_data1/oa_pdf/dc/da/medi-95-e3935.PMC4937904.pdf
Medicine (2016) 95:26(e3959)Received: 17 February 2016 / Received in ﬁnal form: 17 May 2016 / Accepted: 25 May 2016 http://dx.doi.org/10.1097/MD.0000000000003959Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/8e/57/medi-95-e3959.PMC4937906.pdf
Medicine (2016) 95:26(e3961)Received: 9 November 2015 / Received in ﬁnal form: 13 May 2016 / Accepted: 23 May 2016 http://dx.doi.org/10.1097/MD.0000000000003961Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/09/4e/medi-95-e3961.PMC4937907.pdf
"Detailed description of the model develop-ment and estimation of the cost ratios are given in Appendix A (see Appendix A and to that related Table 9, Table 10, and Figures 2 –5, Supplemental Content, http://links.lww.com/MD/ B55, which describe the applied methods in greater detail).",Non-OADS,/arxiv_data1/oa_pdf/09/4e/medi-95-e3961.PMC4937907.pdf
"The patient data for subjects lost to follow-up during the ﬁrst year of the study are given in supplement (see Table 6,Supplemental Content, http://links.lww.com/MD/B55) and show no particular differences from the rest sample.",Non-OADS,/arxiv_data1/oa_pdf/09/4e/medi-95-e3961.PMC4937907.pdf
"Tables presenting the cost data across the 8 health care providers strati ﬁed by cost categories (see Table 7, Supplemental Content, http://links.lww.com/MD/B55) and annualized costs ofHIV care by cost category for both years of CORSAR(see Table 8, Supplemental Content, http://links.lww.com/MD/B55) are given in the supplemental content.",Non-OADS,/arxiv_data1/oa_pdf/09/4e/medi-95-e3961.PMC4937907.pdf
Retrieved from http://aidsinfo.nih.gov/ContentFiles/Adultand.,Non-OADS,/arxiv_data1/oa_pdf/09/4e/medi-95-e3961.PMC4937907.pdf
Retrieved from http://www.gbe-bund.de.,Non-OADS,/arxiv_data1/oa_pdf/09/4e/medi-95-e3961.PMC4937907.pdf
Retrieved from http://www.deutsche-rentenversicherung.de/cae/servlet/contentblob/235592/publicationFile/30904/rehabericht_2012.pdf.,Non-OADS,/arxiv_data1/oa_pdf/09/4e/medi-95-e3961.PMC4937907.pdf
Retrieved from http://www.bmg.bund.de/ ﬁleadmin/ dateien/Downloads/Statistiken/GKV/Geschaeftsergebnisse/120705_Ergebnisse_der_Statistik_KG_5__Vorsorge-_und_Rehabilitationsmassnahmen.pdf.,Non-OADS,/arxiv_data1/oa_pdf/09/4e/medi-95-e3961.PMC4937907.pdf
Retrieved from https://www.kbv.de/41532.html.,Non-OADS,/arxiv_data1/oa_pdf/09/4e/medi-95-e3961.PMC4937907.pdf
Retrieved from https://presse.barmer-gek.de/ barmer/web/Portale/Presseportal/Subportal/Infothek/Studien-und-Reports/Heil-und-Hilfsmittelreport/Einstieg-HeHi-Reports.html.,Non-OADS,/arxiv_data1/oa_pdf/09/4e/medi-95-e3961.PMC4937907.pdf
Retrieved from https://presse.barmer-gek.de/barmer/web/Portale/Presseportal/Subportal/Infothek/Studien-und- Reports/Heil-und-Hilfsmittelreport/Einstieg-HeHi-Reports.html.,Non-OADS,/arxiv_data1/oa_pdf/09/4e/medi-95-e3961.PMC4937907.pdf
Retrieved from https://presse.barmer-gek.de/barmer/web/Portale/Presseportal/Subportal/Infothek/Studien-und-Reports/Heil-und-Hilfsmittelreport/Einstieg-HeHi-Reports.htm.,Non-OADS,/arxiv_data1/oa_pdf/09/4e/medi-95-e3961.PMC4937907.pdf
Medicine (2016) 95:26(e3978)Received: 18 March 2016 / Received in ﬁnal form: 23 May 2016 / Accepted: 27 May 2016http://dx.doi.org/10.1097/MD.0000000000003978Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/36/e2/medi-95-e3978.PMC4937910.pdf
Medicine (2016) 95:26(e3979)Received: 14 January 2016 / Received in ﬁnal form: 22 May 2016 / Accepted: 26 May 2016 http://dx.doi.org/10.1097/MD.0000000000003979Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/1f/3b/medi-95-e3979.PMC4937911.pdf
"However, after the more detailed review of the literature on using systemic anticoagulation in distal digital replantationsurgery, the authors were able to extract the success rate of the artery-only anastomosis cases from each study and compared this with the current study results (See Table, Supplemental Content,http://links.lww.com/MD/B68, which summarizes and compares the systemic anticoagulation regimens and their outcomes after digital replantation surgery).",Non-OADS,/arxiv_data1/oa_pdf/1f/3b/medi-95-e3979.PMC4937911.pdf
Medicine (2016) 95:26(e3982)Received: 16 March 2016 / Received in ﬁnal form: 20 May 2016 / Accepted: 31 May 2016 http://dx.doi.org/10.1097/MD.0000000000003982Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/4e/cc/medi-95-e3982.PMC4937913.pdf
Medicine (2016) 95:26(e3984)Received: 4 February 2016 / Received in ﬁnal form: 11 May 2016 / Accepted: 31 May 2016 http://dx.doi.org/10.1097/MD.0000000000003984Clinical Trial/Experimental Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/5d/94/medi-95-e3984.PMC4937914.pdf
Medicine (2016) 95:26(e3994)Received: 31 March 2016 / Received in ﬁnal form: 26 May 2016 / Accepted: 30 May 2016 http://dx.doi.org/10.1097/MD.0000000000003994Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/90/65/medi-95-e3994.PMC4937918.pdf
"tion and mortality risk among the total and the nonadherent patient group (Table S1, Table S2, http://links.lww.com/MD/B61).",Non-OADS,/arxiv_data1/oa_pdf/90/65/medi-95-e3994.PMC4937918.pdf
Medicine (2016) 95:26(e3996)Received: 20 October 2015 / Received in ﬁnal form: 28 May 2016 / Accepted: 31 May 2016 http://dx.doi.org/10.1097/MD.0000000000003996Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/10/6a/medi-95-e3996.PMC4937920.pdf
Medicine (2016) 95:26(e3999)Received: 22 February 2016 / Received in ﬁnal form: 22 May 2016 / Accepted: 31 May 2016 http://dx.doi.org/10.1097/MD.0000000000003999Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/78/42/medi-95-e3999.PMC4937922.pdf
http://www.nhi.gov.tw/Resource/webdata/21717_1_20120808UniversalHealthCoverage.pdf.,Non-OADS,/arxiv_data1/oa_pdf/78/42/medi-95-e3999.PMC4937922.pdf
Medicine (2016) 95:26(e4000)Received: 17 February 2016 / Received in ﬁnal form: 17 May 2016 / Accepted: 31 May 2016 http://dx.doi.org/10.1097/MD.0000000000004000Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/1d/0d/medi-95-e4000.PMC4937923.pdf
"We conducted additional data analyses and found the mortality was near 2.6-fold greater in the PTb patients than in comparisons (25.2 vs 9.61 per 100) with a slightly lower insurance cancellation (16.0 vs 16.5 per 100) (Supplementtable 1, http://links.lww.com/MD/B72).",Non-OADS,/arxiv_data1/oa_pdf/1d/0d/medi-95-e4000.PMC4937923.pdf
"We further performed a case –control analysis within the PTb patients to compare characteristics between pneumonia cases and those withoutpneumonia developed (Supplement table 2, http://links.lww.com/ MD/B72).",Non-OADS,/arxiv_data1/oa_pdf/1d/0d/medi-95-e4000.PMC4937923.pdf
Medicine (2016) 95:26(e4002)Received: 15 March 2016 / Received in ﬁnal form: 25 May 2016 / Accepted: 1 June 2016 http://dx.doi.org/10.1097/MD.0000000000004002Meta-analysis of Observational Studies in Epidemiology Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/1a/3d/medi-95-e4002.PMC4937924.pdf
"Supplementary Table 1, http://links.lww.com/MD/B85 summarizes the quality domains evalu-ated for each study.",Non-OADS,/arxiv_data1/oa_pdf/1a/3d/medi-95-e4002.PMC4937924.pdf
"1: 62 studies [11–72]including 3034 patients were analyzed (Supplementary Table 2, http://links.lww.com/MD/B85).",Non-OADS,/arxiv_data1/oa_pdf/1a/3d/medi-95-e4002.PMC4937924.pdf
"The response to rescue therapies was detailed inonly 18 cases and included glucocorticoids in 2 (response in both), surgery in 1 (no response), rituximab in 6 (response in 4), and immunosuppressants in 9 (response in 6) (SupplementaryTable 3, http://links.lww.com/MD/B85).",Non-OADS,/arxiv_data1/oa_pdf/1a/3d/medi-95-e4002.PMC4937924.pdf
Medicine (2016) 95:26(e4003)Received: 20 March 2016 / Received in ﬁnal form: 24 May 2016 / Accepted: 31 May 2016http://dx.doi.org/10.1097/MD.0000000000004003Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/73/a9/medi-95-e4003.PMC4937925.pdf
Medicine (2016) 95:26(e4004)Received: 3 December 2015 / Received in ﬁnal form: 25 April 2016 / Accepted: 1 June 2016http://dx.doi.org/10.1097/MD.0000000000004004Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/d7/88/medi-95-e4004.PMC4937926.pdf
Medicine (2016) 95:26(e4006)Received: 1 November 2015 / Received in ﬁnal form: 17 May 2016 / Accepted: 25 May 2016 http://dx.doi.org/10.1097/MD.0000000000004006Clinical Case Report Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/5e/35/medi-95-e4006.PMC4937927.pdf
"GAMES investigators listed in the Appendix, http://links.lww.com/MD/B66.",Non-OADS,/arxiv_data1/oa_pdf/b9/36/medi-95-e4008.PMC4937928.pdf
Medicine (2016) 95:26(e4008)Received: 10 December 2015 / Received in ﬁnal form: 22 May 2016 / Accepted: 31 May 2016 http://dx.doi.org/10.1097/MD.0000000000004008Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/b9/36/medi-95-e4008.PMC4937928.pdf
"S1 of supplementary material, http://links.lww.com/MD/B66).",Non-OADS,/arxiv_data1/oa_pdf/b9/36/medi-95-e4008.PMC4937928.pdf
"The baseline characteristics are summarized inTable S1 of supplementary material, http://links.lww.com/MD/ B66.",OADS,/arxiv_data1/oa_pdf/b9/36/medi-95-e4008.PMC4937928.pdf
"[6,11,12] Patients ’clinical, microbiological, and echocardiographic characteristics are summarized in Table S2 of supplementarymaterial, http://links.lww.com/MD/B66.",Non-OADS,/arxiv_data1/oa_pdf/b9/36/medi-95-e4008.PMC4937928.pdf
Medicine (2016) 95:26(e4013)Received: 19 March 2016 / Received in ﬁnal form: 14 May 2016 / Accepted: 31 May 2016 http://dx.doi.org/10.1097/MD.0000000000004013Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/fa/c2/medi-95-e4013.PMC4937930.pdf
Medicine (2016) 95:26(e4014)Received: 23 April 2016 / Received in ﬁnal form: 25 May 2016 / Accepted: 1 June 2016 http://dx.doi.org/10.1097/MD.0000000000004014Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/bb/65/medi-95-e4014.PMC4937931.pdf
Medicine (2016) 95:26(e4015)Received: 25 December 2015 / Received in ﬁnal form: 21 April 2016 / Accepted: 24 May 2016 http://dx.doi.org/10.1097/MD.0000000000004015Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/0d/c8/medi-95-e4015.PMC4937932.pdf
"http://nhird.nhri.org.tw/en/index.html (cited in April 1, 2016, English version).Table 4 Risk of pyogenic liver abscess strati ﬁed by appendectomy and comorbidities.",Non-OADS,/arxiv_data1/oa_pdf/0d/c8/medi-95-e4015.PMC4937932.pdf
Medicine (2016) 95:26(e4016)Received: 4 February 2016 / Received in ﬁnal form: 14 May 2016 / Accepted: 1 June 2016 http://dx.doi.org/10.1097/MD.0000000000004016Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/fd/51/medi-95-e4016.PMC4937933.pdf
Medicine (2016) 95:26(e4017)Received: 6 March 2016 / Received in ﬁnal form: 28 May 2016 / Accepted: 1 June 2016 http://dx.doi.org/10.1097/MD.0000000000004017Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/56/b5/medi-95-e4017.PMC4937934.pdf
Medicine (2016) 95:26(e4022)Received: 1 August 2015 / Received in ﬁnal form: 15 September 2015 / Accepted: 22 May 2016http://dx.doi.org/10.1097/MD.0000000000004022Clinical Case Report Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/4c/f9/medi-95-e4022.PMC4937936.pdf
"One third each of therenal biopsy specimen was processed for histochemical stains (HE, periodic acid-Schiff [PAS], periodic Schiff-methenamine, and Masson trichrome) with light microscopy; immuno ﬂuorescence stains for the monoclonal IgG, IgA, IgM, C1q, and C3c; and ultrastructural examination with transmission electron microsco- py (Supplementary methods, http://links.lww.com/MD/B76).",Non-OADS,/arxiv_data1/oa_pdf/4c/f9/medi-95-e4022.PMC4937936.pdf
"Number First author Year DiagnosisMaternal age (years)Renal biopsyMGN duration before pregnancyDrug treatment 1 Bates[1]1996 Hepatitis B-associated membranous glomerulonephritis19 Yes 8 years Unclear 2 Katzir[2]2004 Primary membranous glomerulonephritis23 Yes 8 years Yes 3 Sebestyen[3]2008 Primary membranous glomerulonephritis33 Yes 5 years Yes 4 Szucs[4]2010 Primary membranous glomerulonephritis27 Yes 10 years Yes 5 Aoshima[5]2013 Primary membranous glomerulonephritis37 Yes NS →pregnancy →MGN Yes DrugsObstetric historyGestational duration (weeks)Mode of deliveryCondition of neonate BreastfeedMaternal remission/outcomes Unclear G1P1 40 Induction Unclear Unclear Partial Methylprednisolone, prednisone G1P1 34 Cesarean Healthy Unclear Partial Methylprednisolone, azathioprine, antihypertensive, diuretic, anticoagulant therapy, and supplementation with freshfrozen plasma and albuminreceivedG3P2 33 Cesarean Healthy (required pharynx oxygen for only 2 days)Unclear Complete remission at 3 months postpartum;relapse during 4-year follow-up; eventuallyhemodialysis 3 times a week Amlodipine G1P1 39 Vaginal Healthy Exclusive breastfeedingStable renal function Prednisolone, methylprednisolone, prednisoloneG2P1 21 Elective Abortion_ _ Partial References in the table were listed in the supplementary references, http://links.lww.com/MD/B76.",Non-OADS,/arxiv_data1/oa_pdf/4c/f9/medi-95-e4022.PMC4937936.pdf
"NumberFirst author Year DiagnosisRenal biopsyDrug treatment Pregnancies Condition of fetus Maternal remission/outcomes 1 Noel[6]1979 Primary membranous glomerulonephritisYes No 9 (7 women) One abortion, one anencephalic child, 7 successful deliveryOne with increased level of proteinuria, the other 6 with no modiﬁ cation of clinical status 2 Surian[7]1984 Primary and secondary membranousnephropathyYes Unclear 8 Unclear 1 With reversible deterioration of renal function, no complicationsreported in the remaining 7 ladies 3 Barcelo [8]1986 Membranous glomerulonephritisYes Unclear 9 (7 women) 7 Full-term, 2 pre-term, no still births and abortion3 With increased blood pressure, 2 with increased proteinuria, nodeclined renal function was notedin the others 4 Packham [9]1987 Membranous glomerulonephritisYes Unclear 33 (24 women) 24% (8) Fetal loss, 43% (14) prematurity rate and 33% (11) livebirth rate with full-term deliveriesDuring 6 months postpartum follow up: 9% (3) with hypertension,18% (6) with increasedproteinuria, 12% (4) with stable proteinuria, 36% (12) remission of proteinuria 5 Malik [10]2002 Primary membranous glomerulonephritisYes Yes 30 6.6% (2) Fetal loss (include 3.3% spontaneous abortion, 3.3% prenatal mortality); 90% live birth rate (include 10% low-birth-weightbabies, 10% cesarean section,6.6% preterm delivery)1 Develop renal insuf ﬁciency after 6 years follow up References in the table were listed in the supplementary references, http://links.lww.com/MD/B76.Huang et al.",Non-OADS,/arxiv_data1/oa_pdf/4c/f9/medi-95-e4022.PMC4937936.pdf
Medicine (2016) 95:26(e4023)Received: 4 September 2015 / Received in ﬁnal form: 27 April 2016 / Accepted: 22 May 2016http://dx.doi.org/10.1097/MD.0000000000004023Clinical Case Report Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/e5/20/medi-95-e4023.PMC4937937.pdf
Medicine (2016) 95:26(e4024)Received: 9 October 2015 / Received in ﬁnal form: 10 May 2016 / Accepted: 25 May 2016http://dx.doi.org/10.1097/MD.0000000000004024Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/60/0a/medi-95-e4024.PMC4937938.pdf
"Baseline comorbidities (ICD-9- CM codes are provided in Supplementary Table S1, http://links.lww.com/MD/B75) [15,22 –25]were hypertension, DM, hyperlipid- emia, CKD, chronic liver disease, chronic pulmonary disease,stroke, hyperthyroidism, and hyperparathyroidism before theindex date.",Non-OADS,/arxiv_data1/oa_pdf/60/0a/medi-95-e4024.PMC4937938.pdf
Medicine (2016) 95:26(e4033)Received: 20 October 2015 / Received in ﬁnal form: 9 March 2016 / Accepted: 16 May 2016 http://dx.doi.org/10.1097/MD.0000000000004033Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/0a/2c/medi-95-e4033.PMC4937941.pdf
Medicine (2016) 95:26(e4040)Received: 9 December 2015 / Received in ﬁnal form: 13 May 2016 / Accepted: 16 May 2016 http://dx.doi.org/10.1097/MD.0000000000004040Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/7e/b3/medi-95-e4040.PMC4937946.pdf
"In general, carriers and noncarriers were comparable regarding sociodemographic characteristics, work history, and personal hygiene practices (Supplementary ﬁle, Table S2, http://links.lww.com/MD/B73).",Non-OADS,/arxiv_data1/oa_pdf/7e/b3/medi-95-e4040.PMC4937946.pdf
"S2, http://links.lww.com/MD/B73), we proceeded to Poisson regression modeling with speci ﬁed random effects to account for within-person correlation ofrepeated measures.",Non-OADS,/arxiv_data1/oa_pdf/7e/b3/medi-95-e4040.PMC4937946.pdf
[31] 1 Step (EasyStep) Ovulation (LH) Rapid Test; 2015. http://www.san- crystal.com/san2012 (EN)/hospital_use/1 Step TEST_TestQuickly_03.html.,Non-OADS,/arxiv_data1/oa_pdf/7e/b3/medi-95-e4040.PMC4937946.pdf
https://usdiagnostics.roche.com/products/ 03000079190/PARAM281/overlay.html.,Non-OADS,/arxiv_data1/oa_pdf/7e/b3/medi-95-e4040.PMC4937946.pdf
https://usdiagnostics.roche.com/products/ 12145383160/PARAM284/overlay.html.,Non-OADS,/arxiv_data1/oa_pdf/7e/b3/medi-95-e4040.PMC4937946.pdf
Medicine (2016) 95:26(e4041)Received: 28 December 2015 / Received in ﬁnal form: 27 April 2016 / Accepted: 27 May 2016http://dx.doi.org/10.1097/MD.0000000000004041Clinical Case Report Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/b4/77/medi-95-e4041.PMC4937947.pdf
Medicine (2016) 95:26(e4042)Received: 15 January 2016 / Received in ﬁnal form: 12 May 2016 / Accepted: 17 May 2016 http://dx.doi.org/10.1097/MD.0000000000004042Clinical Case Report Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/2f/b7/medi-95-e4042.PMC4937948.pdf
Available:http://www.ginasthma.org.,Non-OADS,/arxiv_data1/oa_pdf/2f/b7/medi-95-e4042.PMC4937948.pdf
Medicine (2016) 95:26(e4044)Received: 21 January 2016 / Received in ﬁnal form: 12 May 2016 / Accepted: 16 May 2016http://dx.doi.org/10.1097/MD.0000000000004044Clinical Case Report Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/3f/f4/medi-95-e4044.PMC4937949.pdf
Medicine (2016) 95:26(e4045)Received: 17 January 2016 / Received in ﬁnal form: 13 May 2016 / Accepted: 17 May 2016 http://dx.doi.org/10.1097/MD.0000000000004045Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/c4/36/medi-95-e4045.PMC4937950.pdf
Medicine (2016) 95:26(e4049)Received: 8 January 2016 / Received in ﬁnal form: 4 May 2016 / Accepted: 2 June 2016 http://dx.doi.org/10.1097/MD.0000000000004049Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/b7/f2/medi-95-e4049.PMC4937952.pdf
"This study is registered with ClinicalTrials.gov, number NCT01239914, available online at http://clinicaltrials.gov.",Non-OADS,/arxiv_data1/oa_pdf/b7/f2/medi-95-e4049.PMC4937952.pdf
Medicine (2016) 95:26(e4050)Received: 14 February 2016 / Received in ﬁnal form: 4 May 2016 / Accepted: 2 June 2016http://dx.doi.org/10.1097/MD.0000000000004050Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/34/4e/medi-95-e4050.PMC4937953.pdf
Medicine (2016) 95:26(e4053)Received: 23 December 2015 / Received in ﬁnal form: 12 May 2016 / Accepted: 2 June 2016 http://dx.doi.org/10.1097/MD.0000000000004053Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/ad/9c/medi-95-e4053.PMC4937954.pdf
"The top 10 secondary diagnoses of admitted nonurgent patients are listed in appendix A, http://links.lww.com/MD/B77.The most frequently seen secondary diagnosis was endocrine,nutritional and metabolic diseases (12.22%) followed by disease of genitourinary system (10.19%), disease of circulatory system (10.10%), disease of digestive system (9.96%), neoplasms(6.04%), disease of musculoskeletal system and connective tissue (4.33%), disease of respiratory system (4.10%), mental disorders (1.26%), disease of nervous system (0.99%), and disease of bloodand blood-forming organs (0.99%).",Non-OADS,/arxiv_data1/oa_pdf/ad/9c/medi-95-e4053.PMC4937954.pdf
Medicine (2016) 95:26(e4060)Received: 10 March 2016 / Received in ﬁnal form: 28 May 2016 / Accepted: 2 June 2016 http://dx.doi.org/10.1097/MD.0000000000004060Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/8e/ec/medi-95-e4060.PMC4937958.pdf
Medicine (2016) 95:26(e4062)Received: 2 February 2016 / Received in ﬁnal form: 22 April 2016 / Accepted: 22 May 2016 http://dx.doi.org/10.1097/MD.0000000000004062Clinical Case Report Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/91/54/medi-95-e4062.PMC4937959.pdf
Medicine (2016) 95:26(e4064)Received: 25 January 2016 / Received in ﬁnal form: 29 April 2016 / Accepted: 2 June 2016 http://dx.doi.org/10.1097/MD.0000000000004064Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/8f/92/medi-95-e4064.PMC4937961.pdf
[Online] Available at: http://www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/price-list.,Non-OADS,/arxiv_data1/oa_pdf/8f/92/medi-95-e4064.PMC4937961.pdf
Medicine (2016) 95:26(e4070)Received: 11 February 2016 / Received in ﬁnal form: 30 May 2016 / Accepted: 3 June 2016 http://dx.doi.org/10.1097/MD.0000000000004070Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/9e/e7/medi-95-e4070.PMC4937962.pdf
"Available at: http://tcr.cph.ntu.edu.tw/ (accessed August 23, 2015).",Non-OADS,/arxiv_data1/oa_pdf/9e/e7/medi-95-e4070.PMC4937962.pdf
"National Health Insurance Administration, Ministry of Health, Execu-tive Yuan; December 2014. http://www.nhi.gov.tw.",Non-OADS,/arxiv_data1/oa_pdf/9e/e7/medi-95-e4070.PMC4937962.pdf
"2016.Available at: http://seer.cancer.gov/statistics/summaries.html (accessedFebruary 2, 2016).",Non-OADS,/arxiv_data1/oa_pdf/9e/e7/medi-95-e4070.PMC4937962.pdf
Medicine (2016) 95:26(e4072)Received: 27 January 2016 / Received in ﬁnal form: 1 June 2016 / Accepted: 6 June 2016http://dx.doi.org/10.1097/MD.0000000000004072Systematic Review And Meta-Analysis Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/c2/82/medi-95-e4072.PMC4937963.pdf
Medicine (2016) 95:26(e4075)Received: 13 February 2016 / Received in ﬁnal form: 25 April 2016 / Accepted: 6 June 2016http://dx.doi.org/10.1097/MD.0000000000004075Systematic Review and Meta-Analysis Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/c4/fc/medi-95-e4075.PMC4937964.pdf
"Two groups of keywords were combined by the Boolean operator “and” (Supplemental Table 1, http://links.lww.com/MD/B79).",OADS,/arxiv_data1/oa_pdf/c4/fc/medi-95-e4075.PMC4937964.pdf
"Statistical analysis All statistical analyses were performed using Review Manager (RevMan) version 5.3 software (The Nordic Cochrane Center,Rigshospitalet, Denmark; http://ims.cochrane.org/revman).",OADS,/arxiv_data1/oa_pdf/c4/fc/medi-95-e4075.PMC4937964.pdf
Medicine (2016) 95:26(e4078)Received: 9 March 2016 / Received in ﬁnal form: 7 June 2016 / Accepted: 7 June 2016 http://dx.doi.org/10.1097/MD.0000000000004078Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/31/af/medi-95-e4078.PMC4937965.pdf
Medicine (2016) 95:26(e4088)Received: 16 February 2016 / Received in ﬁnal form: 7 June 2016 / Accepted: 7 June 2016http://dx.doi.org/DOI: 10.1097/MD.0000000000004088Systematic Review and Meta-Analysis Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/20/27/medi-95-e4088.PMC4937966.pdf
http://www.pubmedcentral.nih.gov/articlerenderhttp:// www.pubmedcentral.nih.gov/articlerender.fcgi?artid =3744257&tool = pmcentrez&rendertype =abstract.,OADS,/arxiv_data1/oa_pdf/20/27/medi-95-e4088.PMC4937966.pdf
http://dx.doi.org/10.1016/j.gpb.2012.07.003⇑Corresponding author.,OADS,/arxiv_data1/oa_pdf/c3/a2/main.PMC4937987.pdf
"To check for the actual expression of the identiﬁed genes, the amphi-oxus EST database ( http://www.amphioxus.icob.sini- ca.edu.tw/ )[29] was mined, by blasting each of the identiﬁed genes.",OADS,/arxiv_data1/oa_pdf/c3/a2/main.PMC4937987.pdf
"To further check the sequence similarity of putative CHSs from B. ﬂoridae with orthologs from other mem- bers of early-branching Metazoans, BLAST analyses ofBﬂ1 and Bﬂ2 were carried out using the biocomputation- al platform Compagen ( http://www.compagen.org )[36].",OADS,/arxiv_data1/oa_pdf/c3/a2/main.PMC4937987.pdf
"Thefamily is indeed very broad: there are more than 26,000entries in the CaZy database ( http://www.cazy.org/ )[57], distributed among Archaea, viruses and eukaryotes.",OADS,/arxiv_data1/oa_pdf/c3/a2/main.PMC4937987.pdf
"Putative CHS sequences could be retrieved in the Meta- zome portal ( http://www.metazome.net ), also for the uro- chordates Ciona intestinalis (accession number XP_002119921, which interestingly contains an OTU-likecysteine protease domain) and C. savigny (ENSC- SAVP00000016559).",Non-OADS,/arxiv_data1/oa_pdf/c3/a2/main.PMC4937987.pdf
"Materials and methodsData mining and sequence analysisThe identiﬁcation of putative full-length CHSs from B. ﬂoridae was carried out by performing BLASTp searches against the B. ﬂoridae ﬁltered gene models database (http://www.genome.jgi-psf.org/pages/blast.jsf?db=Braﬂ1 ) using as query a representative CHS from yeast (CHS2,GenBank Accession No.",OADS,/arxiv_data1/oa_pdf/c3/a2/main.PMC4937987.pdf
Sequence alignmentwas performed with ClustalW2 ( http://www.ebi.ac.uk/ Tools/msa/clustalw2/ )[65].,OADS,/arxiv_data1/oa_pdf/c3/a2/main.PMC4937987.pdf
The identiﬁcation of novel domains in the CHSs was car- ried out with Motif Scan ( http://www.myhits.isb-sib.ch/cgi- bin/motif_scan ).,OADS,/arxiv_data1/oa_pdf/c3/a2/main.PMC4937987.pdf
Isoelectric point and MW determinations were carried out at http://www.web.expasy.org/com- pute_pi/ .,OADS,/arxiv_data1/oa_pdf/c3/a2/main.PMC4937987.pdf
Phosphorylation sites prediction was carried out using the NetPhos 2.0 server ( http://www.cbs.dtu.dk/ser- vices/NetPhos/ )[66].,OADS,/arxiv_data1/oa_pdf/c3/a2/main.PMC4937987.pdf
"Phylogenetic analysis, prediction of transmembrane domains and 3D structure Transmembrane domain prediction was performed using the online program TMHMM ( http://www.cbs.dtu.dk/ser- vices/TMHMM-2.0/ ) and the neighbor-joining phyloge- netic tree was built by aligning the conserved amino acidregions of 33 sequences (Figure S1) using ClustalW [65] and BIONJ [67].",OADS,/arxiv_data1/oa_pdf/c3/a2/main.PMC4937987.pdf
The predicted 3D structures were obtained using the automatic fold recognition server Phyre2 ( http://www.sbg.bio.ic.ac.uk/phyre 2/html/page.cgi?id=index ) [68].,OADS,/arxiv_data1/oa_pdf/c3/a2/main.PMC4937987.pdf
Prediction of ligand binding residues was performed using the 3DLigandSite server ( http://www.sbg.bio.ic.,OADS,/arxiv_data1/oa_pdf/c3/a2/main.PMC4937987.pdf
"Supplementary material Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/ j.gpb.2012.07.003 .",OADS,/arxiv_data1/oa_pdf/c3/a2/main.PMC4937987.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/ licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/b2/2e/rjw123.PMC4937994.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/ licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/84/3b/rjw122.PMC4937995.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/ licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/3b/0e/rjw119.PMC4938004.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/52/de/ccid-9-151.PMC4938118.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/52/de/ccid-9-151.PMC4938118.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Clinical, Cosmetic and Investigational Dermatology 2016:9 151–158Clinical, Cosmetic and Investigational Dermatology Dovepress submit your manuscript | www.dovepress.com Dovepress 151 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CCID.S109946 A prospective study of atopic dermatitis managed  without topical corticosteroids for a 6-month  period Mototsugu Fukaya1 Kenji Sato2 Takahiro Yamada2 Mitsuko Sato3 Shigeki Fujisawa4 Satoko Minaguchi5 Hajime Kimata6 Haruhiko Dozono7 1Tsurumai Kouen Clinic, Nagoya,   2Department of Dermatology, Hannan  Chuo Hospital, 3Sato Pediatric Clinic,   Osaka, 4Fujisawa Dermatology Clinic,   T okyo, 5Ageofutatsunomiya Clinic,   Saitama, 6Kimata Hajime Clinic, Osaka,   7Dozono Medical House, Kagoshima,   JapanAbstract:  Topical corticosteroids (TCS) are regarded as the mainstay treatment for atopic  dermatitis (AD).",Non-OADS,/arxiv_data1/oa_pdf/52/de/ccid-9-151.PMC4938118.pdf
"We believe that our study on the natural course of AD is highly relevant at a time when  Correspondence: Mototsugu Fukaya Tsurumai Kouen Clinic, 5-20-6 Chiyoda Nakaku, Nagoya 460-0012, Japan Tel +81 52 264 0212Email moto@earth.ocn.ne.jpJournal name: Clinical, Cosmetic and Investigational Dermatology Article Designation: ORIGINAL RESEARCHY ear: 2016V olume: 9Running head verso: Fukaya et alRunning head recto: Atopic dermatitis managed without topical corticosteroidsDOI: http://dx.doi.org/10.2147/CCID.S109946 Video abstract Point your SmartPhone at the code above.",Non-OADS,/arxiv_data1/oa_pdf/52/de/ccid-9-151.PMC4938118.pdf
Or use: http://youtu.be/TmDK3dfxNu4,Non-OADS,/arxiv_data1/oa_pdf/52/de/ccid-9-151.PMC4938118.pdf
"Clinical, Cosmetic and Investigational Dermatology 2016:9submit your manuscript | www.dovepress.com Dovepress Dovepress Clinical, Cosmetic and Investigational Dermatology Publish your work in this journal Submit your manuscript here:  https://www.dovepress.com/clinical-cosmetic-and-investigational-dermatology-journal Clinical, Cosmetic and Investigational Dermatology is an interna- tional, peer-reviewed, open access, online journal that focuses on   the latest clinical and experimental research in all aspects of skin   disease and cosmetic interventions.",Non-OADS,/arxiv_data1/oa_pdf/52/de/ccid-9-151.PMC4938118.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authorsDovepress 158 Fukaya et al,Non-OADS,/arxiv_data1/oa_pdf/52/de/ccid-9-151.PMC4938118.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/dd/d3/ott-9-3951.PMC4938131.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2016:9 3951–3962OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  3951Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S10048 1 Pri-let-7a-1 rs10739971 polymorphism is associated  with gastric cancer prognosis and might affect  mature let-7a expression Ying li Qian Xu Jingwei liu caiyun he Quan Yuan chengzhong Xing Yuan Yuan T umor etiology and screening  Department of cancer institute  and general surgery, the First  affiliated hospital of china Medical  University, and Key laboratory of  cancer etiology and Prevention  (china Medical University), liaoning  Provincial education Department,   shenyang, People’s republic of chinaAbstract:  The relationship between the pri-let-7a-1 rs10739971 polymorphism and gastric  cancer (GC) risk has been reported.",Non-OADS,/arxiv_data1/oa_pdf/dd/d3/ott-9-3951.PMC4938131.pdf
"Recent research has linked polymorphisms of some let-7  family members to cancer, for example, the interaction of the pri-let-7a-1 rs10739971  polymorphism and the ERCC6  rs1917799 polymorphism is significantly correlated correspondence: Yuan Yuan Tumor etiology and screening  Department of cancer institute and  General Surgery, the First Affiliated  hospital of china Medical University,  north nanjing street 155#, heping  District, shenyang 110001, People’s  republic of china Tel +86 24 8328 2153 Fax +86 24 8328 2383 email yyuan@mail.cmu.edu.c n Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2016 Volume: 9 Running head verso: Li et al Running head recto: Pri-let-7a-1 polymorphism and GC prognosis DOI: http://dx.doi.org/10.2147/OTT.S100481",Non-OADS,/arxiv_data1/oa_pdf/dd/d3/ott-9-3951.PMC4938131.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/dd/d3/ott-9-3951.PMC4938131.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/dd/d3/ott-9-3951.PMC4938131.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/b2/02/imcrj-9-173.PMC4938132.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/b2/02/imcrj-9-173.PMC4938132.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).International Medical Case Reports Journal 2016:9 173–177International Medical Case Reports Journal Dovepress submit your manuscript | www.dovepress.com Dovepress 173 CASE REPORT open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/IMCRJ.S103566Mirizzi syndrome with an unusual aberrant  hepatic duct fistula: a case report Meng Wang1 Yufei Xing2 Quangen Gao1 Zhiqiang Lv1 Jianmao Yuan1 1Department of General Surgery, The  First People’s Hospital of Wujiang,   Affiliated Wujiang Hospital of Nantong University,  2Digestive Clinical Center,   The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu,  People’s Republic of ChinaAbstract:  Mirizzi syndrome (MS) is a rare complication of chronic cholelithiasis, which is  always caused by a calculus in the cystic duct or neck of the gallbladder, resulting in mechanical  compression of common bile duct and the gallbladder.",Non-OADS,/arxiv_data1/oa_pdf/b2/02/imcrj-9-173.PMC4938132.pdf
"Correspondence: Meng Wang Department of General Surgery, The First People’s Hospital of Wujiang, Affiliated Wujiang Hospital of Nantong University, 169 Gongyuan Road, Suzhou 215200, Jiangsu, People’s Republic of ChinaTel/fax +86 512 6302 4562Email wangmeng2004-2008@163.comJournal name: International Medical Case Reports Journal Article Designation: CASE REPORTY ear: 2016V olume: 9Running head verso: Wang et alRunning head recto: Mirizzi syndrome with an unusual aberrant hepatic duct fistulaDOI: http://dx.doi.org/10.2147/IMCRJ.S103566",Non-OADS,/arxiv_data1/oa_pdf/b2/02/imcrj-9-173.PMC4938132.pdf
"International Medical Case Reports Journal 2016:9submit your manuscript | www.dovepress.com Dovepress Dovepress International Medical Case Reports Journal Publish your work in this journal Submit your manuscript here:  https://www.dovepress.com/international-medical-case-reports-journal-journalThe International Medical Case Reports Journal is an international,  peer-reviewed open-access journal publishing original case reports from all medical specialties.",Non-OADS,/arxiv_data1/oa_pdf/b2/02/imcrj-9-173.PMC4938132.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Dovepress 177 Mirizzi syndrome with an unusual aberrant hepatic duct fistula Disclosure The authors report no conflicts of interest in this work.,Non-OADS,/arxiv_data1/oa_pdf/b2/02/imcrj-9-173.PMC4938132.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/47/bc/ndt-12-1623.PMC4938133.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Neuropsychiatric Disease and Treatment 2016:12 1623–1629Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  1623OrigiNal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/NDT .S9356 25-HTR1A  and 5-HTR2A  genetic polymorphisms  and ssri antidepressant response in depressive  chinese patients Zai-Quan Dong1,* Xi-rong li2,* lin he3,4 guang he3,4 Tao Yu3,4 Xue-li sun1 1Psychological center, West china  hospital, sichuan University, chengdu,   sichuan, 2Mental health center,   First affiliated hospital, chongqing  Medical University, chongqing, 3Bio-X  institutes, Key laboratory for the  genetics of Developmental and  Neuropsychiatric Disorders (Ministry  of education), shanghai Jiao T ong  University, 4shanghai Key laboratory  of Psychotic Disorders, shanghai  Mental health center, shanghai Jiao  T ong University school of Medicine,   shanghai, People’s republic of china *These authors contributed equally  to this workObjective:  Genetic variabilities within the serotoninergic system may predict response or  remission to antidepressant drugs.",Non-OADS,/arxiv_data1/oa_pdf/47/bc/ndt-12-1623.PMC4938133.pdf
"Even with optimal quality- controlled conditions, only about two-thirds of patients show symptomatic improve - ment in the first round of treatment, while only 50% show full remission (no or only  minimal residual symptoms) within 12 weeks; also, for two-thirds of patients, up to  four treatment trials are needed to achieve full remission.1 Response and remission  to medication is highly variable, and there are several potential explanations for the  variability of drug-response rates, including symptom heterogeneity, environmental,  social, and genetic factors.correspondence: Tao Yu Bio-X institutes, Key laboratory for  the genetics of Developmental and  Neuropsychiatric Disorders (Ministry of  education), shanghai Jiao Tong University,  1954 huashan road, shanghai, People’s  republic of china Tel +86 21 6293 2151 Fax +86 21 6293 2151 email yutao03d@foxmail.co m  Xue-li sun Psychological center, West china  hospital, sichuan University, No 28,  south Dianxin street, chengdu, sichuan  610041, People’s republic of china Tel +86 28 8542 2740 Fax +86 28 8542 2740 email sunxueli58@126.co m Journal name: Neuropsychiatric Disease and Treatment Article Designation: Original Research Y ear: 2016 Volume: 12 Running head verso: Dong et al Running head recto: Pharmacogenetics in major depressive disorder DOI: http://dx.doi.org/10.2147/NDT.S93562",Non-OADS,/arxiv_data1/oa_pdf/47/bc/ndt-12-1623.PMC4938133.pdf
"Considering  potential function and frequency, five SNPs in 5-HTR  genes  were selected from Single Nucleotide Polymorphism Data - base ( http://www.ncbi.nl m.nih.go v) or previous literature.",OADS,/arxiv_data1/oa_pdf/47/bc/ndt-12-1623.PMC4938133.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/47/bc/ndt-12-1623.PMC4938133.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/47/bc/ndt-12-1623.PMC4938133.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/f1/93/imcrj-9-169.PMC4938134.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/f1/93/imcrj-9-169.PMC4938134.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).International Medical Case Reports Journal 2016:9 169–172International Medical Case Reports Journal Dovepress submit your manuscript | www.dovepress.com Dovepress 169 CASE REPORT open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/IMCRJ.S106627Amaurosis fugax associated with congenital  vascular defect John W Giltner1 Edward R Thomas2 William K Rundell3 1Boonshoft School of Medicine,   Wright State University, Dayton, OH,   USA; 2Ohio Eyecare Institute, Premier  Health Specialists, Dayton, OH, USA;   3Department of Surgery, Miami Valley  Hospital, Dayton, OH, USAAbstract:  A 68-year-old female with no significant past medical history presented with loss  of vision in the lower half of her left eye that lasted <5 minutes.",Non-OADS,/arxiv_data1/oa_pdf/f1/93/imcrj-9-169.PMC4938134.pdf
"She had never used  Correspondence: John Giltner Boonshoft School of Medicine, Wright State University, 3640 Colonel Glenn Hwy Dayton, OH 45435, USATel +1 330 310 0742Email GiltnerJ@gmail.comJournal name: International Medical Case Reports Journal Article Designation: CASE REPORTY ear: 2016V olume: 9Running head verso: Giltner et alRunning head recto: Amaurosis fugax associated with congenital vascular defectDOI: http://dx.doi.org/10.2147/IMCRJ.S106627",Non-OADS,/arxiv_data1/oa_pdf/f1/93/imcrj-9-169.PMC4938134.pdf
"International Medical Case Reports Journal 2016:9submit your manuscript | www.dovepress.com Dovepress Dovepress International Medical Case Reports Journal Publish your work in this journal Submit your manuscript here:  https://www.dovepress.com/international-medical-case-reports-journal-journalThe International Medical Case Reports Journal is an international,  peer-reviewed open-access journal publishing original case reports from all medical specialties.",Non-OADS,/arxiv_data1/oa_pdf/f1/93/imcrj-9-169.PMC4938134.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Dovepress 172 Giltner et al  3.,Non-OADS,/arxiv_data1/oa_pdf/f1/93/imcrj-9-169.PMC4938134.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/06/0e/ott-9-4053.PMC4938135.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2016:9 4053–4059OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  4053Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S9998 0 Quality of life and cosmetic result of single-port  access endoscopic thyroidectomy via axillary  approach in patients with papillary thyroid  carcinoma Jian-kang huang1 ling Ma2 Wen-hua song1 Bang-yu lu3 Yu-bin huang3 hui-ming Dong1 1Department of surgical Oncology,   2Department of gynecologic T umor,   The First affiliated hospital of Bengbu  Medical college, Bengbu, anhui,   3Department of Minimally invasive  surgery, The First affiliated hospital  of guangxi Medical University,   nanning, guangxi, People’s republic  of chinaBackground:  Endoscopic thyroidectomy for minimally invasive thyroid surgery has been  widely applied in the past decade.",Non-OADS,/arxiv_data1/oa_pdf/06/0e/ott-9-4053.PMC4938135.pdf
"The newly developed endoscopic thyroidectomy has been demonstrated correspondence: ling Ma Department of gynecologic Tumor,  The First Affiliated Hospital of Bengbu  Medical college, 287 changhuai road,  Bengbu 233004, anhui, People’s republic  of china Tel/fax +86 552 308 6319 email lingmabengbu@sina.co m Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2016 Volume: 9 Running head verso: Huang et al Running head recto: Treatment of patients with papillary thyroid carcinoma DOI: http://dx.doi.org/10.2147/OTT.S99980",Non-OADS,/arxiv_data1/oa_pdf/06/0e/ott-9-4053.PMC4938135.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/06/0e/ott-9-4053.PMC4938135.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/06/0e/ott-9-4053.PMC4938135.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/2b/7e/ott-9-4043.PMC4938136.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2016:9 4043–4052OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  4043Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S10814 4 analgesic effectiveness and tolerability of  oral oxycodone/naloxone and pregabalin in  patients with lung cancer and neuropathic pain:  an observational analysis stefano De santis1 cristina Borghesi1 serena ricciardi2 Daniele giovannoni1 alberto Fulvi2 Maria rita Migliorino2 claudio Marcassa3 1Palliative care and cancer Pain  service, Oncological Pulmonary Unit,   2Oncological Pulmonary Unit, san  camillo-Forlanini hospitals, rome,   3cardiologia Fondazione Maugeri  irccs, novara, italyIntroduction:  Cancer-related pain has a severe negative impact on quality of life.",Non-OADS,/arxiv_data1/oa_pdf/2b/7e/ott-9-4043.PMC4938136.pdf
"Although alleviated by opioids,  chronic neuropathic pain seems less responsive than nociceptive pain to opioids, and correspondence: stefano De santis Palliative care and cancer Pain service,  Oncological Pulmonary Unit,  san camillo-Forlanini hospitals,  circonvallazione gianicolense  87, 00151, rome, italy Tel +39 06 5870 4739 Fax +39 06 5870 4738 email desantis.s@hotmail.i t Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2016 Volume: 9 Running head verso: De Santis et al Running head recto: Oral OXN-PR and pregabalin for neuropathic lung cancer pain DOI: http://dx.doi.org/10.2147/OTT.S108144",Non-OADS,/arxiv_data1/oa_pdf/2b/7e/ott-9-4043.PMC4938136.pdf
"Available from: http://qol.thoracic.org/sections/ instruments/pt/pages/sds.htm l. Accessed October 14, 2015.",Non-OADS,/arxiv_data1/oa_pdf/2b/7e/ott-9-4043.PMC4938136.pdf
"Available  from: http://qol.thoracic.org/sections/instruments/pt/pages/sds.htm l.  Accessed October 14, 2015.",Non-OADS,/arxiv_data1/oa_pdf/2b/7e/ott-9-4043.PMC4938136.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/2b/7e/ott-9-4043.PMC4938136.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/2b/7e/ott-9-4043.PMC4938136.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/06/1d/jbm-7-129.PMC4938137.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/06/1d/jbm-7-129.PMC4938137.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Journal of Blood Medicine 2016:7 129–137Journal of Blood Medicine Dovepress submit your manuscript | www.dovepress.com Dovepress  129 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JBM.S104074Matching-adjusted indirect comparisons  of  efficacy of BAY 81-8973 vs two recombinant  factor VIII for the prophylactic treatment of  severe hemophilia A Jennifer Pocoski1 Nanxin Li2 Rajeev Ayyagari2 Nikki Church1 Monika Maas Enriquez1 Quer Xiang2 Sneha Kelkar3 Ella X Du2 Eric Q Wu2 Jipan Xie3 1Bayer HealthCare Pharmaceuticals,   Whippany, NJ, 2Analysis Group, Inc.,   Boston, MA, 3Analysis Group, Inc.,   New Y ork, NY, USABackground: No head-to-head trials comparing recombinant factor VIII (rFVIII) products  currently exist.",Non-OADS,/arxiv_data1/oa_pdf/06/1d/jbm-7-129.PMC4938137.pdf
"1 Approximately 60% of all affected Correspondence: Nanxin Li Analysis Group, Inc.,111 Huntington Avenue, 14th Floor, Boston, MA 02199, USATel +1 617 425 8478Email nick.li@analysisgroup.comJournal name: Journal of Blood Medicine Article Designation: ORIGINAL RESEARCHY ear: 2016V olume: 7Running head verso: Pocoski et alRunning head recto: MAICs of efficacy of BA Y 81-8973 vs two rFVIII for the hemophilia A prophylaxisDOI: http://dx.doi.org/10.2147/JBM.S104074",Non-OADS,/arxiv_data1/oa_pdf/06/1d/jbm-7-129.PMC4938137.pdf
"Journal of Blood Medicine 2016:7submit your manuscript | www.dovepress.com Dovepress Dovepress Journal of Blood Medicine Publish your work in this journal Submit your manuscript here: http://www.dovepress.com/journal-of-blood-medicine-journalThe Journal of Blood Medicine is an international, peer-reviewed, open  access, online journal publishing laboratory, experimental and clinical aspects   of all aspect pertaining to blood based medicine including but not limited to:   Transfusion Medicine; Blood collection, Donor issues, Transmittable diseases,   and Blood banking logistics; Immunohematology; Artificial and alternative blood based therapeutics; Hematology; Biotechnology/nanotechnology of blood related medicine; Legal aspects of blood medicine; Historical perspec-tives.",Non-OADS,/arxiv_data1/oa_pdf/06/1d/jbm-7-129.PMC4938137.pdf
Visit http://www.dovepress.com/ testimonials.php to read real quotes from published authors.Dovepress 137 MAICs of efficacy of BAY 81-8973 vs two rFVIII for the hemophilia A prophylaxis  4.,Non-OADS,/arxiv_data1/oa_pdf/06/1d/jbm-7-129.PMC4938137.pdf
10 October 2014. http://www.scottishmedicines.org.uk/files/advice/daclatasvir_Daklinza_FINAL_Oct_2014_Updated_30.10.14_for_web-site.pdf.,Non-OADS,/arxiv_data1/oa_pdf/06/1d/jbm-7-129.PMC4938137.pdf
"EVEROLIMUS, tablets, 5 mg and 10 mg, Afinitor®, Novartis Pharmaceuticals Australia Pty Ltd. http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2014-03/everolimus-rcc.",Non-OADS,/arxiv_data1/oa_pdf/06/1d/jbm-7-129.PMC4938137.pdf
Available  from: https://clinicaltrials.gov/ct2/show/NCT01029340.,Non-OADS,/arxiv_data1/oa_pdf/06/1d/jbm-7-129.PMC4938137.pdf
Available from: https://clinicaltrials.gov/ct2/show/results/NCT01233258.,Non-OADS,/arxiv_data1/oa_pdf/06/1d/jbm-7-129.PMC4938137.pdf
Available from http://handbook.cochrane.org/.,OADS,/arxiv_data1/oa_pdf/06/1d/jbm-7-129.PMC4938137.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/dd/f2/ott-9-4061.PMC4938138.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2016:9 4061–4074OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  4061Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S10142 3 a meta-analysis of combination therapy versus  single-agent therapy in anthracycline- and taxane- pretreated metastatic breast cancer: results from  nine randomized Phase iii trials liang Xu1,2,* Xiaobo Wu3,* chun hu1,2 Zhiying Zhang4 le Zhang1,2 shujing liang1,2 Yingchun Xu5 Fengchun Zhang1,2 1Department of Oncology, suzhou  Kowloon hospital, shanghai Jiaotong  University school of Medicine, suzhou,   2Department of Oncology, ruijin  hospital, shanghai Jiaotong University  school of Medicine, shanghai,   3Prevention and cure center of  Breast Disease, Third hospital of  nanchang, nanchang, 4graduate  school, Xuzhou Medical college,   Xuzhou, 5Department of Oncology,   renji hospital, shanghai Jiaotong  University school of Medicine,   shanghai, People’s republic of china *These authors contributed equally  to this workAbstract:  Nowadays, the philosophy of treating metastatic breast cancer (MBC) is slowly  evolving.",Non-OADS,/arxiv_data1/oa_pdf/dd/f2/ott-9-4061.PMC4938138.pdf
"For the metastatic breast cancer (MBC)  patients, chemotherapy regimens containing taxanes and anthracyclines are the first-line  standard of care.2 However, anthracyclines and taxanes are routinely used as standard  adjuvant or neoadjuvant treatment for high-risk early breast cancer, thereby limiting  their use in patients who subsequently develop metastasis.3 Therefore, these agents are correspondence: Yingchun Xu Department of Oncology, renji hospital,  shanghai Jiaotong University school of  Medicine, 1630 Dongfang road, shanghai  200127, People’s republic of china Tel +86 135 8557 6486 email 84985540@qq.co m  Fengchun Zhang Department of Oncology, suzhou  Kowloon hospital, shanghai Jiaotong  University school of Medicine,  118 Wansheng street, suzhou  215021, People’s republic of china Tel +86 186 2179 5347 email fczhang2005@163.co m Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2016 Volume: 9 Running head verso: Xu et al Running head recto: Therapy for anthracycline- and taxane-pretreated MBC DOI: http://dx.doi.org/10.2147/OTT.S101423",Non-OADS,/arxiv_data1/oa_pdf/dd/f2/ott-9-4061.PMC4938138.pdf
This was a free software that can be downloaded from  http://sourceforge.net/projects/digitizer /.,Non-OADS,/arxiv_data1/oa_pdf/dd/f2/ott-9-4061.PMC4938138.pdf
"HR calculation  spreadsheet used to calculate HRs and 95% CIs were freely  downloaded from http://www.biomedcentral.com/content/ supplementary/1745-6215-8-16-S1.xl s. Heterogeneity was  estimated by χ2-based Q-test.20 When Pheterogeneity,0.100 or  I2.50%, heterogeneity was considered statistically signifi - cant.",OADS,/arxiv_data1/oa_pdf/dd/f2/ott-9-4061.PMC4938138.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/dd/f2/ott-9-4061.PMC4938138.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/dd/f2/ott-9-4061.PMC4938138.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/61/3f/mder-9-175.PMC4938139.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/61/3f/mder-9-175.PMC4938139.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Medical Devices: Evidence and Research 2016:9 175–183Medical Devices: Evidence and Research Dovepress submit your manuscript | www.dovepress.com Dovepress 175 REVIEW open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/MDER.S93637 Artificial urinary sphincters for male stress  urinary incontinence: current perspectives Billy H Cordon1 Nirmish Singla1 Ajay K Singla2 1Department of Urology, University of  T exas Southwestern Medical Center,   Dallas, TX, 2Department of Urology,   University of T oledo College of Medicine, T oledo, OH, USAAbstract:  The artificial urinary sphincter (AUS), which has evolved over many years, has  become a safe and reliable treatment for stress urinary incontinence and is currently the gold  standard.",Non-OADS,/arxiv_data1/oa_pdf/61/3f/mder-9-175.PMC4938139.pdf
"The first description of an AUS dates back to 1947 3; however, the modern era of sphincters began  in 1983 with the release of the AMS 800 (American Medical Systems,  Minnetonka,  MN, USA; Figure 1).4,5 The AUS is composed of silicone and consists of an inflatable Correspondence: Ajay K Singla Department of Urology, University of Toledo Medical Center, 3000 Arlington Avenue, MS 1091, Toledo, OH 43614, USATel +1 419 383 3582Fax +1 419 383 3785Email ajay.singla@utoledo.eduJournal name: Medical Devices: Evidence and Research Article Designation: REVIEWY ear: 2016V olume: 9Running head verso: Cordon et alRunning head recto: Artificial urinary sphincters: current perspectivesDOI: http://dx.doi.org/10.2147/MDER.S93637",Non-OADS,/arxiv_data1/oa_pdf/61/3f/mder-9-175.PMC4938139.pdf
"Medical Devices: Evidence and Research 2016:9submit your manuscript | www.dovepress.com Dovepress Dovepress Medical Devices: Evidence and Research Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/medical-devices-evidence-and-research-journalMedical Devices: Evidence and Research is an international, peer- reviewed, open access journal that focuses on the evidence, technology, research, and expert opinion supporting the use and application of   medical devices in the diagnosis, monitoring, treatment and management of clinical conditions and physiological processes.",Non-OADS,/arxiv_data1/oa_pdf/61/3f/mder-9-175.PMC4938139.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/93/08/ppa-10-1177.PMC4938140.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Patient Preference and Adherence 2016:10 1177–1187Patient Preference and Adherence Dove press submit your manuscript | www.dovepress.co m Dove press  1177OriginAl reseArchopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/PPA.S10832 6 relevance of low-pressure compression corsets  in physiotherapeutic treatment of patients after  mastectomy and lymphadenectomy rita hansdorfer-Korzon1 Jacek T eodorczyk2 Agnieszka gruszecka3 Jacek Wydra4 Piotr lass2,5 1Department of Physiotherapy, 2Depart- ment of nuclear Medicine, 3Department  of informatics and statistics, Medical  University of gdansk, gdansk,  4Department of Oncological surgery,  “szpital Morski im.",Non-OADS,/arxiv_data1/oa_pdf/93/08/ppa-10-1177.PMC4938140.pdf
"Debinki 7,  80-952 gdansk, Poland Tel +48 58 6601 99199 email badklin@gmail.co m Journal name: Patient Preference and Adherence Article Designation: Original Research Y ear: 2016 Volume: 10 Running head verso: Hansdorfer-Korzon et al Running head recto: Low-pressure compression corsets after mastectomy DOI: http://dx.doi.org/10.2147/PPA.S108326",Non-OADS,/arxiv_data1/oa_pdf/93/08/ppa-10-1177.PMC4938140.pdf
"Patient Preference and Adherence Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/patient-preference-and-adherence-journa lPatient Preference and Adherence is an international, peer-reviewed,  open access journal that focuses on the growing importance of patient   preference  and adherence throughout the therapeutic continuum.",Non-OADS,/arxiv_data1/oa_pdf/93/08/ppa-10-1177.PMC4938140.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/94/4a/opth-10-1229.PMC4938141.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Ophthalmology 2016:10 1229–1235Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  1229Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OPTH.S10972 3 Genetics and age-related macular degeneration:  a practical review for the clinician Stephen G Schwartz1 Blake M Hampton1 Jaclyn L Kovach1 Milam A Brantley Jr2 1Department of Ophthalmology,   Bascom Palmer eye institute,   University of Miami Miller School  of Medicine, Miami, FL, USA;   2Department of Ophthalmology,   vanderbilt eye institute, vanderbilt  University Medical Center, Nashville,   TN, USAAbstract:  Age-related macular degeneration is a complex disease, with both genetic and  environmental risk factors interacting in unknown ways.",Non-OADS,/arxiv_data1/oa_pdf/94/4a/opth-10-1229.PMC4938141.pdf
"Therefore, there is a rationale to screen for the mutation in  asymptomatic individuals, and these diseases are, at least in theory, relatively more  amenable to gene therapies than are complex genetic diseases.1Correspondence: Stephen G Schwartz Department of Ophthalmology, Bascom  Palmer eye institute, University of Miami  Miller School of Medicine, 3880 Tamiami  Trail North, Naples, FL 34103, USA Tel +1 239 659 3937 Fax +1 239 659 3982 email sschwartz2@med.miami.ed u Journal name: Clinical Ophthalmology Article Designation: Review Y ear: 2016 Volume: 10 Running head verso: Schwartz et al Running head recto: Genetics and AMD DOI: http://dx.doi.org/10.2147/OPTH.S109723",Non-OADS,/arxiv_data1/oa_pdf/94/4a/opth-10-1229.PMC4938141.pdf
"Available  from: http://www.aao.org/clinical-statement/recommendations-genetic- testing-of-inherited-eye-d. Accessed June 23, 2016.",Non-OADS,/arxiv_data1/oa_pdf/94/4a/opth-10-1229.PMC4938141.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/94/4a/opth-10-1229.PMC4938141.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/94/4a/opth-10-1229.PMC4938141.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/55/c4/ijwh-8-249.PMC4938142.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of Women’s Health 2016:8 249–259International Journal of Women’s Health Dove press submit your manuscript | www.dovepress.co m Dove press  249OrIg Inal researcHopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJWH.S10831 6 Postrape care services to minors in Kenya: are the  services healing or hurting survivors?",Non-OADS,/arxiv_data1/oa_pdf/55/c4/ijwh-8-249.PMC4938142.pdf
"Recent meta-analyses of child sexual abuse reported a global preva - lence of 18%–20% for girls and 8% for boys.1,2 Extant literature in Africa indicates  that 5%–15% of females experience coerced coitus.3 A large study conducted among  13- to 15-year-old school children in Namibia, Swaziland, Uganda, Zambia, and  Zimbabwe reported an average of 23% lifetime exposure to sexual violence.4 Accord - ing to a Kenyan Violence Against Children 2010 national survey, 7% of females aged  18–24 experienced forced sexual intercourse prior to 18 years of age.5 Twelve months  prior to the survey, ~11% of girls and 4% of boys aged 13–17 years had experienced  some type of sexual violence.5 Physical ramifications of sexual violence include traumatic injury, sexually  transmitted illnesses, unwanted pregnancies, unsafe abortions where abortion is  legally restricted, and complications during pregnancy, including obstetric fistulas.6  Psychological consequences may include clinical depression, posttraumatic stress  disorder, conduct disorders, alcohol and illicit drug abuse, and suicide attempts.7,8 correspondence: cynthia Khamala  Wangamati Department of community Medicine,  Faculty of Medicine, University  of Oslo, PO Box 1130, Blindern,  0318 Oslo, norway Tel +254 711 824 504 email cynthia.wangamati@medisin.uio.n o Journal name: International Journal of Women’s Health Article Designation: Original Research Y ear: 2016 Volume: 8 Running head verso: Wangamati et al Running head recto: Postrape care services to minors in Kenya DOI: http://dx.doi.org/10.2147/IJWH.S108316",Non-OADS,/arxiv_data1/oa_pdf/55/c4/ijwh-8-249.PMC4938142.pdf
"International Journal of Women’s Health Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-womens-health-journa lThe International Journal of Women’s Health is an international, peer- reviewed open-access journal publishing original research, reports,  editorials, reviews and commentaries on all aspects of women’s  healthcare including gynecology, obstetrics, and breast cancer.",Non-OADS,/arxiv_data1/oa_pdf/55/c4/ijwh-8-249.PMC4938142.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real quotes  from published authors.,Non-OADS,/arxiv_data1/oa_pdf/55/c4/ijwh-8-249.PMC4938142.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/22/33/ijwh-8-243.PMC4938143.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of Women’s Health 2016:8 243–248International Journal of Women’s Health Dove press submit your manuscript | www.dovepress.co m Dove press  243OrIg Inal researcHopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJWH.S10664 5 The changing face of obstetric fistula surgery in  ethiopia Jeremy Wright1,2 Fekade Ayenachew1 Karen D Ballard1,2 1Hamlin Fistula ethiopia, addis ababa,   ethiopia; 2school of Health studies,   University of Surrey, Guildford,   Surrey, UKObjective:  To examine the incidence and type of obstetric fistula presenting to Hamlin Fistula  Ethiopia over a 4-year period.",Non-OADS,/arxiv_data1/oa_pdf/22/33/ijwh-8-243.PMC4938143.pdf
"In a study3 of the prevalence of vaginal fistula  symptoms in 19 sub-Saharan countries through a meta-analysis of Demographic Health  Surveys and Multiple Incidence Cluster Surveys, the rate ranged from 0.4 fistula Correspondence: Jeremy Wright Kelwood, 2 Jackmans lane, Woking,  Surrey GU21 7QU, UK Tel +44 148 377 2510 email jeremy.wright@surrey.ac.u k  Fekade Ayenachew Hamlin Fistula ethiopia, PO Box 3609,  addis ababa, ethiopia email ayenachew.f@hamlinfistula.or gJournal name: International Journal of Women’s Health Article Designation: Original Research Y ear: 2016 Volume: 8 Running head verso: Wright et al Running head recto: The changing face of fistula surgery in Ethiopia DOI: http://dx.doi.org/10.2147/IJWH.S106645",Non-OADS,/arxiv_data1/oa_pdf/22/33/ijwh-8-243.PMC4938143.pdf
"International Journal of Women’s Health Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-womens-health-journa lThe International Journal of Women’s Health is an international, peer- reviewed open-access journal publishing original research, reports,  editorials, reviews and commentaries on all aspects of women’s  healthcare including gynecology, obstetrics, and breast cancer.",Non-OADS,/arxiv_data1/oa_pdf/22/33/ijwh-8-243.PMC4938143.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real quotes  from published authors.,Non-OADS,/arxiv_data1/oa_pdf/22/33/ijwh-8-243.PMC4938143.pdf
"Avail - able from: http://www.nationalplanningcycles.org/sites/default/files/ country_docs/Ethiopia/ethiopia_hsdp_iv_final_draft_2010_-2015.pd f.  Accessed September 7, 2015.",Non-OADS,/arxiv_data1/oa_pdf/22/33/ijwh-8-243.PMC4938143.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/9a/bf/ott-9-3771.PMC4938144.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2016:9 3771–3781OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  3771Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S10395 4 Efficacy and safety of adding an agent to  bevacizumab/taxane regimens for the first-line  treatment of Her2-negative patients with locally  recurrent or metastatic breast cancer: results  from seven randomized controlled trials Xiaoqun liu1,* Xiangdong liu2,* Tiankui Qiao1 Wei chen1 sujuan Yuan1 1Department of Oncology,   2Department of Ophthalmology,   affiliated Jinshan hospital, Fudan  University, shanghai, People’s   republic of china *These authors contributed equally  to this workBackground:  The combined therapy of bevacizumab (BEV) with taxane (paclitaxel or  docetaxel) has shown an improvement on progression-free survival (PFS) and objective remission  in Her2-negative patients with locally recurrent or metastatic breast cancer (LR/MBC).",Non-OADS,/arxiv_data1/oa_pdf/9a/bf/ott-9-3771.PMC4938144.pdf
"Keywords:  bevacizumab, paclitaxel, docetaxel, breast cancer, meta-analysis Introduction Worldwide, locally recurrent or metastatic breast cancer (LR/MBC) is one of the most  frequently diagnosed forms of female malignant tumor and one of the most common correspondence: Tiankui Qiao Department of Oncology, Affiliated  Jinshan hospital, Fudan University,  longhang road 1508, Jinshan District,  shanghai 201508, People’s republic  of china Tel +86 189 3077 8786 email qiaotk@163.co m Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2016 Volume: 9 Running head verso: Liu et al Running head recto: First-line treatment of Her2-negative patients DOI: http://dx.doi.org/10.2147/OTT.S103954",Non-OADS,/arxiv_data1/oa_pdf/9a/bf/ott-9-3771.PMC4938144.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/9a/bf/ott-9-3771.PMC4938144.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/9a/bf/ott-9-3771.PMC4938144.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/ef/37/ijn-11-3049.PMC4938145.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of Nanomedicine 2016:11 3049–3063International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  3049OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S10905 9 effects of the protein corona on liposome– liposome and liposome–cell interactions claudia corbo1,2 roberto Molinaro1 Francesca Taraballi1 Naama e T oledano Furman1 Michael B sherman3 alessandro Parodi1 Francesco salvatore2,4 ennio Tasciotti1,5 1center for Biomimetic Medicine,   houston Methodist research  Institute, houston, TX, Usa;   2ceIN ge-Biotecnologie avanzate  s.c.a r.l., Naples, Italy; 3Department  of Biochemistry and Molecular  Biology, sealy center for structural  Biology and Molecular Biophysics,   University of T exas Medical Branch,   galveston, TX, Usa; 4Department  of Molecular Medicine and Medical  Biotechnologies, University of Naples  Federico II, Naples, Italy; 5Department  of Orthopedics, houston Methodist  hospital, houston, TX, UsaAbstract:  A thorough understanding of interactions occurring at the interface between  nanocarriers and biological systems is crucial to predict and interpret their biodistribution,  targeting, and efficacy, and thus design more effective drug delivery systems.",Non-OADS,/arxiv_data1/oa_pdf/ef/37/ijn-11-3049.PMC4938145.pdf
"In terms of NP targeting abilities, the PC can 1) hinder the function of targeting  ligands attached to the NP surface, thereby reducing their accumulation in the targeted  tissue,3,9,10 and 2) modify the carrier surface, facilitating cell internalization.11 The PC  can also modulate immune response.12 Several studies have characterized PC structure,  function, and formation dynamics.13,14 Structurally, proteins that are weakly bound to  the NP surface form the “soft corona,” while proteins strongly bound to the NP surface  form the “hard corona.”15,16 Functionally, the PC is characterized by the presence of  opsonins (complement proteins), immunoglobulins, and lectins,17 which match to correspondence: ennio Tasciotti;   claudia corbo center for Biomimetic Medicine,  houston Methodist research Institute,  6670 Bertner avenue, houston,  TX 77030, Usa   Tel +1 713 441 7319; +1 713 363 9763 email etasciotti@houstonmethodist.or g;  corbo@ceinge.unina.i t Journal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Corbo et al Running head recto: Liposomes and protein corona DOI: http://dx.doi.org/10.2147/IJN.S109059",Non-OADS,/arxiv_data1/oa_pdf/ef/37/ijn-11-3049.PMC4938145.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/ef/37/ijn-11-3049.PMC4938145.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/ef/37/ijn-11-3049.PMC4938145.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/46/96/ott-9-4075.PMC4938146.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2016:9 4075–4087OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  4075Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S9820 3 lncrna gas5 is a critical regulator of metastasis  phenotype of melanoma cells and inhibits tumor  growth in vivo long chen1,2,* huixin Yang1,* Yanbin Xiao3,* Xiaoxia Tang4 Yuqian li1 Qiaoqiao han1 Junping Fu3 Yuye Yang1 Yuechun Zhu1 1Department of Biochemistry and  Molecular Biology, Kunming Medical  University, Kunming, Yunnan, People’s  republic of china; 2PeT/cT center,   Yunan Tumor hospital, the Third  affiliated hospital of Kunming  Medical University, Kunming Medical  University, Kunming, Yunnan, People’s  republic of china; 3Department  of Orthopaedics, Yunan T umor  hospital, the Third affiliated hospital  of Kunming Medical University,   Kunming Medical University, Kunming,   Yunnan, People’s republic of china;   4Department of Pharmacy, the second  affiliated hospital of Kunming  Medical University, Kunming Medical  University, Kunming, Yunnan, People’s  republic of china *These authors contributed equally  to this workAbstract:  The present study intended to demonstrate the effects of long noncoding RNA growth  arrest-specific transcript 5 (GAS5) on the migration and invasion of melanoma cells.",Non-OADS,/arxiv_data1/oa_pdf/46/96/ott-9-4075.PMC4938146.pdf
"Matrix metalloproteinases (MMPs), which can cleave peptide bonds thereby  degrading proteins, play crucial roles in a spectrum of diseases, such as rheumatoid  arthritis, cardiovascular disease, and chronic obstructive pulmonary disease.32–34 correspondence: Yuechun Zhu Department of Biochemistry and  Molecular Biology, Kunming Medical  University, 1168 Yuhua street,  chenggong District, Kunming, Yunnan,  150080, People’s republic of china Tel +86 153 6820 5856 Fax +86 871 6593 6363 email zhuyuechun20091119@163.co m Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2016 Volume: 9 Running head verso: Chen et al Running head recto: LncRNA GAS5 is a critical regulator and inhibits tumor growth DOI: http://dx.doi.org/10.2147/OTT.S98203",Non-OADS,/arxiv_data1/oa_pdf/46/96/ott-9-4075.PMC4938146.pdf
Or use: http://youtu.be/UEMKSVx4_F kVideo abstract,Non-OADS,/arxiv_data1/oa_pdf/46/96/ott-9-4075.PMC4938146.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/46/96/ott-9-4075.PMC4938146.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/46/96/ott-9-4075.PMC4938146.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/32/e2/ott-9-4005.PMC4938147.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2016:9 4005–4013OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  4005Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S10541 8 histone deacetylase inhibitor sodium butyrate  suppresses proliferation and promotes apoptosis  in osteosarcoma cells by regulation of the  MDM2–p53 signaling chuhai Xie Boyi Wu Binwei chen Qunwei shi Jianhong guo Ziwen Fan Yan huang Department of Orthopedics,   The second affiliated hospital  of guangzhou Medical University,   guangzhou, People’s republic  of chinaAbstract:  Histone deacetylase inhibitors have been reported to induce tumor cell growth  arrest, differentiation, and apoptosis.",Non-OADS,/arxiv_data1/oa_pdf/32/e2/ott-9-4005.PMC4938147.pdf
"These OS patients do not benefit correspondence: chuhai Xie Department of Orthopedics, The  Second Affiliated Hospital of Guangzhou  Medical University, number 250,  chang-gang-Dong road, guangzhou  510260, People’s republic of china Tel +86 20 3415 2265 email xiechuuhai@sina.co m Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2016 Volume: 9 Running head verso: Xie et al Running head recto: Sodium butyrate suppresses osteosarcoma cells DOI: http://dx.doi.org/10.2147/OTT.S105418",Non-OADS,/arxiv_data1/oa_pdf/32/e2/ott-9-4005.PMC4938147.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/32/e2/ott-9-4005.PMC4938147.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/32/e2/ott-9-4005.PMC4938147.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/89/61/jpr-9-481.PMC4938148.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/89/61/jpr-9-481.PMC4938148.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Journal of Pain Research  2016:9 481–492Journal of Pain Research Dovepress submit your manuscript | www.dovepress.com Dovepress  481 REVIEW open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JPR.S108884A review of spinal cord stimulation systems for  chronic pain Paul Verrills1 Chantelle Sinclair2  Adele Barnard2 1Metro Pain Group, 2Monash Clinical  Research, Monash House, Clayton,   Victoria, AustraliaAbstract:  Spinal cord stimulation (SCS) applications and technologies are fast advancing.",Non-OADS,/arxiv_data1/oa_pdf/89/61/jpr-9-481.PMC4938148.pdf
"Opioid analgesics are often prescribed, despite the lack of clinical Correspondence: Chantelle Sinclair Monash Clinical Research, Monash House, 271 Clayton Rd, Clayton, Victoria, 3168, Australia Tel +61 3 9595 6180Fax +61 3 9595 6110Email: csinclair@monashcr.com.au Journal name: Journal of Pain Research  Article Designation: REVIEWY ear: 2016V olume: 9Running head verso: Verrills et alRunning head recto: Spinal cord stimulation reviewDOI: http://dx.doi.org/10.2147/JPR.S108884 Video abstract Point your SmartPhone at the code above.",Non-OADS,/arxiv_data1/oa_pdf/89/61/jpr-9-481.PMC4938148.pdf
Or use: http://youtu.be/U9OXqXW9s_Y,Non-OADS,/arxiv_data1/oa_pdf/89/61/jpr-9-481.PMC4938148.pdf
"Journal of Pain Research  2016:9submit your manuscript | www.dovepress.com Dovepress Dovepress Journal of Pain Research  Publish your work in this journal Submit your manuscript here:  https://www.dovepress.com/journal-of-pain-research-journal The Journal of Pain Research is an international, peer reviewed, open  access, online journal that welcomes laboratory and clinical findings   in the fields of pain research and the prevention and management of pain.",Non-OADS,/arxiv_data1/oa_pdf/89/61/jpr-9-481.PMC4938148.pdf
"Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Dovepress 492 Verrills et al  62. de V os CC, Dijkstra C, Lenders MWPM, Holsheimer J. Spinal cord  stimulation with hybrid lead relieves pain in low back and legs.",Non-OADS,/arxiv_data1/oa_pdf/89/61/jpr-9-481.PMC4938148.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/ca/65/cia-11-887.PMC4938238.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Interventions in Aging 2016:11 887–895Clinical Interventions in Aging Dove press submit your manuscript | www.dovepress.co m Dove press  887OrIg InAl reseArChopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CIA.S10384 5Assessment risk of osteoporosis in Chinese  people: relationship among body mass index,  serum lipid profiles, blood glucose, and bone  mineral density rongtao Cui1 lin Zhou2 Zuohong li2 Qing li2 Zhiming Qi2 Junyong Zhang3 1Department of Orthopedic and  Trauma surgery, surgical research,   Duisburg-essen University hospital,   essen, germany; 2Department  of Orthopedics, Dalian Central  hospital, Dalian, 3Department  of gastroenterology, shandong  Provincial hospital, Jinan, People’s  republic of ChinaObjective:  The aim of our study was to investigate the relationship among age, sex, body  mass index (BMI), serum lipid profiles, blood glucose (BG), and bone mineral density (BMD),  making an assessment of the risk of osteoporosis.",Non-OADS,/arxiv_data1/oa_pdf/ca/65/cia-11-887.PMC4938238.pdf
"In the Chinese people, OP is therefore an increasingly serious public  health problem.2Correspondence: Junyong Zhang Department of gastroenterology,  shandong Provincial hospital,  324 Jingwuweiqi rd, Jinan, 250000,  People’s republic of China Tel +86 531 135 8317 3280 email zhangjunyong321@outlook.co m Journal name: Clinical Interventions in Aging Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Cui et al Running head recto: Assessment risk of osteoporosis in Chinese people DOI: http://dx.doi.org/10.2147/CIA.S103845",Non-OADS,/arxiv_data1/oa_pdf/ca/65/cia-11-887.PMC4938238.pdf
"Clinical Interventions in Aging Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-interventions-in-aging-journa lClinical Interventions in Aging is an international, peer-reviewed journal  focusing on evidence-based reports on the value or lack thereof of treatments  intended to prevent or delay the onset of maladaptive correlates of aging  in human beings.",Non-OADS,/arxiv_data1/oa_pdf/ca/65/cia-11-887.PMC4938238.pdf
Visit http://www.dovepress.,Non-OADS,/arxiv_data1/oa_pdf/ca/65/cia-11-887.PMC4938238.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/99/68/copd-11-1515.PMC4938239.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of COPD 2016:11 1515–1520International Journal of COPD Dove press submit your manuscript | www.dovepress.co m Dove press  1515OrIg Inal researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/COPD.S10467 0 Characteristics of elderly patients with COPD  and newly diagnosed lung cancer, and factors  associated with treatment decision Jianwen Qin guangsheng li Jingmin Zhou Department of respiratory and  Critical Care Medicine, Tianjin  Chest hospital, Tianjin, People’s  republic of ChinaObjective:  To investigate the clinical features, diagnosis, and treatment status of elderly patients  with chronic obstructive pulmonary disease (COPD) complicated with lung cancer.",Non-OADS,/arxiv_data1/oa_pdf/99/68/copd-11-1515.PMC4938239.pdf
"In addition, the declined pulmonary function may cause loss of treatment Correspondence: Jianwen Qin Department of respiratory and Critical  Care Medicine, Tianjin Chest hospital,  261 Tianjin Taierzhuang south road,  Jinnan, Tianjin 300222, People’s republic  of China Tel +86 156 9229 6166 Fax +86 22 8818 5338 email qinjianwen2005@aliyun.co m Journal name: International Journal of COPD Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Qin et al Running head recto: Lung cancer in elderly with COPD DOI: http://dx.doi.org/10.2147/COPD.S104670",Non-OADS,/arxiv_data1/oa_pdf/99/68/copd-11-1515.PMC4938239.pdf
"International Journal of COPD Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journa lThe International Journal of COPD is an international, peer-reviewed  journal of therapeutics and pharmacology focusing on concise rapid  reporting of clinical studies and reviews in COPD.",Non-OADS,/arxiv_data1/oa_pdf/99/68/copd-11-1515.PMC4938239.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/99/68/copd-11-1515.PMC4938239.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/5e/16/ijgm-9-221.PMC4938240.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/5e/16/ijgm-9-221.PMC4938240.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).International Journal of General Medicine 2016:9 221–227International Journal of General Medicine Dovepress submit your manuscript | www.dovepress.com Dovepress 221 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/IJGM.S107821Iron deficiency intravenous substitution in a  Swiss academic primary care division: analysis of  practices Monica Varcher1 Sofia Zisimopoulou1 Olivia Braillard1 Bernard Favrat2 Noëlle Junod Perron1 1Department of Community, Primary  and Emergency Care, Division of  Primary Care, Geneva University Hospitals, Geneva,   2Department of  Ambulatory Care and Community Medicine, University of Lausanne,  Lausanne, SwitzerlandBackground: Iron deficiency is a common problem in primary care and is usually treated with  oral iron substitution.",Non-OADS,/arxiv_data1/oa_pdf/5e/16/ijgm-9-221.PMC4938240.pdf
"However, oral administration presents Correspondence: Noëlle Junod Perron Department of Community, Primary and Emergency Care, Division of Primary Care, Geneva University Hospitals, 4 rue Gabrielle Perret-Gentil, 1211 Geneva, SwitzerlandTel +41 22 372 9676Fax +41 22 372 9600Email noelle.junod@hcuge.chJournal name: International Journal of General Medicine Article Designation: ORIGINAL RESEARCHY ear: 2016V olume: 9Running head verso: Varcher et alRunning head recto: Iron deficiency and substitution practicesDOI: http://dx.doi.org/10.2147/IJGM.S107821",Non-OADS,/arxiv_data1/oa_pdf/5e/16/ijgm-9-221.PMC4938240.pdf
Available  from: http://www.who.int/nutrition/publications/micronutrients/anae-mia_iron_deficiency/9789241596657/en/.,Non-OADS,/arxiv_data1/oa_pdf/5e/16/ijgm-9-221.PMC4938240.pdf
Available from: http://www.who.int/nutrition/publications/en/ida_assessment_prevention_control.pdf.,Non-OADS,/arxiv_data1/oa_pdf/5e/16/ijgm-9-221.PMC4938240.pdf
Available from: https://www.swissmedic.ch/zulassungen/00153/00189/00200/01057/index.html?lang=fr.,Non-OADS,/arxiv_data1/oa_pdf/5e/16/ijgm-9-221.PMC4938240.pdf
Available from: http://ec.europa.eu/health/documents/community-register/2013/20130913126618/anx_126618_fr.pdf.,Non-OADS,/arxiv_data1/oa_pdf/5e/16/ijgm-9-221.PMC4938240.pdf
Available from: http://www.abimfoundation.org/Initiatives/Choosing-Wisely.aspx.,Non-OADS,/arxiv_data1/oa_pdf/5e/16/ijgm-9-221.PMC4938240.pdf
Available from: http://www.academies-suisses.ch/fr/index/Schwerpunktthemen/Gesundheitssystem-im-Wandel/Nachhaltiges-Gesundheitssystem.html.,Non-OADS,/arxiv_data1/oa_pdf/5e/16/ijgm-9-221.PMC4938240.pdf
"International Journal of General Medicine 2016:9submit your manuscript | www.dovepress.com Dovepress Dovepress International Journal of General Medicine Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/international-journal-of-general-medicine-journalThe International Journal of General Medicine is an international,  peer-reviewed open-access journal that focuses on general and internal medicine, pathogenesis, epidemiology, diagnosis, monitoring and treat-ment protocols.",Non-OADS,/arxiv_data1/oa_pdf/5e/16/ijgm-9-221.PMC4938240.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Dovepress 227 Iron deficiency and substitution practices 36. WHO.,Non-OADS,/arxiv_data1/oa_pdf/5e/16/ijgm-9-221.PMC4938240.pdf
Available from: http://www.who.int/nutrition/publications/micronutrients/anaemia_iron_deficiency/9789241596107.pdf.,Non-OADS,/arxiv_data1/oa_pdf/5e/16/ijgm-9-221.PMC4938240.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/1b/ca/copd-11-1521.PMC4938241.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of COPD 2016:11 1521–1532International Journal of COPD Dove press submit your manuscript | www.dovepress.co m Dove press  1521OrIg Inal researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/COPD.S10793 8 Smoking-related interstitial fibrosis combined  with pulmonary emphysema: computed  tomography-pathologic correlative study using  lobectomy specimens hideji Otani1 T omonori Tanaka2 Kiyoshi Murata1 Junya Fukuoka2 norihisa nitta1 Yukihiro nagatani1 akinaga sonoda1 Masashi Takahashi3 1Department of radiology, shiga  University of Medical science,   setatsukinowa-cho, Otsu, shiga,   2Department of Pathology, nagasaki  University graduate school of  Biomedical sciences, sakamoto,   nagasaki, 3Department of radiology,   Yujin-Yamazaki hospital, Takegahana- cho, hikone, shiga, JapanPurpose:  To evaluate the incidence and pathologic correlation of thin-section computed  tomography (TSCT) findings in smoking-related interstitial fibrosis (SRIF) with pulmonary  emphysema.",Non-OADS,/arxiv_data1/oa_pdf/1b/ca/copd-11-1521.PMC4938241.pdf
"Localized or nonspecific fibrosis accompanied by  emphysematous changes is also a frequent pathological finding in smokers.13,14 Although  these pathological changes appear to be similar, they are known by different names, ie, Correspondence: hideji Otani Department of radiology, shiga  University of Medical science,  setatsukinowa-cho, Otsu,  shiga 520-2192, Japan Tel +81 77 548 2288 Fax +81 77 544 0986 email otani@belle.shiga-med.ac.j p Journal name: International Journal of COPD Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Otani et al Running head recto: Smoking-related interstitial fibrosis combined with pulmonary emphysema DOI: http://dx.doi.org/10.2147/COPD.S107938",Non-OADS,/arxiv_data1/oa_pdf/1b/ca/copd-11-1521.PMC4938241.pdf
"International Journal of COPD Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journa lThe International Journal of COPD is an international, peer-reviewed  journal of therapeutics and pharmacology focusing on concise rapid  reporting of clinical studies and reviews in COPD.",Non-OADS,/arxiv_data1/oa_pdf/1b/ca/copd-11-1521.PMC4938241.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/1b/ca/copd-11-1521.PMC4938241.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/cd/5a/dddt-10-2155.PMC4938242.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Drug Design, Development and Therapy 2016:10 2155–2165Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  2155Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/DDDT .S10800 4 real-time monitoring of cisplatin cytotoxicity  on three-dimensional spheroid tumor cells namhuk Baek1,* Ok Won seo1,* Jaehwa lee1 John hulme2 seong soo a an2 1Department of research and  Development, nanoentek inc., seoul,   2Department of Bio nano T echnology,   gachon University, gyeonggi-do,   Korea *These authors contributed equally  to this workAbstract:  Three-dimensional (3D) cell cultivation is a powerful technique for monitoring and  understanding diverse cellular mechanisms in developmental cancer and neuronal biology, tissue  engineering, and drug development.",Non-OADS,/arxiv_data1/oa_pdf/cd/5a/dddt-10-2155.PMC4938242.pdf
"Keywords:  cisplatin, real-time monitoring, cytotoxicity, 3D spheroids, ATP productions Introduction Cells are usually grown as two-dimensional (2D) cultures, which are reliable and  convenient for the majority of developmental biology, tissue engineering, tissue  formation, disease mechanism, drug development, and especially large-scale thera - peutic protein production studies.1 The recent development of three-dimensional  (3D) culture systems has offered a model closer to in vivo conditions and promised  to advance our understanding of cell survival, proliferation, differentiation, and gene  and protein expression.2 Morphological and other properties exhibited by cells in 3D  cultures may be better suited for studies of structural organization, cell–cell commu - nication, cell–extracellular matrix interaction, drug sensitivity, cell death, cancer cell  survival, and neighboring cell networks.3 The ensuing results could have a profound  influence on studies in cancer biology, drug toxicity tests, stem cell applications, and correspondence: seong soo a an Department of Bionano Technology,  gachon Medical research institute,  gachon University, 1342 sungnam Daero,  sungnamsi 461-701, Korea Tel +82 31 750 8755 Fax +82 31 750 8755 email seongaan@gachon.ac.k r Journal name: Drug Design, Development and Therapy Article Designation: Original Research Y ear: 2016 Volume: 10 Running head verso: Baek et al Running head recto: Cytotoxicity of cisplatin on 3D spheroid tumor cells DOI: http://dx.doi.org/10.2147/DDDT.S108004 Point your SmartPhone at the code above.",Non-OADS,/arxiv_data1/oa_pdf/cd/5a/dddt-10-2155.PMC4938242.pdf
Or use: http://youtu.be/Aq0bXmYwRH IVideo abstract,Non-OADS,/arxiv_data1/oa_pdf/cd/5a/dddt-10-2155.PMC4938242.pdf
"Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDrug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/cd/5a/dddt-10-2155.PMC4938242.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/cd/5a/dddt-10-2155.PMC4938242.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/57/87/dddt-10-2137.PMC4938243.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Drug Design, Development and Therapy 2016:10 2137–2154Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  2137Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/DDDT .S10811 8 Pharmacophore modeling and in silico toxicity  assessment of potential anticancer agents from  african medicinal plants Fidele ntie-Kang1,2,* conrad Veranso  simoben1,2,* Berin Karaman1 Valery Fuh ngwa3 Philip neville Judson4 Wolfgang sippl1 luc Meva’a Mbaze5 1Department of Pharmaceutical  chemistry, Martin-luther University  of halle-Wittenberg, halle  (saale), germany; 2Department  of chemistry, University of Buea,   Buea, cameroon; 3interuniversity  institute For Biostatistics and  statistical Bioinformatics (i-Bio stat),   University of hasselt, hasselt,   Belgium; 4chemical Bioactivity  information centre, harrogate, UK;   5Department of chemistry, Faculty of  science, University of Douala, Douala,   cameroon *These authors contributed equally  to this workAbstract:  Molecular modeling has been employed in the search for lead compounds of chemo - therapy to fight cancer.",Non-OADS,/arxiv_data1/oa_pdf/57/87/dddt-10-2137.PMC4938243.pdf
"However, the correspondence: Fidele ntie-Kang Department of Pharmaceutical  chemistry, Martin-luther University of  halle-Wittenberg, Wolfgang-langenbeck  street 4, 06120 halle (saale), germany   email ntiekfidele@gmail.co m  luc Meva’a Mbaze Department of chemistry, Faculty  of science, University of Douala,  PO Box 24157, Douala, cameroon   email lmbazze@yahoo.f r Journal name: Drug Design, Development and Therapy Article Designation: Original Research Y ear: 2016 Volume: 10 Running head verso: Ntie-Kang et al Running head recto: Potential anticancer agents from African medicinal plants DOI: http://dx.doi.org/10.2147/DDDT.S108118",Non-OADS,/arxiv_data1/oa_pdf/57/87/dddt-10-2137.PMC4938243.pdf
Materials and methods Data collection and analysis The dataset for naturally occurring compounds with prom - ising anticancer properties (AfroCancer) has been recently  described.32 The compounds of the NPACT database were  downloaded from the official webpage ( http://crdd.osdd.,OADS,/arxiv_data1/oa_pdf/57/87/dddt-10-2137.PMC4938243.pdf
"In order to avoid  artificial enrichment in assessing the performances of the  generated pharmacophore models in virtual screening, decoy  libraries were generated using the commercially available  database Directory of Useful Decoys, Enhanced (DUD-E;  http://dude.docking.or g),65 ie, 50 decoys per active ligand.",OADS,/arxiv_data1/oa_pdf/57/87/dddt-10-2137.PMC4938243.pdf
"Available from: http://www.who.int/mediacentre/factsheets/fs297/en/ index.htm l. Accessed February 4, 2014.",Non-OADS,/arxiv_data1/oa_pdf/57/87/dddt-10-2137.PMC4938243.pdf
"Available from:  http://www.iarc.fr/en/media-centre/iarcnews/2010/globocan2008.ph p.  Accessed August 4, 2013.",Non-OADS,/arxiv_data1/oa_pdf/57/87/dddt-10-2137.PMC4938243.pdf
"Available  from: http://www.lhasalimited.org/products/derek-nexus.ht m. Accessed  May 19, 2015.",Non-OADS,/arxiv_data1/oa_pdf/57/87/dddt-10-2137.PMC4938243.pdf
"Available from: https://www.chemaxon.com/jchem/doc/user/ LibMCS.htm l. Accessed May 19, 2015.",OADS,/arxiv_data1/oa_pdf/57/87/dddt-10-2137.PMC4938243.pdf
"Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDrug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/57/87/dddt-10-2137.PMC4938243.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/57/87/dddt-10-2137.PMC4938243.pdf
"Continuing  mediCAl  eduCA tion High frequency ultrasound with color Doppler in dermatology * Elisa de Oliveira Barcaui1 Antonio	Carlos	Pires	Carvalho1 Flavia Paiva Proença Lobo Lopes1 Juan Piñeiro-Maceira2 Carlos Baptista Barcaui2 DOI: http://dx.doi.org/10.1590/abd1806-4841.20164446 Abstract:  Ultrasonography is a method of imaging that classically is used in dermatology to study changes in  the	hypoderma, 	as 	nodules 	and 	infectious 	and 	inflammatory 	pr ocesses.",Non-OADS,/arxiv_data1/oa_pdf/c3/90/abd-91-03-0262.PMC4938268.pdf
"2016;91(3):274-83.InvestIgatIon Thermographic analysis and autonomic response in the hands of  patients with leprosy* Aretusa Lopes Cavalheiro1 Debora Tacon da Costa1 Ana Luiza Ferro de Menezes1 Janser Moura Pereira1 Eliane Maria de Carvalho1  DOI: http://dx.doi.org/10.1590/abd1806-4841.20164612 Abstract:  Background : Low temperatures and slow blood flow may result from peripheral neuropathy caused by  leprosy, and the simple detection of cold fingers could already be a preliminary classification for these patients.",Non-OADS,/arxiv_data1/oa_pdf/c2/ed/abd-91-03-0274.PMC4938269.pdf
Available from: http://www.R-project.org/.,Non-OADS,/arxiv_data1/oa_pdf/c2/ed/abd-91-03-0274.PMC4938269.pdf
©2016	by	Anais 	 Brasileiros 	 de 	 DermatologiaDOI: http://dx.doi.org/10.1590/abd1806-4841.20164250 Abstract:  Background :	Alopecia	ar eata 	(AA) 	is 	a 	common 	disor der 	of 	unknown 	etiology 	that 	af fects 	appr oxi- mately	0.7% 	to 	3.8% 	of 	patients 	among 	the 	general 	population.,Non-OADS,/arxiv_data1/oa_pdf/bc/d6/abd-91-03-0284.PMC4938270.pdf
Statistical 	anal- yses	wer e	carried 	out 	using 	the 	SISA	statistics 	softwar e 	 (http://www.quantitativeskills.com/sisa/).,OADS,/arxiv_data1/oa_pdf/bc/d6/abd-91-03-0284.PMC4938270.pdf
Disponível em: http://dssbr.org/site/2012/01/a-nova-composicao-racial- brasileira-segundo-o-censo-2010/  17.,Non-OADS,/arxiv_data1/oa_pdf/bc/d6/abd-91-03-0284.PMC4938270.pdf
investigA tion Acne scars in 18-year-old male adolescents: a population-based  study of prevalence and associated factors* Fernanda Tcatch Lauermann1		 Hiram 	 Larangeira 	 de 	Almeida 	 Jr.2 Rodrigo	Pereira	Duquia3 Paulo	Ricardo	Martins	de	Souza4 Juliano	de	A velar 	 Breunig5  DOI: http://dx.doi.org/10.1590/abd1806-4841.20164405 Abstract: Background :	Acne	vulgaris 	is 	a 	pilosebaceous 	follicle 	disor der 	af fecting 	over 	85% 	of 	adolescents 	to 	some 	 degree.,Non-OADS,/arxiv_data1/oa_pdf/20/f0/abd-91-03-0291.PMC4938271.pdf
"investigA tion Detection of apoptosis in pemphigus vulgaris by TUNEL  technique* Juan	Carlos	Cuevas-Gonzalez1 Maria	Elisa	Vega-Memíje2 Francisco	Javier	García-Vázquez3,4	Marco	António 	Aguilar -Urbano4 DOI: http://dx.doi.org/10.1590/abd1806-4841.20164598 Abstract:  Background : Pemphigus is part of a group of blistering diseases that affect the skin and mucous mem - branes.",Non-OADS,/arxiv_data1/oa_pdf/d8/5f/abd-91-03-0296.PMC4938272.pdf
Available from: http://dspace.unav.es/dspace/ bitstream/10171/22532/1/Tesis%20MPilar%20Gil%20S%C3%A1nchez.pdf  18.,OADS,/arxiv_data1/oa_pdf/d8/5f/abd-91-03-0296.PMC4938272.pdf
"investigA tion Incidence, clinical manifestations and clipping of nail psoriasis in  the dermatology center of the Hospital Universitário Evangélico  de Curitiba* Luiz	Eduardo	Fabricio	de	Melo	Garbers1 Helena Slongo1 Lincoln	Helder	Zambaldi	Fabricio1 Juliano	Vilaverde	Schmitt2 Aguinaldo 	Bonalumi	Filho3 DOI: http://dx.doi.org/10.1590/abd1806-4841.20164296 Abstract:  Background :	Psoriasis	is 	a 	chr onic 	inflammatory 	skin 	disease 	that 	often 	pr ogresses 	with 	nail 	alterations.",Non-OADS,/arxiv_data1/oa_pdf/12/13/abd-91-03-0300.PMC4938273.pdf
©2016	by	Anais 	 Brasileiros 	 de 	 DermatologiaDOI: http://dx.doi.org/10.1590/abd1806-4841.20164292 Abstract:  Background : Psoriasis	is 	immune-mediated 	chr onic 	inflammatory 	disease 	with 	pr eference 	for 	skin 	and 	 joints.,Non-OADS,/arxiv_data1/oa_pdf/23/4d/abd-91-03-0306.PMC4938274.pdf
Available  from: http://www.uptodate.com/contents/tumor-necrosis-factor-alpha-inhibitors- an-overview-of-adverse-effects.,Non-OADS,/arxiv_data1/oa_pdf/23/4d/abd-91-03-0306.PMC4938274.pdf
Available from: http://www.uptodate.com/contents/tumor-necrosis-factor-alpha- inhibitors-risk-of-bacterial-viral-and-fungal-infections.,Non-OADS,/arxiv_data1/oa_pdf/23/4d/abd-91-03-0306.PMC4938274.pdf
Available from: http://www.janssen-Cilag.,Non-OADS,/arxiv_data1/oa_pdf/23/4d/abd-91-03-0306.PMC4938274.pdf
"8,9DOI:	http://dx.doi.org/10.1590/abd1806-4841.20164102 Abstract:  Background : Leprosy is an infectious chronic condition associated with potentially serious physical,  social and psychological impacts.",Non-OADS,/arxiv_data1/oa_pdf/44/4b/abd-91-03-0311.PMC4938275.pdf
Available from: http://www.who.int/ wer/2013/wer8835.pdf 7.,Non-OADS,/arxiv_data1/oa_pdf/44/4b/abd-91-03-0311.PMC4938275.pdf
Disponível em: http://www.anvisa.gov.br/hotsite/talidomida/legis/ portaria_n_3125_hanseniase_2010.pdf 12.,Non-OADS,/arxiv_data1/oa_pdf/44/4b/abd-91-03-0311.PMC4938275.pdf
Disponível em: http://www.fortaleza.ce.gov.br/ 17.,Non-OADS,/arxiv_data1/oa_pdf/44/4b/abd-91-03-0311.PMC4938275.pdf
Disponível em: http://bvsms.saude.gov.br/bvs/saudelegis/gm/2009/prt1944_27_08_2009.,Non-OADS,/arxiv_data1/oa_pdf/44/4b/abd-91-03-0311.PMC4938275.pdf
Disponível em:  http://portalsaude.saude.gov.br/images/pdf/2014/junho/11/BE-2013-44--11---- Hanseniase.pdf 27.,Non-OADS,/arxiv_data1/oa_pdf/44/4b/abd-91-03-0311.PMC4938275.pdf
©2016	by	Anais 	 Brasileiros 	 de 	 DermatologiaDOI: http://dx.doi.org/10.1590/abd1806-4841.20164495 Abstract:  Background : Knowledge of epidemiological data on skin diseases is important in planning preventive  strategies in healthcare services.,Non-OADS,/arxiv_data1/oa_pdf/e4/89/abd-91-03-0318.PMC4938276.pdf
Disponivel em: http://tabnet.datasus.gov.br/cgi/deftohtm.exe?idb2012/ d09b.def  13.,OADS,/arxiv_data1/oa_pdf/e4/89/abd-91-03-0318.PMC4938276.pdf
Disponível em: http://www2.inca.gov.br/wps/wcm/connect/ tiposdecancer/site/home/pele_nao_melanoma 18.,Non-OADS,/arxiv_data1/oa_pdf/e4/89/abd-91-03-0318.PMC4938276.pdf
"©2016	by	Anais 	 Brasileiros 	 de 	 DermatologiaDOI: http://dx.doi.org/10.1590/abd1806-4841.20165254 Abstract:	Backgr ound: 	In 	this 	paper , 	the 	basic 	elements 	r elated 	to 	the 	selection 	of 	participants 	for 	a 	health 	 research	ar e 	discussed.",Non-OADS,/arxiv_data1/oa_pdf/96/52/abd-91-03-0326.PMC4938277.pdf
"©2016	by	Anais 	 Brasileiros 	 de 	 DermatologiaDOI: http://dx.doi.org/10.1590/abd1806-4841.20163986 Abstract:	Silicon	is	the 	second 	most 	abundant 	element 	on 	Earth, 	and 	the 	thir d 	most 	abundant 	trace 	element 	in 	 human	body .",Non-OADS,/arxiv_data1/oa_pdf/ce/33/abd-91-03-0331.PMC4938278.pdf
Available from: http://www.lef.org/ 6.,Non-OADS,/arxiv_data1/oa_pdf/ce/33/abd-91-03-0331.PMC4938278.pdf
Available from: http://www.fda.gov/food/ingredientspackaginglabeling/ gras/scogs/ucm261095.htm 19.,Non-OADS,/arxiv_data1/oa_pdf/ce/33/abd-91-03-0331.PMC4938278.pdf
©2016	by	Anais 	 Brasileiros 	 de 	 DermatologiaDOI: http://dx.doi.org/10.1590/abd1806-4841.20164180 Abstract:	Graft-versus-host 	disease 	(GVHD) 	is 	a 	major 	complication 	of 	allogeneic 	hematopoietic 	stem 	cell 	 transplants 	(allo-HSCT) 	associated 	with 	significant 	morbidity 	and 	mortality .,Non-OADS,/arxiv_data1/oa_pdf/af/03/abd-91-03-0336.PMC4938279.pdf
dermA topAthology Type 2 leprosy reaction with Sweet’s syndrome-like presentation* Francielle Chiavelli Chiaratti1 Egon	Luiz	Rodrigues 	Daxbacher1 Antonielle 	Borges	Faria	Neumann1 Thiago Jeunon1 DOI: http://dx.doi.org/10.1590/abd1806-4841.20164111 Abstract:	Lepr osy	is 	a 	chr onic 	disease 	characterized 	by 	manifestations 	in 	the 	peripheral 	nerves 	and 	skin.,Non-OADS,/arxiv_data1/oa_pdf/ba/db/abd-91-03-0345.PMC4938280.pdf
Disponível em: http://bvsms.saude.gov.br/bvs/publicacoes/orientacoes_para_ corticosteroides_hanseniase.pdf 17.,Non-OADS,/arxiv_data1/oa_pdf/ba/db/abd-91-03-0345.PMC4938280.pdf
Disponível em: http://bvsms.saude.gov.br/bvs/saudelegis/ anvisa/2011/res0011_21_03_2011.html  18.,Non-OADS,/arxiv_data1/oa_pdf/ba/db/abd-91-03-0345.PMC4938280.pdf
[acesso 13 out 2014] Disponível em: http://www.projetodiretrizes.org.br/projeto_ diretrizes/056.pdf  20.,Non-OADS,/arxiv_data1/oa_pdf/ba/db/abd-91-03-0345.PMC4938280.pdf
"©2016 by Anais Brasileiros de DermatologiaDOI: http://dx.doi.org/10.1590/abd1806-4841.20163995 Abstract:  Squamous cell carcinoma (SCC) is the second-most common malignant cutaneous cancer, with 60%  occurring in the head and neck region.",Non-OADS,/arxiv_data1/oa_pdf/77/83/abd-91-03-0351.PMC4938281.pdf
"2016;91(3):354-6.CAse report Dermatofibroma simulating seborrheic keratosis  dermoscopically* Daniel Holanda Barroso1 Camila	Pinon	Zoby	Leite1 Gabriela	Diniz	de	Souza	Araujo1 Márcia	Almeida 	 Galvão 	 Teixeira1 Eliane	Ruth	Barbosa	Alencar1 Silvana Maria de Morais Cavalcanti1 DOI: http://dx.doi.org/10.1590/abd1806-4841.20164031 Abstract:		Dermatofibr oma 	is 	a 	fr equent 	benign 	tumor 	of 	easy 	clinical 	diagnosis 	in 	most 	cases, 	but 	that 	can 	mimic 	 other	dermatoses.",Non-OADS,/arxiv_data1/oa_pdf/59/fe/abd-91-03-0354.PMC4938282.pdf
©2016	by	Anais 	 Brasileiros 	 de 	 DermatologiaDOI: http://dx.doi.org/10.1590/abd1806-4841.20163999 Abstract:  Myiasis refers to Diptera larvae infesting vertebrate animals.,Non-OADS,/arxiv_data1/oa_pdf/19/5d/abd-91-03-0358.PMC4938283.pdf
"©2016	by	Anais 	 Brasileiros 	 de 	 DermatologiaDOI: http://dx.doi.org/10.1590/abd1806-4841.20163821 Abstract:	A	patient	with 	systemic 	involvement, 	initially 	tr eated 	as 	tuber culosis, 	is 	pr esented 	in 	this 	r eport.",Non-OADS,/arxiv_data1/oa_pdf/42/9e/abd-91-03-0362.PMC4938284.pdf
365CAse report Imported cutaneous leishmaniasis caused by Leishmania major  in a Chinese laborer who worked in Saudi Arabia* Min	Zhang1 Fang Liu1 Haibo Liu2 Wenxing Hu2 Hong Sang1 DOI: http://dx.doi.org/10.1590/abd1806-4841.20163820 Abstract:	W e	r eport 	an 	imported 	case 	of 	cutaneous 	leishmaniasis 	in 	a 	37-year -old 	man 	fr om 	Saudi 	Arabia 	caused 	 by	Leishmania 	major .,Non-OADS,/arxiv_data1/oa_pdf/f0/01/abd-91-03-0365.PMC4938285.pdf
"CAse report Total earlobe reconstruction with a superiorly  based preauricular flap* João Goulão1 João	Alves1 DOI: http://dx.doi.org/10.1590/abd1806-4841.20163897 Abstract:	An	86-year -old 	woman 	was 	r eferred 	for 	tr eatment 	of 	a 	lentigo 	maligna 	melanoma 	on 	the 	left 	earlobe, 	 confirmed 	by 	cutaneous 	biopsy .",Non-OADS,/arxiv_data1/oa_pdf/3b/19/abd-91-03-0372.PMC4938287.pdf
©2016	by	Anais 	 Brasileiros 	 de 	 DermatologiaDOI: http://dx.doi.org/10.1590/abd1806-4841.20163960 Abstract:  Methotrexate is one of the most used drugs in the treatment of psoriasis with indication of systemic  therapy.,Non-OADS,/arxiv_data1/oa_pdf/a0/db/abd-91-03-0375.PMC4938288.pdf
"Manuela Panteliades1 Claudia Marcia Resende Silva1 Bernardo	Gontijo1  DOI: http://dx.doi.org/10.1590/abd1806-4841.20165897 s Received on 07.04.2016 Approved 	by	the	Advisory 	 Board 	 and 	 accepted 	 for 	 publication 	 on 	 17.05.2016 *	 Work	performed 	at	the	Hospital	das	Clínicas	da	Universidade 	Federal	de	Minas	Gerais	(HC-UFMG) 	–	Belo	Horizonte	(MG),	Brazil.",Non-OADS,/arxiv_data1/oa_pdf/ab/e3/abd-91-03-0378.PMC4938289.pdf
"2016;91(3):381-3.imAges  in dermA tology Primary cutaneous aspergillosis and idiopathic  bone marrow aplasia* Karina Colossi Furlan1 Mario	Cezar	Pires2 Priscila	Kakizaki1 Juliana Cabral Nunes Chartuni3 Neusa	Y uriko 	 Sakai 	 Valente1  DOI: http://dx.doi.org/10.1590/abd1806-4841.20164889 Abstract:	W e	describe 	the 	case 	of 	a 	9-year -old 	boy 	with 	idiopathic 	bone 	marr ow 	aplasia 	and 	sever e 	neutr openia, 	 who developed skin ulcers under cardiac monitoring electrodes.",Non-OADS,/arxiv_data1/oa_pdf/be/ab/abd-91-03-0381.PMC4938290.pdf
"©2016	by	Anais 	 Brasileiros 	 de 	 DermatologiaDOI: http://dx.doi.org/10.1590/abd1806-4841.20164953 Abstract:	The	authors 	r eport 	aspects 	of 	paracoccidioidomycosis, 	acute-subacute 	clinical 	form, 	juvenile 	type, 	in 	 a	19-year -old 	female 	patient.",Non-OADS,/arxiv_data1/oa_pdf/24/c1/abd-91-03-0384.PMC4938291.pdf
"©2016	by	Anais 	 Brasileiros 	 de 	 DermatologiaDOI: http://dx.doi.org/10.1590/abd1806-4841.20164298387 CASE REPORT Female	patient, 	50 	years 	old, 	pr esenting 	asymp - tomatic	erythematous 	lesions 	for 	two 	months, 	initially 	 in	the	arms, 	which 	have 	spr ead 	to 	thighs, 	for earms 	and 	 anterior chest.",Non-OADS,/arxiv_data1/oa_pdf/6e/86/abd-91-03-0387.PMC4938292.pdf
©2016	by	Anais 	 Brasileiros 	 de 	 DermatologiaDOI: http://dx.doi.org/10.1590/abd1806-4841.20164604 Abstract:	In	Brazil	ther e 	is 	no 	classification 	of 	dermatological 	pr oducts 	by 	the 	pr esence 	of 	vehicles 	with 	sensitiz - ing	potential.,Non-OADS,/arxiv_data1/oa_pdf/95/aa/abd-91-03-0390.PMC4938293.pdf
"CommuniCA tion Brazilian Society of Dermatology against leprosy* Joel Carlos Lastória1 Marilda	Apar ecida 	 Milanez 	 Morgado 	 de 	Abr eu2 DOI: http://dx.doi.org/10.1590/abd1806-4841.20164648 Abstract:	The	Brazilian 	Society 	of 	Dermatology 	pr omoted 	a 	national 	campaign 	against 	lepr osy 	in 	2012, 	involving 	 their	State	Regional, 	Accr edited 	Services 	of 	Dermatology 	and 	Referral 	Services 	in 	Lepr osy.",Non-OADS,/arxiv_data1/oa_pdf/a8/83/abd-91-03-0393.PMC4938294.pdf
Disponível em: http://portalsaude.saude.gov.br/ images/pdf/2014/dezembro/01/Dados-2013.pdf.,Non-OADS,/arxiv_data1/oa_pdf/a8/83/abd-91-03-0393.PMC4938294.pdf
"Member of SBD and SBH  		 ©2016	by	Anais 	 Brasileiros 	 de 	 DermatologiaDOI: http://dx.doi.org/10.1590/abd1806-4841.2016910301 Dear	readers, Reading the revision of the article entitled  ‘HANSENIASE 	EM 	MENORES 	DE 	15 	ANOS” 	pub- lished	in	An 	Bras 	Dermatol 	2016;91 	(2):196-203 	I 	no- ticed	some 	mistakes 	that 	I 	believe 	should 	be 	clarified 	 due	to	the	r elevance 	of 	the 	subject, 	especially 	when 	the 	 Ministry	of 	Health, 	thr ough 	CGHDE, 	is 	investing 	in 	 campaigns at schools aiming at early diagnosis of lep - rosy	in	subjects	younger	than	15	years	of	age.1   The	article 	was 	r eceived 	at 	the 	Annals 	on 	28/ APR/2014 	and 	after 	appr oved 	by 	the 	Editorial 	Boar d, 	 accepted for publication on 16/SEP/2014.",Non-OADS,/arxiv_data1/oa_pdf/27/82/abd-91-03-0396.PMC4938295.pdf
"©2016	by	Anais 	 Brasileiros 	 de 	 DermatologiaDOI: http://dx.doi.org/10.1590/abd1806-4841.2016910302 Dear	Dr.	Maria	Eugenia	Noviski	Gallo, Thank you for your suggestions.",Non-OADS,/arxiv_data1/oa_pdf/0a/53/abd-91-03-0397.PMC4938296.pdf
"We would like to remind you that in January 2016 was published Ordinance 149 regard - ing	the	Guidelines 	for 	vigillance, 	attention 	and 	elim - ination of leprosy as a problem of public health that maintains the orientation about BCG and widens the orientation for vigillance of household contact with leprosy (http://portalsaude.saude.gov.br/images/pdf/2016/fevereiro/04/diretrizes-eliminacao-han - seniase-4fev16-web.pdf )	and		standartization 	of 	the 	 protocol of care and vigillance  is fundamental for the  quality	of	assistance 	to 	the 	patients 	and 	r eduction 	of 	 risk of illness among contacts.",Non-OADS,/arxiv_data1/oa_pdf/22/82/abd-91-03-0398.PMC4938297.pdf
"q letters   Rosa Castália França Ribeiro Soares1 Received on 25.05.2016 Approved 	by	the	Advisory 	 Board 	 and 	 accepted 	 for 	 publication 	 on 	 25.05.2016 1	 General 	Coordination 	of	Leprosy	and	Diseases	Targeted	for	Elimination 	CGHDE/SVS/MS 	 		 ©2016	by	Anais 	 Brasileiros 	 de 	 DermatologiaDOI: http://dx.doi.org/10.1590/abd1806-4841.2016910303 Dear	Editors	of	Anais 	 Brasileiros 	 de 	 Dermatologia,  Considering the relevance of this scientif - ic	journal	that 	has 	as 	priorities 	publications 	about 	 Hansen’s	disease, 	as 	well 	as 	the 	importance 	of 	these 	 publications 	to 	the 	medical 		community , 	mainly 	der- matologists, 	I 	am 	sending 	considerations 	r egarding 	 the article “Hanseníase em menores de 15 anos” de  2016;91(2):196 	- 	203.",Non-OADS,/arxiv_data1/oa_pdf/22/82/abd-91-03-0398.PMC4938297.pdf
DOI: http://dx.doi.org/10.1590/abd1806-4841.2016910304 An Bras Dermatol.,Non-OADS,/arxiv_data1/oa_pdf/7a/1b/abd-91-03-0399.PMC4938298.pdf
2011;86(4 	 Suppl 	 1):S193-5.DOI: http://dx.doi.org/10.1590/abd1806-4841.2016910305,Non-OADS,/arxiv_data1/oa_pdf/16/8c/abd-91-03-0400.PMC4938299.pdf
"6, e1151593 (12 pages)http://dx.doi.org/10.1080/2162402X.2016.1151593",Non-OADS,/arxiv_data1/oa_pdf/6e/2b/koni-05-06-1151593.PMC4938303.pdf
J Natl Cancer Inst 2013; 105:1172-87; PMID:23852952; http://dx.doi.org/10.1093/jnci/djt184 2.,Non-OADS,/arxiv_data1/oa_pdf/6e/2b/koni-05-06-1151593.PMC4938303.pdf
Mol Immu-nol 2002; 39:181-202; PMID:12200050; http://dx.doi.org/10.1016/ S0161-5890(02)00101-3 3.,OADS,/arxiv_data1/oa_pdf/6e/2b/koni-05-06-1151593.PMC4938303.pdf
Nat Rev Immunol 2003; 3:952-61; PMID:14647477; http://dx.doi.org/10.1038/nri1250 4.,Non-OADS,/arxiv_data1/oa_pdf/6e/2b/koni-05-06-1151593.PMC4938303.pdf
Immunity 2004; 21:137-48;PMID:15308095; http://dx.doi.org/10.1016/j.immuni.2004.07.017 5.,OADS,/arxiv_data1/oa_pdf/6e/2b/koni-05-06-1151593.PMC4938303.pdf
Nature 2012; 482:405-9; PMID:22318517; http://dx.doi.org/10.1038/ nature10803 7.,Non-OADS,/arxiv_data1/oa_pdf/6e/2b/koni-05-06-1151593.PMC4938303.pdf
Semin Cancer Biol 2012; 22:350-8;PMID:22465194; http://dx.doi.org/10.1016/j.semcancer.2012.03.003 9.,Non-OADS,/arxiv_data1/oa_pdf/6e/2b/koni-05-06-1151593.PMC4938303.pdf
Cancer Immunol Immunother 2007; 56:709-17; PMID:16960691; http://dx.doi.org/10.1007/s00262-006-0226-710.,Non-OADS,/arxiv_data1/oa_pdf/6e/2b/koni-05-06-1151593.PMC4938303.pdf
Immunogenetics 2008; 60:439-47; PMID:18545995; http://dx.doi.org/10.1007/s00251-008-0303-5 11.,Non-OADS,/arxiv_data1/oa_pdf/6e/2b/koni-05-06-1151593.PMC4938303.pdf
Cancer Immunol Immunother 2008; 57:1719-26; PMID:18408926; http://dx.doi.org/10.1007/s00262- 008-0515-4 13.,Non-OADS,/arxiv_data1/oa_pdf/6e/2b/koni-05-06-1151593.PMC4938303.pdf
Clin Cancer Res 2011; 17:2668-78; PMID:21248298; http://dx.doi.org/10.1158/1078-0432.CCR-10-2114 14.,Non-OADS,/arxiv_data1/oa_pdf/6e/2b/koni-05-06-1151593.PMC4938303.pdf
Cancer Immunol Immunother 2012; 61:249-54; PMID:22120755; http://dx.doi.org/10.1007/s00262-011-1153-9 15.,Non-OADS,/arxiv_data1/oa_pdf/6e/2b/koni-05-06-1151593.PMC4938303.pdf
Cancer Immunol Immunother 2008; 57:647-54; PMID:18046553; http://dx.doi.org/10.1007/s00262-007-0402-4 16.,Non-OADS,/arxiv_data1/oa_pdf/6e/2b/koni-05-06-1151593.PMC4938303.pdf
Oncogene 2008; 27:5869- 85; PMID:18836468; http://dx.doi.org/10.1038/onc.2008.273 17.,Non-OADS,/arxiv_data1/oa_pdf/6e/2b/koni-05-06-1151593.PMC4938303.pdf
Immunity 2007; 27:549-59; PMID:17967410; http://dx.doi.org/10.1016/j.immuni.2007.10.002 18.,OADS,/arxiv_data1/oa_pdf/6e/2b/koni-05-06-1151593.PMC4938303.pdf
J Immunol 2010; 185:1681-91; PMID:20610642; http://dx.doi.org/10.4049/jimmunol.0903900 19.,Non-OADS,/arxiv_data1/oa_pdf/6e/2b/koni-05-06-1151593.PMC4938303.pdf
J Biol Chem 2010; 285:26223-32; PMID:20538593; http://dx.doi.org/10.1074/jbc.M110.109736 20.,OADS,/arxiv_data1/oa_pdf/6e/2b/koni-05-06-1151593.PMC4938303.pdf
Cell 2010; 141:483-96; PMID:20434986; http://dx.doi.org/10.1016/j.cell.2010.03.040 21.,OADS,/arxiv_data1/oa_pdf/6e/2b/koni-05-06-1151593.PMC4938303.pdf
J Immu-nol 2010; 184:1990-2000; PMID:20061403; http://dx.doi.org/ 10.4049/jimmunol.0900557 22.,Non-OADS,/arxiv_data1/oa_pdf/6e/2b/koni-05-06-1151593.PMC4938303.pdf
J Immunol 2011; 186:1333-7; PMID:21191067; http://dx.doi.org/ 10.4049/jimmunol.1003111 23.,Non-OADS,/arxiv_data1/oa_pdf/6e/2b/koni-05-06-1151593.PMC4938303.pdf
Proc Natl Acad Sci U S A 2010; 107:13794-9; PMID:20639463; http://dx.doi.org/10.1073/ pnas.1008684107 24.,OADS,/arxiv_data1/oa_pdf/6e/2b/koni-05-06-1151593.PMC4938303.pdf
Nat Rev Immunol 2012; 12:813-20;PMID:23175229; http://dx.doi.org/10.1038/nri3339 25.,Non-OADS,/arxiv_data1/oa_pdf/6e/2b/koni-05-06-1151593.PMC4938303.pdf
J Immunol 2011; 186:994-1000;PMID:21148033; http://dx.doi.org/10.4049/jimmunol.1002094 26.,Non-OADS,/arxiv_data1/oa_pdf/6e/2b/koni-05-06-1151593.PMC4938303.pdf
J Immunol 2012; 189:516-20; PMID:22711889; http://dx.doi.org/10.4049/jimmunol.1200064ONCOIMMUNOLOGY 11,Non-OADS,/arxiv_data1/oa_pdf/6e/2b/koni-05-06-1151593.PMC4938303.pdf
J Immunol 2012; 188:3820-8; PMID:22412192; http://dx.doi.org/10.4049/jimmunol.1102671 28.,Non-OADS,/arxiv_data1/oa_pdf/6e/2b/koni-05-06-1151593.PMC4938303.pdf
Cell Res 2012; 22:836-47; PMID:22491475; http://dx.doi.org/10.1038/cr.2012.56 29.,OADS,/arxiv_data1/oa_pdf/6e/2b/koni-05-06-1151593.PMC4938303.pdf
J Biol Chem 2012; 287:24294-303; PMID:22645137; http://dx.doi.org/10.1074/jbc.M112.364604 30.,OADS,/arxiv_data1/oa_pdf/6e/2b/koni-05-06-1151593.PMC4938303.pdf
JImmunol 2012; 188:4951-8; PMID:22490869; http://dx.doi.org/10.4049/jimmunol.1103160 31.,Non-OADS,/arxiv_data1/oa_pdf/6e/2b/koni-05-06-1151593.PMC4938303.pdf
Biochem Biophys Res Commun 2012; 418:786-91; PMID:22310711; http://dx.doi.org/10.1016/j.bbrc.2012.01.104 33.,OADS,/arxiv_data1/oa_pdf/6e/2b/koni-05-06-1151593.PMC4938303.pdf
PLoS Genet 2015; 11:e1005088; PMID:25811463; http://dx.doi.org/10.1371/journal.pgen.1005088 34.,Non-OADS,/arxiv_data1/oa_pdf/6e/2b/koni-05-06-1151593.PMC4938303.pdf
Cancer Res 2001; 61:1095-9; PMID:11221838; http://dx.doi.org/10.1002/0471142735.im2001s39.,Non-OADS,/arxiv_data1/oa_pdf/6e/2b/koni-05-06-1151593.PMC4938303.pdf
Science 1993; 259:368- 70; PMID:7678351; http://dx.doi.org/10.1126/science.7678351 37.,Non-OADS,/arxiv_data1/oa_pdf/6e/2b/koni-05-06-1151593.PMC4938303.pdf
Nat Rev Immunol 2003; 3:939-51; PMID:14647476; http://dx.doi.org/10.1038/nri1248 38.,Non-OADS,/arxiv_data1/oa_pdf/6e/2b/koni-05-06-1151593.PMC4938303.pdf
J Immunol 2011; 186:5131-41;PMID:21430227; http://dx.doi.org/10.4049/jimmunol.1001221 39.,Non-OADS,/arxiv_data1/oa_pdf/6e/2b/koni-05-06-1151593.PMC4938303.pdf
J Immunol Methods 2003; 281:65-78; PMID:14580882; http://dx.doi.org/10.1016/ S0022-1759(03)00265-5 40.,Non-OADS,/arxiv_data1/oa_pdf/6e/2b/koni-05-06-1151593.PMC4938303.pdf
Annu RevMed 2013; 64:71-90; PMID:23092383; http://dx.doi.org/10.1146/ annurev-med-112311-083918 41.,Non-OADS,/arxiv_data1/oa_pdf/6e/2b/koni-05-06-1151593.PMC4938303.pdf
Cancer Cell 2015; 27:439-49; PMID:25858803; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/6e/2b/koni-05-06-1151593.PMC4938303.pdf
Nat Rev Cancer 2012; 12:307-13;PMID:22378190; http://dx.doi.org/10.1038/nrc3246 43.,Non-OADS,/arxiv_data1/oa_pdf/6e/2b/koni-05-06-1151593.PMC4938303.pdf
Cell Res 2012; 22:822-35; PMID:22473004; http://dx.doi.org/10.1038/cr.2012.53 44.,OADS,/arxiv_data1/oa_pdf/6e/2b/koni-05-06-1151593.PMC4938303.pdf
Nature 2001; 410:1107-11; PMID:11323675; http://dx.doi.org/10.1038/ 35074122 45.,Non-OADS,/arxiv_data1/oa_pdf/6e/2b/koni-05-06-1151593.PMC4938303.pdf
Mol Ther 2014; 22:206-18; PMID:24196579; http://dx.doi.org/10.1038/mt.2013.255 46.,OADS,/arxiv_data1/oa_pdf/6e/2b/koni-05-06-1151593.PMC4938303.pdf
Adop- tive cell transfer: a clinical path to effective cancer immunotherapy.Nat Rev Cancer 2008; 8:299-308; PMID:18354418; http://dx.doi.org/10.1038/nrc2355 47.,Non-OADS,/arxiv_data1/oa_pdf/6e/2b/koni-05-06-1151593.PMC4938303.pdf
Nature 2011; 471:581-2; PMID:21455165; http://dx.doi.org/10.1038/471581a 48.,Non-OADS,/arxiv_data1/oa_pdf/6e/2b/koni-05-06-1151593.PMC4938303.pdf
Nat Rev Cancer 2012; 12:671-84; PMID:22996603; http://dx.doi.org/10.1038/nrc3322 49.,Non-OADS,/arxiv_data1/oa_pdf/6e/2b/koni-05-06-1151593.PMC4938303.pdf
Cell Signal 2007; 19:806-16; PMID:17126530; http://dx.doi.org/10.1016/j.cellsig.2006.10.00312 G. M. RODRIGUEZ ET AL.,OADS,/arxiv_data1/oa_pdf/6e/2b/koni-05-06-1151593.PMC4938303.pdf
"6, e1168557 (9 pages)http://dx.doi.org/10.1080/2162402X.2016.1168557",Non-OADS,/arxiv_data1/oa_pdf/86/b8/koni-05-06-1168557.PMC4938304.pdf
J Cell Biol 2011; 192:675-90; PMID:21339333; http://dx.doi.org/10.1083/jcb.201009135 2.,OADS,/arxiv_data1/oa_pdf/86/b8/koni-05-06-1168557.PMC4938304.pdf
Hum Anti-bodies Hybridomas 1994; 5:41-7; PMID:7858182; http://dx.doi.org/10.3233/HAB-1994-51-206 3.,OADS,/arxiv_data1/oa_pdf/86/b8/koni-05-06-1168557.PMC4938304.pdf
OncoImmunology 2015; 4:e989776; PMID:26137406; http://dx.doi.org/10.4161/2162402X.2014 4.,Non-OADS,/arxiv_data1/oa_pdf/86/b8/koni-05-06-1168557.PMC4938304.pdf
FEBS Lett 2014; 588:288-97;PMID:24295643; http://dx.doi.org/10.1016/j.febslet.2013.11.030 5.,OADS,/arxiv_data1/oa_pdf/86/b8/koni-05-06-1168557.PMC4938304.pdf
Science2008; 321:974-7; PMID:18703743; http://dx.doi.org/10.1126/ science.1158545 6.,Non-OADS,/arxiv_data1/oa_pdf/86/b8/koni-05-06-1168557.PMC4938304.pdf
Cancer Immunol Immunother 2010; 59:1197-209; PMID:20309546; http://dx.doi.org/10.1007/s00262-010-0844-y 7.,Non-OADS,/arxiv_data1/oa_pdf/86/b8/koni-05-06-1168557.PMC4938304.pdf
Clin Cancer Res 2009; 15:5323-37; PMID:19723653; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/86/b8/koni-05-06-1168557.PMC4938304.pdf
Int J Cancer 2014; 136:476-486; PMID:24895182; http://dx.doi.org/10.1002/ijc.29007 9.,Non-OADS,/arxiv_data1/oa_pdf/86/b8/koni-05-06-1168557.PMC4938304.pdf
Int J Cancer 2015; 136:476-86; PMID:24895182; http://dx.doi.org/10.1002/ijc.29007 10.,Non-OADS,/arxiv_data1/oa_pdf/86/b8/koni-05-06-1168557.PMC4938304.pdf
J Clin Oncol 2012a; 30:3264-70; PMID:22869886; http://dx.doi.org/10.1200/JCO.2011.41.3807 11.,Non-OADS,/arxiv_data1/oa_pdf/86/b8/koni-05-06-1168557.PMC4938304.pdf
OncoIm- munology 2012b; 1:477-86; PMID:22754766; http://dx.doi.org/10.4161/ onci.19864 12.,Non-OADS,/arxiv_data1/oa_pdf/86/b8/koni-05-06-1168557.PMC4938304.pdf
Clin Cancer Res 2012; 18:465-74;PMID:22096026; http://dx.doi.org/10.1158/1078-0432.CCR-11-1270 14.,Non-OADS,/arxiv_data1/oa_pdf/86/b8/koni-05-06-1168557.PMC4938304.pdf
Semin Oncol 2014; 41:589-612; PMID:25440605;http://dx.doi.org/10.1053/j.seminoncol.2014.07.003 15.,Non-OADS,/arxiv_data1/oa_pdf/86/b8/koni-05-06-1168557.PMC4938304.pdf
Methods2004; 34:184-99; PMID:15312672; http://dx.doi.org/10.1016/j.ymeth.2004.04.007e1168557-8 M. CHENG ET AL.,OADS,/arxiv_data1/oa_pdf/86/b8/koni-05-06-1168557.PMC4938304.pdf
Biochim Biophys Acta 2014; 1844:2016-23; PMID:25038323;http://dx.doi.org/10.1016/j.bbapap.2014.07.005 17.,OADS,/arxiv_data1/oa_pdf/86/b8/koni-05-06-1168557.PMC4938304.pdf
"Kipriyanov SM, Moldenhauer G, Schuhmacher J, Cochlovius B, Von der Lieth CW, Matys ER, Little M. Bispeci ﬁc tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics.J Mol Biol 1999; 293:41-56; PMID:10512714; http://dx.doi.org/ 10.1006/jmbi.1999.3156 18.",OADS,/arxiv_data1/oa_pdf/86/b8/koni-05-06-1168557.PMC4938304.pdf
Protein Eng Des Sel 2004; 17:357-66; PMID:15126676; http://dx.doi.org/10.1093/ protein/gzh039 19.,OADS,/arxiv_data1/oa_pdf/86/b8/koni-05-06-1168557.PMC4938304.pdf
Protein Eng Des Sel 2010; 23:549-57; PMID:20457695;http://dx.doi.org/10.1093/protein/gzq028 20.,OADS,/arxiv_data1/oa_pdf/86/b8/koni-05-06-1168557.PMC4938304.pdf
Nucl Med Biol 2011; 38:223-33; PMID:21315278; http://dx.doi.org/10.1016/j.nucmedbio.2010.08.013 21.,OADS,/arxiv_data1/oa_pdf/86/b8/koni-05-06-1168557.PMC4938304.pdf
Nat Rev Cancer 2012; 12:278-87; PMID:22437872; http://dx.doi.org/10.1038/nrc3236 22.,Non-OADS,/arxiv_data1/oa_pdf/86/b8/koni-05-06-1168557.PMC4938304.pdf
Mol Immunol 2015; 67:95-106; PMID:25637431; http://dx.doi.org/10.1016/j.molimm.2015.01.003 23.,Non-OADS,/arxiv_data1/oa_pdf/86/b8/koni-05-06-1168557.PMC4938304.pdf
Expert Opin Ther Targets 2015; 19:349-62;PMID:25604432; http://dx.doi.org/10.1517/14728222.20.986459 24.,Non-OADS,/arxiv_data1/oa_pdf/86/b8/koni-05-06-1168557.PMC4938304.pdf
Sci Rep 2014; 4:3673; PMID:24419156; http://dx.doi.org/10.1038/srep03673 2 5 .,Non-OADS,/arxiv_data1/oa_pdf/86/b8/koni-05-06-1168557.PMC4938304.pdf
Lancet Oncol 2015; 16:57-66; PMID:25524800; http://dx.doi.org/ 10.1016/S1470-2045(14)71170-2 26.,Non-OADS,/arxiv_data1/oa_pdf/86/b8/koni-05-06-1168557.PMC4938304.pdf
Cancer Immunol Res 2015; 3:266-77; PMID:25542634; http://dx.doi.org/10.1158/2326-6066.CIR-14-0230-T 2 9 .,Non-OADS,/arxiv_data1/oa_pdf/86/b8/koni-05-06-1168557.PMC4938304.pdf
Pediatr Blood Cancer 2012; 59:1198-205; PMID:22707078; http://dx.doi.org/10.1002/pbc.24237 30.,Non-OADS,/arxiv_data1/oa_pdf/86/b8/koni-05-06-1168557.PMC4938304.pdf
N Engl J Med 2010; 363:1324-34; PMID:20879881; http://dx.doi.org/10.1056/NEJMoa0911123 31.,Non-OADS,/arxiv_data1/oa_pdf/86/b8/koni-05-06-1168557.PMC4938304.pdf
J Biol Chem 2015; 290:13017-27; PMID:25851904; http://dx.doi.org/ 10.1074/jbc.M115.650903ONCOIMMUNOLOGY e1168557-9,Non-OADS,/arxiv_data1/oa_pdf/86/b8/koni-05-06-1168557.PMC4938304.pdf
"6, e1101206 (11 pages)http://dx.doi.org/10.1080/2162402X.2015.1101206",Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j.cell.2011.02.0132.,OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Ann Rev Immunol 2013; 31:51-72; PMID:23157435;http://dx.doi.org/10.1146/annurev-immunol-032712-100008 3.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Anatomia Histologia Embryologia 2002; 31:214-23; PMID:12196263; http://dx.doi.org/10.1046/j.1439-0264.2002.00398.x 4.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Front Microbiol 2011;2:3; PMID:21687402; http://dx.doi.org/10.3389/fmicb.2011.00003 5.,OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Biochimica Et Biophysica Acta 2009; 1793:1432-43; PMID:19362111; http://dx.doi.org/10.1016/j.bbamcr.2009.03.010 6.,OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Immunity 2013; 38:209-23; PMID:23438821; http://dx.doi.org/10.1016/j.immuni.2013.02.003 7.,OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
FrontImmunol 2012; 3:277; PMID:22969769; http://dx.doi.org/10.3389/ ﬁmmu.2012.00277 8.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Oncoim-munol 2013; 2:e24501; PMID:23894711; http://dx.doi.org/10.4161/onci.24501 10.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Cell Death Differ 2014; 21:39-49; PMID:23832118; http://dx.doi.org/10.1038/cdd.2013.84 11.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Cancer Immunol Immunother2014; 63:29-36; PMID:24052136; http://dx.doi.org/10.1007/s00262- 013-1474-y 12.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Cytotherapy 2013; 15:492-506; PMID:23480952; http://dx.doi.org/10.1016/j.jcyt.2012.12.002 13.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Int J Cancer J Int Du Cancer 1995; 61:272-9; PMID:7705958;http://dx.doi.org/10.1002/ijc.2910610222 14.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Cell Death Differ 2005; 12:38-51; PMID:15592361; http://dx.doi.org/ 10.1038/sj.cdd.4401510 15.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
J Leukocyte Biol 2007; 81:15-27; PMID:16931602; http://dx.doi.org/10.1189/jlb.0306167 16.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Cancer 2005; 104:1129-37;PMID:16080176; http://dx.doi.org/10.1002/cncr.21324 17.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Cancer Lett 2015; 356:137-44; PMID:24139967; http://dx.doi.org/10.1016/j.canlet.2013.09.031 18.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Immunother 2014; 6:597-610; PMID:24896628; http://dx.doi.org/10.2217/imt.14.38ONCOIMMUNOLOGY e1101206-9,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Int J Radiat Oncol Biol Phys2004; 58:862-70; PMID:14967443; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Lancet Oncol 2015; 16:795-803;PMID:26095785; http://dx.doi.org/10.1016/S1470-2045(15)00054-6 21.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
N Eng J Med 2012; 366:925-31; PMID:22397654; http://dx.doi.org/10.1056/NEJM-oa1112824 22.,OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Oncotarget 2014; 5:403-16; PMID:24480782; http://dx.doi.org/10.18632/oncotarget.1719 23.,OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Sem Oncol 2012; 39:323-39; PMID:22595055; http://dx.doi.org/10.1053/j.semin-oncol.2012.02.006 24.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Oncoimmunol 2014; 3:e28518;PMID:25071979; http://dx.doi.org/10.4161/onci.28518 25.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Oncoimmunol 2014; 3:e954929;PMID:25941606; http://dx.doi.org/10.4161/21624011.2014.954929 26. van der Zee J.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Ann Oncol 2002; 13:1173-84; PMID:12181239; http://dx.doi.org/10.1093/annonc/mdf280 27.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Cancer Treatment Rev 2015; 41(9):742-53;PMID:26051911; http://dx.doi.org/10.1016/j.ctrv.2015.05.009 29.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Int J Hyperthermia 2012; 28:528-42;PMID:22690925; http://dx.doi.org/10.3109/02656736.2012.677933 30.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Int J hyperthermia 2008; 24:41-56; PMID:18214768; http://dx.doi.org/10.1080/02656730701858297 31.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Int J Hyperther 2011; 27:591-603; PMID:21846195; http://dx.doi.org/10.3109/02656736.2011.589234 32.,OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Radiother Oncol 2011; 101:109-15; PMID:21704416; http://dx.doi.org/10.1016/j.radonc.2011.05.056 33.,OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Clin Transl Oncol 2013; 15:95-105; PMID:23180345; http://dx.doi.org/10.1007/s12094-012-0947-3 34.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
CellDeath Dis 2015; 6:e1761; PMID:25973681; http://dx.doi.org/10.1038/ cddis.2015.129 35.,OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Sem Oncol 2015; 42:466-73; PMID:25965365; http://dx.doi.org/10.1053/j.seminoncol.2015.02.008 36.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Clin Cancer Res 2006; 12:289-97; PMID:16397054; http://dx.doi.org/ 10.1158/1078-0432.CCR-05-0210 37.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Oncoimmunol 2014; 3:e29028; PMID:25083327; http://dx.doi.org/10.4161/onci.29028 38.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Eur J Immunol 1975; 5:112-7; PMID:1234049; http://dx.doi.org/10.1002/eji.1830050208 39.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Nature 1986; 319:675-8; PMID:3951539; http://dx.doi.org/10.1038/319675a0 40.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Oncoimmunol 2013; 2: e26097; PMID:24353908; http://dx.doi.org/10.4161/onci.26097 41.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Science 2011; 331:44-9; PMID:21212348;http://dx.doi.org/10.1126/science.1198687 42.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Immunol Rev 2006; 214:47-55; PMID:17100875; http://dx.doi.org/10.1111/j.1600-065X.2006.00454.x 43.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Blood 2009; 113:5488-96; PMID:19234143; http://dx.doi.org/10.1182/blood- 2008-10-187179 44.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Annu Rev Immunol 2006; 24:257-86; PMID:16551250; http://dx.doi.org/10.1146/annurev.immunol.24.021605.090700 45.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Oncoimmunol 2015; 4:e981483; PMID:25949862; http://dx.doi.org/10.4161/21624-02X.2014.981483 46.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
J Leukocyte Biol 2008; 83:106-11; PMID:17940219; http://dx.doi.org/10.1189/jlb.0707496 47.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Nat Immunol 2004; 5:1260-5; PMID:15531883; http://dx.doi.org/10.1038/ni1138 48.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Nat Rev Cancer 2002;2:850-61; PMID:12415255; http://dx.doi.org/10.1038/nrc928 49.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Cancer Immunol Immunother 2006; 55:1122-31;PMID:16273350; http://dx.doi.org/10.1007/s00262-005-0089-3 50.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Immunol 2011; 186:3304-8; PMID:21307295; http://dx.doi.org/ 10.4049/jimmunol.1004122 51.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Oncoimmunol 2014; 3:e955691; PMID:25941621; http://dx.doi.org/10.4161/21624011.2014.955691 52.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Onkologie 2003; 26:295-302; PMID:12845217; http://dx.doi.org/; http://dx.doi.org/10.1159/0000-71628 53.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Front Oncol 2012;2:75; PMID:22848871; http://dx.doi.org/10.3389/fonc.2012.00075 54.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Front Immunol 2015; 6:46; PMID:25709607; http://dx.doi.org/10.3389/ ﬁmmu.2015.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Therapeutic Adv Med Oncol 2015; 7:107-21; PMID:25755683; http://dx.doi.org/10.1177/1758834014566619 56.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
"Surg Clin N Am 2014; 94:1017-30,;PMID:25245965; http://dx.doi.org/10.1016/j.suc.2014.07.005 57.",OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Science 2015; 348:62-8; PMID:25838374; http://dx.doi.org/10.1126/science.aaa4967 58.,OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Cell 2003; 113:717-30; PMID:12809603; http://dx.doi.org/10.1016/S0092-8674(03)00422-7 59.,OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Nature 2002; 418:191-5; PMID:12110890; http://dx.doi.org/10.1038/nature00858 60.,OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Nat Med 2007; 13:1050-9; PMID:17704786;http://dx.doi.org/10.1038/nm1622 61.,OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
J Immunol 2004; 173:307-13; http://dx.doi.org/10.4049/jimmunol.173.1.307 62.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Mol Immunol 2005; 42:433-44; PMID:15607795; http://dx.doi.org/10.1016/j.molimm.2004.07.023 63.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
J Immunol 2007; 179:5523-33; PMID:17911639; http://dx.doi.org/ 10.4049/jimmunol.179.8.5523 65.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
J Leukocyte Biol 2007; 81:84-91; PMID:17035340;http://dx.doi.org/10.1189/jlb.0306171 66.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Int J Cancer J Int Du Cancer 2015; 136:1381-9;PMID:25098891; http://dx.doi.org/10.1002/ijc.29125 67.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
JImmunother 2008; 31:458-65; PMID:18463539; http://dx.doi.org/ 10.1097/CJI.0b013e318174a512 68.,OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
J Immunol 2006; 176:1517-24; PMID:16424180; http://dx.doi.org/ 10.4049/jimmunol.176.3.1517 69.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
J Immunol Met 2012; 378:1- 10; PMID:22306357; http://dx.doi.org/10.1016/j.jim.2012.01.008 70.,OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Oncol Rep 2014; 31:2015-20; PMID:24626639; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
J Leukocyte Biol 2011; 90:777-85;PMID:21712396; http://dx.doi.org/10.1189/jlb.0411208 72.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
A shed NKG2Dligand that promotes natural killer cell activation and tumor rejection.Science 2015; 348:136-9; PMID:25745066; http://dx.doi.org/10.1126/ science.1258867 73.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
”Blood 2005; 106:2252- 8; PMID:15933055; http://dx.doi.org/10.1182/blood-2005-03-1154 74.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Cancer Res 2014; 74:5458-68; PMID:25274032; http://dx.doi.org/10.1158/0008-5472.CAN-14-1258 75.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Lancet Oncol 2015; 16:742-3; PMID:26095779; http://dx.doi.org/ 10.1016/S1470-2045(15)00055-8 76.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Curr Med Chem 2012; 19:1751-64; PMID:22414083; http://dx.doi.org/10.2174/092986712800099811 77.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
J Immunotoxicol 2010; 7:194-204; PMID:20205624;http://dx.doi.org/10.3109/15476911003657414 79.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Cytometry Part A 2006; 69:541-51; PMID:16604519; http://dx.doi.org/10.1002/cyto.a.20258 80.,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
Met Mol Biol 2004; 271:37-58; PMID:15146111; http://dx.doi.org/10.1385/1-59259-796-3:037ONCOIMMUNOLOGY e1101206-11,Non-OADS,/arxiv_data1/oa_pdf/cd/f9/koni-05-06-1101206.PMC4938308.pdf
"6, e1151592 (7 pages)http://dx.doi.org/10.1080/2162402X.2016.1151592",Non-OADS,/arxiv_data1/oa_pdf/c4/b3/koni-05-06-1151592.PMC4938315.pdf
Scand J Immunol 2015; 82(3):208-17; PMID:26111359;http://dx.doi.org/10.1111/sji.12333 2.,Non-OADS,/arxiv_data1/oa_pdf/c4/b3/koni-05-06-1151592.PMC4938315.pdf
Arthritis Res Ther 2011; 13:R115; PMID:21752263; http://dx.doi.org/10.1186/ar3400 3.,Non-OADS,/arxiv_data1/oa_pdf/c4/b3/koni-05-06-1151592.PMC4938315.pdf
OncoImmunol- ogy 2015; 5:e1057385; PMID:26942065; http://dx.doi.org/10.1080/ 2162402X.2015.1057385.,Non-OADS,/arxiv_data1/oa_pdf/c4/b3/koni-05-06-1151592.PMC4938315.pdf
Immunology 2014; 143(1):109-19; PMID:24679047; http://dx.doi.org/10.1111/imm.12293 6.,Non-OADS,/arxiv_data1/oa_pdf/c4/b3/koni-05-06-1151592.PMC4938315.pdf
J Biomed Biotechnol 2010; 2010:505694; PMID:20111744; http://dx.doi.org/10.1155/2010/505694 7.,Non-OADS,/arxiv_data1/oa_pdf/c4/b3/koni-05-06-1151592.PMC4938315.pdf
Trends Immunol 2002; 23:445-9; PMID:12200066; http://dx.doi.org/ 10.1016/S1471-4906(02)02281-0 8.,Non-OADS,/arxiv_data1/oa_pdf/c4/b3/koni-05-06-1151592.PMC4938315.pdf
Semin Immunol 2001; 13:267-74;PMID:11502161; http://dx.doi.org/10.1006/smim.2001.0322 10.,Non-OADS,/arxiv_data1/oa_pdf/c4/b3/koni-05-06-1151592.PMC4938315.pdf
Clin Immunol 2012; 142:373- 82; PMID:22281426 http://dx.doi.org/10.1016/j.clim.2011.12.009 11.,Non-OADS,/arxiv_data1/oa_pdf/c4/b3/koni-05-06-1151592.PMC4938315.pdf
J Immunol 2002; 168:2914-21; PMID:11884462; http://dx.doi.org/10.4049/jimmunol.168.6.2914 12.,Non-OADS,/arxiv_data1/oa_pdf/c4/b3/koni-05-06-1151592.PMC4938315.pdf
Trends Immunol 2013; 34:521-30; PMID:23973621; http://dx.doi.org/10.1016/j.it.2013.07.006 13.,OADS,/arxiv_data1/oa_pdf/c4/b3/koni-05-06-1151592.PMC4938315.pdf
Blood 2002; 99:3263-72; PMID:11964292; http://dx.doi.org/10.1182/blood.V99.9.3263 14.,Non-OADS,/arxiv_data1/oa_pdf/c4/b3/koni-05-06-1151592.PMC4938315.pdf
Nat Immunol 2000; 1:475-82; PMID:11101868; http://dx.doi.org/10.1038/82717 16.,Non-OADS,/arxiv_data1/oa_pdf/c4/b3/koni-05-06-1151592.PMC4938315.pdf
Nat Immunol 2000; 1:465-6; PMID:11101865; http://dx.doi.org/ 10.1038/82707 17.,Non-OADS,/arxiv_data1/oa_pdf/c4/b3/koni-05-06-1151592.PMC4938315.pdf
Nat Rev Cancer 2012; 12:265-77; PMID:22437871; http://dx.doi.org/ 10.1038/nrc3258 18.,Non-OADS,/arxiv_data1/oa_pdf/c4/b3/koni-05-06-1151592.PMC4938315.pdf
Leuk Lym-phoma 2013; 54:1602-13; PMID:23206225; http://dx.doi.org/10.3109/ 10428194.2012.755178 20.,Non-OADS,/arxiv_data1/oa_pdf/c4/b3/koni-05-06-1151592.PMC4938315.pdf
Br Med Bull 2008; 87:49-62; PMID:18755702;http://dx.doi.org/10.1093/bmb/ldn034 21.,Non-OADS,/arxiv_data1/oa_pdf/c4/b3/koni-05-06-1151592.PMC4938315.pdf
Cancer Immunol Immunother 2012; 61:865-79;PMID:22086161; http://dx.doi.org/10.1007/s00262-011-1149-5ONCOIMMUNOLOGY e1151592-7,Non-OADS,/arxiv_data1/oa_pdf/c4/b3/koni-05-06-1151592.PMC4938315.pdf
"6, e1072674 (2 pages)http://dx.doi.org/10.1080/2162402X.2015.1072674",Non-OADS,/arxiv_data1/oa_pdf/e2/6b/koni-05-06-1072674.PMC4938317.pdf
Semin Cancer Biol 2012; 22:23-32; PMID:22210181; http://dx.doi.org/10.1016/j.semcancer.2011.12.004 2.,Non-OADS,/arxiv_data1/oa_pdf/e2/6b/koni-05-06-1072674.PMC4938317.pdf
Nature 2000; 407:810-6; PMID:11048733; http://dx.doi.org/ 10.1038/35037747 3.,Non-OADS,/arxiv_data1/oa_pdf/e2/6b/koni-05-06-1072674.PMC4938317.pdf
Nat Rev Immunol 2009; 9:353-63;PMID:19365408; http://dx.doi.org/10.1038/nri2545 4.,Non-OADS,/arxiv_data1/oa_pdf/e2/6b/koni-05-06-1072674.PMC4938317.pdf
2010 Jan; 1805(1):53-71; PMID:19720113; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/e2/6b/koni-05-06-1072674.PMC4938317.pdf
Nat Rev Cancer 2012; 12(12):860-75; PMID:23151605; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/e2/6b/koni-05-06-1072674.PMC4938317.pdf
Nat Rev Cancer 2012; 12(4):265-77; PMID:22437871; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/e2/6b/koni-05-06-1072674.PMC4938317.pdf
J Cancer 2013; 4(1):36-44; PMID:23386903;http://dx.doi.org/10.7150/jca.5046 8.,Non-OADS,/arxiv_data1/oa_pdf/e2/6b/koni-05-06-1072674.PMC4938317.pdf
Treatment of skin cancer and pre-cancer using topical ALA-PDT - a single hospital experience.Photodiagnosis Photodyn Ther 2008; 5:127-33; PMID:19356643; http://dx.doi.org/10.1016/j.pdpdt.2008.05.003 9.,Non-OADS,/arxiv_data1/oa_pdf/e2/6b/koni-05-06-1072674.PMC4938317.pdf
Exp Derma- tol 2013; 22(5):262-3; PMID:23528211; http://dx.doi.org/10.1111/ exd.12132 10.,Non-OADS,/arxiv_data1/oa_pdf/e2/6b/koni-05-06-1072674.PMC4938317.pdf
"6, e1160182 (10 pages)http://dx.doi.org/10.1080/2162402X.2016.1160182",Non-OADS,/arxiv_data1/oa_pdf/57/7a/koni-05-06-1160182.PMC4938318.pdf
Cell 2010; 140:883-99; PMID:20303878; http://dx.doi.org/ 10.1016/j.cell.2010.01.025 4.,OADS,/arxiv_data1/oa_pdf/57/7a/koni-05-06-1160182.PMC4938318.pdf
Ann Med 2010; 42:161-70; PMID:20384432; http://dx.doi.org/10.3109/07853890903405753 5.,Non-OADS,/arxiv_data1/oa_pdf/57/7a/koni-05-06-1160182.PMC4938318.pdf
Nat Rev Cancer 2009; 9:361-71; PMID:19343034; http://dx.doi.org/10.1038/nrc2628 6.,Non-OADS,/arxiv_data1/oa_pdf/57/7a/koni-05-06-1160182.PMC4938318.pdf
Cancer Cell 2009; 15:79-80; PMID:19185839;http://dx.doi.org/10.1016/j.ccr.2009.01.009 7.,Non-OADS,/arxiv_data1/oa_pdf/57/7a/koni-05-06-1160182.PMC4938318.pdf
Cancer Res 2007; 67:1062-71; PMID:17283139; http://dx.doi.org/10.1158/0008-5472.CAN-06-2956 8.,Non-OADS,/arxiv_data1/oa_pdf/57/7a/koni-05-06-1160182.PMC4938318.pdf
J Clin Invest 1991; 87:1066-71; PMID:1999487; http://dx.doi.org/10.1172/JCI115067 9.,Non-OADS,/arxiv_data1/oa_pdf/57/7a/koni-05-06-1160182.PMC4938318.pdf
Ann Rheum Dis 2013; 72 Suppl 2:ii96-9; PMID:23253918; http://dx.doi.org/10.1136/annrheumdis-2012-202252 10.,Non-OADS,/arxiv_data1/oa_pdf/57/7a/koni-05-06-1160182.PMC4938318.pdf
Protein Cell 2014; 5:12-20;PMID:24474192; http://dx.doi.org/10.1007/s13238-013-0001-4 11.,OADS,/arxiv_data1/oa_pdf/57/7a/koni-05-06-1160182.PMC4938318.pdf
Nature 2012; 488:670-4; PMID:22801494; http://dx.doi.org/10.1038/nature11290ONCOIMMUNOLOGY e1160182-9,Non-OADS,/arxiv_data1/oa_pdf/57/7a/koni-05-06-1160182.PMC4938318.pdf
J Biol Chem 1999; 274:5953-62; PMID:10026221; http://dx.doi.org/ 10.1074/jbc.274.9.5953 14.,OADS,/arxiv_data1/oa_pdf/57/7a/koni-05-06-1160182.PMC4938318.pdf
Annu Rev Immunol 2009; 27:519-50; PMID:19302047; http://dx.doi.org/10.1146/ annurev.immunol.021908.132612 15.,Non-OADS,/arxiv_data1/oa_pdf/57/7a/koni-05-06-1160182.PMC4938318.pdf
"Nat Immunol 2012; 13:343-51; PMID:22430787; http://dx.doi.org/10.1038/ni.2224 1 6 .V o r o n o vE ,S h o u v a lD S ,K r e l i nY ,C a g n a n oE ,B e n h a r r o c hD , I w a k u r aY ,D i n a r e l l oC A ,A p t eR N .I L - 1i sr e q u i r e df o rt u m o rinvasiveness and angiogenesis.",Non-OADS,/arxiv_data1/oa_pdf/57/7a/koni-05-06-1160182.PMC4938318.pdf
J Invest Dermatol 2007; 127:1956-63; PMID:17429439; http://dx.doi.org/10.1038/sj.jid.5700819 19.,Non-OADS,/arxiv_data1/oa_pdf/57/7a/koni-05-06-1160182.PMC4938318.pdf
Br JDermatol 1994; 131:250-6; PMID:7917990; http://dx.doi.org/10.1111/ j.1365-2133.1994.tb08500.x 20.,OADS,/arxiv_data1/oa_pdf/57/7a/koni-05-06-1160182.PMC4938318.pdf
JInvest Dermatol 2000; 114:928-34; PMID:10771473; http://dx.doi.org/10.1038/sj.jid.5600685 21.,Non-OADS,/arxiv_data1/oa_pdf/57/7a/koni-05-06-1160182.PMC4938318.pdf
J Immunol 2014; 192:763-70; PMID:24337744; http://dx.doi.org/10.4049/jimmunol.1301434.,Non-OADS,/arxiv_data1/oa_pdf/57/7a/koni-05-06-1160182.PMC4938318.pdf
Infect Immun 2014; 82:2310-7; PMID:24643540; http://dx.doi.org/10.1128/IAI.01572-1423.,Non-OADS,/arxiv_data1/oa_pdf/57/7a/koni-05-06-1160182.PMC4938318.pdf
Am J Pathol 2015; 185:3115-24; PMID:26506473; http://dx.doi.org/10.1016/j.ajpath.,OADS,/arxiv_data1/oa_pdf/57/7a/koni-05-06-1160182.PMC4938318.pdf
J Immunol 2013; 191:3514-8; PMID:24643540; http://dx.doi.org/ 10.4049/jimmunol.1301331 25.,Non-OADS,/arxiv_data1/oa_pdf/57/7a/koni-05-06-1160182.PMC4938318.pdf
J Biol Chem 2012; 287:36384- 92; PMID:22948139; http://dx.doi.org/10.1074/jbc.M112.390039 26.,OADS,/arxiv_data1/oa_pdf/57/7a/koni-05-06-1160182.PMC4938318.pdf
Mol Cancer Res 2013; 11:1193-202; PMID:23864729; http://dx.doi.org/ 10.1158/1541-7786.MCR-13-0145 27.,Non-OADS,/arxiv_data1/oa_pdf/57/7a/koni-05-06-1160182.PMC4938318.pdf
Nature 2009; 458:514-8; PMID:19158675; http://dx.doi.org/10.1038/nature07725 28.,Non-OADS,/arxiv_data1/oa_pdf/57/7a/koni-05-06-1160182.PMC4938318.pdf
Environ Health Perspect 2009; 117:1108-15; PMID:19654921; http://dx.doi.org/10.1289/ehp.0800199 29.,Non-OADS,/arxiv_data1/oa_pdf/57/7a/koni-05-06-1160182.PMC4938318.pdf
Arch Toxicol 2014; 88:1619-29; PMID:25005685; http://dx.doi.org/10.1007/s00204-014-1305-8 30.,Non-OADS,/arxiv_data1/oa_pdf/57/7a/koni-05-06-1160182.PMC4938318.pdf
"The Korean Society for Radiation Oncologywww.e-roj.orgThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/ licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/23/1e/roj-2016-01725.PMC4938343.pdf
"Tel: +82-51-890-8606, Fax: +82-51-891-1754,  E-mail: rtyoon@gmail.comRadiat Oncol J 2016;34(2):113-120 http://dx.doi.org/10.3857/roj.2016.01725 pISSN 2234-1900 · eISSN 2234-3156   Purpose:  The association between metabolism and cancer has been recently emphasized.",Non-OADS,/arxiv_data1/oa_pdf/23/1e/roj-2016-01725.PMC4938343.pdf
"Yunseon Choi, et al114 www.e-roj.org http://dx.doi.org/10.3857/roj.2016.01725(RT) significantly reduces the local failure rate [13].",OADS,/arxiv_data1/oa_pdf/23/1e/roj-2016-01725.PMC4938343.pdf
"MaxStat (http://www.maxstat.de/), a maximal chi- square method in R 2.13.0 (R Development Core Team, Vienna,  Austria, http://www.R-project.org) was used to identify optimal  cutting points.",OADS,/arxiv_data1/oa_pdf/23/1e/roj-2016-01725.PMC4938343.pdf
"Yunseon Choi, et al116 www.e-roj.org http://dx.doi.org/10.3857/roj.2016.01725experienced both regional failure and distant metastases.",OADS,/arxiv_data1/oa_pdf/23/1e/roj-2016-01725.PMC4938343.pdf
"Impact of obesity in advanced rectal cancer117 www.e-roj.org http://dx.doi.org/10.3857/roj.2016.01725analysis identified obesity as an independent prognostic factor  of LC (hazard ratio [HR], 3.542; p = 0.039) (Table 4).",Non-OADS,/arxiv_data1/oa_pdf/23/1e/roj-2016-01725.PMC4938343.pdf
"Yunseon Choi, et al118 www.e-roj.org http://dx.doi.org/10.3857/roj.2016.01725which is known to be related to both rectal cancer occurrence  and lipid metabolism, is closely connected with the IGF-1  pathway [23].",OADS,/arxiv_data1/oa_pdf/23/1e/roj-2016-01725.PMC4938343.pdf
"Impact of obesity in advanced rectal cancer119 www.e-roj.org http://dx.doi.org/10.3857/roj.2016.01725have been treated with inadequate doses of chemotherapy,  which could affect LC.",Non-OADS,/arxiv_data1/oa_pdf/23/1e/roj-2016-01725.PMC4938343.pdf
http://dx.doi.org/10.1097/ COC.0000000000000150.,Non-OADS,/arxiv_data1/oa_pdf/23/1e/roj-2016-01725.PMC4938343.pdf
"Yunseon Choi, et al120 www.e-roj.org http://dx.doi.org/10.3857/roj.2016.01725RP, Oyen WJ, Bussink J.",OADS,/arxiv_data1/oa_pdf/23/1e/roj-2016-01725.PMC4938343.pdf
"The Korean Society for Radiation Oncologywww.e-roj.orgThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/ licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/d0/e0/roj-2016-01753.PMC4938344.pdf
re.krRadiat Oncol J 2016;34(2):88-95 http://dx.doi.org/10.3857/roj.2016.01753 pISSN 2234-1900 · eISSN 2234-3156   Purpose:  The purpose of this study was to estimate the clinical utilization of radiation therapy (RT) in Korea between 2009 and  2013.,Non-OADS,/arxiv_data1/oa_pdf/d0/e0/roj-2016-01753.PMC4938344.pdf
Clinical utilization of RT89 www.e-roj.org http://dx.doi.org/10.3857/roj.2016.01753clinical utilization of RT for understanding the status and  development of cancer treatment in Korea.,OADS,/arxiv_data1/oa_pdf/d0/e0/roj-2016-01753.PMC4938344.pdf
"Jin-Kyu Kang, et al90 www.e-roj.org http://dx.doi.org/10.3857/roj.2016.017532011, 2012, and 2013 were 42,585, 46,248, 50,883, 55,049,  and 57,004, respectively.",OADS,/arxiv_data1/oa_pdf/d0/e0/roj-2016-01753.PMC4938344.pdf
Clinical utilization of RT91 www.e-roj.org http://dx.doi.org/10.3857/roj.2016.01753Table 3.,Non-OADS,/arxiv_data1/oa_pdf/d0/e0/roj-2016-01753.PMC4938344.pdf
"Jin-Kyu Kang, et al92 www.e-roj.org http://dx.doi.org/10.3857/roj.2016.01753Table 4.",OADS,/arxiv_data1/oa_pdf/d0/e0/roj-2016-01753.PMC4938344.pdf
Clinical utilization of RT93 www.e-roj.org http://dx.doi.org/10.3857/roj.2016.01753the diseases with code ‘D.,Non-OADS,/arxiv_data1/oa_pdf/d0/e0/roj-2016-01753.PMC4938344.pdf
"Jin-Kyu Kang, et al94 www.e-roj.org http://dx.doi.org/10.3857/roj.2016.01753it is estimated to be within the same range.",OADS,/arxiv_data1/oa_pdf/d0/e0/roj-2016-01753.PMC4938344.pdf
Clinical utilization of RT95 www.e-roj.org http://dx.doi.org/10.3857/roj.2016.01753 8.,Non-OADS,/arxiv_data1/oa_pdf/d0/e0/roj-2016-01753.PMC4938344.pdf
http://dx.doi.org/10.4143/crt.2015.370.,Non-OADS,/arxiv_data1/oa_pdf/d0/e0/roj-2016-01753.PMC4938344.pdf
"The Korean Society for Radiation Oncologywww.e-roj.orgThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/ licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/51/ca/roj-2016-01732.PMC4938345.pdf
"Tel: +1-304-598-4706, Fax: +1-304-598-1151, E-mail:  malcolm.mattes@gmail.comRadiat Oncol J 2016;34(2):156-159 http://dx.doi.org/10.3857/roj.2016.01732 pISSN 2234-1900 · eISSN 2234-3156   Although carbohydrate antigen (CA) 19-9 is a useful tumor marker for pancreatic cancer, it can also become elevated from a variety  of benign and malignant conditions.",Non-OADS,/arxiv_data1/oa_pdf/51/ca/roj-2016-01732.PMC4938345.pdf
"Radiation-induced elevation in CA 19-9157 www.e-roj.org http://dx.doi.org/10.3857/roj.2016.01732negative for any new pulmonary abnormalities, but did report  an incidental finding of dilation of the main pancreatic duct.",Non-OADS,/arxiv_data1/oa_pdf/51/ca/roj-2016-01732.PMC4938345.pdf
"Malcolm D. Mattes, et al158 www.e-roj.org http://dx.doi.org/10.3857/roj.2016.01732elevations in CA 19-9 [1-3].",OADS,/arxiv_data1/oa_pdf/51/ca/roj-2016-01732.PMC4938345.pdf
Radiation-induced elevation in CA 19-9159 www.e-roj.org http://dx.doi.org/10.3857/roj.2016.01732References   1.,OADS,/arxiv_data1/oa_pdf/51/ca/roj-2016-01732.PMC4938345.pdf
Available from: http://ctep.cancer.,Non-OADS,/arxiv_data1/oa_pdf/51/ca/roj-2016-01732.PMC4938345.pdf
"The Korean Society for Radiation Oncologywww.e-roj.orgThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/ licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/74/fe/roj-2016-01683.PMC4938346.pdf
"Tel: +82-53-250-7665, Fax: +82-53-250-7487, E-mail:  jhkim@dsmc.or.krRadiat Oncol J 2016;34(2):121-127 http://dx.doi.org/10.3857/roj.2016.01683 pISSN 2234-1900 · eISSN 2234-3156   Purpose:  To investigate treatment outcome and long term complication after surgery and radiotherapy (RT) for pituitary  adenoma.",Non-OADS,/arxiv_data1/oa_pdf/74/fe/roj-2016-01683.PMC4938346.pdf
"Mi Young Kim, et al122 www.e-roj.org http://dx.doi.org/10.3857/roj.2016.01683secreting adenoma, medical treatment is the treatment of  choice.",Non-OADS,/arxiv_data1/oa_pdf/74/fe/roj-2016-01683.PMC4938346.pdf
"Radiotherapy for pituitary adenoma123 www.e-roj.org http://dx.doi.org/10.3857/roj.2016.01683Median tumor dose was 45 Gy (range, 45 to 59.4 Gy) with 1.8  Gy per fraction, once a day, 5 times a week.",Non-OADS,/arxiv_data1/oa_pdf/74/fe/roj-2016-01683.PMC4938346.pdf
"Mi Young Kim, et al124 www.e-roj.org http://dx.doi.org/10.3857/roj.2016.01683radiation dose, and tumor size did not affect the tumor  control.",OADS,/arxiv_data1/oa_pdf/74/fe/roj-2016-01683.PMC4938346.pdf
Radiotherapy for pituitary adenoma125 www.e-roj.org http://dx.doi.org/10.3857/roj.2016.01683[1] reported the results of 411 patients including secreting  and non-secreting adenomas.,Non-OADS,/arxiv_data1/oa_pdf/74/fe/roj-2016-01683.PMC4938346.pdf
"Mi Young Kim, et al126 www.e-roj.org http://dx.doi.org/10.3857/roj.2016.01683RT, surgical manipulation to the hypothalamus—pituitary axis  may be an important causative factor of hypopituitarism.",Non-OADS,/arxiv_data1/oa_pdf/74/fe/roj-2016-01683.PMC4938346.pdf
Radiotherapy for pituitary adenoma127 www.e-roj.org http://dx.doi.org/10.3857/roj.2016.01683adenoma: beneficial effect on local control without additional  negative impact on pituitary function and life expectancy.,Non-OADS,/arxiv_data1/oa_pdf/74/fe/roj-2016-01683.PMC4938346.pdf
"The Korean Society for Radiation Oncologywww.e-roj.orgThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/ licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/3f/f3/roj-2016-01697.PMC4938347.pdf
"ac.kr, shin.kyunghwan@gmail.comRadiat Oncol J 2016;34(2):81-87 http://dx.doi.org/10.3857/roj.2016.01697 pISSN 2234-1900 · eISSN 2234-3156   Hypofractionated whole breast irradiation (HF-WBI) has been proved effective and safe and even better for late or acute radiation  toxicity for early breast cancer.",Non-OADS,/arxiv_data1/oa_pdf/3f/f3/roj-2016-01697.PMC4938347.pdf
"Kyung Su Kim, et al82 www.e-roj.org http://dx.doi.org/10.3857/roj.2016.01697[4,5], the UK Standardisation of Breast Radiotherapy (START)  trial A and B [6-8], and the Canadian trial [9]—have supported  the establishment of HF-WBI with recent publication of 10- year outcomes.",Non-OADS,/arxiv_data1/oa_pdf/3f/f3/roj-2016-01697.PMC4938347.pdf
Review of hypofractionated whole breast irradiation83 www.e-roj.org http://dx.doi.org/10.3857/roj.2016.01697Table 1.,Non-OADS,/arxiv_data1/oa_pdf/3f/f3/roj-2016-01697.PMC4938347.pdf
"Kyung Su Kim, et al84 www.e-roj.org http://dx.doi.org/10.3857/roj.2016.01697influence of fraction schedule on IBTR was not different  regardless of age.",OADS,/arxiv_data1/oa_pdf/3f/f3/roj-2016-01697.PMC4938347.pdf
"Review of hypofractionated whole breast irradiation85 www.e-roj.org http://dx.doi.org/10.3857/roj.2016.01697and 9 Gy in 3 sequential fractions of 3 Gy to the lumpectomy  cavity, all within 3.2 weeks.",Non-OADS,/arxiv_data1/oa_pdf/3f/f3/roj-2016-01697.PMC4938347.pdf
"Kyung Su Kim, et al86 www.e-roj.org http://dx.doi.org/10.3857/roj.2016.01697concerning greater fraction size, reports on acute reaction with  hypofractionation were published recently [24-26].",OADS,/arxiv_data1/oa_pdf/3f/f3/roj-2016-01697.PMC4938347.pdf
Review of hypofractionated whole breast irradiation87 www.e-roj.org http://dx.doi.org/10.3857/roj.2016.0169713 fractions followed by a tumor bed boost sequentially  delivering 9 Gy in 3 fractions in early-stage breast cancer.,Non-OADS,/arxiv_data1/oa_pdf/3f/f3/roj-2016-01697.PMC4938347.pdf
Available from: https://clinicaltrials.gov/ct2/show/ NCT00470236.,Non-OADS,/arxiv_data1/oa_pdf/3f/f3/roj-2016-01697.PMC4938347.pdf
"The Korean Society for Radiation Oncologywww.e-roj.orgThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/ licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/07/26/roj-2016-01760.PMC4938348.pdf
135Radiat Oncol J 2016;34(2):135-144 http://dx.doi.org/10.3857/roj.2016.01760 pISSN 2234-1900 · eISSN 2234-3156   Purpose: The purpose of this study was to evaluate the efficacy of art therapy to control fatigue in cancer patients during course  of radiotherapy and its impact on quality of life (QoL).,Non-OADS,/arxiv_data1/oa_pdf/07/26/roj-2016-01760.PMC4938348.pdf
"Woong Sub Koom, et al136 www.e-roj.org http://dx.doi.org/10.3857/roj.2016.01760addition, cancer treatments are clearly one cause of fatigue  [5].",Non-OADS,/arxiv_data1/oa_pdf/07/26/roj-2016-01760.PMC4938348.pdf
Art therapy for fatigue during RT137 www.e-roj.org http://dx.doi.org/10.3857/roj.2016.01760the painting attract patients’ interest?,Non-OADS,/arxiv_data1/oa_pdf/07/26/roj-2016-01760.PMC4938348.pdf
"Woong Sub Koom, et al138 www.e-roj.org http://dx.doi.org/10.3857/roj.2016.01760The median age was 50 years (range, 34 to 68 years) and  patients had a good performance status (ECOG, 0 or 1).",OADS,/arxiv_data1/oa_pdf/07/26/roj-2016-01760.PMC4938348.pdf
Art therapy for fatigue during RT139 www.e-roj.org http://dx.doi.org/10.3857/roj.2016.01760Table 3.,Non-OADS,/arxiv_data1/oa_pdf/07/26/roj-2016-01760.PMC4938348.pdf
"Woong Sub Koom, et al140 www.e-roj.org http://dx.doi.org/10.3857/roj.2016.01760item “enhance coping mechanism” was also found to be lower  than other items.",OADS,/arxiv_data1/oa_pdf/07/26/roj-2016-01760.PMC4938348.pdf
"Art therapy for fatigue during RT141 www.e-roj.org http://dx.doi.org/10.3857/roj.2016.01760FACIT-F TOI score (mean ± 2SE)(Score range 0-108) Time pointG Baseline, before RTVisit 2020100 60 40 Visit 1 Visit 3 Visit 4 End of RT80 FACIT-F total score (mean ± 2SE)(Score range 0-160) Time pointI Baseline, before RTVisit 2020160 100 80 Visit 1 Visit 3 Visit 4 End of RT60 40120140FACT-G total score (mean ± 2SE)(Score range 0-108) Time pointH Baseline, before RTVisit 2020100 60 40 Visit 1 Visit 3 Visit 4 End of RT80 Fig.",Non-OADS,/arxiv_data1/oa_pdf/07/26/roj-2016-01760.PMC4938348.pdf
"Woong Sub Koom, et al142 www.e-roj.org http://dx.doi.org/10.3857/roj.2016.01760dropped out, enrolled patients seemed to be interested  in the appreciation of famous painting to control fatigue  and emotional distress.",Non-OADS,/arxiv_data1/oa_pdf/07/26/roj-2016-01760.PMC4938348.pdf
Art therapy for fatigue during RT143 www.e-roj.org http://dx.doi.org/10.3857/roj.2016.01760Conflict of Interest No potential conflict of interest relevant to this article was  reported.,Non-OADS,/arxiv_data1/oa_pdf/07/26/roj-2016-01760.PMC4938348.pdf
Available from: http://www.facit.org/FACITOrg/Questionnaires.,Non-OADS,/arxiv_data1/oa_pdf/07/26/roj-2016-01760.PMC4938348.pdf
"Woong Sub Koom, et al144 www.e-roj.org http://dx.doi.org/10.3857/roj.2016.0176028.",OADS,/arxiv_data1/oa_pdf/07/26/roj-2016-01760.PMC4938348.pdf
"The Korean Society for Radiation Oncologywww.e-roj.orgThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/ licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/d5/b2/roj-2015-01585.PMC4938349.pdf
"A few weeks after completing  CCRT, total mesorectal excision is performed in accordance Original Article Radiat Oncol J 2016;34(2):106-112 http://dx.doi.org/10.3857/roj.2015.01585 pISSN 2234-1900 · eISSN 2234-3156",Non-OADS,/arxiv_data1/oa_pdf/d5/b2/roj-2015-01585.PMC4938349.pdf
The predictors of pCR for rectal cancer107 www.e-roj.org http://dx.doi.org/10.3857/roj.2015.01585with recent treatment guidelines [2-6].,Non-OADS,/arxiv_data1/oa_pdf/d5/b2/roj-2015-01585.PMC4938349.pdf
"Euncheol Choi, et al108 www.e-roj.org http://dx.doi.org/10.3857/roj.2015.01585Results The median age was 60 years (range, 32 to 78 years)  and 69.8% of patients were males.",OADS,/arxiv_data1/oa_pdf/d5/b2/roj-2015-01585.PMC4938349.pdf
The predictors of pCR for rectal cancer109 www.e-roj.org http://dx.doi.org/10.3857/roj.2015.01585p = 0.055).,Non-OADS,/arxiv_data1/oa_pdf/d5/b2/roj-2015-01585.PMC4938349.pdf
"Euncheol Choi, et al110 www.e-roj.org http://dx.doi.org/10.3857/roj.2015.01585GU complication.",OADS,/arxiv_data1/oa_pdf/d5/b2/roj-2015-01585.PMC4938349.pdf
The predictors of pCR for rectal cancer111 www.e-roj.org http://dx.doi.org/10.3857/roj.2015.01585<2.5 ng/dL (p = 0.010) was associated with pCR in univariate  analysis.,OADS,/arxiv_data1/oa_pdf/d5/b2/roj-2015-01585.PMC4938349.pdf
"Euncheol Choi, et al112 www.e-roj.org http://dx.doi.org/10.3857/roj.2015.01585patients with locally advanced rectal cancers.",Non-OADS,/arxiv_data1/oa_pdf/d5/b2/roj-2015-01585.PMC4938349.pdf
"The Korean Society for Radiation Oncologywww.e-roj.orgThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/ licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/1a/46/roj-2016-01718.PMC4938350.pdf
"Tel: +82-2-2228-8116, Fax: +82-2-312-9033, E-mail:  MDGOLD@yuhs.acRadiat Oncol J 2016;34(2):128-134 http://dx.doi.org/10.3857/roj.2016.01718 pISSN 2234-1900 · eISSN 2234-3156   Purpose:  To evaluate the clinical outcomes of patients who underwent radiation therapy with or without targeted molecular  therapy for the treatment of spinal metastasis from renal cell carcinoma (RCC).",Non-OADS,/arxiv_data1/oa_pdf/1a/46/roj-2016-01718.PMC4938350.pdf
"RT for spinal metastasis from RCC129 www.e-roj.org http://dx.doi.org/10.3857/roj.2016.01718introduction of targeted molecular agents such as sunitinib,  a vascular endothelial growth factor (VEGF) tyrosine kinase  inhibitor (TKI), and temsirolimus, a mammalian target of  rapamycin (mTOR) inhibitor [9].",Non-OADS,/arxiv_data1/oa_pdf/1a/46/roj-2016-01718.PMC4938350.pdf
"Sangjoon Park, et al130 www.e-roj.org http://dx.doi.org/10.3857/roj.2016.017185.",OADS,/arxiv_data1/oa_pdf/1a/46/roj-2016-01718.PMC4938350.pdf
RT for spinal metastasis from RCC131 www.e-roj.org http://dx.doi.org/10.3857/roj.2016.01718with targeted molecular therapy at least once during the  course of their disease.,Non-OADS,/arxiv_data1/oa_pdf/1a/46/roj-2016-01718.PMC4938350.pdf
"Sangjoon Park, et al132 www.e-roj.org http://dx.doi.org/10.3857/roj.2016.01718Discussion and Conclusion We evaluated the outcomes of spinal RT and investigated the  effect of concurrent use of targeted molecular therapy for  spinal metastasis from RCC.",OADS,/arxiv_data1/oa_pdf/1a/46/roj-2016-01718.PMC4938350.pdf
RT for spinal metastasis from RCC133 www.e-roj.org http://dx.doi.org/10.3857/roj.2016.01718patients with spinal metastasis from RCC.,Non-OADS,/arxiv_data1/oa_pdf/1a/46/roj-2016-01718.PMC4938350.pdf
"Sangjoon Park, et al134 www.e-roj.org http://dx.doi.org/10.3857/roj.2016.0171816.",OADS,/arxiv_data1/oa_pdf/1a/46/roj-2016-01718.PMC4938350.pdf
"The Korean Society for Radiation Oncologywww.e-roj.orgThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/ licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/74/e6/roj-2016-01704.PMC4938351.pdf
"Tel: +82-53-200-5352, Fax: +82-53-426-3303, E-mail: jckim@knu.ac.krRadiat Oncol J 2016;34(2):96-105 http://dx.doi.org/10.3857/roj.2016.01704 pISSN 2234-1900 · eISSN 2234-3156   Purpose:  The standard  radiation dose for patients with locally rectal cancer treated with preoperative chemoradiotherapy is  45–50 Gy in 25–28 fractions.",Non-OADS,/arxiv_data1/oa_pdf/74/e6/roj-2016-01704.PMC4938351.pdf
"Preoperative chemoradiation for rectal cancer97 www.e-roj.org http://dx.doi.org/10.3857/roj.2016.01704pathologic tumor response, improved tolerance, and increased  likelihood of sphincter preservation in the distal rectum [5].",Non-OADS,/arxiv_data1/oa_pdf/74/e6/roj-2016-01704.PMC4938351.pdf
"Shin-Hyung Park, et al98 www.e-roj.org http://dx.doi.org/10.3857/roj.2016.01704emission tomography scans, were performed, based on patient  symptoms or signs.",OADS,/arxiv_data1/oa_pdf/74/e6/roj-2016-01704.PMC4938351.pdf
3.1.3) (http://www.R-project.org).,Non-OADS,/arxiv_data1/oa_pdf/74/e6/roj-2016-01704.PMC4938351.pdf
Preoperative chemoradiation for rectal cancer99 www.e-roj.org http://dx.doi.org/10.3857/roj.2016.01704Results 1.,Non-OADS,/arxiv_data1/oa_pdf/74/e6/roj-2016-01704.PMC4938351.pdf
"Shin-Hyung Park, et al100 www.e-roj.org http://dx.doi.org/10.3857/roj.2016.017044.",OADS,/arxiv_data1/oa_pdf/74/e6/roj-2016-01704.PMC4938351.pdf
Preoperative chemoradiation for rectal cancer101 www.e-roj.org http://dx.doi.org/10.3857/roj.2016.01704with DMFS.,Non-OADS,/arxiv_data1/oa_pdf/74/e6/roj-2016-01704.PMC4938351.pdf
"Shin-Hyung Park, et al102 www.e-roj.org http://dx.doi.org/10.3857/roj.2016.01704= 0.021), good responsiveness of TRG (p = 0.018), ypT category  (p < 0.001), ypN category (p < 0.001), and carcinoembryonic  antigen level (p = 0.045) were significantly correlated with  DFS.",OADS,/arxiv_data1/oa_pdf/74/e6/roj-2016-01704.PMC4938351.pdf
"Preoperative chemoradiation for rectal cancer103 www.e-roj.org http://dx.doi.org/10.3857/roj.2016.01704univariate (p = 0.031) and multivariate analyses (HR, 6.27; 95%  CI, 1.21 to 32.54; p = 0.029).",Non-OADS,/arxiv_data1/oa_pdf/74/e6/roj-2016-01704.PMC4938351.pdf
"Shin-Hyung Park, et al104 www.e-roj.org http://dx.doi.org/10.3857/roj.2016.01704and TRG, have some prognostic value, radiation dose escalation  for the achievement of them are need to be cautious.",OADS,/arxiv_data1/oa_pdf/74/e6/roj-2016-01704.PMC4938351.pdf
Preoperative chemoradiation for rectal cancer105 www.e-roj.org http://dx.doi.org/10.3857/roj.2016.01704 7.,Non-OADS,/arxiv_data1/oa_pdf/74/e6/roj-2016-01704.PMC4938351.pdf
"Tel: +1-212-639-8168, Fax: +1-212-717-3104, E-mail: barkerc@mskcc.org *Current affiliation: Department of Radiation Oncology, West Virginia University Medical Center, Morgantown, WV, USA CC  This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/ licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Radiat Oncol J 2016;34(2):145-155 http://dx.doi.org/10.3857/roj.2015.01592 pISSN 2234-1900 · eISSN 2234-3156  Original Article",Non-OADS,/arxiv_data1/oa_pdf/8b/38/roj-2015-01592.PMC4938352.pdf
"Malcolm D. Mattes , et al146 www.e-roj.org http://dx.doi.org/10.3857/roj.2015.01592basin radiotherapy for other locally advanced and high-risk  skin cancers (such as cutaneous squamous cell carcinoma and  angiosarcoma) is also likely effective [3,4], but has not been  studied in randomized trials.",Non-OADS,/arxiv_data1/oa_pdf/8b/38/roj-2015-01592.PMC4938352.pdf
"Iodinated intravenous contrast (100–150 cm3  at 1–2 cm3/s; Omnipaque, GE Healthcare, Princeton, NJ, USA)  was administered via the antecubital vein contralateral to the Malcolm D. Mattes , et al 2 www.e-roj.org http://dx.doi.org/10.3857/roj.2016.34.2.1basin radiotherapy for other locally advanced and high-risk  skin cancers (such as cutaneous squamous cell carcinoma and angiosarcoma) is also likely effective [3,4], but has not been studied in randomized trials.",Non-OADS,/arxiv_data1/oa_pdf/8b/38/roj-2015-01592.PMC4938352.pdf
147 RT techniques for advanced skin cancer www.e-roj.org http://dx.doi.org/10.3857/roj.2015.01592target in patients without medical contraindications.,Non-OADS,/arxiv_data1/oa_pdf/8b/38/roj-2015-01592.PMC4938352.pdf
"Malcolm D. Mattes , et al148 www.e-roj.org http://dx.doi.org/10.3857/roj.2015.01592defined as the minimum dose to y percent (or cm3 as indicated)  of structure.",Non-OADS,/arxiv_data1/oa_pdf/8b/38/roj-2015-01592.PMC4938352.pdf
149 RT techniques for advanced skin cancer www.e-roj.org http://dx.doi.org/10.3857/roj.2015.01592used to generate the treatment plans for this analysis.,Non-OADS,/arxiv_data1/oa_pdf/8b/38/roj-2015-01592.PMC4938352.pdf
"Large magnitude  statistically significant improvements in OAR sparing using  3D-CRT compared to 2D-RT were observed for the anorectum  Dmax, bowel bag D200cc, femur D50, genitalia Dmax, skin D50cc,  5RT techniques for advanced skin cancer www.e-roj.org http://dx.doi.org/10.3857/roj.2016.34.2.1used to generate the treatment plans for this analysis.",Non-OADS,/arxiv_data1/oa_pdf/8b/38/roj-2015-01592.PMC4938352.pdf
"Malcolm D. Mattes , et al150 www.e-roj.org http://dx.doi.org/10.3857/roj.2015.01592 Table 2.",OADS,/arxiv_data1/oa_pdf/8b/38/roj-2015-01592.PMC4938352.pdf
151 RT techniques for advanced skin cancer www.e-roj.org http://dx.doi.org/10.3857/roj.2015.01592and lumbosacral plexus Dmax.,Non-OADS,/arxiv_data1/oa_pdf/8b/38/roj-2015-01592.PMC4938352.pdf
7RT techniques for advanced skin cancer www.e-roj.org http://dx.doi.org/10.3857/roj.2016.34.2.1and lumbosacral plexus Dmax.,Non-OADS,/arxiv_data1/oa_pdf/8b/38/roj-2015-01592.PMC4938352.pdf
"Malcolm D. Mattes , et al152 www.e-roj.org http://dx.doi.org/10.3857/roj.2015.01592 Table 3.",OADS,/arxiv_data1/oa_pdf/8b/38/roj-2015-01592.PMC4938352.pdf
153 RT techniques for advanced skin cancer www.e-roj.org http://dx.doi.org/10.3857/roj.2015.01592leading to the elevations in the low-dose region of the lung  dose volume histogram (DVH) (as represented by higher V5).,Non-OADS,/arxiv_data1/oa_pdf/8b/38/roj-2015-01592.PMC4938352.pdf
"Malcolm D. Mattes , et al154 www.e-roj.org http://dx.doi.org/10.3857/roj.2015.01592There are several limitations to this study.",Non-OADS,/arxiv_data1/oa_pdf/8b/38/roj-2015-01592.PMC4938352.pdf
155 RT techniques for advanced skin cancer www.e-roj.org http://dx.doi.org/10.3857/roj.2015.01592brachial plexus.,Non-OADS,/arxiv_data1/oa_pdf/8b/38/roj-2015-01592.PMC4938352.pdf
Available from: http://www.rtog.,Non-OADS,/arxiv_data1/oa_pdf/8b/38/roj-2015-01592.PMC4938352.pdf
"6, e1169353 (13 pages)http://dx.doi.org/10.1080/2162402X.2016.1169353",Non-OADS,/arxiv_data1/oa_pdf/46/7c/koni-05-06-1169353.PMC4938367.pdf
NEngl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/ 10.1056/NEJMoa1003466 2.,OADS,/arxiv_data1/oa_pdf/46/7c/koni-05-06-1169353.PMC4938367.pdf
N Engl J Med 2012; 366:2443-54; PMID:22658127; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/46/7c/koni-05-06-1169353.PMC4938367.pdf
Combined nivolumab and ipilimumab or monotherapy in untreated melanoma.N Engl J Med 2015; 373:23-34; PMID:26027431; http://dx.doi.org/10.1056/NEJMoa1504030 4.,Non-OADS,/arxiv_data1/oa_pdf/46/7c/koni-05-06-1169353.PMC4938367.pdf
N Engl J Med2014; 371:2189-99; PMID:25409260; http://dx.doi.org/10.1056/ NEJMoa1406498 5.,OADS,/arxiv_data1/oa_pdf/46/7c/koni-05-06-1169353.PMC4938367.pdf
Nature 2014; 515:577-81; PMID:25428507; http://dx.doi.org/10.1038/nature13988 6.,Non-OADS,/arxiv_data1/oa_pdf/46/7c/koni-05-06-1169353.PMC4938367.pdf
PloS One2012; 7:e41112; PMID:22829916; http://dx.doi.org/10.1371/journal.pone.0041112 7.,Non-OADS,/arxiv_data1/oa_pdf/46/7c/koni-05-06-1169353.PMC4938367.pdf
Int J Cancer 2006; 118:123-8; PMID:16003736; http://dx.doi.org/10.1002/ijc.21219 9.,Non-OADS,/arxiv_data1/oa_pdf/46/7c/koni-05-06-1169353.PMC4938367.pdf
Immunol Cell Biol 2006; 84:303-17; PMID:16681828; http://dx.doi.org/10.1111/j.1440- 1711.2006.01446.x 10.,Non-OADS,/arxiv_data1/oa_pdf/46/7c/koni-05-06-1169353.PMC4938367.pdf
Clin Cancer Res 2004; 10:890-6; PMID:14871964; http://dx.doi.org/10.1158/1078-0432.CCR-1086-3 12.,Non-OADS,/arxiv_data1/oa_pdf/46/7c/koni-05-06-1169353.PMC4938367.pdf
J Immunol 2005; 174:1751-9; PMID:15661941; http://dx.doi.org/10.4049/jimmunol.174.3.1751 13.,Non-OADS,/arxiv_data1/oa_pdf/46/7c/koni-05-06-1169353.PMC4938367.pdf
J Clin Oncol 2011; 29:917-24; PMID:21282551; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/46/7c/koni-05-06-1169353.PMC4938367.pdf
Proc Natl Acad Sci USA 2006; 103:14453-8; PMID:16984998; http://dx.doi.org/ 10.1073/pnas.0606512103 16.,OADS,/arxiv_data1/oa_pdf/46/7c/koni-05-06-1169353.PMC4938367.pdf
mAbs 2009;1:71-85; PMID:20046577; http://dx.doi.org/10.4161/mabs.1.1.7492 19.,Non-OADS,/arxiv_data1/oa_pdf/46/7c/koni-05-06-1169353.PMC4938367.pdf
Eur J Immunol 2010; 40:899-910; PMID:20039301; http://dx.doi.org/ 10.1002/eji.200939857 20.,Non-OADS,/arxiv_data1/oa_pdf/46/7c/koni-05-06-1169353.PMC4938367.pdf
"Expert Opin Biol Ther 2008; 8:1645-57; PMID:18847301; http://dx.doi.org/10.1517/14712598.8.11.1645 21. van Drunen Littel-van den Hurk S, Hannaman D. Electroporation for DNA immunization: clinical application.",Non-OADS,/arxiv_data1/oa_pdf/46/7c/koni-05-06-1169353.PMC4938367.pdf
Expert Rev Vaccines 2010; 9:503-17; PMID:20450325; http://dx.doi.org/10.1586/erv.10.42 22.,Non-OADS,/arxiv_data1/oa_pdf/46/7c/koni-05-06-1169353.PMC4938367.pdf
Clin Cancer Res 2009; 15:4467-74; PMID:19531622; http://dx.doi.org/10.1158/1078- 0432.CCR-09-058225.,Non-OADS,/arxiv_data1/oa_pdf/46/7c/koni-05-06-1169353.PMC4938367.pdf
Clin Cancer Res 2010; 16:4607-15; PMID:20670945; http://dx.doi.org/10.1158/1078-0432.CCR-10-1485 27.,Non-OADS,/arxiv_data1/oa_pdf/46/7c/koni-05-06-1169353.PMC4938367.pdf
J Virol 2008; 82:86-95; PMID:17959670; http://dx.doi.org/10.1128/ JVI.01289-07 28.,Non-OADS,/arxiv_data1/oa_pdf/46/7c/koni-05-06-1169353.PMC4938367.pdf
J Virol 2007; 81:4766-75; PMID:17314172; http://dx.doi.org/ 10.1128/JVI.02608-06 29.,Non-OADS,/arxiv_data1/oa_pdf/46/7c/koni-05-06-1169353.PMC4938367.pdf
Blood 2007; 109:5346-54; PMID:17327412; http://dx.doi.org/10.1182/blood-2006-10-051318 30.,Non-OADS,/arxiv_data1/oa_pdf/46/7c/koni-05-06-1169353.PMC4938367.pdf
Ann Rev Immunol 1996; 14:301- 31; PMID:8717517; http://dx.doi.org/10.1146/annurev.immunol.14.1.301 32.,Non-OADS,/arxiv_data1/oa_pdf/46/7c/koni-05-06-1169353.PMC4938367.pdf
Science 1994; 265:106-9; PMID:8016643; http://dx.doi.org/10.1126/science.8016643 33.,Non-OADS,/arxiv_data1/oa_pdf/46/7c/koni-05-06-1169353.PMC4938367.pdf
Cancer Res 2013; 73:595-604; PMID:23204239; http://dx.doi.org/10.1158/0008-5472.CAN-12-1123 34.,Non-OADS,/arxiv_data1/oa_pdf/46/7c/koni-05-06-1169353.PMC4938367.pdf
J Exp Med 2001; 194:823-32; PMID:11560997; http://dx.doi.org/10.1084/jem.194.6.823 36.,Non-OADS,/arxiv_data1/oa_pdf/46/7c/koni-05-06-1169353.PMC4938367.pdf
Ann N Y Acad Sci 2009; 1174:99-106; PMID:19769742; http://dx.doi.org/10.1111/j.1749-6632.2009.04939.x 37.,OADS,/arxiv_data1/oa_pdf/46/7c/koni-05-06-1169353.PMC4938367.pdf
Nat Med 2012;18:1254-61; PMID:22842478; http://dx.doi.org/10.1038/nm.2883 38.,OADS,/arxiv_data1/oa_pdf/46/7c/koni-05-06-1169353.PMC4938367.pdf
Proc NatlAcad Sci USA 2010; 107:4275-80; PMID:20160101; http://dx.doi.org/ 10.1073/pnas.0915174107 41.,OADS,/arxiv_data1/oa_pdf/46/7c/koni-05-06-1169353.PMC4938367.pdf
Sci Transl Med 2013; 5:200ra116; PMID:23986400; http://dx.doi.org/10.1126/scitranslmed.3006504 42.,Non-OADS,/arxiv_data1/oa_pdf/46/7c/koni-05-06-1169353.PMC4938367.pdf
Br J Cancer 2015; 112:1501-9;PMID:25867264; http://dx.doi.org/10.1038/bjc.2015.101 43.,Non-OADS,/arxiv_data1/oa_pdf/46/7c/koni-05-06-1169353.PMC4938367.pdf
Cancer Res 2006; 66:3381-5; PMID:16585157; http://dx.doi.org/10.1158/0008-5472.CAN-05-4303 44.,Non-OADS,/arxiv_data1/oa_pdf/46/7c/koni-05-06-1169353.PMC4938367.pdf
Cancer 2010; 116:1757-66; PMID:20143437; http://dx.doi.org/10.1002/cncr.24899 45.,Non-OADS,/arxiv_data1/oa_pdf/46/7c/koni-05-06-1169353.PMC4938367.pdf
N Engl JMed 2015; 372:320-30; PMID:25399552; http://dx.doi.org/10.1056/NEJMoa1412082 48.,OADS,/arxiv_data1/oa_pdf/46/7c/koni-05-06-1169353.PMC4938367.pdf
J Exp Med 2009; 206:3015-29; PMID:20008522; http://dx.doi.org/10.1084/jem.20090847 49.,Non-OADS,/arxiv_data1/oa_pdf/46/7c/koni-05-06-1169353.PMC4938367.pdf
Int Immunol 2009; 21:1065-77; PMID:19651643; http://dx.doi.org/10.1093/intimm/dxp072 50.,Non-OADS,/arxiv_data1/oa_pdf/46/7c/koni-05-06-1169353.PMC4938367.pdf
J Exp Med 2013; 210:1695- 710; PMID:23897981; http://dx.doi.org/10.1084/jem.20130579 51.,Non-OADS,/arxiv_data1/oa_pdf/46/7c/koni-05-06-1169353.PMC4938367.pdf
Toxicol Sci 2013; 135:81-90; PMID:23798565; http://dx.doi.org/10.1093/toxsci/kft140 52.,OADS,/arxiv_data1/oa_pdf/46/7c/koni-05-06-1169353.PMC4938367.pdf
J Exp Med 1998; 187:265-70; PMID:9432985; http://dx.doi.org/10.1084/jem.187.2.265 53.,OADS,/arxiv_data1/oa_pdf/46/7c/koni-05-06-1169353.PMC4938367.pdf
J Immunol 2000; 165:948-55; PMID:10878370; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/46/7c/koni-05-06-1169353.PMC4938367.pdf
Proc Natl Acad Sci USA 2004; 101:9363-8; PMID:15197261; http://dx.doi.org/ 10.1073/pnas.0403271101 56.,OADS,/arxiv_data1/oa_pdf/46/7c/koni-05-06-1169353.PMC4938367.pdf
PloS One2012; 7:e44707; PMID:22970293; http://dx.doi.org/10.1371/journal.pone.0044707 57.,Non-OADS,/arxiv_data1/oa_pdf/46/7c/koni-05-06-1169353.PMC4938367.pdf
J Immunol 2003; 171:6283-9; PMID:14634146; http://dx.doi.org/10.4049/jimmunol.171.11.6283 58.,Non-OADS,/arxiv_data1/oa_pdf/46/7c/koni-05-06-1169353.PMC4938367.pdf
Vaccine 2010; 28(32):5338-5346; PMID:20665979; http://dx.doi.org/10.1016/j.vaccine.2010.05.044 61.,Non-OADS,/arxiv_data1/oa_pdf/46/7c/koni-05-06-1169353.PMC4938367.pdf
J Exp Med 2000; 191:625-30; PMID:10684854; http://dx.doi.org/10.1084/jem.191.4.625 62.,Non-OADS,/arxiv_data1/oa_pdf/46/7c/koni-05-06-1169353.PMC4938367.pdf
CancerImmunol Immunother 2009; 58:325-38; PMID:18663444; http://dx.doi.org/10.1007/s00262-008-0556-8 63.,Non-OADS,/arxiv_data1/oa_pdf/46/7c/koni-05-06-1169353.PMC4938367.pdf
Cancer Immunol Immunother 2008; 57:1185-95; PMID:18253733; http://dx.doi.org/10.1007/s00262-008- 0450-4 64.,Non-OADS,/arxiv_data1/oa_pdf/46/7c/koni-05-06-1169353.PMC4938367.pdf
"6, e1153208 (10 pages)http://dx.doi.org/10.1080/2162402X.2016.1153208",Non-OADS,/arxiv_data1/oa_pdf/d1/9b/koni-05-06-1153208.PMC4938373.pdf
PLoS Med2010; 7:e1000279; PMID:20520800; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/d1/9b/koni-05-06-1153208.PMC4938373.pdf
J Clin Invest 2010; 120:2030-9; PMID:20501944; http://dx.doi.org/10.1172/JCI42002 3.,Non-OADS,/arxiv_data1/oa_pdf/d1/9b/koni-05-06-1153208.PMC4938373.pdf
Cancer Cell 2008; 13:58-68;PMID:18167340; http://dx.doi.org/10.1016/j.ccr.2007.12.003 4.,Non-OADS,/arxiv_data1/oa_pdf/d1/9b/koni-05-06-1153208.PMC4938373.pdf
Clin Cancer Res 2013; 19:6389-97; PMID:24298069; http://dx.doi.org/10.1158/1078-0432.CCR-13-0838 5.,Non-OADS,/arxiv_data1/oa_pdf/d1/9b/koni-05-06-1153208.PMC4938373.pdf
Science 2011; 331:1565-70; PMID:21436444; http://dx.doi.org/10.1126/science.1203486 6.,Non-OADS,/arxiv_data1/oa_pdf/d1/9b/koni-05-06-1153208.PMC4938373.pdf
J Pathol 2014; 232:199-209; PMID:24122236; http://dx.doi.org/10.1002/ path.4287 7 .,Non-OADS,/arxiv_data1/oa_pdf/d1/9b/koni-05-06-1153208.PMC4938373.pdf
J Clin Oncol 2011; 29:610-8; PMID:21245428; http://dx.do i.org/10.1200/JCO.2010.30.5425 8.,Non-OADS,/arxiv_data1/oa_pdf/d1/9b/koni-05-06-1153208.PMC4938373.pdf
Nat Rev Cancer 2012; 12:298-306; PMID:22419253; http://dx.doi.org/10.1038/nrc3245 9.,Non-OADS,/arxiv_data1/oa_pdf/d1/9b/koni-05-06-1153208.PMC4938373.pdf
Science 2006; 313:1960-4; PMID:17008531; http://dx.doi.org/10.1126/science.1129139 10.,OADS,/arxiv_data1/oa_pdf/d1/9b/koni-05-06-1153208.PMC4938373.pdf
Immunity 2013; 39:11-26; PMID:23890060; http://dx.doi.org/10.1016/j.immuni.2013.07.008 11.,OADS,/arxiv_data1/oa_pdf/d1/9b/koni-05-06-1153208.PMC4938373.pdf
Breast Cancer Res Treat 2011; 130:645-55; PMID:21717105; http://dx.doi.org/10.1007/s10549-011-1647-3 13.,Non-OADS,/arxiv_data1/oa_pdf/d1/9b/koni-05-06-1153208.PMC4938373.pdf
J Clin Oncol 2011; 29:1949-55;PMID:21483002; http://dx.doi.org/10.1200/JCO.2010.30.5037 14.,Non-OADS,/arxiv_data1/oa_pdf/d1/9b/koni-05-06-1153208.PMC4938373.pdf
Ann Oncol 2014; 25:1536-43; PMID:24915873; http://dx.doi.org/10.1093/annonc/mdu191 15.,Non-OADS,/arxiv_data1/oa_pdf/d1/9b/koni-05-06-1153208.PMC4938373.pdf
Oncoimmunology 2014; 3:e27926; PMID:25340002; http://dx.doi.org/10.4161/onci.27926 16.,Non-OADS,/arxiv_data1/oa_pdf/d1/9b/koni-05-06-1153208.PMC4938373.pdf
J Clin Oncol 2010; 28:105-13; PMID:19917869; http://dx.doi.org/10.1200/JCO.2009.23.7370 17.,Non-OADS,/arxiv_data1/oa_pdf/d1/9b/koni-05-06-1153208.PMC4938373.pdf
Breast Cancer Res 2011; 13:R126; PMID:22151962; http://dx.doi.org/ 10.1186/bcr3072 18.,Non-OADS,/arxiv_data1/oa_pdf/d1/9b/koni-05-06-1153208.PMC4938373.pdf
Breast Cancer Res Treat 2012; 132:793-805;PMID:21562709; http://dx.doi.org/10.1007/s10549-011-1554-7 19.,Non-OADS,/arxiv_data1/oa_pdf/d1/9b/koni-05-06-1153208.PMC4938373.pdf
NEngl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/ 10.1056/NEJMoa1003466 20.,OADS,/arxiv_data1/oa_pdf/d1/9b/koni-05-06-1153208.PMC4938373.pdf
N Engl J Med 2012; 366:2443-54; PMID:22658127; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/d1/9b/koni-05-06-1153208.PMC4938373.pdf
Clin Cancer Res 2014; 20:5064-74;PMID:24714771; http://dx.doi.org/10.1158/1078-0432.CCR-13-3271 22.,Non-OADS,/arxiv_data1/oa_pdf/d1/9b/koni-05-06-1153208.PMC4938373.pdf
Clin Cancer Res 2010; 16:3485- 94; PMID:20479064; http://dx.doi.org/10.1158/1078-0432.CCR-10-0505 23.,Non-OADS,/arxiv_data1/oa_pdf/d1/9b/koni-05-06-1153208.PMC4938373.pdf
J Clin Invest 2013; 123:2873-92; PMID:23778140; http://dx.doi.org/10.1172/ JCI67428 24.,Non-OADS,/arxiv_data1/oa_pdf/d1/9b/koni-05-06-1153208.PMC4938373.pdf
Ann Oncol 2014; 26:259-71; PMID:25214542; http://dx.doi.org/10.1093/annonc/mdu450 25.,OADS,/arxiv_data1/oa_pdf/d1/9b/koni-05-06-1153208.PMC4938373.pdf
Oncoim- munology 2013; 2:e26836; PMID:24498556; http://dx.doi.org/10.4161/onci.26836 26.,OADS,/arxiv_data1/oa_pdf/d1/9b/koni-05-06-1153208.PMC4938373.pdf
Nat Rev Cancer 2005; 5:591-602; PMID:16056258; http://dx.doi.org/10.1038/nrc1670 27.,Non-OADS,/arxiv_data1/oa_pdf/d1/9b/koni-05-06-1153208.PMC4938373.pdf
Cancer Res 2007; 67:5064-6; PMID:17545580; http://dx.doi.org/10.1158/0008-5472.CAN-07-0912 28.,Non-OADS,/arxiv_data1/oa_pdf/d1/9b/koni-05-06-1153208.PMC4938373.pdf
Nat Rev Cancer 2004; 4:71-8; PMID: 14708027; http://dx.doi.org/10.1038/nrc1256 29.,Non-OADS,/arxiv_data1/oa_pdf/d1/9b/koni-05-06-1153208.PMC4938373.pdf
Glia 2010; 58:1477-89; PMID:20549749; http://dx.doi.org/10.1002/glia.21022 30.,Non-OADS,/arxiv_data1/oa_pdf/d1/9b/koni-05-06-1153208.PMC4938373.pdf
Cancer Cell 2009; 16:91-102; PMID:19647220; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/d1/9b/koni-05-06-1153208.PMC4938373.pdf
Hum Pathol 2013; 44:2055-63; PMID:23701942; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/d1/9b/koni-05-06-1153208.PMC4938373.pdf
Breast Cancer Res 2012; 14:R48; PMID:22420471; http://dx.doi.org/10.1186/bcr3148 33.,Non-OADS,/arxiv_data1/oa_pdf/d1/9b/koni-05-06-1153208.PMC4938373.pdf
Br J Cancer 2015; 112:1782-90; PMID:25942397; http://dx.doi.org/10.1038/bjc.2015.145 34.,Non-OADS,/arxiv_data1/oa_pdf/d1/9b/koni-05-06-1153208.PMC4938373.pdf
Immunity 2001; 14:111-21; PMID:11239444; http://dx.doi.org/10.1016/S1074-7613(01)00094-2 35.,OADS,/arxiv_data1/oa_pdf/d1/9b/koni-05-06-1153208.PMC4938373.pdf
"J Clin Oncol 2008; 26:4410-7; PMID:18802153; http://dx.doi.org/10.1200/JCO.2007.15.0284 36. de Chaisemartin L, Goc J, Damotte D, Validire P, Magdeleinat P, Ali- fano M, Cremer I, Fridman WH, Saut /C18es-Fridman C, Dieu-Nosjean MC.",Non-OADS,/arxiv_data1/oa_pdf/d1/9b/koni-05-06-1153208.PMC4938373.pdf
J Clin Oncol 2010; 28:3271-7; PMID:20498394; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/d1/9b/koni-05-06-1153208.PMC4938373.pdf
Cancer Cell 2005; 7:411-23; PMID:15894262; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/d1/9b/koni-05-06-1153208.PMC4938373.pdf
Cancer Res 2011; 71:3505-15; PMID:21444674; http://dx.doi.org/ 10.1158/0008-5472.CAN-10-4316 41.,Non-OADS,/arxiv_data1/oa_pdf/d1/9b/koni-05-06-1153208.PMC4938373.pdf
Cancer Immunol Immunother 2003; 52:715-38;PMID:12920480; http://dx.doi.org/10.1007/s00262-003-0409-4e1153208-10 B. SOBOTTKA ET AL.,Non-OADS,/arxiv_data1/oa_pdf/d1/9b/koni-05-06-1153208.PMC4938373.pdf
"6, e1123368 (14 pages)http://dx.doi.org/10.1080/2162402X.2015.1123368",Non-OADS,/arxiv_data1/oa_pdf/67/f7/koni-05-06-1123368.PMC4938377.pdf
"(IEDB analysis resource, consensus method, http://tools.immu neepitope.org/analyze/html/mhc_II_binding.html).28,29The software analyzed 15 amino-acid-long sequences offset toencompass the entire IMP-3 protein.",OADS,/arxiv_data1/oa_pdf/67/f7/koni-05-06-1123368.PMC4938377.pdf
Cancer Sci 2015; 106:505-11; PMID:25726868; http://dx.doi.org/10.1111/cas.12650 2.,Non-OADS,/arxiv_data1/oa_pdf/67/f7/koni-05-06-1123368.PMC4938377.pdf
J Oral Pathol Med 2013; 42:125-32; PMID:22643116; http://dx.doi.org/10.1111/j.1600-0714.,Non-OADS,/arxiv_data1/oa_pdf/67/f7/koni-05-06-1123368.PMC4938377.pdf
Hum Pathol 2010; 41:477-84; PMID:20004948; http://dx.doi.org/ 10.1016/j.humpath.2009.10.004 4.,OADS,/arxiv_data1/oa_pdf/67/f7/koni-05-06-1123368.PMC4938377.pdf
Am J Surg Pathol 2008; 32:304-15; PMID:18223334;http://dx.doi.org/10.1097/PAS.0b013e3181483ff8 5.,Non-OADS,/arxiv_data1/oa_pdf/67/f7/koni-05-06-1123368.PMC4938377.pdf
Reproduction 2005; 130:203-12; PMID:16049158; http://dx.doi.org/10.1530/rep.1.00664 6.,Non-OADS,/arxiv_data1/oa_pdf/67/f7/koni-05-06-1123368.PMC4938377.pdf
Cancer Sci 2011; 102:71-8;PMID:21087352; http://dx.doi.org/10.1111/j.1349-7006.2010.01780.x 7.,Non-OADS,/arxiv_data1/oa_pdf/67/f7/koni-05-06-1123368.PMC4938377.pdf
Cancer Sci 2008; 99: 1448-54; PMID:18452554; http://dx.doi.org/10.1111/j.1349-7006.2008.,Non-OADS,/arxiv_data1/oa_pdf/67/f7/koni-05-06-1123368.PMC4938377.pdf
J Biol Chem 2005; 280:18517-24; PMID:15753088; http://dx.doi.org/10.1074/jbc.M500270200 9.,OADS,/arxiv_data1/oa_pdf/67/f7/koni-05-06-1123368.PMC4938377.pdf
EMBO J 2006; 25:1456-68; PMID:16541107; http://dx.doi.org/10.1038/sj.emboj.7601039 10.,Non-OADS,/arxiv_data1/oa_pdf/67/f7/koni-05-06-1123368.PMC4938377.pdf
Clin Cancer Res 2008; 14:1701-6;PMID:18347170; http://dx.doi.org/10.1158/1078-0432.CCR-07-2039 11.,Non-OADS,/arxiv_data1/oa_pdf/67/f7/koni-05-06-1123368.PMC4938377.pdf
BMC Cancer 2010; 10:59; PMID:20178612; http://dx.doi.org/10.1186/1471- 2407-10-59e1123368-12 M. HIRAYAMA ET AL.,OADS,/arxiv_data1/oa_pdf/67/f7/koni-05-06-1123368.PMC4938377.pdf
Head Neck 2011; 33:368-74; PMID:20652886; http://dx.doi.org/10.1002/hed.21609 13.,Non-OADS,/arxiv_data1/oa_pdf/67/f7/koni-05-06-1123368.PMC4938377.pdf
Cancer Sci 2007; 98:1803-8; PMID:17784873; http://dx.doi.org/10.1111/j.1349-7006.2007.00603.x 14.,Non-OADS,/arxiv_data1/oa_pdf/67/f7/koni-05-06-1123368.PMC4938377.pdf
Cancer Sci 2009; 100:1502-9; PMID:19459850; http://dx.doi.org/10.1111/j.1349-7006.2009.01200.x 15.,Non-OADS,/arxiv_data1/oa_pdf/67/f7/koni-05-06-1123368.PMC4938377.pdf
J Transl Med 2012; 10:141; PMID:22776426; http://dx.doi.org/10.1186/1479- 5876-10-141 16.,Non-OADS,/arxiv_data1/oa_pdf/67/f7/koni-05-06-1123368.PMC4938377.pdf
Clin Cancer Res 2015; 21:312-21; PMID:25391695; http://dx.doi.org/10.1158/1078-0432.CCR-14-0202 17.,Non-OADS,/arxiv_data1/oa_pdf/67/f7/koni-05-06-1123368.PMC4938377.pdf
Nat Rev Cancer2008; 8:351-60; PMID:18418403; http://dx.doi.org/10.1038/nrc2373 18.,Non-OADS,/arxiv_data1/oa_pdf/67/f7/koni-05-06-1123368.PMC4938377.pdf
Eur J Immunol 2008; 38:1033-42; PMID:18350546; http://dx.doi.org/10.1002/eji.200737995 19.,Non-OADS,/arxiv_data1/oa_pdf/67/f7/koni-05-06-1123368.PMC4938377.pdf
Nature 2003; 421:852-6; PMID:12594515; http://dx.doi.org/10.1038/nature01441 20.,Non-OADS,/arxiv_data1/oa_pdf/67/f7/koni-05-06-1123368.PMC4938377.pdf
J Immunol 2006; 177:2862-72; PMID: 16920921; http://dx.doi.org/10.4049/jimmunol.177.5.2862 21.,Non-OADS,/arxiv_data1/oa_pdf/67/f7/koni-05-06-1123368.PMC4938377.pdf
Cancer Res 2004; 64:386-90; PMID:14729649; http://dx.doi.org/10.1158/0008-5472.CAN-03-2596 22.,Non-OADS,/arxiv_data1/oa_pdf/67/f7/koni-05-06-1123368.PMC4938377.pdf
Nature 2013;494:361-5; PMID:23376950; http://dx.doi.org/10.1038/nature11824 23.,Non-OADS,/arxiv_data1/oa_pdf/67/f7/koni-05-06-1123368.PMC4938377.pdf
Can- cer Res 2010; 70:8368-77; PMID:20940398; http://dx.doi.org/10.1158/0008-5472.CAN-10-1322 24.,Non-OADS,/arxiv_data1/oa_pdf/67/f7/koni-05-06-1123368.PMC4938377.pdf
Cancer Immunol Immunother 2007; 56:331-42;PMID:16896967; http://dx.doi.org/10.1007/s00262-006-0192-0 25.,Non-OADS,/arxiv_data1/oa_pdf/67/f7/koni-05-06-1123368.PMC4938377.pdf
J Exp Med 2010; 207:637-50; PMID:20156971; http://dx.doi.org/10.1084/jem.20091918 26.,Non-OADS,/arxiv_data1/oa_pdf/67/f7/koni-05-06-1123368.PMC4938377.pdf
J Exp Med 2010; 207:651-67; PMID:20156973; http://dx.doi.org/10.1084/jem.20091921 27.,Non-OADS,/arxiv_data1/oa_pdf/67/f7/koni-05-06-1123368.PMC4938377.pdf
PLoS Comput Biol 2008; 4:e1000048; PMID:18389056; http://dx.doi.org/10.1371/journal.pcbi.1000048 29.,Non-OADS,/arxiv_data1/oa_pdf/67/f7/koni-05-06-1123368.PMC4938377.pdf
"Wang P, Sidney J, Kim Y, Sette A, Lund O, Nielsen M, Peters B. Peptide binding predictions for HLA DR, DP and DQ molecules.BMC Bioinformatics 2010; 11:568; PMID:21092157; http://dx.doi.org/ 10.1186/1471-2105-11-568 30.",OADS,/arxiv_data1/oa_pdf/67/f7/koni-05-06-1123368.PMC4938377.pdf
Biomaterials 2013; 34:5711-21; PMID: 23639528; http://dx.doi.org/10.1016/j.biomaterials.2013.04.007 31.,OADS,/arxiv_data1/oa_pdf/67/f7/koni-05-06-1123368.PMC4938377.pdf
Nat Rev Immunol 2004; 4:595-602; PMID:15286726; http://dx.doi.org/10.1038/nri1413 33.,Non-OADS,/arxiv_data1/oa_pdf/67/f7/koni-05-06-1123368.PMC4938377.pdf
Nature 1998; 393:480-3; PMID:9624005; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/67/f7/koni-05-06-1123368.PMC4938377.pdf
Cancer Res 2013; 73:19-29;PMID:23087058; http://dx.doi.org/10.1158/0008-5472.CAN-12-1127 35.,Non-OADS,/arxiv_data1/oa_pdf/67/f7/koni-05-06-1123368.PMC4938377.pdf
J Clin Oncol 2009; 27:4685-92; PMID:19720923; http://dx.doi.org/10.1200/JCO.2008.20.6789 36.,Non-OADS,/arxiv_data1/oa_pdf/67/f7/koni-05-06-1123368.PMC4938377.pdf
J Immunol 2000; 165:6123-32; PMID:11086045; http://dx.doi.org/10.4049/ jimmunol.165.11.6123 37.,Non-OADS,/arxiv_data1/oa_pdf/67/f7/koni-05-06-1123368.PMC4938377.pdf
J Exp Med 1995; 182:1579-84; PMID:7595228; http://dx.doi.org/10.1084/jem.182.5.1579 38.,Non-OADS,/arxiv_data1/oa_pdf/67/f7/koni-05-06-1123368.PMC4938377.pdf
J Exp Med 1995; 182:1591-6; PMID:7595230; http://dx.doi.org/10.1084/jem.182.5.1591 39.,Non-OADS,/arxiv_data1/oa_pdf/67/f7/koni-05-06-1123368.PMC4938377.pdf
Immunity 2014; 41:63-74; PMID:24981853; http://dx.doi.org/10.1016/j.immuni.2014.06.003 41.,OADS,/arxiv_data1/oa_pdf/67/f7/koni-05-06-1123368.PMC4938377.pdf
J Exp Med 2002; 196:619-28; PMID:12208877; http://dx.doi.org/10.1084/jem.20012142 42.,Non-OADS,/arxiv_data1/oa_pdf/67/f7/koni-05-06-1123368.PMC4938377.pdf
Nat Med 2004;10:942-9; PMID:15322536; http://dx.doi.org/10.1038/nm1093 43.,OADS,/arxiv_data1/oa_pdf/67/f7/koni-05-06-1123368.PMC4938377.pdf
Clin Cancer Res 2007; 13:6301-11; PMID:17975141; http://dx.doi.org/10.1158/1078-0432.CCR-07-1403 44.,Non-OADS,/arxiv_data1/oa_pdf/67/f7/koni-05-06-1123368.PMC4938377.pdf
Cancer Res 2009; 69:4335-45; PMID:19435913; http://dx.doi.org/10.1158/0008-5472.CAN-08-3726 45.,Non-OADS,/arxiv_data1/oa_pdf/67/f7/koni-05-06-1123368.PMC4938377.pdf
Oncoimmunology 2012; 1:670-86; PMID:22934259; http://dx.doi.org/10.4161/onci.20426 50.,Non-OADS,/arxiv_data1/oa_pdf/67/f7/koni-05-06-1123368.PMC4938377.pdf
IntJ Oncol 2015; 46:28-36; PMID:25354479; http://dx.doi.org/10.3892/ ijo.2014.2737 53.,Non-OADS,/arxiv_data1/oa_pdf/67/f7/koni-05-06-1123368.PMC4938377.pdf
Cancer Res 2013; 73:3591-603; PMID:23633484; http://dx.doi.org/10.1158/0008-5472.CAN-12-4100 54.,Non-OADS,/arxiv_data1/oa_pdf/67/f7/koni-05-06-1123368.PMC4938377.pdf
Int JCancer 2008; 123:2616-25; PMID:18770861; http://dx.doi.org/ 10.1002/ijc.23823 55.,OADS,/arxiv_data1/oa_pdf/67/f7/koni-05-06-1123368.PMC4938377.pdf
Clin Cancer Res 2013; 19:4508-20; PMID:23714729;http://dx.doi.org/10.1158/1078-0432.CCR-13-0197 56.,Non-OADS,/arxiv_data1/oa_pdf/67/f7/koni-05-06-1123368.PMC4938377.pdf
Int J Cancer 2014; 134:352-66; PMID:24734272; http://dx.doi.org/ 10.1002/ijc.28376 57.,Non-OADS,/arxiv_data1/oa_pdf/67/f7/koni-05-06-1123368.PMC4938377.pdf
Oncoimmunology 2014; 3:e28100;PMID:25340007; http://dx.doi.org/10.4161/onci.28100 58.,Non-OADS,/arxiv_data1/oa_pdf/67/f7/koni-05-06-1123368.PMC4938377.pdf
OncoImmunology 2016; 5:e1062209; PMID:26942076; http://dx.doi.org/10.1080/2162402X.2015.1062209 59.,Non-OADS,/arxiv_data1/oa_pdf/67/f7/koni-05-06-1123368.PMC4938377.pdf
Hum Immunol 1998; 59:549-60; PMID:9757911; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/67/f7/koni-05-06-1123368.PMC4938377.pdf
Biotech Health Sci 2015; 2:e27414; http://dx.doi.org/10.17795/bhs27414e1123368-14 M. HIRAYAMA ET AL.,OADS,/arxiv_data1/oa_pdf/67/f7/koni-05-06-1123368.PMC4938377.pdf
"11,12 Endothelial-surface proteoglycans Cellular Biology Circulation Research is available at http://circres.ahajournals.org DOI: 10.1161/CIRCRESAHA.116.308504Rationale:  Lymphatic vessel growth is mediated by major prolymphangiogenic factors, such as vascular endothelial  growth factor (VEGF-C) and VEGF-D, among other endothelial effectors.",Non-OADS,/arxiv_data1/oa_pdf/d9/95/res-119-210.PMC4938725.pdf
*S.C. Johns and X.Yin are joint first authors.The online-only Data Supplement is available with this article at http://circres.ahajournals.org/lookup/suppl/doi:10.1161/CIRCRESAHA.,Non-OADS,/arxiv_data1/oa_pdf/d9/95/res-119-210.PMC4938725.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), permitting all non-commer cial use, distribution, and reproduction in any medium, provided the original work is properly cited.1 Citation: Infection Ecology and Epidemiology 2016, 6: 31782 - http://dx.doi.org/10.3402/iee.v6.31782 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/32/46/IEE-6-31782.PMC4938893.pdf
"2 (page number not for citation purpose)Citation: Infection Ecology and Epidemiology 2016, 6: 31782 - http://dx.doi.org/10.3402/iee.v6.31782",Non-OADS,/arxiv_data1/oa_pdf/32/46/IEE-6-31782.PMC4938893.pdf
"Green/C30Va¨stergo ¨tland , Y ellow /C30O¨stergo ¨tland ,R e d/C30Ska˚ne, Blue/C30Endemic region ( O¨land).WGS of Swedish Salmonella Dublin isolates Citation: Infection Ecology and Epidemiology 2016, 6: 31782 - http://dx.doi.org/10.3402/iee.v6.31782 3 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/32/46/IEE-6-31782.PMC4938893.pdf
"4 (page number not for citation purpose)Citation: Infection Ecology and Epidemiology 2016, 6: 31782 - http://dx.doi.org/10.3402/iee.v6.31782",Non-OADS,/arxiv_data1/oa_pdf/32/46/IEE-6-31782.PMC4938893.pdf
"There were no known contacts between the herds in the endemic region ( O¨land).WGS of Swedish Salmonella Dublin isolates Citation: Infection Ecology and Epidemiology 2016, 6: 31782 - http://dx.doi.org/10.3402/iee.v6.31782 5 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/32/46/IEE-6-31782.PMC4938893.pdf
"6 (page number not for citation purpose)Citation: Infection Ecology and Epidemiology 2016, 6: 31782 - http://dx.doi.org/10.3402/iee.v6.31782",Non-OADS,/arxiv_data1/oa_pdf/32/46/IEE-6-31782.PMC4938893.pdf
"Vet Microbiol 2012; 159: 509 /C114.WGS of Swedish Salmonella Dublin isolates Citation: Infection Ecology and Epidemiology 2016, 6: 31782 - http://dx.doi.org/10.3402/iee.v6.31782 7 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/32/46/IEE-6-31782.PMC4938893.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/37/7a/ircmj-18-04-26452.PMC4939066.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCom - mercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial us - ages, provided the original work is properly cited.1.",Non-OADS,/arxiv_data1/oa_pdf/fd/8e/ircmj-18-04-23839.PMC4939067.pdf
"This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, andindicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/45/88/12325_2016_Article_355.PMC4939147.pdf
Pathogen safety data sheet—infectioussubstances 2012. http://www.phac-aspc.gc.ca/lab- bio/res/psds-ftss/var-zo-eng.php .,OADS,/arxiv_data1/oa_pdf/45/88/12325_2016_Article_355.PMC4939147.pdf
News and events 2006. http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/2006/ucm108659.,OADS,/arxiv_data1/oa_pdf/45/88/12325_2016_Article_355.PMC4939147.pdf
Shingles vaccination: what everyone should know 2016. http://www.cdc.gov/vaccines/vpd-vac/ shingles/vacc-need-know.htm .,Non-OADS,/arxiv_data1/oa_pdf/45/88/12325_2016_Article_355.PMC4939147.pdf
"In short, trabectedin is anEnhanced content To view enhance content for this article go to http://www.medengine.com/Redeem/D1D 4F06053A388AB .",Non-OADS,/arxiv_data1/oa_pdf/ac/25/12325_2016_Article_344.PMC4939148.pdf
"This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/ac/25/12325_2016_Article_344.PMC4939148.pdf
American Cancer Society at http://www.cancer.org/ acs/.,Non-OADS,/arxiv_data1/oa_pdf/ac/25/12325_2016_Article_344.PMC4939148.pdf
51. http://www.clinicaltrials.gov .,Non-OADS,/arxiv_data1/oa_pdf/ac/25/12325_2016_Article_344.PMC4939148.pdf
Funding : This work was supported by the University of Malaya’s High Impact Research grant UM.C/625/1/HIR/MOHE/05.Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/D7D 4F06054432A56 .,Non-OADS,/arxiv_data1/oa_pdf/07/1a/12325_2016_Article_357.PMC4939150.pdf
"This article is distributed under the terms of the Creative CommonsAttribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit tothe original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/07/1a/12325_2016_Article_357.PMC4939150.pdf
"Luseogliﬂozin signiﬁcantly lowered ‘‘lowest glucose’’ (deﬁned as the lowest level measured throughout a 24-h period) similarly in PGR and PGNR ( -19.2 and -24.0 mg/dL; both p\0.05), signiﬁcantly reduced the meanEnhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/54D4 F0602980E586 .",Non-OADS,/arxiv_data1/oa_pdf/47/b1/12325_2016_Article_350.PMC4939154.pdf
"This article is distributed under the terms of the Creative CommonsAttribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommercial use, distribution, and reproduction in anymedium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/47/b1/12325_2016_Article_350.PMC4939154.pdf
"In the USA, incidence of prostate cancer is within this European range atEnhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/75D4 F06043F0A7DE .",Non-OADS,/arxiv_data1/oa_pdf/ea/65/12325_2016_Article_351.PMC4939158.pdf
"License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate creditto the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/ea/65/12325_2016_Article_351.PMC4939158.pdf
2012. http://seer.cancer.gov/ statfacts/html/prost.html .,Non-OADS,/arxiv_data1/oa_pdf/ea/65/12325_2016_Article_351.PMC4939158.pdf
Available at:http://www.ema.europa.eu/docs/en_GB/document _library/EPAR_-_Product_Information/human/002 639/WC500144996.pdf .,Non-OADS,/arxiv_data1/oa_pdf/ea/65/12325_2016_Article_351.PMC4939158.pdf
"The incidence, severity, onset,Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ 85D4F06061A0B6E0 .",Non-OADS,/arxiv_data1/oa_pdf/57/68/12325_2016_Article_353.PMC4939160.pdf
"This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, andindicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/57/68/12325_2016_Article_353.PMC4939160.pdf
http://www.ich.org/ﬁleadmin/Public_ Web_Site/ICH_Products/ Guidelines/Efﬁcacy/E6/ E6_R1_Guideline.pdf .,Non-OADS,/arxiv_data1/oa_pdf/57/68/12325_2016_Article_353.PMC4939160.pdf
"We also ate food cooked in bulk with minimal, if any, nutrition and always with moreEnhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ 14D4F0606572B3CB .",Non-OADS,/arxiv_data1/oa_pdf/38/ff/12325_2016_Article_349.PMC4939162.pdf
Look-back for comorbidity prevalenceEnhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/62D4 F0603A5B541A .,Non-OADS,/arxiv_data1/oa_pdf/7e/91/12325_2016_Article_346.PMC4939171.pdf
"This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, andindicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/7e/91/12325_2016_Article_346.PMC4939171.pdf
Available from: http://www.ema.europa.,Non-OADS,/arxiv_data1/oa_pdf/7e/91/12325_2016_Article_346.PMC4939171.pdf
Available from: http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncement s/ucm478791.htm .,Non-OADS,/arxiv_data1/oa_pdf/7e/91/12325_2016_Article_346.PMC4939171.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/48/f9/ircmj-18-05-30120.PMC4939225.pdf
Available from: http://tanasob.mihanblog.com/post/225 .,Non-OADS,/arxiv_data1/oa_pdf/48/f9/ircmj-18-05-30120.PMC4939225.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCom - mercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial us - ages, provided the original work is properly cited.1.",Non-OADS,/arxiv_data1/oa_pdf/5c/bd/ircmj-18-05-30309.PMC4939226.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/aa/f8/ircmj-18-05-26039.PMC4939227.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCom - mercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial us - ages, provided the original work is properly cited.1.",Non-OADS,/arxiv_data1/oa_pdf/6a/97/ircmj-18-05-23075.PMC4939228.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCom - mercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial us - ages, provided the original work is properly cited.1.",Non-OADS,/arxiv_data1/oa_pdf/56/7e/ircmj-18-05-25407.PMC4939229.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-Non - Commercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial  usages, provided the original work is properly cited.1.",Non-OADS,/arxiv_data1/oa_pdf/99/4c/ijp-26-02-3839.PMC4939230.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/5a/95/ircmj-18-05-25183.PMC4939231.pdf
"Supplements Appendix 1 (including references 1, 6, 18, 19, 23- 37, 39-42, 44-50 and 52-55) is available at below link: http://ircmj.com/?page=download&ﬁle_id=57882 Acknowledgments This study is a part of a PhD dissertation ﬁnancially sup- ported by Iran University of Medical Sciences.",Non-OADS,/arxiv_data1/oa_pdf/5a/95/ircmj-18-05-25183.PMC4939231.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCom - mercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial us - ages, provided the original work is properly cited.1.",Non-OADS,/arxiv_data1/oa_pdf/b6/05/ircmj-18-05-23556.PMC4939232.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCom - mercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial us - ages, provided the original work is properly cited.1.",Non-OADS,/arxiv_data1/oa_pdf/d1/97/ircmj-18-05-21942.PMC4939233.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-Non - Commercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial  usages, provided the original work is properly cited.1.",Non-OADS,/arxiv_data1/oa_pdf/27/de/ijp-26-02-2493.PMC4939234.pdf
The 30 coding regions (exons 3 - 32) of the ABCA3 gene  (NCBI NM_001089) and the intron-exon boundaries were  amplified by PCR with designed primer pairs using Prim - er3 software (Table 1) (http://primer3.ut.ee/).,OADS,/arxiv_data1/oa_pdf/27/de/ijp-26-02-2493.PMC4939234.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCom - mercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial us - ages, provided the original work is properly cited.1.",Non-OADS,/arxiv_data1/oa_pdf/ba/38/ircmj-18-05-26097.PMC4939235.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCom - mercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial us - ages, provided the original work is properly cited.1.",Non-OADS,/arxiv_data1/oa_pdf/d2/f6/ircmj-18-05-25089.PMC4939236.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/ca/24/ircmj-18-05-24960.PMC4939237.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCom - mercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial us - ages, provided the original work is properly cited.1.",Non-OADS,/arxiv_data1/oa_pdf/af/ee/ircmj-18-05-21858.PMC4939238.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/83/c5/main.PMC4939318.pdf
"Since  many  years  cytogenetic  analysis  of  dicentric chromosomes  has  been  the  gold  standard  for  biological  dosime- try,  however,  sensitivity  of  this  assay  is  limited  to  doses  >100  mGy http://dx.doi.org/10.1016/j.ejro.2016.06.001 2352-0477/© 2016  The  Authors.",Non-OADS,/arxiv_data1/oa_pdf/83/c5/main.PMC4939318.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.,Non-OADS,/arxiv_data1/oa_pdf/83/c5/main.PMC4939318.pdf
"2016, http://www.fda.gov/Radiation-EmittingProducts/ RadiationEmittingProductsandProcedures/MedicalImaging/MedicalX-Rays/ucm115329.htm (accessed  10.06.16).",OADS,/arxiv_data1/oa_pdf/83/c5/main.PMC4939318.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: Marine sediment Dokdo IslandWhole genome shot-gun sequencing Speci ﬁcations Organism/cell line/tissue Sunxiuqinia dokdonensis Strain DH1 T Sequencer or array type HiSeq (Illumina)Data format AnalyzedExperimental factors Microbial strainExperimental features Whole genome analysis and gene annotation of DH1 T Consent N/ASample source location Marine sediment in Dokdo Island 1.,Non-OADS,/arxiv_data1/oa_pdf/f4/df/main.PMC4939319.pdf
Direct link to deposited data http://www.ncbi.nlm.nih.gov/assembly/GCF_001270965.1/ .,OADS,/arxiv_data1/oa_pdf/f4/df/main.PMC4939319.pdf
http://dx.doi.org/10.1016/j.gdata.2016.06.016 2213-5960/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/f4/df/main.PMC4939319.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f4/df/main.PMC4939319.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a5/7f/main.PMC4939321.pdf
Phagocytosis is a complex process that involves patternContents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/redoxRedox Biology http://dx.doi.org/10.1016/j.redox.2016.06.003 2213-2317/ &2016 The Authors.,OADS,/arxiv_data1/oa_pdf/a5/7f/main.PMC4939321.pdf
"This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Abbreviations: HNE, 4-hydroxynonenal; ROS, reactive oxygen species; PMA, 3- phorbol myristate acetate; XF assay, extracellular ﬂux assay; PBMC, peripheral blood mononuclear cells; PMN, polymorphonuclear granulocytes; S. aureus ,Sta- phylococcus aureus ; NADPH, nicotinamide adenine dinucleotide phosphate; NOX, NADPH Oxidase nCorrespondence to: Department of Pathology, University of Alabama at Bir- mingham, Biomedical Research Building II, Rm.508, 901 19th Street South, Bir-mingham, AL 35294, United States.",Non-OADS,/arxiv_data1/oa_pdf/a5/7f/main.PMC4939321.pdf
"This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any noncom-mercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.THYROID Volume 26, Number 7, 2016Mary Ann Liebert, Inc.DOI: 10.1089/thy.2015.0538 965",Non-OADS,/arxiv_data1/oa_pdf/69/87/thy.2015.0538.PMC4939365.pdf
"This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncom-mercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.JOURNAL OF WOMEN’S HEALTH Volume 25, Number 7, 2016Mary Ann Liebert, Inc.DOI: 10.1089/jwh.2015.5509 752",Non-OADS,/arxiv_data1/oa_pdf/18/41/jwh.2015.5509.PMC4939369.pdf
"This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any non-commercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.THE JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE Volume 22, Number 7, 2016, pp.",Non-OADS,/arxiv_data1/oa_pdf/b9/d0/acm.2016.0025.PMC4939370.pdf
"This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any noncommercial use,distribution, and reproduction in any medium, provided the original author(s) and the source are credited.FOODBORNE PATHOGENS AND DISEASE Volume 13, Number 7, 2016Mary Ann Liebert, Inc.DOI: 10.1089/fpd.2015.2088 350",Non-OADS,/arxiv_data1/oa_pdf/97/3a/fpd.2015.2088.PMC4939371.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/08/0f/main.PMC4939375.pdf
"1 A),Contents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/redoxRedox Biology http://dx.doi.org/10.1016/j.redox.2016.06.002 2213-2317/ &2016 The Authors.",OADS,/arxiv_data1/oa_pdf/08/0f/main.PMC4939375.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/08/0f/main.PMC4939375.pdf
"This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any noncommercial use, distribution, and re- production in any medium, provided the original author(s) and the source are credited.",Non-OADS,/arxiv_data1/oa_pdf/5b/9d/tmj.2015.0194.PMC4939376.pdf
"This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any noncommercial use,distribution, and reproduction in any medium, provided the original author(s) and the source are credited.STEM CELLS AND DEVELOPMENT Volume 25, Number 14, 2016 Mary Ann Liebert, Inc. DOI: 10.1089/scd.2015.0366 1060",Non-OADS,/arxiv_data1/oa_pdf/92/29/scd.2015.0366.PMC4939377.pdf
"This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any noncommercial use,distribution, and reproduction in any medium, provided the original author(s) and the source are credited.THYROID Volume 26, Number 7, 2016Mary Ann Liebert, Inc.DOI: 10.1089/thy.2016.0244 872",Non-OADS,/arxiv_data1/oa_pdf/7b/5b/thy.2016.0244.PMC4939382.pdf
"This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.01/) which permits any noncommercial use,distribution, and reproduction in any medium, provided the original author(s) and the source are credited.MICROBIAL DRUG RESISTANCE Volume 22, Number 5, 2016Mary Ann Liebert, Inc.DOI: 10.1089/mdr.2015.0251 372",Non-OADS,/arxiv_data1/oa_pdf/2e/37/mdr.2015.0251.PMC4939386.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: PerampanelMyoclonus Lance –Adams syndrome Efﬁcacy 1.,Non-OADS,/arxiv_data1/oa_pdf/3f/05/main.PMC4939387.pdf
http://dx.doi.org/10.1016/j.ebcr.2016.05.001 2213-3232/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/3f/05/main.PMC4939387.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/3f/05/main.PMC4939387.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: fMRIVascular reactivityStrokeBreath-holdNeurovascular uncoupling 1.,Non-OADS,/arxiv_data1/oa_pdf/5a/5e/main.PMC4939388.pdf
http://dx.doi.org/10.1016/j.nicl.2016.06.016 2213-1582/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/5a/5e/main.PMC4939388.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/5a/5e/main.PMC4939388.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: MR imagingVBMTBSSDM1Neuropsychology 1.,Non-OADS,/arxiv_data1/oa_pdf/9e/31/main.PMC4939389.pdf
http://dx.doi.org/10.1016/j.nicl.2016.06.0112213-1582/© 2016 Published by Elsevier Inc.,Non-OADS,/arxiv_data1/oa_pdf/9e/31/main.PMC4939389.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/9e/31/main.PMC4939389.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/80/45/main.PMC4939390.pdf
Contents lists available at ScienceDirect International Journal for Parasitology: Parasites and Wildlife journal homepage: www.elsevier.com/locate/ijppaw http://dx.doi.org/10.1016/j.ijppaw.2016.06.004 2213-2244/ ©2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/80/45/main.PMC4939390.pdf
http://dx.doi.org/10.1007/s10393-015-1088-2 .,Non-OADS,/arxiv_data1/oa_pdf/80/45/main.PMC4939390.pdf
This is an open access article under the CC BY- NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/ 4.0/).,Non-OADS,/arxiv_data1/oa_pdf/4f/0e/main.PMC4939401.pdf
http://dx.doi.org/10.1016/j.jdcr.2016.04.004 253,OADS,/arxiv_data1/oa_pdf/4f/0e/main.PMC4939401.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/df/12/ircmj-18-05-24402.PMC4939412.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/13/35/ircmj-18-05-33982.PMC4939413.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCom - mercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial us - ages, provided the original work is properly cited.1.",Non-OADS,/arxiv_data1/oa_pdf/4c/aa/ircmj-18-05-27061.PMC4939414.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/fa/63/ircmj-18-05-36732.PMC4939415.pdf
This is an open access article under the CC BY- NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/ 4.0/).,Non-OADS,/arxiv_data1/oa_pdf/ae/3a/main.PMC4939421.pdf
http://dx.doi.org/10.1016/j.jdcr.2016.05.015 257,OADS,/arxiv_data1/oa_pdf/ae/3a/main.PMC4939421.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: GliomaIsocitrate dehydrogenase 1 (IDH1) mutationMetabolic reprogramming Hyperpolarized 13C Magnetic Resonance Spec- troscopy (MRS) 1.,Non-OADS,/arxiv_data1/oa_pdf/08/4e/main.PMC4939422.pdf
http://dx.doi.org/10.1016/j.nicl.2016.06.0182213-1582/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/08/4e/main.PMC4939422.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/08/4e/main.PMC4939422.pdf
http://dx.doi.org/10.18632/oncotarget.,OADS,/arxiv_data1/oa_pdf/08/4e/main.PMC4939422.pdf
Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious DiseasesThis is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) http://dx.doi.org/10.1016/j.nmni.2016.06.010,Non-OADS,/arxiv_data1/oa_pdf/ba/d1/main.PMC4939470.pdf
massiliensis ’is available at http://www.mediterranee-infection.com/article.php?,Non-OADS,/arxiv_data1/oa_pdf/ba/d1/main.PMC4939470.pdf
"Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases, NMNI ,13,6 0 –61 This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).",Non-OADS,/arxiv_data1/oa_pdf/ba/d1/main.PMC4939470.pdf
"ORIGINAL ARTICLE Copyright © 2016 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgKorean J Intern Med 2016;31:762-771  http://dx.doi.org/10.3904/kjim.2013.019INTRODUCTION The incidence of spinal infection has grown rapidly  with increasing uses of invasive spinal procedures and  intravascular cathetes that can act as a means of inoc -ulation and spreading of pathogens into the vertebra,  intervertebral disks, and adjacent muscles [1].",Non-OADS,/arxiv_data1/oa_pdf/8f/f5/kjim-2013-019.PMC4939487.pdf
"CT-guided bone biopsy in spinal infection www.kjim.org http://dx.doi.org/10.3904/kjim.2013.019of magnetic resonance imaging (MRI) has improved the  sensitivity and specificity of this disease entity, the diag - nosis of spondylitis has been a challenge for physicians  for many years [6].",Non-OADS,/arxiv_data1/oa_pdf/8f/f5/kjim-2013-019.PMC4939487.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2013.019with death, relapse or repetitive surgery during the fol - low-up period.",Non-OADS,/arxiv_data1/oa_pdf/8f/f5/kjim-2013-019.PMC4939487.pdf
CT-guided bone biopsy in spinal infection www.kjim.org http://dx.doi.org/10.3904/kjim.2013.019Clinical characteristics of tuberculous and pyogenic  groups  Clinical characteristics of patients with tuberculous and  pyogenic spondylitis are compared in Table 2.,Non-OADS,/arxiv_data1/oa_pdf/8f/f5/kjim-2013-019.PMC4939487.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2013.019The most commonly involved vertebrae were lumbar  (56%), followed by thoracic (19%) and thoracolumbar  (9%).",OADS,/arxiv_data1/oa_pdf/8f/f5/kjim-2013-019.PMC4939487.pdf
CT-guided bone biopsy in spinal infection www.kjim.org http://dx.doi.org/10.3904/kjim.2013.019diagnosis even though patients presented with epidural  and paravertebral abscesses.,Non-OADS,/arxiv_data1/oa_pdf/8f/f5/kjim-2013-019.PMC4939487.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2013.019all of bacterial spondylitis cases in this study.",Non-OADS,/arxiv_data1/oa_pdf/8f/f5/kjim-2013-019.PMC4939487.pdf
"CT-guided bone biopsy in spinal infection www.kjim.org http://dx.doi.org/10.3904/kjim.2013.019sure, 4 or more days was related to negative outcome  [19].",Non-OADS,/arxiv_data1/oa_pdf/8f/f5/kjim-2013-019.PMC4939487.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2013.019Conflict of interest No potential conflict of interest relevant to this article  was reported.",Non-OADS,/arxiv_data1/oa_pdf/8f/f5/kjim-2013-019.PMC4939487.pdf
CT-guided bone biopsy in spinal infection www.kjim.org http://dx.doi.org/10.3904/kjim.2013.019Maugars Y.,Non-OADS,/arxiv_data1/oa_pdf/8f/f5/kjim-2013-019.PMC4939487.pdf
"Korean J Intern Med 2016;31:788-790 http://dx.doi.org/10.3904/kjim.2014.282 Copyright © 2016 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/13/d6/kjim-2014-282.PMC4939488.pdf
"LETTER TO THE EDITOR pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgDepartments of 1Internal Medicine  and 2Pathology, Chungnam National  University School of Medicine,  Daejeon; 3Department of Internal  Medicine, Seosan Jungang General  Hospital, Seosan, Korea The polypoid ganglioneuroma associated with  hyperplastic polyposis Gu Hyum Kang1, Byung Seok Lee1, Dae Young Kang2, and Hoon Choi3 Received : September  16, 2014 Revised : December  5, 2014 Accepted : August 31, 2015 Correspondence to  Byung Seok Lee, M.D .",Non-OADS,/arxiv_data1/oa_pdf/13/d6/kjim-2014-282.PMC4939488.pdf
The polypoid ganglioneuroma http://dx.doi.org/10.3904/kjim.2014.282logic examination of multiple gastric biopsies revealed  hyperplastic polyps.,Non-OADS,/arxiv_data1/oa_pdf/13/d6/kjim-2014-282.PMC4939488.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2014.282has been reported [4], but colonic mucosal GN associated  with colonic polyps is a very unusual finding.",Non-OADS,/arxiv_data1/oa_pdf/13/d6/kjim-2014-282.PMC4939488.pdf
"ORIGINAL ARTICLE Copyright © 2016 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgKorean J Intern Med 2016;31:653-659 http://dx.doi.org/10.3904/kjim.2014.313INTRODUCTION Tall people face an increased risk for cancer.",Non-OADS,/arxiv_data1/oa_pdf/c3/3e/kjim-2014-313.PMC4939489.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2014.313Moreover, it is unclear to what extent height-associat - ed risks vary by adenoma size, number, and histological  type, or how other factors, such as smoking and met - abolic syndrome, affect these associations.",Non-OADS,/arxiv_data1/oa_pdf/c3/3e/kjim-2014-313.PMC4939489.pdf
Height and colorectal adenoma www.kjim.org http://dx.doi.org/10.3904/kjim.2014.313adjusted using multivariate logistic regression analysis  to examine the effect of potential confounders on the  association between height and colorectal adenoma.,OADS,/arxiv_data1/oa_pdf/c3/3e/kjim-2014-313.PMC4939489.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2014.313summarized the results of 16 prospective studies that  reported on the associations between height and CRC;  nine of the studies reviewed reported no association be - tween height and cancer risk.",OADS,/arxiv_data1/oa_pdf/c3/3e/kjim-2014-313.PMC4939489.pdf
"Height and colorectal adenoma www.kjim.org http://dx.doi.org/10.3904/kjim.2014.313people have longer intestinal tracts (and, therefore, in - creased epithelial cell proliferation) [23] and also because  acromegaly has been associated with an increased risk  for CRC [24].",Non-OADS,/arxiv_data1/oa_pdf/c3/3e/kjim-2014-313.PMC4939489.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2014.313vated fasting plasma glucose, glucose intolerance, in - creased BMI, and metabolic syndrome, are associated  with an increased risk for CRC [27,28].",Non-OADS,/arxiv_data1/oa_pdf/c3/3e/kjim-2014-313.PMC4939489.pdf
Height and colorectal adenoma www.kjim.org http://dx.doi.org/10.3904/kjim.2014.313REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/c3/3e/kjim-2014-313.PMC4939489.pdf
"LETTER TO THE EDITOR Copyright © 2016 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgKorean J Intern Med 2016;31:794-797  http://dx.doi.org/10.3904/kjim.2014.3201Department of Internal Medicine,  2Biomedical Research Insititute,   Pusan National University Hospital,  Busan, KoreaEctopic ACTH syndrome caused by pulmonary  carcinoid tumor mimicking long-standing   sclerosing hemangioma Sung Yong Han1, Bo Hyun Kim1,2, Hee Ryeong Jang1, Won Jin Kim1,2, Yun Kyung Jeon1,2, Sang Soo Kim1,2,   and In Ju Kim1,2  Received : October 17, 2014 Revised : December 26, 2014 Accepted : February  22, 2015 Correspondence to  Bo Hyun Kim, M.D.",Non-OADS,/arxiv_data1/oa_pdf/ff/7b/kjim-2014-320.PMC4939490.pdf
"795 www.kjim.org http://dx.doi.org/10.3904/kjim.2014.320Han SY, et al.",OADS,/arxiv_data1/oa_pdf/ff/7b/kjim-2014-320.PMC4939490.pdf
               796 www.kjim.org http://dx.doi.org/10.3904/kjim.2014.320The Korean Journal of Internal Medicine Vol.,Non-OADS,/arxiv_data1/oa_pdf/ff/7b/kjim-2014-320.PMC4939490.pdf
"797 www.kjim.org http://dx.doi.org/10.3904/kjim.2014.320Han SY, et al.",OADS,/arxiv_data1/oa_pdf/ff/7b/kjim-2014-320.PMC4939490.pdf
"ORIGINAL ARTICLE Copyright © 2016 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgKorean J Intern Med 2016;31:730-738  http://dx.doi.org/10.3904/kjim.2014.328INTRODUCTION End-stage renal disease (ESRD) and chronic liver dis - ease are serious and common medical problems world - wide.",Non-OADS,/arxiv_data1/oa_pdf/19/fc/kjim-2014-328.PMC4939491.pdf
Liver cirrhosis and survival in ESRD www.kjim.org http://dx.doi.org/10.3904/kjim.2014.328beginning renal replacement therapy in a national co - hort study in Taiwan [6].,Non-OADS,/arxiv_data1/oa_pdf/19/fc/kjim-2014-328.PMC4939491.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2014.328LC group.",OADS,/arxiv_data1/oa_pdf/19/fc/kjim-2014-328.PMC4939491.pdf
"Liver cirrhosis and survival in ESRD www.kjim.org http://dx.doi.org/10.3904/kjim.2014.328low-up time alive on dialysis in the LC group was 35.0  ± 32.7 months, and that in the non-LC group was 38.0 ±  33.7 months.",Non-OADS,/arxiv_data1/oa_pdf/19/fc/kjim-2014-328.PMC4939491.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2014.328found in six patients  (13.6%).",OADS,/arxiv_data1/oa_pdf/19/fc/kjim-2014-328.PMC4939491.pdf
Liver cirrhosis and survival in ESRD www.kjim.org http://dx.doi.org/10.3904/kjim.2014.328dependent predictor of mortality.,Non-OADS,/arxiv_data1/oa_pdf/19/fc/kjim-2014-328.PMC4939491.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2014.328sis is an increasingly frequent cause of morbidity and  mortality.",Non-OADS,/arxiv_data1/oa_pdf/19/fc/kjim-2014-328.PMC4939491.pdf
Liver cirrhosis and survival in ESRD www.kjim.org http://dx.doi.org/10.3904/kjim.2014.328HD in patients with LC has several limitations.,Non-OADS,/arxiv_data1/oa_pdf/19/fc/kjim-2014-328.PMC4939491.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2014.3282008;28:113-117.",OADS,/arxiv_data1/oa_pdf/19/fc/kjim-2014-328.PMC4939491.pdf
"LETTER TO THE EDITOR Copyright © 2016 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgKorean J Intern Med 2016;31:798-801  http://dx.doi.org/10.3904/kjim.2014.376Division of Nephrology, Department  of Internal Medicine, College of  Medicine, The Catholic University of  Korea, Seoul, KoreaUrachal abscess precipitated as acute pyelonephritis  in an adult patient with diabetes  Yoo A Choi, Se Young Kim, Kyung Yoon Chang, Hyeon Seok Hwang, Suk Young Kim, and     Yoon Kyung Chang Received : December 10 , 2014 Revised : February 2 , 2015 Accepted : May  11, 2015 Correspondence to    Yoon Kyung Chang, M.D.",Non-OADS,/arxiv_data1/oa_pdf/10/aa/kjim-2014-376.PMC4939492.pdf
"799 www.kjim.org http://dx.doi.org/10.3904/kjim.2014.376Choi YA, et al.",OADS,/arxiv_data1/oa_pdf/10/aa/kjim-2014-376.PMC4939492.pdf
              800 www.kjim.org http://dx.doi.org/10.3904/kjim.2014.376The Korean Journal of Internal Medicine Vol.,Non-OADS,/arxiv_data1/oa_pdf/10/aa/kjim-2014-376.PMC4939492.pdf
"801 www.kjim.org http://dx.doi.org/10.3904/kjim.2014.376Choi YA, et al.",OADS,/arxiv_data1/oa_pdf/10/aa/kjim-2014-376.PMC4939492.pdf
"ORIGINAL ARTICLE Copyright © 2016 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgKorean J Intern Med 2016;31:660-668  http://dx.doi.org/10.3904/kjim.2015.007INTRODUCTION Elevation of serum lipase activity is included in the diag - nostic criteria for acute pancreatitis [1].",Non-OADS,/arxiv_data1/oa_pdf/d2/58/kjim-2015-007.PMC4939493.pdf
Serum lipase subtype analysis www.kjim.org http://dx.doi.org/10.3904/kjim.2015.007tion exposure or high expense.,Non-OADS,/arxiv_data1/oa_pdf/d2/58/kjim-2015-007.PMC4939493.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2015.007The diagnostic performance of serum lipase subtypes  was assessed using the receiver-operating characteristic  (ROC) curve, which plots sensitivity over 1-specificity.",OADS,/arxiv_data1/oa_pdf/d2/58/kjim-2015-007.PMC4939493.pdf
"Serum lipase subtype analysis www.kjim.org http://dx.doi.org/10.3904/kjim.2015.007the patients without acute pancreatitis, although the dif - ference was statistically insignificant ([median, 626 pg/ mL; IQR, 465 to 1,664.2] vs. [median, 407.8 pg/mL; IQR,  200 to 766.5], p = 0.17).",Non-OADS,/arxiv_data1/oa_pdf/d2/58/kjim-2015-007.PMC4939493.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2015.007Table 2.",Non-OADS,/arxiv_data1/oa_pdf/d2/58/kjim-2015-007.PMC4939493.pdf
Serum lipase subtype analysis www.kjim.org http://dx.doi.org/10.3904/kjim.2015.007Table 4.,Non-OADS,/arxiv_data1/oa_pdf/d2/58/kjim-2015-007.PMC4939493.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2015.007Multivariate analysis for the associations of acute  pancreatitis In multivariate analysis for the associations of acute  pancreatitis, only FPL using a cut-off value of 0.0027 was  associated with acute pancreatitis (OR, 8.3; 95% CI, 1.3 to  51.7; p = 0.02) (Table 4).",OADS,/arxiv_data1/oa_pdf/d2/58/kjim-2015-007.PMC4939493.pdf
"Serum lipase subtype analysis www.kjim.org http://dx.doi.org/10.3904/kjim.2015.007although statistically insignificantly [18,19].",Non-OADS,/arxiv_data1/oa_pdf/d2/58/kjim-2015-007.PMC4939493.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2015.007Chem Lab Med 2012;50:419-421.",OADS,/arxiv_data1/oa_pdf/d2/58/kjim-2015-007.PMC4939493.pdf
"LETTER TO THE EDITOR Copyright © 2016 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgKorean J Intern Med 2016;31:802-804 http://dx.doi.org/10.3904/kjim.2015.0261Division of Hematology and  Medical Oncology, Department of  Internal Medicine, Seoul National  University Hospital, Seoul; 2Division  of Hematology and Medical  Oncology, Department of Internal  Medicine, 3Department of General  Surgery, Seoul Metropolitan  Government Seoul National  University Boramae Medical Center,  Seoul; 4Department of Internal  Medicine, Seoul National University  Hospital, Seoul; 5Department of  Pathology, Seoul Metropolitan  Government Seoul National  University Boramae Medical Center,  Seoul, Korea A rare case of Rosai-Dorfman disease without  lymphadenopathy Hyerim Ha1, Ki Hwan Kim2, Young Joon Ahn3, Ji Hye Kim4, Ji Eun Kim5, and Sung-Soo Yoon1 Received : February  2, 2015 Revised : March  9, 2015 Accepted : April  15, 2015 Correspondence to Ki Hwan Kim, M.D.",Non-OADS,/arxiv_data1/oa_pdf/dd/77/kjim-2015-026.PMC4939494.pdf
"803 www.kjim.org http://dx.doi.org/10.3904/kjim.2015.026Ha H, et al.",OADS,/arxiv_data1/oa_pdf/dd/77/kjim-2015-026.PMC4939494.pdf
              804 www.kjim.org http://dx.doi.org/10.3904/kjim.2015.026The Korean Journal of Internal Medicine Vol.,Non-OADS,/arxiv_data1/oa_pdf/dd/77/kjim-2015-026.PMC4939494.pdf
"ORIGINAL ARTICLE Copyright © 2016 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgKorean J Intern Med 2016;31:678-684  http://dx.doi.org/10.3904/kjim.2015.045INTRODUCTION Drug-eluting stents (DESs) have been widely viewed as  the gold standard for the treatment of coronary artery  diseases since the Food and Drug Administration (FDA)  approved use of the first DES in April 2003.",Non-OADS,/arxiv_data1/oa_pdf/56/2e/kjim-2015-045.PMC4939495.pdf
"Long-term outcomes of off-label drug eluting stents www.kjim.org http://dx.doi.org/10.3904/kjim.2015.045Several studies have been conducted on the clinical  outcomes of off-label DES use, but the clinical follow-up  data used was limited to 1 year [6-9].",Non-OADS,/arxiv_data1/oa_pdf/56/2e/kjim-2015-045.PMC4939495.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2015.045prehensively reviewing medical records at routine  outpatient visits or by telephone interview during the  5-year follow-up period.",Non-OADS,/arxiv_data1/oa_pdf/56/2e/kjim-2015-045.PMC4939495.pdf
Long-term outcomes of off-label drug eluting stents www.kjim.org http://dx.doi.org/10.3904/kjim.2015.045egorical variables.,OADS,/arxiv_data1/oa_pdf/56/2e/kjim-2015-045.PMC4939495.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2015.045length, a smaller mean stent diameter, and more stents.",OADS,/arxiv_data1/oa_pdf/56/2e/kjim-2015-045.PMC4939495.pdf
"Long-term outcomes of off-label drug eluting stents www.kjim.org http://dx.doi.org/10.3904/kjim.2015.045= 0.0001) and MACEs (17.6% vs. 28.2%,  p = 0.0001).",OADS,/arxiv_data1/oa_pdf/56/2e/kjim-2015-045.PMC4939495.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2015.045Conflict of interest No potential conflict of interest relevant to this article  was reported.",Non-OADS,/arxiv_data1/oa_pdf/56/2e/kjim-2015-045.PMC4939495.pdf
"Copyright © 2016 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgIMAGE OF INTEREST Korean J Intern Med 2016;31:807-808  http://dx.doi.org/10.3904/kjim.2015.064A 48-year-old man visited our hospital  due to exertional chest pain.",Non-OADS,/arxiv_data1/oa_pdf/02/9d/kjim-2015-064.PMC4939496.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2015.064lesion was performed successfully with a drug-eluting  stent.",Non-OADS,/arxiv_data1/oa_pdf/02/9d/kjim-2015-064.PMC4939496.pdf
"ORIGINAL ARTICLE Copyright © 2016 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgKorean J Intern Med 2016;31:779-787  http://dx.doi.org/10.3904/kjim.2015.066INTRODUCTION Rheumatoid arthritis (RA) is a chron - ic inflammatory disease of unknown  etiology characterized by symmetric,  peripheral polyarthritis.",Non-OADS,/arxiv_data1/oa_pdf/5f/7a/kjim-2015-066.PMC4939497.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2015.066fostered the development of new therapeutics, resulting  in improved outcomes.",Non-OADS,/arxiv_data1/oa_pdf/5f/7a/kjim-2015-066.PMC4939497.pdf
Low-dose tacrolimus for active RA www.kjim.org http://dx.doi.org/10.3904/kjim.2015.066The primary efficacy endpoint was the ACR20 re - sponse at the end of treatment.,Non-OADS,/arxiv_data1/oa_pdf/5f/7a/kjim-2015-066.PMC4939497.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2015.066mean KHAQ at baseline was 16.79, and the mean change  from baseline at 16 weeks was –2.29, which was statisti - cally significant.Safety  A summary of the AEs is provided in Table 3.",OADS,/arxiv_data1/oa_pdf/5f/7a/kjim-2015-066.PMC4939497.pdf
"Low-dose tacrolimus for active RA www.kjim.org http://dx.doi.org/10.3904/kjim.2015.066ed AEs, each reported by 3 patients.",Non-OADS,/arxiv_data1/oa_pdf/5f/7a/kjim-2015-066.PMC4939497.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2015.066notion that if a low dose (1.5 mg) can show sufficient effi - cacy, it would be more favorable in terms of safety.",Non-OADS,/arxiv_data1/oa_pdf/5f/7a/kjim-2015-066.PMC4939497.pdf
"Low-dose tacrolimus for active RA www.kjim.org http://dx.doi.org/10.3904/kjim.2015.066tients who have comorbidities such as severe interstitial  lung disease, nontuberculous mycobacterial infection,  chronic hepatitis B infection, and cachexia.",Non-OADS,/arxiv_data1/oa_pdf/5f/7a/kjim-2015-066.PMC4939497.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2015.066treatment options for RA are needed.",OADS,/arxiv_data1/oa_pdf/5f/7a/kjim-2015-066.PMC4939497.pdf
Low-dose tacrolimus for active RA www.kjim.org http://dx.doi.org/10.3904/kjim.2015.066antirheumatic drugs.,Non-OADS,/arxiv_data1/oa_pdf/5f/7a/kjim-2015-066.PMC4939497.pdf
"ORIGINAL ARTICLE Copyright © 2016 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgKorean J Intern Med 2016;31:669-677  http://dx.doi.org/10.3904/kjim.2015.087INTRODUCTION Angiodysplastic lesions are characterized by a thin- walled, fragile vascular network with a disrupted archi - tecture, increased permeability, and susceptibility to  rupture.",Non-OADS,/arxiv_data1/oa_pdf/1c/f5/kjim-2015-087.PMC4939498.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2015.087or slightly raised, bright red in color, and well circum - scribed or fernlike stellar dendrite lesions usually 2 to 10  mm in diameter.",Non-OADS,/arxiv_data1/oa_pdf/1c/f5/kjim-2015-087.PMC4939498.pdf
Angiodysplasia as UGIB www.kjim.org http://dx.doi.org/10.3904/kjim.2015.087Table 1.,Non-OADS,/arxiv_data1/oa_pdf/1c/f5/kjim-2015-087.PMC4939498.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2015.087RESULTS The clinical characteristics of patients with UGIB from  angiodysplasia compared with asymptomatic control  group are shown in Table 1.",Non-OADS,/arxiv_data1/oa_pdf/1c/f5/kjim-2015-087.PMC4939498.pdf
"Angiodysplasia as UGIB www.kjim.org http://dx.doi.org/10.3904/kjim.2015.087giectasia, and vascular ectasia.",Non-OADS,/arxiv_data1/oa_pdf/1c/f5/kjim-2015-087.PMC4939498.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2015.087one episode of overt UGIB, multiple lesions were found  in 63% of cases [17].",Non-OADS,/arxiv_data1/oa_pdf/1c/f5/kjim-2015-087.PMC4939498.pdf
"Angiodysplasia as UGIB www.kjim.org http://dx.doi.org/10.3904/kjim.2015.087Clinical presentation of UGIB from angiodysplasias  is usually characterized by maroon-colored stool, me - lena, or hematochezia.",Non-OADS,/arxiv_data1/oa_pdf/1c/f5/kjim-2015-087.PMC4939498.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2015.087Conflict of interest No potential conflict of interest relevant to this article  was reported.",Non-OADS,/arxiv_data1/oa_pdf/1c/f5/kjim-2015-087.PMC4939498.pdf
Angiodysplasia as UGIB www.kjim.org http://dx.doi.org/10.3904/kjim.2015.087ide production in the failing heart.,Non-OADS,/arxiv_data1/oa_pdf/1c/f5/kjim-2015-087.PMC4939498.pdf
"LETTER TO THE EDITOR pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgCopyright © 2016 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Korean J Intern Med 2016;31:791-793  http://dx.doi.org/10.3904/kjim.2015.104Department of Cardiovascular Me - dicine, Chonnam National Univer - sity Hospital, Gwangju, KoreaIntermittent, subtle change of ST segment in   narrow QRS regular tachycardia Hyeong Won Seo, Hyung Wook Park, Ki Hong Lee, Joon-Ho Ahn, Ji Eun Yu, Nam Sik Yoon,  and Jeong Gwan Cho Received : April 16, 2015 Revised : June 16, 2015 Accepted : June 24, 2015 Correspondence to   Hyung Wook Park, M.D.",Non-OADS,/arxiv_data1/oa_pdf/a7/a4/kjim-2015-104.PMC4939499.pdf
792 www.kjim.org http://dx.doi.org/10.3904/kjim.2015.104The Korean Journal of Internal Medicine Vol.,Non-OADS,/arxiv_data1/oa_pdf/a7/a4/kjim-2015-104.PMC4939499.pdf
"793 www.kjim.org http://dx.doi.org/10.3904/kjim.2015.104Seo HW, et al.",OADS,/arxiv_data1/oa_pdf/a7/a4/kjim-2015-104.PMC4939499.pdf
"ORIGINAL ARTICLE Copyright © 2016 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgKorean J Intern Med 2016;31:685-693 http://dx.doi.org/10.3904/kjim.2015.114INTRODUCTION Smoking is a leading cause of morbidity and mortal - ity worldwide [1-3].",Non-OADS,/arxiv_data1/oa_pdf/b7/18/kjim-2015-114.PMC4939500.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2015.114patterns in the North Korean population are mostly un - known due to a lack of statistical research.",OADS,/arxiv_data1/oa_pdf/b7/18/kjim-2015-114.PMC4939500.pdf
Smoking patterns in the North Korean men www.kjim.org http://dx.doi.org/10.3904/kjim.2015.114between having a family member who smokes and  the intention to quit smoking or previous attempts to  quit were also compared using the Student t test.,Non-OADS,/arxiv_data1/oa_pdf/b7/18/kjim-2015-114.PMC4939500.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2015.114questions, both in total subjects and in current smokers.",Non-OADS,/arxiv_data1/oa_pdf/b7/18/kjim-2015-114.PMC4939500.pdf
Smoking patterns in the North Korean men www.kjim.org http://dx.doi.org/10.3904/kjim.2015.114Table 4.,Non-OADS,/arxiv_data1/oa_pdf/b7/18/kjim-2015-114.PMC4939500.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2015.114smoking.",OADS,/arxiv_data1/oa_pdf/b7/18/kjim-2015-114.PMC4939500.pdf
Smoking patterns in the North Korean men www.kjim.org http://dx.doi.org/10.3904/kjim.2015.114cessation success rate was 18.9% without any medical as - sistance.,Non-OADS,/arxiv_data1/oa_pdf/b7/18/kjim-2015-114.PMC4939500.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2015.114sponsored educational facility, for administering data  collection.",Non-OADS,/arxiv_data1/oa_pdf/b7/18/kjim-2015-114.PMC4939500.pdf
Available from: http://kosis.kr/statHtml/ statHtml.do?orgId=117&tblId=DT_117_12_Y009&vw_ cd=MT_ZTITLE&list_id=117_11758_008&seqNo=&lang_ mode=ko&language=kor&obj_var_id=&itm_id=&conn_ path=E1 .,OADS,/arxiv_data1/oa_pdf/b7/18/kjim-2015-114.PMC4939500.pdf
Smoking patterns in the North Korean men www.kjim.org http://dx.doi.org/10.3904/kjim.2015.11423.,Non-OADS,/arxiv_data1/oa_pdf/b7/18/kjim-2015-114.PMC4939500.pdf
"ORIGINAL ARTICLE Copyright © 2016 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgKorean J Intern Med 2016;31:703-711 http://dx.doi.org/10.3904/kjim.2015.198INTRODUCTION Subclinical hypothyroidism (SCH) is defined as an ele - vated level of serum thyroid stimulating hormone (TSH)  with a normal level of serum free thyroxine (FT4) [1].",Non-OADS,/arxiv_data1/oa_pdf/8c/d4/kjim-2015-198.PMC4939501.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2015.198the incidence of SCH is tend to increase in the last few  decades [8].",Non-OADS,/arxiv_data1/oa_pdf/8c/d4/kjim-2015-198.PMC4939501.pdf
"Subclinical hypothyroidism in diabetes www.kjim.org http://dx.doi.org/10.3904/kjim.2015.198Statistical analysis All numerical variables are expressed as the mean ±  standard deviation, and categorical data were expressed  as percentages.",OADS,/arxiv_data1/oa_pdf/8c/d4/kjim-2015-198.PMC4939501.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2015.198Table 1.",Non-OADS,/arxiv_data1/oa_pdf/8c/d4/kjim-2015-198.PMC4939501.pdf
"Subclinical hypothyroidism in diabetes www.kjim.org http://dx.doi.org/10.3904/kjim.2015.198When subjects with T2DM were categorized into three  groups according to HbA1c, the prevalence of SCH was  higher in the poorly glycemic control group (Fig.",Non-OADS,/arxiv_data1/oa_pdf/8c/d4/kjim-2015-198.PMC4939501.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2015.198to < 7%, 4.77; 95% CI, 1.18 to 19.29; p = 0.028, and OR, 4.58;  95% CI, 1.41 to 14.87; p = 0.011, respectively).",OADS,/arxiv_data1/oa_pdf/8c/d4/kjim-2015-198.PMC4939501.pdf
"Subclinical hypothyroidism in diabetes www.kjim.org http://dx.doi.org/10.3904/kjim.2015.198showed SCH risk for T2DM was not prominent by com - parison with overt hypothyroidism [22], SCH doesn’t  seem to be more frequent in diabetes but confirmatory  evidences are needed.",Non-OADS,/arxiv_data1/oa_pdf/8c/d4/kjim-2015-198.PMC4939501.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2015.198in the present study.",Non-OADS,/arxiv_data1/oa_pdf/8c/d4/kjim-2015-198.PMC4939501.pdf
Subclinical hypothyroidism in diabetes www.kjim.org http://dx.doi.org/10.3904/kjim.2015.198N Engl J Med 2001;345:260-265.,Non-OADS,/arxiv_data1/oa_pdf/8c/d4/kjim-2015-198.PMC4939501.pdf
"ORIGINAL ARTICLE Copyright © 2016 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgKorean J Intern Med 2016;31:722-729 http://dx.doi.org/10.3904/kjim.2015.230INTRODUCTION Tumor necrosis factor α (TNF- α) is a pro-inflammato - ry polypeptide cytokine implicated in various diseases,  and circulating TNF- α was found to be elevated in ure - mic patients [1].",Non-OADS,/arxiv_data1/oa_pdf/5e/f1/kjim-2015-230.PMC4939502.pdf
TNF- α and infection in PD patients www.kjim.org http://dx.doi.org/10.3904/kjim.2015.230patients have been conducted by several investigators  [12-14].,Non-OADS,/arxiv_data1/oa_pdf/5e/f1/kjim-2015-230.PMC4939502.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2015.230variables.",OADS,/arxiv_data1/oa_pdf/5e/f1/kjim-2015-230.PMC4939502.pdf
"TNF- α and infection in PD patients www.kjim.org http://dx.doi.org/10.3904/kjim.2015.230tions with serum albumin, serum creatinine, and body  mass index (BMI) which are considered as nutritional  indicators (Table 4).",Non-OADS,/arxiv_data1/oa_pdf/5e/f1/kjim-2015-230.PMC4939502.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2015.230tional markers including serum albumin, serum creati - nine, and BMI [26], which is consistent with the previous  reports showing the irrelevance of TNF- α to the status  of nutrition [10,27].",Non-OADS,/arxiv_data1/oa_pdf/5e/f1/kjim-2015-230.PMC4939502.pdf
TNF- α and infection in PD patients www.kjim.org http://dx.doi.org/10.3904/kjim.2015.230infections as well as it correlates with plasma TNF- α  levels.,Non-OADS,/arxiv_data1/oa_pdf/5e/f1/kjim-2015-230.PMC4939502.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2015.230likely that the production of TNF- α (molecular weight  17 kDa) may be increased in proportion to uremic toxins  in blood, resulting in the inverse relationship between  plasma TNF- α levels and Kt/V.",Non-OADS,/arxiv_data1/oa_pdf/5e/f1/kjim-2015-230.PMC4939502.pdf
TNF- α and infection in PD patients www.kjim.org http://dx.doi.org/10.3904/kjim.2015.2307.,Non-OADS,/arxiv_data1/oa_pdf/5e/f1/kjim-2015-230.PMC4939502.pdf
"ORIGINAL ARTICLE Copyright © 2016 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgKorean J Intern Med 2016;31:750-761 http://dx.doi.org/10.3904/kjim.2015.234INTRODUCTION Graft versus host disease (GVHD) remains the major  cause of morbidity and mortality after allogenic hema - topoietic stem cell transplantation (HSCT).",Non-OADS,/arxiv_data1/oa_pdf/58/e7/kjim-2015-234.PMC4939503.pdf
"The effect of ATG in matched donor HSCT www.kjim.org http://dx.doi.org/10.3904/kjim.2015.234globulin (ATG) reduces the incidence of GVHD in the  matched unrelated-, mismatched unrelated-, and hap - loidentical-donor transplantation [3-8].",Non-OADS,/arxiv_data1/oa_pdf/58/e7/kjim-2015-234.PMC4939503.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2015.234mus instead of MTX.",Non-OADS,/arxiv_data1/oa_pdf/58/e7/kjim-2015-234.PMC4939503.pdf
The effect of ATG in matched donor HSCT www.kjim.org http://dx.doi.org/10.3904/kjim.2015.234Genetic relapse was assessed by chimerism status and  presence of tumor target gene marker.,OADS,/arxiv_data1/oa_pdf/58/e7/kjim-2015-234.PMC4939503.pdf
"All  statistical analyses were performed using SPSS version  14.0 (SPSS Inc., Chicago, IL, USA) and an R 3.1.3 version  freely available on the web (http://cran.r-project.org/).",OADS,/arxiv_data1/oa_pdf/58/e7/kjim-2015-234.PMC4939503.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2015.234ATG 28.9%; p = 0.312) (Table 2).",OADS,/arxiv_data1/oa_pdf/58/e7/kjim-2015-234.PMC4939503.pdf
"The effect of ATG in matched donor HSCT www.kjim.org http://dx.doi.org/10.3904/kjim.2015.234II to IV acute GVHD at day 100, and chronic GVHD.",Non-OADS,/arxiv_data1/oa_pdf/58/e7/kjim-2015-234.PMC4939503.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2015.234effects of risk stratification on overall and disease-free  survival were no longer statistically significant in multi - variate Cox proportional hazard regression analysis.Relapse, non-relapse mortality, incidence of death,  and causes of mortality Relapse and non-relapse mortality are shown in Ta - ble 6.",OADS,/arxiv_data1/oa_pdf/58/e7/kjim-2015-234.PMC4939503.pdf
The effect of ATG in matched donor HSCT www.kjim.org http://dx.doi.org/10.3904/kjim.2015.234corresponding 3-year relapse rates were 37.5% and 20%.,Non-OADS,/arxiv_data1/oa_pdf/58/e7/kjim-2015-234.PMC4939503.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2015.234died during the follow-up period.",Non-OADS,/arxiv_data1/oa_pdf/58/e7/kjim-2015-234.PMC4939503.pdf
"The effect of ATG in matched donor HSCT www.kjim.org http://dx.doi.org/10.3904/kjim.2015.234ATG group, and infection in the high-dose ATG group.",Non-OADS,/arxiv_data1/oa_pdf/58/e7/kjim-2015-234.PMC4939503.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2015.234studies, it is hard to say whether results of those studies  may still have been subtly influenced by those variables.",Non-OADS,/arxiv_data1/oa_pdf/58/e7/kjim-2015-234.PMC4939503.pdf
The effect of ATG in matched donor HSCT www.kjim.org http://dx.doi.org/10.3904/kjim.2015.23411.,Non-OADS,/arxiv_data1/oa_pdf/58/e7/kjim-2015-234.PMC4939503.pdf
"ORIGINAL ARTICLE Copyright © 2016 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgKorean J Intern Med 2016;31:712-721 http://dx.doi.org/10.3904/kjim.2015.274INTRODUCTION In recent years, the proportion of single-person house - holds has rapidly increased in Korea from 23.9% in 2010 to 25.3% in 2012 and 27.1% in 2015 [1,2].",Non-OADS,/arxiv_data1/oa_pdf/b6/e0/kjim-2015-274.PMC4939504.pdf
"Single household as a risk factor for osteoporosis www.kjim.org http://dx.doi.org/10.3904/kjim.2015.274shows a consistent increase in the proportion of single  households, although the reasons for this increase are  not fully understood [4].",Non-OADS,/arxiv_data1/oa_pdf/b6/e0/kjim-2015-274.PMC4939504.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2015.274ter (1470 Wizard, PerkinElmer, Turku, Finland).",OADS,/arxiv_data1/oa_pdf/b6/e0/kjim-2015-274.PMC4939504.pdf
Single household as a risk factor for osteoporosis www.kjim.org http://dx.doi.org/10.3904/kjim.2015.274statistically significant (Fig.,Non-OADS,/arxiv_data1/oa_pdf/b6/e0/kjim-2015-274.PMC4939504.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2015.274and lowest in the two-more in urban group.",OADS,/arxiv_data1/oa_pdf/b6/e0/kjim-2015-274.PMC4939504.pdf
"Single household as a risk factor for osteoporosis www.kjim.org http://dx.doi.org/10.3904/kjim.2015.274physical activity, heavy alcoholics, smoking status, daily  food intake, and nutrient support, lumbar spine BMD  was still significantly lower in the single in rural group  than in the two-more in urban group.",Non-OADS,/arxiv_data1/oa_pdf/b6/e0/kjim-2015-274.PMC4939504.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2015.274between the two-more in rural and the single in urban  groups.",Non-OADS,/arxiv_data1/oa_pdf/b6/e0/kjim-2015-274.PMC4939504.pdf
Single household as a risk factor for osteoporosis www.kjim.org http://dx.doi.org/10.3904/kjim.2015.274DISCUSSION We assessed whether osteoporosis was associated with  household size and residential area in postmenopaus - al women included in the fourth and fifth KNHANES.,Non-OADS,/arxiv_data1/oa_pdf/b6/e0/kjim-2015-274.PMC4939504.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2015.274Conflict of interest No potential conflict of interest relevant to this article  was reported.",Non-OADS,/arxiv_data1/oa_pdf/b6/e0/kjim-2015-274.PMC4939504.pdf
Available from: http://kostat.go.kr/portal/korea/ kor_nw/2/1/index.board?bmode=read&aSeq=269194.,OADS,/arxiv_data1/oa_pdf/b6/e0/kjim-2015-274.PMC4939504.pdf
Available from: http://kostat.go.kr/portal/korea/ kor_nw/2/2/6/index.board?bmode=read&aSeq=255176.,OADS,/arxiv_data1/oa_pdf/b6/e0/kjim-2015-274.PMC4939504.pdf
Single household as a risk factor for osteoporosis www.kjim.org http://dx.doi.org/10.3904/kjim.2015.274Ann Intern Med 1998;129:81-88.,Non-OADS,/arxiv_data1/oa_pdf/b6/e0/kjim-2015-274.PMC4939504.pdf
"Copyright © 2016 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgIMAGE OF INTEREST Korean J Intern Med 2016;31:805-806  http://dx.doi.org/10.3904/kjim.2015.341A 72-year-old man was referred to our  hospital with an endobronchial mass  spotted on chest computed tomog - raphy (CT).",Non-OADS,/arxiv_data1/oa_pdf/7a/96/kjim-2015-341.PMC4939505.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2015.341obstructive pneumonia.",Non-OADS,/arxiv_data1/oa_pdf/7a/96/kjim-2015-341.PMC4939505.pdf
"ORIGINAL ARTICLE Copyright © 2016 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgKorean J Intern Med 2016;31:772-778 http://dx.doi.org/10.3904/kjim.2015.353INTRODUCTION Coinfection with human immunodeficiency virus (HIV)  and hepatitis C virus (HCV) is common since both in - fections share similar routes of transmission.",Non-OADS,/arxiv_data1/oa_pdf/24/97/kjim-2015-353.PMC4939506.pdf
HCV incidence in HIV patients www.kjim.org http://dx.doi.org/10.3904/kjim.2015.353ic hepatitis C has becomes a major cause of mortality in  HIV-infected patients [2].,Non-OADS,/arxiv_data1/oa_pdf/24/97/kjim-2015-353.PMC4939506.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2015.353RESULTS Demographics Between January 2000 and December 2013, 996 HIV-in - fected patients visited our hospital.",Non-OADS,/arxiv_data1/oa_pdf/24/97/kjim-2015-353.PMC4939506.pdf
"HCV incidence in HIV patients www.kjim.org http://dx.doi.org/10.3904/kjim.2015.353in MSM who denied IDU, and 0 (95% CI, 0 to 3.67)/1,000  PYs in man who had sex with women (MSW) who de - nied IDU.",OADS,/arxiv_data1/oa_pdf/24/97/kjim-2015-353.PMC4939506.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2015.353DISCUSSION There was no significant increase of HCV incidence  in South Korea.",Non-OADS,/arxiv_data1/oa_pdf/24/97/kjim-2015-353.PMC4939506.pdf
HCV incidence in HIV patients www.kjim.org http://dx.doi.org/10.3904/kjim.2015.353drug use history.,OADS,/arxiv_data1/oa_pdf/24/97/kjim-2015-353.PMC4939506.pdf
Available  from: https://aidsinfo.nih.gov/guidelines.,Non-OADS,/arxiv_data1/oa_pdf/24/97/kjim-2015-353.PMC4939506.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2015.353with men linked to high-risk sexual behaviours.",Non-OADS,/arxiv_data1/oa_pdf/24/97/kjim-2015-353.PMC4939506.pdf
Avail - able from: http://nih.go.kr/NIH_NEW/main.jsp .,Non-OADS,/arxiv_data1/oa_pdf/24/97/kjim-2015-353.PMC4939506.pdf
Avail - able from: http://nih.go.kr/NIH_NEW/main.jsp .,Non-OADS,/arxiv_data1/oa_pdf/24/97/kjim-2015-353.PMC4939506.pdf
"ORIGINAL ARTICLE Copyright © 2016 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgKorean J Intern Med 2016;31:739-749  http://dx.doi.org/10.3904/kjim.2015.392INTRODUCTION The incidence of kidney cancer has been dramatically  increasing worldwide during the past decade.",Non-OADS,/arxiv_data1/oa_pdf/63/52/kjim-2015-392.PMC4939507.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2015.392detection of localized RCC has been increased and now  comprises more than half of newly diagnosed RCCs [3].",OADS,/arxiv_data1/oa_pdf/63/52/kjim-2015-392.PMC4939507.pdf
Pathologic exam of non-neoplastic kidney www.kjim.org http://dx.doi.org/10.3904/kjim.2015.392tumor (at a minimum 2 cm away).,Non-OADS,/arxiv_data1/oa_pdf/63/52/kjim-2015-392.PMC4939507.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2015.392ureterectomy.",Non-OADS,/arxiv_data1/oa_pdf/63/52/kjim-2015-392.PMC4939507.pdf
Pathologic exam of non-neoplastic kidney www.kjim.org http://dx.doi.org/10.3904/kjim.2015.392dominant (39.2%).,Non-OADS,/arxiv_data1/oa_pdf/63/52/kjim-2015-392.PMC4939507.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2015.392nephrectomy ( p = 0.002) compared to partial nephrecto - my (Table 4).",OADS,/arxiv_data1/oa_pdf/63/52/kjim-2015-392.PMC4939507.pdf
"Pathologic exam of non-neoplastic kidney www.kjim.org http://dx.doi.org/10.3904/kjim.2015.392diagnosis than those without diagnosis (51.5% vs. 15.4%,  p = 0.044), and in patients who have lower preoperative  eGFR ( p = 0.002) and higher semi-quantitative histolog - ic score ( p = 0.002).",Non-OADS,/arxiv_data1/oa_pdf/63/52/kjim-2015-392.PMC4939507.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2015.392other pathologic processes in this study.",Non-OADS,/arxiv_data1/oa_pdf/63/52/kjim-2015-392.PMC4939507.pdf
"Pathologic exam of non-neoplastic kidney www.kjim.org http://dx.doi.org/10.3904/kjim.2015.392glomerulonephritis had normal urinalysis initially, but  this patient had de novo  CKD after nephrectomy.",Non-OADS,/arxiv_data1/oa_pdf/63/52/kjim-2015-392.PMC4939507.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2015.392Conflict of interest No potential conflict of interest relevant to this article  was reported.",Non-OADS,/arxiv_data1/oa_pdf/63/52/kjim-2015-392.PMC4939507.pdf
Pathologic exam of non-neoplastic kidney www.kjim.org http://dx.doi.org/10.3904/kjim.2015.3922002;347:738-748.,Non-OADS,/arxiv_data1/oa_pdf/63/52/kjim-2015-392.PMC4939507.pdf
"ORIGINAL ARTICLE Copyright © 2016 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgKorean J Intern Med 2016;31:694-702 http://dx.doi.org/10.3904/kjim.2015.407INTRODUCTION Pulmonary tuberculosis (TB) is a chronic disease caused  by the bacillus Mycobacterium tuberculosis  and spreads  from person to person through airborne transmission.",Non-OADS,/arxiv_data1/oa_pdf/4b/03/kjim-2015-407.PMC4939508.pdf
"Usefulness of NSE in TB activity www.kjim.org http://dx.doi.org/10.3904/kjim.2015.407monary TB, symptoms include chronic cough, chest  pain, hemoptysis, weakness or fatigue, weight loss, fe - ver, and night sweats [4].",Non-OADS,/arxiv_data1/oa_pdf/4b/03/kjim-2015-407.PMC4939508.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2015.407pletion of anti-TB treatment.",Non-OADS,/arxiv_data1/oa_pdf/4b/03/kjim-2015-407.PMC4939508.pdf
"Usefulness of NSE in TB activity www.kjim.org http://dx.doi.org/10.3904/kjim.2015.407with secondary antibodies (Alexa Fluor 546-conjugated  anti-mouse antibody and Alexa Fluor 488-conjugated  anti-rabbit antibody, Invitrogen, Carlsbad, CA, USA) for  1 hour.",Non-OADS,/arxiv_data1/oa_pdf/4b/03/kjim-2015-407.PMC4939508.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2015.407sity values of CD68 and NSE staining from immunoflu - orescence analysis of the tissue microarray are described  in Supplementary Table 2.",Non-OADS,/arxiv_data1/oa_pdf/4b/03/kjim-2015-407.PMC4939508.pdf
"Usefulness of NSE in TB activity www.kjim.org http://dx.doi.org/10.3904/kjim.2015.407our observations, Collazos et al.",OADS,/arxiv_data1/oa_pdf/4b/03/kjim-2015-407.PMC4939508.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2015.407of individuals who might develop TB, particularly when  they become immunocompromised.",Non-OADS,/arxiv_data1/oa_pdf/4b/03/kjim-2015-407.PMC4939508.pdf
"Usefulness of NSE in TB activity www.kjim.org http://dx.doi.org/10.3904/kjim.2015.407flammatory lung diseases, such as bacterial pneumonia.",Non-OADS,/arxiv_data1/oa_pdf/4b/03/kjim-2015-407.PMC4939508.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2015.40713.",OADS,/arxiv_data1/oa_pdf/4b/03/kjim-2015-407.PMC4939508.pdf
Usefulness of NSE in TB activitywww.kjim.org http://dx.doi.org/10.3904/kjim.2015.407No.,Non-OADS,/arxiv_data1/oa_pdf/4b/03/kjim-2015-407.PMC4939508.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2015.407No.",OADS,/arxiv_data1/oa_pdf/4b/03/kjim-2015-407.PMC4939508.pdf
"Usefulness of NSE in TB activitywww.kjim.org http://dx.doi.org/10.3904/kjim.2015.407  IDVPercentage,  %a AreaAver - ageBack - ground NSE 1n 289,390 0.2 257,013 1 0 2n 528,332 0.3 257,013 2 0 3n 191,960 0.1 257,013 1 0 4n 233,109 0.1 257,013 1 0 5n 460,667 0.3 257,013 2 0 6n 287,986 0.2 257,013 1 0 7n 62,885 0 257,013 0 0 8n 277,562 0.2 257,013 1 0 9n 1,778,598 1 257,013 7 0 10n 740,833 0.4 257,013 3 0 11n 1,731,046 1 257,013 7 0 12n 3,370,721 2 257,013 13 0 13n 1,670,958 1 257,013 7 0 14n 1,448,048 0.8 257,013 6 0 15n 2,302,506 1.3 257,013 9 0 16n 1,237,756 0.7 257,013 5 0 17n 2,280,311 1.3 257,013 9 0 18n 1,605,987 0.9 257,013 6 0 19n 582,166 0.3 257,013 2 0 20n 716,241 0.4 257,013 3 0 21n 898,941 0.5 257,013 3 0 22n 3,119,361 1.8 257,013 12 0 23n 2,276,551 1.3 257013 9 0 24n 3,293,353 1.9 257,013 13 0 25n 919,081 0.5 257,013 4 0 26n 4,159,633 2.4 257,013 16 0 27n 4,394,070 2.6 257,013 17 0 28n 1,356,688 0.8 257,013 5 0 29n 6,816,635 4 257,013 27 0 30n 5,862,373 3.4 257,013 23 0 31n 985,531 0.6 257,013 4 0 32n 880,021 0.5 257,013 3 0 33n 2,241,568 1.3 257,013 9 0 34n 1,518,495 0.9 257,013 6 0 35n 2,085,702 1.2 257,013 8 0 36n 918,074 0.5 257,013 4 0 37n 1,357,300 0.8 257,013 5 0 38n 1,293,726 0.8 257,013 5 0 39n 1,143,014 0.7 257,013 4 0 40n 682,373 0.4 257,013 3 0 41n 1,132,523 0.7 257,013 4 0  IDVPercentage,  %a AreaAver - ageBack - ground 42n 3,571,188 2.1 257,013 14 0 43n 2,987,711 1.7 257,013 12 0 44n 9,301,566 5.4 257,013 36 0 45n 4,425,785 2.6 257,013 17 0 46n 4,290,017 2.5 257,013 17 0 47n 6,180,615 3.6 257,013 24 0 48n 1,415,700 0.8 257,013 6 0 49n 2,371,584 1.4 257,013 9 0 50n 1,347,886 0.8 257,013 5 0 51n 2,306,523 1.3 257,013 9 0 52n 1,895,044 1.1 257,013 7 0 53n 478,427 0.3 257,013 2 0 54n 2,537,642 1.5 257,013 10 0 55n 2,440,400 1.4 257,013 9 0 56n 3,337,054 2 257,013 13 0 57n 1,177,716 0.7 257,013 5 0 58n 1,479,189 0.9 257,013 6 0 59n 643,524 0.4 257,013 3 0 60n 465,200 0.3 257,013 2 0 61n 764,269 0.4 257,013 3 0 62n 1,870,285 1.1 257,013 7 0 63n 1,554,462 0.9 257,013 6 0 64n 2,734,037 1.6 257,013 11 0 65n 3,939,395 2.3 257,013 15 0 66n 2,984,966 1.7 257,013 12 0 67n 587,407 0.3 257,013 2 0 68n 3,827,133 2.2 257,013 15 0 69n 3,186,392 1.9 257,013 12 0 70n 640,659 0.4 257,013 2 0 71n 676,958 0.4 257,013 3 0 72n 526,925 0.3 257,013 2 0 73n 1,230,976 0.7 257,013 5 0 74n 1,197,358 0.7 257,013 5 0 75n 4,532,963 2.7 257,013 18 0 76n 1,094,212 0.6 257,013 4 0 77n 704,976 0.4 257,013 3 0 78n 3,106,983 1.8 257,013 12 0 79n 2,885,705 1.7 257,013 11 0 80n 579,921 0.3 257,013 2 0 81n 536,515 0.3 257,013 2 0 82n 350,529 0.2 257,013 1 0 83n 1,883,078 1.1 257,013 7 0Supplementary Table 2.",Non-OADS,/arxiv_data1/oa_pdf/4b/03/kjim-2015-407.PMC4939508.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2015.407  IDVPercentage,  %a AreaAver - ageBack - ground 84n 1,189,119 0.7 257,013 5 0 85n 351,591 0.2 257,013 1 0 86n 597,704 0.3 257,013 2 0 87n 1,256,178 0.7 257,013 5 0 88n 647,212 0.4 257,013 3 0 89n 679,439 0.4 257,013 3 0 90n 626,299 0.4 257,013 2 0 91n 89,269 0.1 257,013 0 0 92n 60,288 0 257,013 0 0 93n 350,349 0.2 257,013 1 0 94n 111,856 0.1 257,013 0 0 95n 684,124 0.4 257,013 3 0 96n 176,048 0.1 257,013 1 0 97n 194,467 0.1 257,013 1 0 98n 276,262 0.2 257,013 1 0 99n 336,814 0.2 257,013 1 0 100n 160,489 0.1 257,013 1 0 CD68 1n 272,621 0.2 252,909 1 0 2n 352,239 0.2 252,909 1 0 3n 297,696 0.2 252,909 1 0 4n 298,099 0.2 252,909 1 0 5n 331,632 0.2 252,909 1 0 6n 479,061 0.3 252,909 2 0 7n 413,092 0.2 252,909 2 0 8n 286,233 0.2 252,909 1 0 9n 659,294 0.4 252,909 3 0 10n 1,210,446 0.7 252,909 5 0 11n 1,578,189 0.9 252,909 6 0 12n 4,157,119 2.4 252,909 16 0 13n 1,474,054 0.9 252,909 6 0 14n 2,309,394 1.3 252,909 9 0 15n 2,750,785 1.6 252,909 11 0 16n 2,397,878 1.4 252,909 9 0 17n 1,842,310 1.1 252,909 7 0 18n 1,178,920 0.7 252,909 5 0 19n 998,922 0.6 252,909 4 0 20n 388,898 0.2 252,909 2 0 21n 962,098 0.6 252,909 4 0 22n 2,531,475 1.5 252,909 10 0 23n 3,136,515 1.8 252,909 12 0 24n 3,134,319 1.8 252,909 12 0  IDVPercentage,  %a AreaAver - ageBack - ground 25n 842,473 0.5 252,909 3 0 26n 4,438,663 2.6 252,909 18 0 27n 2,819,689 1.6 252,909 11 0 28n 2,236,082 1.3 252,909 9 0 29n 4,297,880 2.5 252,909 17 0 30n 3,408,665 2 252,909 13 0 31n 1,790,610 1 252,909 7 0 32n 1,198,925 0.7 252,909 5 0 33n 1,830,000 1.1 252,909 7 0 34n 1,206,842 0.7 252,909 5 0 35n 2,148,506 1.2 252,909 8 0 36n 1,286,946 0.7 252,909 5 0 37n 1,329,067 0.8 252,909 5 0 38n 792,885 0.5 252,909 3 0 39n 1,772,235 1 252,909 7 0 40n 934,009 0.5 252,909 4 0 41n 2,257,974 1.3 252,909 9 0 42n 5,885,393 3.4 252,909 23 0 43n 3,708,362 2.1 252,909 15 0 44n 8,024,035 4.6 252,909 32 0 45n 2,995,090 1.7 252,909 12 0 46n 3,036,194 1.8 252,909 12 0 47n 3,530,252 2 252,909 14 0 48n 1,296,583 0.8 252,909 5 0 49n 1,590,917 0.9 252,909 6 0 50n 703,308 0.4 252,909 3 0 51n 1,584,921 0.9 252,909 6 0 52n 2,370,691 1.4 252,909 9 0 53n 1,193,708 0.7 252,909 5 0 54n 2,181,904 1.3 252,909 9 0 55n 2,789,296 1.6 252,909 11 0 56n 3,252,925 1.9 252,909 13 0 57n 2,098,914 1.2 252,909 8 0 58n 2,712,999 1.6 252,909 11 0 59n 559,076 0.3 252,909 2 0 60n 444,888 0.3 252,909 2 0 61n 1,206,509 0.7 252,909 5 0 62n 1,733,087 1 252,909 7 0 63n 4,210,400 2.4 252,909 17 0 64n 3,969,648 2.3 252,909 16 0 65n 3,394,936 2 252,909 13 0 66n 2,493,201 1.4 252,909 10 0Supplementary Table 2.",Non-OADS,/arxiv_data1/oa_pdf/4b/03/kjim-2015-407.PMC4939508.pdf
"Usefulness of NSE in TB activitywww.kjim.org http://dx.doi.org/10.3904/kjim.2015.407  IDVPercentage,  %a AreaAver - ageBack - ground 67n 470,272 0.3 252,909 2 0 68n 2,717,459 1.6 252,909 11 0 69n 3,419,852 2 252,909 14 0 70n 219,899 0.1 252,909 1 0 71n 1,735,223 1 252,909 7 0 72n 1,145,693 0.7 252,909 5 0 73n 2,245,016 1.3 252,909 9 0 74n 1,716,389 1 252,909 7 0 75n 3,554,535 2.1 252,909 14 0 76n 1,199,815 0.7 252,909 5 0 77n 1,171,464 0.7 252,909 5 0 78n 2,624,528 1.5 252,909 10 0 79n 2,598,483 1.5 252,909 10 0 80n 1,158,304 0.7 252,909 5 0 81n 691,254 0.4 252,909 3 0 82n 426,622 0.2 252,909 2 0 83n 2,597,715 1.5 252,909 10 0 84n 1,342,238 0.8 252,909 5 0 85n 430,158 0.2 252,909 2 0 86n 776,410 0.4 252,909 3 0 87n 948,635 0.5 252,909 4 0 88n 526,053 0.3 252,909 2 0 89n 347,639 0.2 252,909 1 0 90n 94,294 0.1 252,909 0 0 91n 240,027 0.1 252,909 1 0 92n 165,098 0.1 252,909 1 0 93n 413,046 0.2 252,909 2 0 94n 322,459 0.2 252,909 1 0 95n 902,481 0.5 252,909 4 0 96n 371,290 0.2 252,909 1 0 97n 286,806 0.2 252,909 1 0 98n 242,282 0.1 252,909 1 0 99n 364,952 0.2 252,909 1 0 100n 96,157 0.1 252,909 0 0 NSE, neuron-specific enolase; IDV, integrated density value.",Non-OADS,/arxiv_data1/oa_pdf/4b/03/kjim-2015-407.PMC4939508.pdf
"Copyright © 2016 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.org REVIEW Korean J Intern Med 2016;31:643-650 http://dx.doi.org/10.3904/kjim.2016.015INTRODUCTION  Muscle tissue has diverse functions, including maintain - ing body posture and producing mobility and movement  in cooperation with the skeleton [1].",Non-OADS,/arxiv_data1/oa_pdf/b4/ae/kjim-2016-015.PMC4939509.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2016.015[2,11-13].",OADS,/arxiv_data1/oa_pdf/b4/ae/kjim-2016-015.PMC4939509.pdf
Skeletal muscle mass index www.kjim.org http://dx.doi.org/10.3904/kjim.2016.015widely used as an alternative method together with the  height squared-adjusted index described by Baumgart - ner et al.,OADS,/arxiv_data1/oa_pdf/b4/ae/kjim-2016-015.PMC4939509.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2016.015rea have been conducted using these national data.",OADS,/arxiv_data1/oa_pdf/b4/ae/kjim-2016-015.PMC4939509.pdf
Skeletal muscle mass index www.kjim.org http://dx.doi.org/10.3904/kjim.2016.015for defining low muscle mass.,Non-OADS,/arxiv_data1/oa_pdf/b4/ae/kjim-2016-015.PMC4939509.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2016.015stantial attention because of its potential relationship  with diverse adverse health outcomes in elderly people  including falling, fractures, infections, cardiovascular  risks, metabolic impairments, and ultimately, mortality.",Non-OADS,/arxiv_data1/oa_pdf/b4/ae/kjim-2016-015.PMC4939509.pdf
Skeletal muscle mass index www.kjim.org http://dx.doi.org/10.3904/kjim.2016.015European consensus on definition and diagnosis: report  of the European Working Group on Sarcopenia in Older  People.,Non-OADS,/arxiv_data1/oa_pdf/b4/ae/kjim-2016-015.PMC4939509.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2016.015nia relate differently to insulin resistance.",Non-OADS,/arxiv_data1/oa_pdf/b4/ae/kjim-2016-015.PMC4939509.pdf
"Copyright © 2016 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.org REVIEW Korean J Intern Med 2016;31:625-633 http://dx.doi.org/10.3904/kjim.2016.017INTRODUCTION  The 5-year survival rate of cancer patients in Korea has  increased by 68.1%; consequently, the estimated num - ber of patients who underwent cancer treatment was up  to 1.37 million people in 2013 [1].",Non-OADS,/arxiv_data1/oa_pdf/48/11/kjim-2016-017.PMC4939510.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2016.017The early generation anthracycline compounds dauno - rubicin and doxorubicin can cause fatal heart failure  [5].",Non-OADS,/arxiv_data1/oa_pdf/48/11/kjim-2016-017.PMC4939510.pdf
"Anthracycline-induced cardiotoxicity www.kjim.org http://dx.doi.org/10.3904/kjim.2016.017demonstrated the destruction of the microstructures of  myocardial cells, including myofilament dropout (Fig.",Non-OADS,/arxiv_data1/oa_pdf/48/11/kjim-2016-017.PMC4939510.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2016.017ty.",OADS,/arxiv_data1/oa_pdf/48/11/kjim-2016-017.PMC4939510.pdf
"Anthracycline-induced cardiotoxicity www.kjim.org http://dx.doi.org/10.3904/kjim.2016.017hypertension, diabetes, dyslipidemia, and obesity in sur - vivors of childhood cancer has been reported, and these  factors may play a role in the development of late-onset  cardiotoxicity [39].",Non-OADS,/arxiv_data1/oa_pdf/48/11/kjim-2016-017.PMC4939510.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2016.017racycline treatment but did not recommend how long  cardiac function should be followed-up after chemo - therapy.",Non-OADS,/arxiv_data1/oa_pdf/48/11/kjim-2016-017.PMC4939510.pdf
Anthracycline-induced cardiotoxicity www.kjim.org http://dx.doi.org/10.3904/kjim.2016.017treatment at the proper time can prevent progression  to overt heart failure after anthracycline therapy to in - crease the odds of long-term survival.,Non-OADS,/arxiv_data1/oa_pdf/48/11/kjim-2016-017.PMC4939510.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2016.01714.",OADS,/arxiv_data1/oa_pdf/48/11/kjim-2016-017.PMC4939510.pdf
Anthracycline-induced cardiotoxicity www.kjim.org http://dx.doi.org/10.3904/kjim.2016.01738.,Non-OADS,/arxiv_data1/oa_pdf/48/11/kjim-2016-017.PMC4939510.pdf
"pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.org REVIEW Copyright © 2016 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Korean J Intern Med 2016;31:634-642 http://dx.doi.org/10.3904/kjim.2016.098INTRODUCTION  Rheumatoid arthritis (RA) is a chronic and debilitating  autoimmune disease characterized by the interaction of  various inflammatory mediators and cells [1].",Non-OADS,/arxiv_data1/oa_pdf/65/c9/kjim-2016-098.PMC4939511.pdf
"MIF: a porential therapeutic target for RA www.kjim.org http://dx.doi.org/10.3904/kjim.2016.098MIF is stored in pre-formed cytoplasmic pools and is  rapidly released in response to stimuli such as micro - bial products, proliferative signals, and hypoxia [7,16,17].",Non-OADS,/arxiv_data1/oa_pdf/65/c9/kjim-2016-098.PMC4939511.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2016.098proinflammatory cytokines and plays a major role in in - nate immunity against bacterial infections, by enhanc - ing TNF- α secretion [5], Toll-like receptor 4 expression  [43], phagocytosis, and intracellular killing mechanisms  [44].",Non-OADS,/arxiv_data1/oa_pdf/65/c9/kjim-2016-098.PMC4939511.pdf
"MIF: a porential therapeutic target for RA www.kjim.org http://dx.doi.org/10.3904/kjim.2016.098induction by MIF of a uniquely sustained phosphoryla - tion of ERK [19], associated with increased NIH/3T3 pro - liferation and enhanced phospholipase A2 activity.",Non-OADS,/arxiv_data1/oa_pdf/65/c9/kjim-2016-098.PMC4939511.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2016.098renalectomy prior to AA induction results in increased  joint inflammation; in these animals, serum and pitu - itary MIF levels are increased but, surprisingly, the lev - els in the synovium are decreased.",Non-OADS,/arxiv_data1/oa_pdf/65/c9/kjim-2016-098.PMC4939511.pdf
MIF: a porential therapeutic target for RA www.kjim.org http://dx.doi.org/10.3904/kjim.2016.098may provide new therapeutic options for managing RA  patients.,Non-OADS,/arxiv_data1/oa_pdf/65/c9/kjim-2016-098.PMC4939511.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2016.098fluid of patients with conventional and optic-spinal  forms of multiple sclerosis and neuro-Behcet’s disease.",OADS,/arxiv_data1/oa_pdf/65/c9/kjim-2016-098.PMC4939511.pdf
MIF: a porential therapeutic target for RA www.kjim.org http://dx.doi.org/10.3904/kjim.2016.098Nishihira J. Macrophage migration inhibitory factor  induces phagocytosis of foreign particles by macro - phages in autocrine and paracrine fashion.,Non-OADS,/arxiv_data1/oa_pdf/65/c9/kjim-2016-098.PMC4939511.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2016.09868.",OADS,/arxiv_data1/oa_pdf/65/c9/kjim-2016-098.PMC4939511.pdf
"EDITORIAL Copyright © 2016 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgKorean J Intern Med 2016;31:651-652 http://dx.doi.org/10.3904/kjim.2016.196High prevalence of chronic obstructive pulmonary  disease in Korea Chin Kook Rhee Division of Pulmonary, Allergy  and Critical Care Medicine,  Department of Internal Medicine,  College of Medicine, Seoul St.  Mary’s Hospital, The Catholic  University of Korea, Seoul, Korea Received : June 22, 2016 Accepted: June 24, 2016 Correspondence to Chin Kook Rhee , M.D.",Non-OADS,/arxiv_data1/oa_pdf/d8/95/kjim-2016-196.PMC4939512.pdf
"4, July 2016 http://dx.doi.org/10.3904/kjim.2016.196The high rate of COPD in South Korea and probably  considerably higher rate in North Korea represent a  huge socioeconomic burden.",Non-OADS,/arxiv_data1/oa_pdf/d8/95/kjim-2016-196.PMC4939512.pdf
http://dx.doi.org/10.1016/j.stemcr.2016.02.004 This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/b9/69/main.PMC4939549.pdf
SUPPLEMENTAL INFORMATION Supplemental Information includes ﬁve ﬁgures and one table andcan be found with this article online at http://dx.doi.org/10.1016/ j.stemcr.2016.02.004 .,Non-OADS,/arxiv_data1/oa_pdf/b9/69/main.PMC4939549.pdf
"[http://dx.doi.org/10.1542/peds.2010-2217 ] [PMID: 21518717 ] [3] Vergnano S, Sharland M, Kazembe P, Mwansambo C, Heath PT.",Non-OADS,/arxiv_data1/oa_pdf/29/1a/TOMICROJ-10-133.PMC4939603.pdf
[http://dx.doi.org/10.1136/adc.2002.022863 ] [PMID: 15846011 ] [4] Melin P. Neonatal group B streptococcal disease: from pathogenesis to preventive strategies.,Non-OADS,/arxiv_data1/oa_pdf/29/1a/TOMICROJ-10-133.PMC4939603.pdf
"[http://dx.doi.org/10.1111/j.1469-0691.2011.03576.x ] [PMID: 21672083 ] [5] Verani JR, McGee L, Schrag SJ.",OADS,/arxiv_data1/oa_pdf/29/1a/TOMICROJ-10-133.PMC4939603.pdf
"[http://dx.doi.org/10.3201/eid1302.060680 ] [PMID: 17479883 ] [7] Luck S, Torny M, d’Agapeyeff K, et al.",OADS,/arxiv_data1/oa_pdf/29/1a/TOMICROJ-10-133.PMC4939603.pdf
"[http://dx.doi.org/10.1016/S0140-6736(03)13553-2 ] [PMID: 12801740 ] [8] Verani JR, Spina NL, Lynfield R, et al.",OADS,/arxiv_data1/oa_pdf/29/1a/TOMICROJ-10-133.PMC4939603.pdf
"[http://dx.doi.org/10.1097/AOG.0000000000000163 ] [PMID: 24785612 ] [9] Moore MR, Schrag SJ, Schuchat A.",OADS,/arxiv_data1/oa_pdf/29/1a/TOMICROJ-10-133.PMC4939603.pdf
"[http://dx.doi.org/10.1016/S1473-3099(03)00577-2 ] [PMID: 12679263 ] [10] Unhanand M, Mustafa MM, McCracken GH Jr, Nelson JD.",OADS,/arxiv_data1/oa_pdf/29/1a/TOMICROJ-10-133.PMC4939603.pdf
"[http://dx.doi.org/10.1016/S0022-3476(05)83480-8 ] [PMID: 8419603 ] [11] Murphy K, Weiner J.",OADS,/arxiv_data1/oa_pdf/29/1a/TOMICROJ-10-133.PMC4939603.pdf
"[http://dx.doi.org/10.1097/INF.0b013e31822ffc17 ] [PMID: 21860335 ] [12] Hofer N, Zacharias E, Müller W, Resch B.",OADS,/arxiv_data1/oa_pdf/29/1a/TOMICROJ-10-133.PMC4939603.pdf
"[http://dx.doi.org/10.1515/jpm-2011-0308 ] [PMID: 23120762 ] [13] Resch B, Edlinger S, Müller W. White blood cell counts in neonatal early-onset sepsis.",Non-OADS,/arxiv_data1/oa_pdf/29/1a/TOMICROJ-10-133.PMC4939603.pdf
"[http://dx.doi.org/10.1097/INF.0b013e31824e4740 ] [PMID: 22510996 ] [14] Hofer N, Müller W, Resch B. Non-infectious conditions and gestational age influence C-reactive protein values in newborns during the first 3 days of life.",Non-OADS,/arxiv_data1/oa_pdf/29/1a/TOMICROJ-10-133.PMC4939603.pdf
"[http://dx.doi.org/10.1515/CCLM.2011.048 ] [PMID: 21126207 ] [15] Hofer N, Kothari R, Morris N, Müller W, Resch B.",OADS,/arxiv_data1/oa_pdf/29/1a/TOMICROJ-10-133.PMC4939603.pdf
"[http://dx.doi.org/10.1016/j.ajog.2013.08.030 ] [PMID: 23994220 ] [16] Chan GJ, Lee AC, Baqui AH, Tan J, Black RE.",OADS,/arxiv_data1/oa_pdf/29/1a/TOMICROJ-10-133.PMC4939603.pdf
"[http://dx.doi.org/10.1371/journal.pmed.1001502 ] [PMID: 23976885 ] [17] Hornik CP, Benjamin DK, Becker KC, et al.",OADS,/arxiv_data1/oa_pdf/29/1a/TOMICROJ-10-133.PMC4939603.pdf
"[http://dx.doi.org/10.1097/INF.0b013e318256905c ] [PMID: 22531231 ] [18] Soni S, Wadhwa N, Kumar R, Faridi MM.",Non-OADS,/arxiv_data1/oa_pdf/29/1a/TOMICROJ-10-133.PMC4939603.pdf
"[http://dx.doi.org/10.1097/INF.0b013e31826108da ] [PMID: 22982953 ] [19] Makkar M, Gupta C, Pathak R, Garg S, Mahajan NC.",OADS,/arxiv_data1/oa_pdf/29/1a/TOMICROJ-10-133.PMC4939603.pdf
"[http://dx.doi.org/10.4103/2249-4847.109243 ] [PMID: 24027741 ] [20] Hofer N, Edlinger S, Resch B.",OADS,/arxiv_data1/oa_pdf/29/1a/TOMICROJ-10-133.PMC4939603.pdf
"Comparison Between Pathogen Associated Laboratory and Clinical Parameters The Open Microbiology Journal, 2016, Volume 10    139 [http://dx.doi.org/10.1016/j.pedneo.2013.12.006 ] [PMID: 24751401 ] [21] Mayor-Lynn K, González-Quintero VH, O’Sullivan MJ, Hartstein AI, Roger S, Tamayo M. Comparison of early-onset neonatal sepsis caused by Escherichia coli  and group B Streptococcus.",OADS,/arxiv_data1/oa_pdf/29/1a/TOMICROJ-10-133.PMC4939603.pdf
"[http://dx.doi.org/10.1016/j.ajog.2004.12.031 ] [PMID: 15902130 ] [22] Weisman LE, Stoll BJ, Cruess DF, et al.",OADS,/arxiv_data1/oa_pdf/29/1a/TOMICROJ-10-133.PMC4939603.pdf
"[http://dx.doi.org/10.1016/S0022-3476(05)81801-3 ] [PMID: 1517922 ] [23] Wu JH, Chen CY, Tsao PN, Hsieh WS, Chou HC.",OADS,/arxiv_data1/oa_pdf/29/1a/TOMICROJ-10-133.PMC4939603.pdf
"[http://dx.doi.org/10.1016/S1875-9572(09)60042-5 ] [PMID: 19579754 ] [24] Stoll BJ, Hansen N, Fanaroff AA, et al.",OADS,/arxiv_data1/oa_pdf/29/1a/TOMICROJ-10-133.PMC4939603.pdf
"[http://dx.doi.org/10.1056/NEJMoa012657 ] [PMID: 12140299 ] [25] Bizzarro MJ, Dembry LM, Baltimore RS, Gallagher PG.",OADS,/arxiv_data1/oa_pdf/29/1a/TOMICROJ-10-133.PMC4939603.pdf
"[http://dx.doi.org/10.1542/peds.2007-2171 ] [PMID: 18381532 ] [26] Volante E, Moretti S, Pisani F, Bevilacqua G. Early diagnosis of bacterial infection in the neonate.",Non-OADS,/arxiv_data1/oa_pdf/29/1a/TOMICROJ-10-133.PMC4939603.pdf
"[http://dx.doi.org/10.1080/jmf.16.2.13.16 ] [PMID: 15590427 ] [27] Modi N, Doré CJ, Saraswatula A, et al.",OADS,/arxiv_data1/oa_pdf/29/1a/TOMICROJ-10-133.PMC4939603.pdf
[http://dx.doi.org/10.1136/adc.2007.126458 ] [PMID: 18499771 ] © Resch  et al.,OADS,/arxiv_data1/oa_pdf/29/1a/TOMICROJ-10-133.PMC4939603.pdf
"This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) ( https://creativecommons.org/licenses/by-nc/4.0/legalcode ), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/29/1a/TOMICROJ-10-133.PMC4939603.pdf
"Stem Cell Reports Article Intercellular Adhesion-Dependent Cell Survival and ROCK-Regulated Actomyosin-Driven Forces Mediate Self-Formation of a Retinal Organoid Albert Lowe,1Raven Harris,1Punita Bhansali,1Ales Cvekl,1,2and Wei Liu1,2,* 1Department of Genetics 2Department of Ophthalmology and Visual Sciences Albert Einstein College of Medicine, Bronx, NY 10461, USA *Correspondence: wei.liu@einstein.yu.edu http://dx.doi.org/10.1016/j.stemcr.2016.03.011 SUMMARY In this study we dissected retinal organoid morphogenesis in human embryonic stem cell (hESC)-derived cultures and established a convenient method for isolating large quantities of retinal organoids for modeling human retinal development and disease.",Non-OADS,/arxiv_data1/oa_pdf/fd/e1/main.PMC4939656.pdf
"6 j743–756 jMay 10, 2016 jª2016 The Authors 743 This is an open access article under the CC BY -NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).",Non-OADS,/arxiv_data1/oa_pdf/fd/e1/main.PMC4939656.pdf
"SUPPLEMENTAL INFORMATION Supplemental Information includes Supplemental Experimental Procedures, seven ﬁgures, and three movies and can be foundwith this article online at http://dx.doi.org/10.1016/j.stemcr.",Non-OADS,/arxiv_data1/oa_pdf/fd/e1/main.PMC4939656.pdf
http://dx.doi.org/10.1016/j.stemcr.2016.04.001 SUMMARY Generation of induced pluripotent stem cells (iPSCs) from human urine-derived cells (hUCs) provides a convenient and non-invasive way to obtain patient-speciﬁc iPSCs.,Non-OADS,/arxiv_data1/oa_pdf/1d/85/main.PMC4939659.pdf
"6 j717–728 jMay 10, 2016 jª2016 The Authors 717 This is an open access article under the CC BY -NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).",Non-OADS,/arxiv_data1/oa_pdf/1d/85/main.PMC4939659.pdf
SUPPLEMENTAL INFORMATION Supplemental Information includes three ﬁgures and can be found with this article online at http://dx.doi.org/10.1016/j.stemcr.2016.,Non-OADS,/arxiv_data1/oa_pdf/1d/85/main.PMC4939659.pdf
"   Case Rep Gastroenterol 2016;10:241 –247  DOI: 10.1159/000446576   Published online: May 27, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/crg   This article is licensed und er the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/ee/75/crg-0010-0241.PMC4939663.pdf
"   Case Rep Gastroenterol 2016;10:302 –307  DOI: 10.1159/000446764   Published online: June 14, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/crg   This article is l icensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/62/21/crg-0010-0302.PMC4939664.pdf
"   Case Rep Oncol 2016;9:321 –327  DOI: 10.1159/000446911   Published online: June 14, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/cro   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/90/36/cro-0009-0321.PMC4939665.pdf
"   Case Rep Gastroenterol 2016;10:224 –232  DOI: 10.1159/000446018   Published online: May 26, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/crg   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Servic es/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/a5/ea/crg-0010-0224.PMC4939666.pdf
"   Case Rep Oncol 2016;9:338 –343  DOI: 10.1159/000447353   Published online: June 27, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/cro   This article is licensed under the  Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/6b/58/cro-0009-0338.PMC4939667.pdf
https://ash.confex.com/ash/2014/webprogram/Paper72932.,Non-OADS,/arxiv_data1/oa_pdf/6b/58/cro-0009-0338.PMC4939667.pdf
"   Case Rep Oncol 2016;9:312 –316  DOI: 10.1159/000446696   Published online: June 10, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/cro   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/0a/2a/cro-0009-0312.PMC4939668.pdf
"   Case Rep Oncol 2016;9:363 –367  DOI: 10.1159/000447088   Published online: June 27, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/cro   This article is licensed under the C reative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/3e/76/cro-0009-0363.PMC4939669.pdf
"   Case Rep Oncol 2016;9:344 –350  DOI: 10.1159/000447352   Published online: June 27, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/cro   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/47/91/cro-0009-0344.PMC4939670.pdf
"   Case Rep Gastroenterol 2016;10:283 –291  DOI: 10.1159/000445105   Published online: June 14, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/crg   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/ca/b9/crg-0010-0283.PMC4939671.pdf
"   Case Rep Oncol 2016;9:317 –320  DOI: 10.1159/000446695   Published online: June 10, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/cro   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/14/16/cro-0009-0317.PMC4939672.pdf
http://www.cyramzahcp.com/gastric/safety/rainbow -adverse -reactions.html.,Non-OADS,/arxiv_data1/oa_pdf/14/16/cro-0009-0317.PMC4939672.pdf
"   Case Rep Oncol 2016;9:305 –311  DOI: 10.1159/000446694   Published online: June 10, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/cro   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/e2/12/cro-0009-0305.PMC4939673.pdf
"   Case Rep Gastroenterol 2016;10:264 –268  DOI: 10.1159/000446838   Published online: June 6, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/crg   This article is licensed under the Creative Commons Attribu tion-NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/12/0e/crg-0010-0264.PMC4939674.pdf
"   Case Rep Gastroenterol 2016;10:269 –274  DOI: 10.1159/000446642   Published online: June 14, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/crg   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/37/e2/crg-0010-0269.PMC4939676.pdf
"   Case Rep Oncol 2016;9:358 –362  DOI: 10.1159/000447350   Published online: June 27, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/cro   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/80/6e/cro-0009-0358.PMC4939677.pdf
"   Case Rep Oncol 2016;9:328 –330  DOI: 10.1159/000447257   Published online: June 14, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/cro   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/fd/75/cro-0009-0328.PMC4939678.pdf
"   Case Rep Neurol 2016;8:120 –126  DOI: 10.1159/000446872   Published online: June 6, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/crn   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/Open AccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/43/14/crn-0008-0120.PMC4939679.pdf
Nucleotide -level variation analysis of the exome sequence data was performed  using various  tools available on the DNA nexus platform (https://dnanexus.com/).,OADS,/arxiv_data1/oa_pdf/43/14/crn-0008-0120.PMC4939679.pdf
"The variants obtained  were further annotated using the Ensembl variant effect predictor tool (Ensembl release 75,  February 2014; http://useast.ensembl.org/info/docs/tools/vep /index.html).",OADS,/arxiv_data1/oa_pdf/43/14/crn-0008-0120.PMC4939679.pdf
"   Case Rep Neurol 2016;8:127 –133  DOI: 10.1159/000447295   Published online: June 14, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/crn   This article is licensed unde r the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/aa/90/crn-0008-0127.PMC4939680.pdf
"   Case Rep Gastroenterol 2016;10:206 –211  Published online: May 20, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/crg   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/67/68/crg-0010-0206.PMC4939681.pdf
"   Case Rep Gastroenterol 2016;10:292 –301  DOI: 10.1159/000444277   Published online: June 14, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/crg   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/65/25/crg-0010-0292.PMC4939682.pdf
"   Case Rep Neurol 2016;8:115 –119  DOI: 10.1159/000446643   Published online: June 6, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/crn   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/0e/5f/crn-0008-0115.PMC4939683.pdf
"   Case Rep Gastroenterol 2016;10:248 –256  DOI: 10.1159/000445374   Published online: May 27, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/crg   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/e6/02/crg-0010-0248.PMC4939684.pdf
"   Case Rep Gastroenterol 2016;10:218 –223  DOI: 10.1159/000444014   Published online: May 26, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/crg   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/c5/3d/crg-0010-0218.PMC4939685.pdf
"Cleveland Clinic, 2013.  http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/hematology - oncology/esophageal -cancer/.",Non-OADS,/arxiv_data1/oa_pdf/c5/3d/crg-0010-0218.PMC4939685.pdf
"   Case Rep Gastroenterol 2016;10:275 –282  DOI: 10.1159/000446579   Published online: June 14, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/crg   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/a4/d4/crg-0010-0275.PMC4939686.pdf
"   Case Rep Oncol 2016;9:368 –372  DOI: 10.1159/000447488   Published online: June 27, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/cro   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  Intern ational License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/4f/24/cro-0009-0368.PMC4939687.pdf
"   Case Rep Oncol 2016;9:290 –297  DOI: 10.1159/000446473   Published online: May 31, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/cro   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/bb/dd/cro-0009-0290.PMC4939688.pdf
"   Case Rep Oncol 2016;9:331 –337  DOI: 10.1159/000447258   Published online: June 27, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/cro   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/a2/d6/cro-0009-0331.PMC4939689.pdf
"We searched the PubMed database  (http://www.ncbi.nlm.nih.gov/pubmed) for reports on adenocarcinomas associated with  MCTs written in English using the key words ‘adenocarcinoma’ , ‘malignant transformation’,  and ‘mature cystic teratoma’.",Non-OADS,/arxiv_data1/oa_pdf/a2/d6/cro-0009-0331.PMC4939689.pdf
"   Case Rep Gastroenterol 2016;10:257 –263  DOI: 10.1159/000446767   Published online: June 6, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/crg   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (C C BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/54/aa/crg-0010-0257.PMC4939690.pdf
"   Case Rep Oncol 2016;9:373 –378  DOI: 10.1159/000447508   Published online: June 27, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/cro   This article is licensed under t he Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/7b/02/cro-0009-0373.PMC4939691.pdf
"Bristol -Myers Squibb, January 28, 2016. http://news.bms.com/press - release/checkmate -141-pivotal -phase -3-opdivo -nivolumab -head -and-neck -cancer -trial -stopped -earl.",Non-OADS,/arxiv_data1/oa_pdf/7b/02/cro-0009-0373.PMC4939691.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/eb/52/aww121.PMC4939693.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/cd/62/aww099.PMC4939694.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/b3/f6/aww113.PMC4939696.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/ae/51/aww118.PMC4939700.pdf
©2016TheAuthor(s).PublishedbyElsevierInc.ThisisanopenaccessarticleundertheCCBY-NC-ND license( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/79/fc/main.PMC4939707.pdf
